text,title,id,project_number,terms,administration,organization,mechanism,year,funding,score
"Disease marker genome annotation system Omicia, Inc. intends to deliver genomic information services to individuals that allows them to make use of current genetic and clinical research better to manage their health. The motivation behind Phase II of this SBIR grant is to finalize the mapping and annotation of Mendelian mutations as tabulated in the Online Mendelian Inheritance in Man (""OMIM"") database within the current human genome sequence assembly. In addition, modified mapping methods are also used to include individual mutations from the Human Genome Mutation Database (""HGMD""), as well as polymorphisms from databases such as dbSNP. A key aspect of research in genetics is the association of sequence variation with disease genes and phenotypes. Sequence variation data is currently available from OMIM, HGMD and others, both of which provide phenotypic information and describe amino acid variation. Unfortunately, in most cases these variation references do not provide sufficient information to support their direct mapping onto current genomic sequences and the associated annotated genes. Single nucleotide polymorphism (SNP) data is held in dbSNP and other publicly accessible databases. While these databases contain millions of entries each including the position of the SNP on the genome, they do not provide significant phenotypic information about the SNPs. In order to use these databases to deliver accurate and reliable genomic information to individuals, these gaps must be resolved. The specific aims of this Phase II program are: first, to finalze the implementation from Phase I of a software system to support the mutation mapping and annotation from various databases; second, to map uniquely and accurately the positions of mutations associated with a human phenotype onto the human genome assembly using a computer-assisted expert driven manual approach; third, and finally, to capture the mutation-disease associations for each of these markers in a meaningful and electronically tractable way using links to the MeSH disease ontology. An initial selected set of 97 disease genes, developed during Phase I, will be used to validate each software development step. The goal of the project is to map and clinically annotate a very comprehensive set of disease genes estimated to be between 2,000 - 3,000 genes. The deliverables from this project will become integral components of Omicia's business of delivering broad- based, personalized, genetic profile information to its customers. Furthermore, Omicia expects to license its genotype-phenotype database and Biofinormatics infrastructure to interested commercial entities in biotechnology and Pharma. An initial collaboration project with a small biotechnology company, Human Genetic Signatures Pty.Ltd., has already started. n/a",Disease marker genome annotation system,7485276,R44HG002993,"['Address', 'Algorithms', 'Alleles', 'Amino Acid Sequence', 'Amino Acids', 'Automated Annotation', 'Biological Assay', 'Biotechnology', 'Businesses', 'Clinical', 'Clinical Research', 'Collaborations', 'Communities', 'Complement', 'Computer Assisted', 'Computer information processing', 'Computer software', 'Computing Methodologies', 'Controlled Vocabulary', 'DNA', 'DNA Markers', 'Data', 'Data Analyses', 'Databases', 'Development', 'Disease', 'Disease Association', 'Disease Marker', 'Future', 'Gene Mutation', 'Genes', 'Genetic', 'Genetic Markers', 'Genetic Polymorphism', 'Genetic Research', 'Genetic Variation', 'Genome', 'Genomics', 'Genotype', 'Goals', 'Grant', 'Hand', 'Haplotypes', 'Health', 'Human', 'Human Genetics', 'Human Genome', 'Individual', 'Information Services', 'Inherited', 'Letters', 'Licensing', 'Link', 'Literature', 'Manuals', 'Maps', 'MeSH Thesaurus', 'Medicine', 'Methods', 'Molecular', 'Motivation', 'Mutation', 'Nucleotides', 'Online Mendelian Inheritance In Man', 'Ontology', 'Patients', 'Peptide Sequence Determination', 'Personal Genetic Information', 'Pharmacogenomics', 'Pharmacologic Substance', 'Phase', 'Phenotype', 'Positioning Attribute', 'Publishing', 'Research', 'Research Infrastructure', 'Scientist', 'Semantics', 'Services', 'Single Nucleotide Polymorphism', 'Small Business Funding Mechanisms', 'Small Business Innovation Research Grant', 'Source', 'Standards of Weights and Measures', 'SwissProt', 'System', 'Techniques', 'Technology', 'Text', 'Thesauri', 'Time', 'Today', 'Toxicogenomics', 'United States National Library of Medicine', 'Update', 'Variant', 'Visual', 'Writing', 'base', 'clinical phenotype', 'cost', 'design', 'disease phenotype', 'disease-causing mutation', 'gene discovery', 'genetic profiling', 'genome sequencing', 'innovation', 'interest', 'man', 'novel', 'programs', 'software development', 'software systems', 'statistics', 'text searching', 'tool', 'trend']",NHGRI,"OMICIA, INC.",R44,2007,211148,0.11539481439119685
"Improve predictions of structure and function by PredictProtein    DESCRIPTION (provided by applicant):       SUMMARY: Over 25,000 researchers in the US and over 50,000 in 120 other countries have exploited the PredictProtein (PP) Internet server to analyze proteins by homology-transfer and by eye novo predictions of protein structure and function. Here, we propose technical and scientific solutions that will improve the functionality of PP and its extension portal META-PP. Many technical changes will remain hidden to users and are required to increase the maintainability, scalability, and portability of these servers. New Graphical User Interfaces are one proposed solution that will visibly impact the service. The scientific solutions address two related tasks pertaining to the prediction of structure and function. The first is to predict the effect of mutations. We propose the development of novel machine learning-based methods to distinguish between mutations that affect structure, function, or have no apparent phenotype. Our final method will be applied to the screening of SNP data from our experimental colleagues at Columbia, as well as to the prediction of SNP effects in public databases. The second major task is the identification of natively unstructured regions and their functional classification. Proteins that do not adopt regular structures in isolation are increasingly becoming an important research area; they may provide a key to the evolution of complexity from prokaryotes to eukaryotes. We propose the development of a machine learning-based identification of features specific to this important class of molecules. We also plan to attack the problem from a very different angle by using predictions of interaction densities inside proteins. The resulting novel tools will allow a proteome-wide analysis of the role of these molecules. All methods will be made available through PP.      RELEVANCE: Information about protein structure adds an entire dimension to protein analysis and genome annotation. This addition is often essential to infer function even for natively unstructured proteins. The PredictProtein server is unique in its combination and exploitation of evolution, structure, and function; many thousands of theoretical, experimental, and clinical researches have benefited from this. The long-term goal of the research proposed here is to improve our ability to use the evolutionary record of amino acid substitutions, i.e. to ultimately understand the amino acid ""language"". The short-term goal is to address two tasks that are closely related to human diseases, namely the distinction between silent and important mutations and the mapping of unstructured proteins onto networks and diseases.          n/a",Improve predictions of structure and function by PredictProtein,7842572,R01LM007329,"['Address', 'Adopted', 'Affect', 'Amino Acid Substitution', 'Amino Acids', 'Area', 'Biology', 'Budgets', 'Classification', 'Clinical Research', 'Code', 'Communities', 'Country', 'Data', 'Data Set', 'Databases', 'Development', 'Devices', 'Dimensions', 'Disease', 'Eukaryota', 'Evolution', 'Eye', 'Funding', 'Genome', 'Genomics', 'Goals', 'Grant', 'Induced Mutation', 'Internet', 'Investigation', 'Language', 'Linux', 'Machine Learning', 'Maintenance', 'Maps', 'Medical', 'Membrane', 'Methods', 'Mutation', 'Nucleotides', 'Output', 'Phenotype', 'Plug-in', 'Point Mutation', 'Progress Reports', 'Prokaryotic Cells', 'Property', 'Protein Analysis', 'Proteins', 'Proteome', 'Research', 'Research Personnel', 'Resolution', 'Role', 'Screening procedure', 'Sequence Analysis', 'Services', 'Solutions', 'Structure', 'Testing', 'Training', 'base', 'data modeling', 'density', 'design', 'graphical user interface', 'human disease', 'improved', 'novel', 'portability', 'protein function', 'protein protein interaction', 'protein structure', 'protein structure function', 'protein structure prediction', 'tool']",NLM,COLUMBIA UNIV NEW YORK MORNINGSIDE,R01,2010,327180,0.15362003596996107
"Improve predictions of structure and function by PredictProtein    DESCRIPTION (provided by applicant):       SUMMARY: Over 25,000 researchers in the US and over 50,000 in 120 other countries have exploited the PredictProtein (PP) Internet server to analyze proteins by homology-transfer and by eye novo predictions of protein structure and function. Here, we propose technical and scientific solutions that will improve the functionality of PP and its extension portal META-PP. Many technical changes will remain hidden to users and are required to increase the maintainability, scalability, and portability of these servers. New Graphical User Interfaces are one proposed solution that will visibly impact the service. The scientific solutions address two related tasks pertaining to the prediction of structure and function. The first is to predict the effect of mutations. We propose the development of novel machine learning-based methods to distinguish between mutations that affect structure, function, or have no apparent phenotype. Our final method will be applied to the screening of SNP data from our experimental colleagues at Columbia, as well as to the prediction of SNP effects in public databases. The second major task is the identification of natively unstructured regions and their functional classification. Proteins that do not adopt regular structures in isolation are increasingly becoming an important research area; they may provide a key to the evolution of complexity from prokaryotes to eukaryotes. We propose the development of a machine learning-based identification of features specific to this important class of molecules. We also plan to attack the problem from a very different angle by using predictions of interaction densities inside proteins. The resulting novel tools will allow a proteome-wide analysis of the role of these molecules. All methods will be made available through PP.      RELEVANCE: Information about protein structure adds an entire dimension to protein analysis and genome annotation. This addition is often essential to infer function even for natively unstructured proteins. The PredictProtein server is unique in its combination and exploitation of evolution, structure, and function; many thousands of theoretical, experimental, and clinical researches have benefited from this. The long-term goal of the research proposed here is to improve our ability to use the evolutionary record of amino acid substitutions, i.e. to ultimately understand the amino acid ""language"". The short-term goal is to address two tasks that are closely related to human diseases, namely the distinction between silent and important mutations and the mapping of unstructured proteins onto networks and diseases.          n/a",Improve predictions of structure and function by PredictProtein,7625220,R01LM007329,"['Address', 'Adopted', 'Affect', 'Amino Acid Substitution', 'Amino Acids', 'Area', 'Biology', 'Budgets', 'Classification', 'Clinical Research', 'Code', 'Communities', 'Country', 'Data', 'Data Set', 'Databases', 'Development', 'Devices', 'Dimensions', 'Disease', 'Eukaryota', 'Evolution', 'Eye', 'Funding', 'Genome', 'Genomics', 'Goals', 'Grant', 'Induced Mutation', 'Internet', 'Investigation', 'Language', 'Linux', 'Machine Learning', 'Maintenance', 'Maps', 'Medical', 'Membrane', 'Methods', 'Mutation', 'Nucleotides', 'Output', 'Phenotype', 'Plug-in', 'Point Mutation', 'Progress Reports', 'Prokaryotic Cells', 'Property', 'Protein Analysis', 'Proteins', 'Proteome', 'Research', 'Research Personnel', 'Resolution', 'Role', 'Screening procedure', 'Sequence Analysis', 'Services', 'Solutions', 'Structure', 'Testing', 'Training', 'base', 'data modeling', 'density', 'design', 'graphical user interface', 'human disease', 'improved', 'novel', 'portability', 'protein function', 'protein protein interaction', 'protein structure', 'protein structure function', 'protein structure prediction', 'tool']",NLM,COLUMBIA UNIVERSITY HEALTH SCIENCES,R01,2009,330166,0.15362003596996107
"Improve predictions of structure and function by PredictProtein    DESCRIPTION (provided by applicant):       SUMMARY: Over 25,000 researchers in the US and over 50,000 in 120 other countries have exploited the PredictProtein (PP) Internet server to analyze proteins by homology-transfer and by eye novo predictions of protein structure and function. Here, we propose technical and scientific solutions that will improve the functionality of PP and its extension portal META-PP. Many technical changes will remain hidden to users and are required to increase the maintainability, scalability, and portability of these servers. New Graphical User Interfaces are one proposed solution that will visibly impact the service. The scientific solutions address two related tasks pertaining to the prediction of structure and function. The first is to predict the effect of mutations. We propose the development of novel machine learning-based methods to distinguish between mutations that affect structure, function, or have no apparent phenotype. Our final method will be applied to the screening of SNP data from our experimental colleagues at Columbia, as well as to the prediction of SNP effects in public databases. The second major task is the identification of natively unstructured regions and their functional classification. Proteins that do not adopt regular structures in isolation are increasingly becoming an important research area; they may provide a key to the evolution of complexity from prokaryotes to eukaryotes. We propose the development of a machine learning-based identification of features specific to this important class of molecules. We also plan to attack the problem from a very different angle by using predictions of interaction densities inside proteins. The resulting novel tools will allow a proteome-wide analysis of the role of these molecules. All methods will be made available through PP.      RELEVANCE: Information about protein structure adds an entire dimension to protein analysis and genome annotation. This addition is often essential to infer function even for natively unstructured proteins. The PredictProtein server is unique in its combination and exploitation of evolution, structure, and function; many thousands of theoretical, experimental, and clinical researches have benefited from this. The long-term goal of the research proposed here is to improve our ability to use the evolutionary record of amino acid substitutions, i.e. to ultimately understand the amino acid ""language"". The short-term goal is to address two tasks that are closely related to human diseases, namely the distinction between silent and important mutations and the mapping of unstructured proteins onto networks and diseases.          n/a",Improve predictions of structure and function by PredictProtein,7389563,R01LM007329,"['Address', 'Adopted', 'Affect', 'Amino Acid Substitution', 'Amino Acids', 'Area', 'Biology', 'Budgets', 'Class', 'Classification', 'Clinical Research', 'Code', 'Communities', 'Country', 'Data', 'Data Set', 'Databases', 'Development', 'Devices', 'Dimensions', 'Disease', 'Eukaryota', 'Eukaryotic Cell', 'Evolution', 'Eye', 'Funding', 'Genome', 'Genomics', 'Goals', 'Grant', 'Induced Mutation', 'Internet', 'Investigation', 'Language', 'Linux', 'Machine Learning', 'Maintenance', 'Maps', 'Medical', 'Membrane', 'Methods', 'Mutation', 'Nucleotides', 'Numbers', 'Output', 'Phenotype', 'Plug-in', 'Point Mutation', 'Progress Reports', 'Prokaryotic Cells', 'Property', 'Protein Analysis', 'Proteins', 'Proteome', 'Range', 'Research', 'Research Personnel', 'Resolution', 'Role', 'Screening procedure', 'Sequence Analysis', 'Services', 'Solutions', 'Standards of Weights and Measures', 'Structure', 'Testing', 'Training', 'base', 'data modeling', 'density', 'design', 'graphical user interface', 'human disease', 'improved', 'novel', 'portability', 'protein function', 'protein protein interaction', 'protein structure', 'protein structure function', 'protein structure prediction', 'tool']",NLM,COLUMBIA UNIVERSITY HEALTH SCIENCES,R01,2008,320418,0.15362003596996107
"Improve predictions of structure and function by PredictProtein    DESCRIPTION (provided by applicant):       SUMMARY: Over 25,000 researchers in the US and over 50,000 in 120 other countries have exploited the PredictProtein (PP) Internet server to analyze proteins by homology-transfer and by eye novo predictions of protein structure and function. Here, we propose technical and scientific solutions that will improve the functionality of PP and its extension portal META-PP. Many technical changes will remain hidden to users and are required to increase the maintainability, scalability, and portability of these servers. New Graphical User Interfaces are one proposed solution that will visibly impact the service. The scientific solutions address two related tasks pertaining to the prediction of structure and function. The first is to predict the effect of mutations. We propose the development of novel machine learning-based methods to distinguish between mutations that affect structure, function, or have no apparent phenotype. Our final method will be applied to the screening of SNP data from our experimental colleagues at Columbia, as well as to the prediction of SNP effects in public databases. The second major task is the identification of natively unstructured regions and their functional classification. Proteins that do not adopt regular structures in isolation are increasingly becoming an important research area; they may provide a key to the evolution of complexity from prokaryotes to eukaryotes. We propose the development of a machine learning-based identification of features specific to this important class of molecules. We also plan to attack the problem from a very different angle by using predictions of interaction densities inside proteins. The resulting novel tools will allow a proteome-wide analysis of the role of these molecules. All methods will be made available through PP.      RELEVANCE: Information about protein structure adds an entire dimension to protein analysis and genome annotation. This addition is often essential to infer function even for natively unstructured proteins. The PredictProtein server is unique in its combination and exploitation of evolution, structure, and function; many thousands of theoretical, experimental, and clinical researches have benefited from this. The long-term goal of the research proposed here is to improve our ability to use the evolutionary record of amino acid substitutions, i.e. to ultimately understand the amino acid ""language"". The short-term goal is to address two tasks that are closely related to human diseases, namely the distinction between silent and important mutations and the mapping of unstructured proteins onto networks and diseases.          n/a",Improve predictions of structure and function by PredictProtein,7207482,R01LM007329,"['Address', 'Adopted', 'Affect', 'Amino Acid Substitution', 'Amino Acids', 'Area', 'Biology', 'Budgets', 'Class', 'Classification', 'Clinical Research', 'Code', 'Communities', 'Country', 'Data', 'Data Set', 'Databases', 'Development', 'Devices', 'Dimensions', 'Disease', 'Eukaryota', 'Eukaryotic Cell', 'Evolution', 'Eye', 'Funding', 'Genome', 'Genomics', 'Goals', 'Grant', 'Induced Mutation', 'Internet', 'Investigation', 'Language', 'Linux', 'Machine Learning', 'Maintenance', 'Maps', 'Medical', 'Membrane', 'Methods', 'Mutation', 'Nucleotides', 'Numbers', 'Output', 'Phenotype', 'Plug-in', 'Point Mutation', 'Progress Reports', 'Prokaryotic Cells', 'Property', 'Protein Analysis', 'Proteins', 'Proteome', 'Range', 'Research', 'Research Personnel', 'Resolution', 'Role', 'Screening procedure', 'Sequence Analysis', 'Services', 'Solutions', 'Standards of Weights and Measures', 'Structure', 'Testing', 'Training', 'base', 'data modeling', 'density', 'design', 'graphical user interface', 'human disease', 'improved', 'novel', 'portability', 'protein function', 'protein protein interaction', 'protein structure', 'protein structure function', 'protein structure prediction', 'tool']",NLM,COLUMBIA UNIVERSITY HEALTH SCIENCES,R01,2007,323192,0.15362003596996107
"Rewiring the yeast brain:  Redundancy and interference in genetic networks    DESCRIPTION (Provided by the applicant)   Abstract: Similar to neural networks in animals, molecular networks in cells can generate bistable or oscillatory dynamics that maintain memories of previous events (e.g. epigenetic switch) or order periodic events (e.g. cell cycle), respectively. In cells, networks of genes interacting with one another through regulatory feedback implement such dynamics. Analogous to learning in brains, cells can """"learn"""" correlations in their environmental signals by encoding such correlations into their gene network dynamics through mutation, a """"re-wiring"""" process that occurs on the timescale of generations. The issue of learning the statistical regularities and correlations of environmental signals is best exemplified by the evolution of """"circadian clocks"""", which are oscillatory gene circuits that have learned to internalize the 24-hour light-dark circadian cycle. Strikingly, circadian clocks have evolved independently multiple times, which suggests there exists some selection pressure and/or evolutionary mechanism that repeatedly favor the convergent evolution of autonomous oscillation. The hypothesis of my research proposal is that certain types of loss-of-function mutations in duplicated genes (known as dominant-negative mutations) can easily generate bistability and oscillation in existing regulatory networks. Gene duplication followed by a loss-of-function mutation can generate a dominant-negative. A dominant negative mutation is a partial loss-of-function mutation that renders a gene duplicate functionally inactive, yet still capable of interacting with the original duplicate, the upstream effectors, and/or downstream targets. Thus, dominant-negatives can easily interfere with the proper regulation and activity of the original duplicate. Because both gene duplication and loss-of-function mutations occur frequently in evolution, this presents an evolutionary mechanism for rapidly generating bistability and autonomous oscillation in gene regulatory networks. My proposed research over the next five years will integrate experiment and theory to understand the extent to which gene duplication and dominant-negative mutations facilitate the evolution of epigenetic switches and circadian clocks in regulatory networks. We will use computer simulation and an experimental directed evolution approach in a tractable, model eukaryote (Saccharomyces cerevisiae) to test the ability of cells to learn the statistical regularities of their coupled environmental signals. Understanding how and why single-cell microbes and parasites have learned to predict their environment is essential for understanding their future evolution to changing host conditions.   Public Health Relevance: The ability of parasites to learn and adapt to changing host conditions and environments presents a challenge to human health. The objective of my research proposal is to understand the capacity of gene networks in single cells to learn and predict the statistical regularities of their environment. Discovering the limitations and abilities of parasites to evolve and anticipate changes in their host environment will be invaluable for the treatment of many human diseases.       n/a",Rewiring the yeast brain:  Redundancy and interference in genetic networks,8146626,DP2OD008654,"['Animals', 'Biological Neural Networks', 'Brain', 'Cell Cycle', 'Cells', 'Circadian Rhythms', 'Computer Simulation', 'Coupled', 'Dominant-Negative Mutation', 'Environment', 'Epigenetic Process', 'Eukaryota', 'Event', 'Evolution', 'Feedback', 'Future', 'Gene Duplication', 'Generations', 'Genes', 'Genetic', 'Health', 'Hour', 'Human', 'Learning', 'Light', 'Machine Learning', 'Memory', 'Microbe', 'Modeling', 'Molecular', 'Mutation', 'Parasites', 'Process', 'Regulation', 'Regulator Genes', 'Research', 'Research Proposals', 'Saccharomyces cerevisiae', 'Signal Transduction', 'Testing', 'Time', 'Yeasts', 'abstracting', 'brain cell', 'circadian pacemaker', 'directed evolution', 'duplicate genes', 'human disease', 'loss of function mutation', 'pressure', 'public health relevance', 'research study', 'theories']",OD,DUKE UNIVERSITY,DP2,2011,2355000,0.22733135013531977
"Text Mining Point Mutations for Genetic Diagnosis Array Text mining applications seek to alleviate the problems with identifying, searching, and extracting relevant information from large sets of literature. The goal of this proposal is to create a text mining application to extract protein point mutations from biomedical literature. The developed application will be used to extract point mutations from literature discussing human genetic disorders, and the retrieved database of point mutations used to design a DMA microarray chip for prenatal genetic diagnosis. First, the text mining application will be developed using machine learning and statistical natural language processing techniques. Second, the point mutation mining application will be applied to a large set of literature related to genetic disorders, and the retrieved point mutations deposited in an electronic database. This collection of point mutations will be examined to find polymorphisms in genes that are markers for genetic disorders. These polymorphic positions in the human genome will be gathered and used to design a DMA microarray chip that can genotype tens of thousands of single nucelotide polymorphisms. The microarray chip can be used for prenatal genetic diagnosis purposes to screen for hundreds of genetic disorders. n/a",Text Mining Point Mutations for Genetic Diagnosis Array,7156197,F37LM008883,[' '],NLM,UNIVERSITY OF CALIFORNIA SAN FRANCISCO,F37,2007,45812,0.15349743544409042
"Text Mining Point Mutations for Genetic Diagnosis Array DESCRIPTION:    Text mining applications seek to alleviate the problems with identifying, searching, and extracting relevant information from large sets of literature. The goal of this proposal is to create a text mining application to extract protein point mutations from biomedical literature. The developed application will be used to extract point mutations from literature discussing human genetic disorders, and the retrieved database of point mutations used to design a DNA microarray chip for prenatal genetic diagnosis. First, the text mining application will be developed using machine learning and statistical natural language processing techniques. Second, the point mutation mining application will be applied to a large set of literature related to genetic disorders, and the retrieved point mutations deposited in an electronic database. This collection of point mutations will be examined to find polymorphisms in genes that are markers for genetic disorders. These polymorphic positions in the human genome will be gathered and used to design a DMA microarray chip that can genotype tens of thousands of single nucleotide polymorphisms. The microarray chip can be used for prenatal genetic diagnosis purposes to screen for hundreds of genetic disorders. n/a",Text Mining Point Mutations for Genetic Diagnosis Array,6993320,F37LM008883,"['biotechnology', 'information retrieval', 'microarray technology', 'molecular biology information system', 'point mutation', 'predoctoral investigator', 'technology /technique development']",NLM,UNIVERSITY OF CALIFORNIA SAN FRANCISCO,F37,2005,45812,0.15492688060507376
"Informatic Profiling of Clinically Relevant Mutation    DESCRIPTION (provided by applicant): Our group focuses on genetic variants that disrupt molecular functions that cause human disease. In this renewal R01 application, we propose to begin the process of realizing our long-term goals, and to expand our original scope of research to include the challenge of understanding genetic disease mutations and polymorphisms that affect gene expression regulation in noncoding regions. Additionally, we have formed collaborations with genetic data managers and will apply these methods to aid in their research and identify new testable hypotheses. We will do this in three aims. First, we will integrate predictions of protein-disease associations with mutation predictions to develop a new quantitative model of genotype and phenotype. Second, we will integrate each of these together to develop a systems level, molecular function genome annotator with functionality to import into the genome databases. Finally, we will continue to build new methods for characterization of mutations using sequence, function and structure and begin testing our published hypotheses. Each of these aims will include collaboration with the maintainers of genetic datasets to better understand their underlying molecular effects.           PrjctNrrative Tis cmetigrnwlR1aims t nerstn owgntic vritindat iscvrdi gnom sqecin  effortsdisrpts mlclr fnctinad te tsts wetertesemlclr fnctindisrptigvrintsar  mreliklytola to umn gneticdisaseusigbiiformtics.",Informatic Profiling of Clinically Relevant Mutation,8722025,R01LM009722,"['Affect', 'Algorithms', 'Amino Acid Substitution', 'Area', 'Bioinformatics', 'Biomedical Research', 'Classification', 'Code', 'Collaborations', 'Complex', 'Computer software', 'DNA Resequencing', 'Data', 'Data Set', 'Disease', 'Disease Association', 'Disease model', 'Feedback', 'Focus Groups', 'Functional RNA', 'Funding', 'Gene Expression Regulation', 'Genes', 'Genetic', 'Genetic Polymorphism', 'Genetic Sequence Databases', 'Genome', 'Genomics', 'Genotype', 'Goals', 'Hereditary Disease', 'Human', 'Human Genome', 'Individual', 'Informatics', 'Inherited', 'Internet', 'Laboratories', 'Leadership', 'Left', 'Letters', 'Machine Learning', 'Malignant Neoplasms', 'Meta-Analysis', 'Methods', 'Modeling', 'Molecular', 'Mutation', 'Mutation Analysis', 'Paper', 'Performance', 'Pharmacogenetics', 'Phenotype', 'Process', 'Proteins', 'Publishing', 'Research', 'Research Personnel', 'Research Proposals', 'Resources', 'Role', 'Science', 'Scientist', 'Staging', 'Structure', 'System', 'Testing', 'Transcript', 'Untranslated Regions', 'Variant', 'Work', 'base', 'cancer genome', 'career', 'clinically relevant', 'data management', 'disease phenotype', 'disease-causing mutation', 'exome sequencing', 'genetic regulatory protein', 'genetic variant', 'genome annotation', 'genome database', 'genome sequencing', 'human disease', 'improved', 'innovation', 'multidisciplinary', 'novel', 'novel strategies', 'protein structure function', 'software development', 'tool', 'user-friendly']",NLM,BUCK INSTITUTE FOR RESEARCH ON AGING,R01,2014,114720,0.2509420090886468
"Informatic profiling of clinically relevant mutation    DESCRIPTION (provided by applicant): Our group focuses on genetic variants that disrupt molecular functions that cause human disease. In this renewal R01 application, we propose to begin the process of realizing our long-term goals, and to expand our original scope of research to include the challenge of understanding genetic disease mutations and polymorphisms that affect gene expression regulation in noncoding regions. Additionally, we have formed collaborations with genetic data managers and will apply these methods to aid in their research and identify new testable hypotheses. We will do this in three aims. First, we will integrate predictions of protein-disease associations with mutation predictions to develop a new quantitative model of genotype and phenotype. Second, we will integrate each of these together to develop a systems level, molecular function genome annotator with functionality to import into the genome databases. Finally, we will continue to build new methods for characterization of mutations using sequence, function and structure and begin testing our published hypotheses. Each of these aims will include collaboration with the maintainers of genetic datasets to better understand their underlying molecular effects.           PrjctNrrative Tis cmetigrnwlR1aims t nerstn owgntic vritindat iscvrdi gnom sqecin  effortsdisrpts mlclr fnctinad te tsts wetertesemlclr fnctindisrptigvrintsar  mreliklytola to umn gneticdisaseusigbiiformtics.",Informatic profiling of clinically relevant mutation,8526549,R01LM009722,"['Affect', 'Algorithms', 'Amino Acid Substitution', 'Area', 'Bioinformatics', 'Biomedical Research', 'Classification', 'Code', 'Collaborations', 'Complex', 'Computer software', 'DNA Resequencing', 'Data', 'Data Set', 'Disease', 'Disease Association', 'Disease model', 'Feedback', 'Focus Groups', 'Functional RNA', 'Funding', 'Gene Expression Regulation', 'Genes', 'Genetic', 'Genetic Polymorphism', 'Genetic Sequence Databases', 'Genome', 'Genomics', 'Genotype', 'Goals', 'Hereditary Disease', 'Human', 'Human Genome', 'Individual', 'Informatics', 'Inherited', 'Internet', 'Laboratories', 'Leadership', 'Left', 'Letters', 'Machine Learning', 'Malignant Neoplasms', 'Meta-Analysis', 'Methods', 'Modeling', 'Molecular', 'Mutation', 'Mutation Analysis', 'Paper', 'Performance', 'Pharmacogenetics', 'Phenotype', 'Process', 'Proteins', 'Publishing', 'Research', 'Research Personnel', 'Research Proposals', 'Resources', 'Role', 'Science', 'Scientist', 'Staging', 'Structure', 'System', 'Testing', 'Transcript', 'Untranslated Regions', 'Variant', 'Work', 'base', 'cancer genome', 'career', 'clinically relevant', 'data management', 'disease phenotype', 'disease-causing mutation', 'exome sequencing', 'genetic regulatory protein', 'genetic variant', 'genome annotation', 'genome database', 'genome sequencing', 'human disease', 'improved', 'innovation', 'multidisciplinary', 'novel', 'novel strategies', 'protein structure function', 'software development', 'tool', 'user-friendly']",NLM,BUCK INSTITUTE FOR RESEARCH ON AGING,R01,2013,444076,0.2509420090886468
"Informatic profiling of clinically relevant mutation    DESCRIPTION (provided by applicant): Our group focuses on genetic variants that disrupt molecular functions that cause human disease. In this renewal R01 application, we propose to begin the process of realizing our long-term goals, and to expand our original scope of research to include the challenge of understanding genetic disease mutations and polymorphisms that affect gene expression regulation in noncoding regions. Additionally, we have formed collaborations with genetic data managers and will apply these methods to aid in their research and identify new testable hypotheses. We will do this in three aims. First, we will integrate predictions of protein-disease associations with mutation predictions to develop a new quantitative model of genotype and phenotype. Second, we will integrate each of these together to develop a systems level, molecular function genome annotator with functionality to import into the genome databases. Finally, we will continue to build new methods for characterization of mutations using sequence, function and structure and begin testing our published hypotheses. Each of these aims will include collaboration with the maintainers of genetic datasets to better understand their underlying molecular effects.           PrjctNrrative Tis cmetigrnwlR1aims t nerstn owgntic vritindat iscvrdi gnom sqecin  effortsdisrpts mlclr fnctinad te tsts wetertesemlclr fnctindisrptigvrintsar  mreliklytola to umn gneticdisaseusigbiiformtics.",Informatic profiling of clinically relevant mutation,8328943,R01LM009722,"['Affect', 'Algorithms', 'Amino Acid Substitution', 'Area', 'Bioinformatics', 'Biomedical Research', 'Classification', 'Code', 'Collaborations', 'Complex', 'Computer software', 'DNA Resequencing', 'Data', 'Data Set', 'Disease', 'Disease Association', 'Disease model', 'Feedback', 'Focus Groups', 'Functional RNA', 'Funding', 'Gene Expression Regulation', 'Genes', 'Genetic', 'Genetic Polymorphism', 'Genetic Sequence Databases', 'Genome', 'Genomics', 'Genotype', 'Goals', 'Hereditary Disease', 'Human', 'Human Genome', 'Individual', 'Informatics', 'Inherited', 'Internet', 'Laboratories', 'Leadership', 'Left', 'Letters', 'Machine Learning', 'Malignant Neoplasms', 'Meta-Analysis', 'Methods', 'Modeling', 'Molecular', 'Mutation', 'Mutation Analysis', 'Paper', 'Performance', 'Pharmacogenetics', 'Phenotype', 'Process', 'Proteins', 'Publishing', 'Research', 'Research Personnel', 'Research Proposals', 'Resources', 'Role', 'Science', 'Scientist', 'Staging', 'Structure', 'System', 'Testing', 'Transcript', 'Untranslated Regions', 'Variant', 'Work', 'base', 'cancer genome', 'career', 'clinically relevant', 'data management', 'disease phenotype', 'disease-causing mutation', 'exome', 'genetic regulatory protein', 'genetic variant', 'genome database', 'genome sequencing', 'human disease', 'improved', 'innovation', 'multidisciplinary', 'novel', 'novel strategies', 'protein structure function', 'software development', 'tool', 'user-friendly']",NLM,BUCK INSTITUTE FOR RESEARCH ON AGING,R01,2012,461516,0.2509420090886468
"Informatic profiling of clinically relevant mutation    DESCRIPTION (provided by applicant): Our group focuses on genetic variants that disrupt molecular functions that cause human disease. In this renewal R01 application, we propose to begin the process of realizing our long-term goals, and to expand our original scope of research to include the challenge of understanding genetic disease mutations and polymorphisms that affect gene expression regulation in noncoding regions. Additionally, we have formed collaborations with genetic data managers and will apply these methods to aid in their research and identify new testable hypotheses. We will do this in three aims. First, we will integrate predictions of protein-disease associations with mutation predictions to develop a new quantitative model of genotype and phenotype. Second, we will integrate each of these together to develop a systems level, molecular function genome annotator with functionality to import into the genome databases. Finally, we will continue to build new methods for characterization of mutations using sequence, function and structure and begin testing our published hypotheses. Each of these aims will include collaboration with the maintainers of genetic datasets to better understand their underlying molecular effects.           PrjctNrrative Tis cmetigrnwlR1aims t nerstn owgntic vritindat iscvrdi gnom sqecin  effortsdisrpts mlclr fnctinad te tsts wetertesemlclr fnctindisrptigvrintsar  mreliklytola to umn gneticdisaseusigbiiformtics.",Informatic profiling of clinically relevant mutation,8238173,R01LM009722,"['Affect', 'Algorithms', 'Amino Acid Substitution', 'Area', 'Bioinformatics', 'Biomedical Research', 'Classification', 'Code', 'Collaborations', 'Complex', 'Computer software', 'DNA Resequencing', 'Data', 'Data Set', 'Disease', 'Disease Association', 'Disease model', 'Feedback', 'Focus Groups', 'Functional RNA', 'Funding', 'Gene Expression Regulation', 'Genes', 'Genetic', 'Genetic Polymorphism', 'Genetic Sequence Databases', 'Genome', 'Genomics', 'Genotype', 'Goals', 'Hereditary Disease', 'Human', 'Human Genome', 'Individual', 'Informatics', 'Inherited', 'Internet', 'Laboratories', 'Leadership', 'Left', 'Letters', 'Machine Learning', 'Malignant Neoplasms', 'Meta-Analysis', 'Methods', 'Modeling', 'Molecular', 'Mutation', 'Mutation Analysis', 'Paper', 'Performance', 'Pharmacogenetics', 'Phenotype', 'Process', 'Proteins', 'Publishing', 'Research', 'Research Personnel', 'Research Proposals', 'Resources', 'Role', 'Science', 'Scientist', 'Staging', 'Structure', 'System', 'Testing', 'Transcript', 'Untranslated Regions', 'Variant', 'Work', 'base', 'cancer genome', 'career', 'clinically relevant', 'data management', 'disease phenotype', 'disease-causing mutation', 'exome', 'genetic regulatory protein', 'genetic variant', 'genome database', 'genome sequencing', 'human disease', 'improved', 'innovation', 'multidisciplinary', 'novel', 'novel strategies', 'protein structure function', 'software development', 'tool', 'user-friendly']",NLM,BUCK INSTITUTE FOR RESEARCH ON AGING,R01,2011,500661,0.2509420090886468
"Informatic profiling of clinically relevant mutation    DESCRIPTION (provided by applicant):       We are submitting this proposal pursuant to NOT-0D-09-058, NIH Announces the Availability of Recovery Act Funds for Competitive Revision Applications.       Our group focuses on understanding how amino acid substitutions disrupt molecular functions that cause human disease. In our currently funded R01, we are developing methods we call in silico functional profiling. This method works by learning residue-specific protein function and then estimates when it is disrupted. This research funds our efforts to characterize what the underlying molecular disruption a protein mutation is causing and thereby improve accuracy of these approaches. In this competitive revision application, we are proposing to expand our efforts to the challenge of understanding genetic disease mutations and polymorphisms that affect gene expression regulation or transcript splicing. Additionally, we have formed collaborations with genetic data managers and will apply all of our methods to aid in their research and identify new testable hypotheses. We will do this in three supplemental aims. First, we will evaluate genomic features for prediction of regulatory nucleotide substitutions and construct new methods to aid in their classification. Second, we will collaboratively work to develop machine learning methods for classification of nucleotide substitutions that disrupt transcript splicing. Finally, we will work to collaboratively annotate genetic data found in inherited disease, pharmacogenetics and somatic mutations in cancer. Together this Recovery Act proposal will fund two groups in bioinformatics and will support trainees, technical staff, and two faculty members.           7. Narrative In this research, we will identify genetic variants that are likely to disrupt genome function, mRNA transcript processing and protein function. We will develop new methods and databases that will hypothesize the underlying molecular mechanism of genetic disease and genetic phenotypes.",Informatic profiling of clinically relevant mutation,7809730,R01LM009722,"['Affect', 'American', 'Amino Acid Sequence', 'Amino Acid Substitution', 'Area', 'Binding Sites', 'Bioinformatics', 'Classification', 'Clinical', 'Code', 'Collaborations', 'Computer Simulation', 'CpG Islands', 'DNA Resequencing', 'Data', 'Data Collection', 'Databases', 'Dideoxy Chain Termination DNA Sequencing', 'Disease', 'Economics', 'Elements', 'Epigenetic Process', 'Faculty', 'Focus Groups', 'Funding', 'Gene Expression Regulation', 'Gene Mutation', 'Generations', 'Genetic', 'Genetic Polymorphism', 'Genetic Predisposition to Disease', 'Genetic Variation', 'Genome', 'Genomics', 'Hereditary Disease', 'Indium', 'Informatics', 'Inherited', 'Laboratories', 'Laboratory Research', 'Learning', 'Letters', 'Machine Learning', 'Malignant Neoplasms', 'Messenger RNA', 'Methods', 'Missense Mutation', 'Modeling', 'Molecular', 'Mutation', 'Mutation Analysis', 'Nucleotides', 'Paper', 'Peptide Sequence Determination', 'Pharmacogenetics', 'Phenotype', 'Postdoctoral Fellow', 'Process', 'Protein Analysis', 'Proteins', 'RNA Splicing', 'Recovery', 'Research', 'Research Personnel', 'Research Priority', 'Scientist', 'Site', 'Somatic Mutation', 'Tertiary Protein Structure', 'Time', 'Training', 'Transcript', 'United States National Institutes of Health', 'Variant', 'Work', 'base', 'clinical application', 'clinically relevant', 'data management', 'data mining', 'disease-causing mutation', 'genetic variant', 'human disease', 'improved', 'innovation', 'member', 'molecular phenotype', 'novel strategies', 'protein function', 'sound', 'tool', 'transcription factor']",NLM,BUCK INSTITUTE FOR RESEARCH ON AGING,R01,2009,145500,0.1936236942666281
"Informatic profiling of clinically relevant mutation    DESCRIPTION (provided by applicant):       Informatic profiling of clinically relevant mutation      Many approaches have been developed to predict whether a mutation associated with a disease is actually causative. In contrast to other approaches to predicting deleterious mutations, our approach, called in silico functional profiling, starts with learning residue-specific protein function and then estimates when it is disrupted. This research will continue our efforts to characterize what the underlying molecular disruption a mutation is causing and thereby improve accuracy of these approaches. We will do this by building a database that links clinical observation with molecular phenotype and using this to develop bioinformatic models of mutation. This is particularly relevant to cancer, since many mutations in cancer are both poorly understood and simply associated with cancer. The hypothesis of this proposal is that computational methods that predict a specific residue function using protein sequence and structure can classify known disease-associated mutations based on their function better than existing computational methods, and less expensively than experimental assays. In short, we will describe each phenotypically annotated mutation as possibly affecting catalysis, protein interactions, posttranslational modification and stability of the protein. The structural environments around disease associated mutations can be characterized using a combination of computational biochemical methods based on first principles of biomolecular structure and function and statistical informatics methods. We will continue this research by implementing the following steps: First, we will build a database of how often mutations in cancer, pharmacogenetics, Mendelian and complex disease are disrupted by phosphorylation, stability, catalysis, protein interaction and other posttranslational modifications. Second, we will build a bioinformatic model of disruption using machine learning methods trained with these and other commonly used features. Finally, we will link these to clinical observation by annotating disease causing mutation with an ontology of diseases and integrate these predictions into databases of mutation. Thus, we will link clinical observation with molecular phenotypes by building a useful database and new models of how mutations cause disease.          n/a",Informatic profiling of clinically relevant mutation,7929905,R01LM009722,"['Acetylation', 'Address', 'Affect', 'Amino Acid Sequence', 'Amino Acid Substitution', 'Basic Science', 'Biochemical', 'Bioinformatics', 'Biological Assay', 'Biology', 'Catalysis', 'Catalytic Domain', 'Clinical', 'Clinical Informatics', 'Collaborations', 'Complex', 'Computational Biology', 'Computer Simulation', 'Computing Methodologies', 'DNA-Binding Proteins', 'Data', 'Data Set', 'Databases', 'Disease', 'Environment', 'Funding', 'Genetic', 'Genetic Variation', 'Goals', 'Hereditary Disease', 'Human Resources', 'Informatics', 'Inherited', 'Laboratories', 'Laboratory Research', 'Learning', 'Link', 'Machine Learning', 'Malignant Neoplasms', 'Medicine', 'Methods', 'Modeling', 'Molecular', 'Mutation', 'Mutation Spectra', 'Ontology', 'Peptide Sequence Determination', 'Pharmacogenetics', 'Phosphorylation', 'Positioning Attribute', 'Post-Translational Protein Processing', 'Principal Investigator', 'Productivity', 'Proteins', 'Research', 'Research Personnel', 'Resources', 'Site', 'Structure', 'Testing', 'Training', 'Ubiquitination', 'Variant', 'Work', 'base', 'cancer classification', 'clinical care', 'clinically relevant', 'computer science', 'computerized tools', 'disease phenotype', 'disease-causing mutation', 'experience', 'falls', 'improved', 'innovation', 'molecular phenotype', 'novel strategies', 'programs', 'protein function', 'protein protein interaction', 'protein structure', 'protein structure function', 'tool', 'translational medicine']",NLM,BUCK INSTITUTE FOR RESEARCH ON AGING,R01,2010,383293,0.34857846045306234
"Informatic profiling of clinically relevant mutation    DESCRIPTION (provided by applicant):       Informatic profiling of clinically relevant mutation      Many approaches have been developed to predict whether a mutation associated with a disease is actually causative. In contrast to other approaches to predicting deleterious mutations, our approach, called in silico functional profiling, starts with learning residue-specific protein function and then estimates when it is disrupted. This research will continue our efforts to characterize what the underlying molecular disruption a mutation is causing and thereby improve accuracy of these approaches. We will do this by building a database that links clinical observation with molecular phenotype and using this to develop bioinformatic models of mutation. This is particularly relevant to cancer, since many mutations in cancer are both poorly understood and simply associated with cancer. The hypothesis of this proposal is that computational methods that predict a specific residue function using protein sequence and structure can classify known disease-associated mutations based on their function better than existing computational methods, and less expensively than experimental assays. In short, we will describe each phenotypically annotated mutation as possibly affecting catalysis, protein interactions, posttranslational modification and stability of the protein. The structural environments around disease associated mutations can be characterized using a combination of computational biochemical methods based on first principles of biomolecular structure and function and statistical informatics methods. We will continue this research by implementing the following steps: First, we will build a database of how often mutations in cancer, pharmacogenetics, Mendelian and complex disease are disrupted by phosphorylation, stability, catalysis, protein interaction and other posttranslational modifications. Second, we will build a bioinformatic model of disruption using machine learning methods trained with these and other commonly used features. Finally, we will link these to clinical observation by annotating disease causing mutation with an ontology of diseases and integrate these predictions into databases of mutation. Thus, we will link clinical observation with molecular phenotypes by building a useful database and new models of how mutations cause disease.          n/a",Informatic profiling of clinically relevant mutation,7878232,R01LM009722,"['Acetylation', 'Address', 'Affect', 'Amino Acid Sequence', 'Amino Acid Substitution', 'Basic Science', 'Biochemical', 'Bioinformatics', 'Biological Assay', 'Biology', 'Catalysis', 'Catalytic Domain', 'Clinical', 'Clinical Informatics', 'Collaborations', 'Complex', 'Computational Biology', 'Computer Simulation', 'Computing Methodologies', 'DNA-Binding Proteins', 'Data', 'Data Set', 'Databases', 'Disease', 'Environment', 'Funding', 'Genetic', 'Genetic Variation', 'Goals', 'Hereditary Disease', 'Human Resources', 'Informatics', 'Inherited', 'Laboratories', 'Laboratory Research', 'Learning', 'Link', 'Machine Learning', 'Malignant Neoplasms', 'Medicine', 'Methods', 'Modeling', 'Molecular', 'Mutation', 'Mutation Spectra', 'Ontology', 'Peptide Sequence Determination', 'Pharmacogenetics', 'Phosphorylation', 'Positioning Attribute', 'Post-Translational Protein Processing', 'Principal Investigator', 'Productivity', 'Proteins', 'Research', 'Research Personnel', 'Resources', 'Site', 'Structure', 'Testing', 'Training', 'Ubiquitination', 'Variant', 'Work', 'base', 'cancer classification', 'clinical care', 'clinically relevant', 'computer science', 'computerized tools', 'disease phenotype', 'disease-causing mutation', 'experience', 'falls', 'improved', 'innovation', 'molecular phenotype', 'novel strategies', 'programs', 'protein function', 'protein protein interaction', 'protein structure', 'protein structure function', 'tool', 'translational medicine']",NLM,BUCK INSTITUTE FOR RESEARCH ON AGING,R01,2009,46511,0.34857846045306234
"Informatic profiling of clinically relevant mutation    DESCRIPTION (provided by applicant):       Informatic profiling of clinically relevant mutation      Many approaches have been developed to predict whether a mutation associated with a disease is actually causative. In contrast to other approaches to predicting deleterious mutations, our approach, called in silico functional profiling, starts with learning residue-specific protein function and then estimates when it is disrupted. This research will continue our efforts to characterize what the underlying molecular disruption a mutation is causing and thereby improve accuracy of these approaches. We will do this by building a database that links clinical observation with molecular phenotype and using this to develop bioinformatic models of mutation. This is particularly relevant to cancer, since many mutations in cancer are both poorly understood and simply associated with cancer. The hypothesis of this proposal is that computational methods that predict a specific residue function using protein sequence and structure can classify known disease-associated mutations based on their function better than existing computational methods, and less expensively than experimental assays. In short, we will describe each phenotypically annotated mutation as possibly affecting catalysis, protein interactions, posttranslational modification and stability of the protein. The structural environments around disease associated mutations can be characterized using a combination of computational biochemical methods based on first principles of biomolecular structure and function and statistical informatics methods. We will continue this research by implementing the following steps: First, we will build a database of how often mutations in cancer, pharmacogenetics, Mendelian and complex disease are disrupted by phosphorylation, stability, catalysis, protein interaction and other posttranslational modifications. Second, we will build a bioinformatic model of disruption using machine learning methods trained with these and other commonly used features. Finally, we will link these to clinical observation by annotating disease causing mutation with an ontology of diseases and integrate these predictions into databases of mutation. Thus, we will link clinical observation with molecular phenotypes by building a useful database and new models of how mutations cause disease.          n/a",Informatic profiling of clinically relevant mutation,7675482,R01LM009722,"['Acetylation', 'Address', 'Affect', 'Amino Acid Sequence', 'Amino Acid Substitution', 'Basic Science', 'Biochemical', 'Bioinformatics', 'Biological Assay', 'Biology', 'Catalysis', 'Catalytic Domain', 'Clinical', 'Clinical Informatics', 'Collaborations', 'Complex', 'Computational Biology', 'Computer Simulation', 'Computing Methodologies', 'DNA-Binding Proteins', 'Data', 'Data Set', 'Databases', 'Disease', 'Environment', 'Funding', 'Genetic', 'Genetic Variation', 'Goals', 'Hereditary Disease', 'Human Resources', 'Informatics', 'Inherited', 'Laboratories', 'Laboratory Research', 'Learning', 'Link', 'Machine Learning', 'Malignant Neoplasms', 'Medicine', 'Methods', 'Modeling', 'Molecular', 'Mutation', 'Mutation Spectra', 'Ontology', 'Peptide Sequence Determination', 'Pharmacogenetics', 'Phosphorylation', 'Positioning Attribute', 'Post-Translational Protein Processing', 'Principal Investigator', 'Productivity', 'Proteins', 'Research', 'Research Personnel', 'Resources', 'Site', 'Structure', 'Testing', 'Training', 'Ubiquitination', 'Variant', 'Work', 'base', 'cancer classification', 'clinical care', 'clinically relevant', 'computer science', 'computerized tools', 'disease phenotype', 'disease-causing mutation', 'experience', 'falls', 'improved', 'innovation', 'molecular phenotype', 'novel strategies', 'programs', 'protein function', 'protein protein interaction', 'protein structure', 'protein structure function', 'tool', 'translational medicine']",NLM,BUCK INSTITUTE FOR RESEARCH ON AGING,R01,2009,401422,0.34857846045306234
"Informatic profiling of clinically relevant mutation    DESCRIPTION (provided by applicant):       Informatic profiling of clinically relevant mutation      Many approaches have been developed to predict whether a mutation associated with a disease is actually causative. In contrast to other approaches to predicting deleterious mutations, our approach, called in silico functional profiling, starts with learning residue-specific protein function and then estimates when it is disrupted. This research will continue our efforts to characterize what the underlying molecular disruption a mutation is causing and thereby improve accuracy of these approaches. We will do this by building a database that links clinical observation with molecular phenotype and using this to develop bioinformatic models of mutation. This is particularly relevant to cancer, since many mutations in cancer are both poorly understood and simply associated with cancer. The hypothesis of this proposal is that computational methods that predict a specific residue function using protein sequence and structure can classify known disease-associated mutations based on their function better than existing computational methods, and less expensively than experimental assays. In short, we will describe each phenotypically annotated mutation as possibly affecting catalysis, protein interactions, posttranslational modification and stability of the protein. The structural environments around disease associated mutations can be characterized using a combination of computational biochemical methods based on first principles of biomolecular structure and function and statistical informatics methods. We will continue this research by implementing the following steps: First, we will build a database of how often mutations in cancer, pharmacogenetics, Mendelian and complex disease are disrupted by phosphorylation, stability, catalysis, protein interaction and other posttranslational modifications. Second, we will build a bioinformatic model of disruption using machine learning methods trained with these and other commonly used features. Finally, we will link these to clinical observation by annotating disease causing mutation with an ontology of diseases and integrate these predictions into databases of mutation. Thus, we will link clinical observation with molecular phenotypes by building a useful database and new models of how mutations cause disease.          n/a",Informatic profiling of clinically relevant mutation,7502757,R01LM009722,"['Acetylation', 'Address', 'Affect', 'Amino Acid Sequence', 'Amino Acid Substitution', 'Basic Science', 'Biochemical', 'Bioinformatics', 'Biological Assay', 'Biology', 'Caring', 'Catalysis', 'Catalytic Domain', 'Clinical', 'Clinical Informatics', 'Collaborations', 'Complex', 'Computational Biology', 'Computer Simulation', 'Computing Methodologies', 'DNA-Binding Proteins', 'Data', 'Data Set', 'Databases', 'Disease', 'Disruption', 'Environment', 'Funding', 'Genetic', 'Genetic Variation', 'Goals', 'Hereditary Disease', 'Human Resources', 'Informatics', 'Inherited', 'Laboratories', 'Laboratory Research', 'Learning', 'Link', 'Machine Learning', 'Malignant Neoplasms', 'Medicine', 'Methods', 'Modeling', 'Molecular', 'Mutation', 'Mutation Spectra', 'Ontology', 'Peptide Sequence Determination', 'Pharmacogenetics', 'Phenotype', 'Phosphorylation', 'Positioning Attribute', 'Post-Translational Protein Processing', 'Principal Investigator', 'Productivity', 'Proteins', 'Research', 'Research Personnel', 'Resources', 'Score', 'Site', 'Structure', 'Testing', 'Training', 'Ubiquitination', 'Variant', 'Work', 'base', 'cancer classification', 'clinically relevant', 'computer science', 'computerized tools', 'disease phenotype', 'disease-causing mutation', 'experience', 'falls', 'improved', 'innovation', 'novel strategies', 'programs', 'protein function', 'protein protein interaction', 'protein structure', 'protein structure function', 'tool', 'translational medicine']",NLM,INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS,R01,2008,158863,0.34857846045306234
"Informatic profiling of clinically relevant mutation    DESCRIPTION (provided by applicant):       Informatic profiling of clinically relevant mutation      Many approaches have been developed to predict whether a mutation associated with a disease is actually causative. In contrast to other approaches to predicting deleterious mutations, our approach, called in silico functional profiling, starts with learning residue-specific protein function and then estimates when it is disrupted. This research will continue our efforts to characterize what the underlying molecular disruption a mutation is causing and thereby improve accuracy of these approaches. We will do this by building a database that links clinical observation with molecular phenotype and using this to develop bioinformatic models of mutation. This is particularly relevant to cancer, since many mutations in cancer are both poorly understood and simply associated with cancer. The hypothesis of this proposal is that computational methods that predict a specific residue function using protein sequence and structure can classify known disease-associated mutations based on their function better than existing computational methods, and less expensively than experimental assays. In short, we will describe each phenotypically annotated mutation as possibly affecting catalysis, protein interactions, posttranslational modification and stability of the protein. The structural environments around disease associated mutations can be characterized using a combination of computational biochemical methods based on first principles of biomolecular structure and function and statistical informatics methods. We will continue this research by implementing the following steps: First, we will build a database of how often mutations in cancer, pharmacogenetics, Mendelian and complex disease are disrupted by phosphorylation, stability, catalysis, protein interaction and other posttranslational modifications. Second, we will build a bioinformatic model of disruption using machine learning methods trained with these and other commonly used features. Finally, we will link these to clinical observation by annotating disease causing mutation with an ontology of diseases and integrate these predictions into databases of mutation. Thus, we will link clinical observation with molecular phenotypes by building a useful database and new models of how mutations cause disease.          n/a",Informatic profiling of clinically relevant mutation,7841085,R01LM009722,"['Acetylation', 'Address', 'Affect', 'Amino Acid Sequence', 'Amino Acid Substitution', 'Basic Science', 'Biochemical', 'Bioinformatics', 'Biological Assay', 'Biology', 'Caring', 'Catalysis', 'Catalytic Domain', 'Clinical', 'Clinical Informatics', 'Collaborations', 'Complex', 'Computational Biology', 'Computer Simulation', 'Computing Methodologies', 'DNA-Binding Proteins', 'Data', 'Data Set', 'Databases', 'Disease', 'Disruption', 'Environment', 'Funding', 'Genetic', 'Genetic Variation', 'Goals', 'Hereditary Disease', 'Human Resources', 'Informatics', 'Inherited', 'Laboratories', 'Laboratory Research', 'Learning', 'Link', 'Machine Learning', 'Malignant Neoplasms', 'Medicine', 'Methods', 'Modeling', 'Molecular', 'Mutation', 'Mutation Spectra', 'Ontology', 'Peptide Sequence Determination', 'Pharmacogenetics', 'Phenotype', 'Phosphorylation', 'Positioning Attribute', 'Post-Translational Protein Processing', 'Principal Investigator', 'Productivity', 'Proteins', 'Research', 'Research Personnel', 'Resources', 'Score', 'Site', 'Structure', 'Testing', 'Training', 'Ubiquitination', 'Variant', 'Work', 'base', 'cancer classification', 'clinically relevant', 'computer science', 'computerized tools', 'disease phenotype', 'disease-causing mutation', 'experience', 'falls', 'improved', 'innovation', 'novel strategies', 'programs', 'protein function', 'protein protein interaction', 'protein structure', 'protein structure function', 'tool', 'translational medicine']",NLM,BUCK INSTITUTE FOR RESEARCH ON AGING,R01,2008,163321,0.34857846045306234
"Informatic profiling of clinically relevant mutation    DESCRIPTION (provided by applicant):       Informatic profiling of clinically relevant mutation      Many approaches have been developed to predict whether a mutation associated with a disease is actually causative. In contrast to other approaches to predicting deleterious mutations, our approach, called in silico functional profiling, starts with learning residue-specific protein function and then estimates when it is disrupted. This research will continue our efforts to characterize what the underlying molecular disruption a mutation is causing and thereby improve accuracy of these approaches. We will do this by building a database that links clinical observation with molecular phenotype and using this to develop bioinformatic models of mutation. This is particularly relevant to cancer, since many mutations in cancer are both poorly understood and simply associated with cancer. The hypothesis of this proposal is that computational methods that predict a specific residue function using protein sequence and structure can classify known disease-associated mutations based on their function better than existing computational methods, and less expensively than experimental assays. In short, we will describe each phenotypically annotated mutation as possibly affecting catalysis, protein interactions, posttranslational modification and stability of the protein. The structural environments around disease associated mutations can be characterized using a combination of computational biochemical methods based on first principles of biomolecular structure and function and statistical informatics methods. We will continue this research by implementing the following steps: First, we will build a database of how often mutations in cancer, pharmacogenetics, Mendelian and complex disease are disrupted by phosphorylation, stability, catalysis, protein interaction and other posttranslational modifications. Second, we will build a bioinformatic model of disruption using machine learning methods trained with these and other commonly used features. Finally, we will link these to clinical observation by annotating disease causing mutation with an ontology of diseases and integrate these predictions into databases of mutation. Thus, we will link clinical observation with molecular phenotypes by building a useful database and new models of how mutations cause disease.          n/a",Informatic profiling of clinically relevant mutation,7351411,R01LM009722,"['Acetylation', 'Address', 'Affect', 'Amino Acid Sequence', 'Amino Acid Substitution', 'Basic Science', 'Biochemical', 'Bioinformatics', 'Biological Assay', 'Biology', 'Caring', 'Catalysis', 'Catalytic Domain', 'Clinical', 'Clinical Informatics', 'Collaborations', 'Complex', 'Computational Biology', 'Computer Simulation', 'Computing Methodologies', 'DNA-Binding Proteins', 'Data', 'Data Set', 'Databases', 'Disease', 'Disruption', 'Environment', 'Funding', 'Genetic', 'Genetic Variation', 'Goals', 'Hereditary Disease', 'Human Resources', 'Informatics', 'Inherited', 'Laboratories', 'Laboratory Research', 'Learning', 'Link', 'Machine Learning', 'Malignant Neoplasms', 'Medicine', 'Methods', 'Modeling', 'Molecular', 'Mutation', 'Mutation Spectra', 'Ontology', 'Peptide Sequence Determination', 'Pharmacogenetics', 'Phenotype', 'Phosphorylation', 'Positioning Attribute', 'Post-Translational Protein Processing', 'Principal Investigator', 'Productivity', 'Proteins', 'Research', 'Research Personnel', 'Resources', 'Score', 'Site', 'Structure', 'Testing', 'Training', 'Ubiquitination', 'Variant', 'Work', 'base', 'cancer classification', 'clinically relevant', 'computer science', 'computerized tools', 'disease phenotype', 'disease-causing mutation', 'experience', 'falls', 'improved', 'innovation', 'novel strategies', 'programs', 'protein function', 'protein protein interaction', 'protein structure', 'protein structure function', 'tool', 'translational medicine']",NLM,INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS,R01,2007,329240,0.34857846045306234
"Learning the rules of enhancer activity to understand non-coding genetic variation in autoimmune disease Project Summary/Abstract Genome-wide association studies have given us many clues about the mutations that cause common genetic diseases, including autoimmune diseases like lupus and rheumatoid arthritis. However, many of the mutations implicated in disease lie outside of the genes themselves and instead lie in the regions controlling expression of the genes, and so probably contribute to disease by producing the wrong amount of the gene in the wrong tissue or at the wrong time. Mutations in regulatory regions are thought to cause disease by altering the binding of regulatory proteins to the DNA, changing the DNA sequence from one that the protein can bind to one that it cannot (or vice versa). However, the ways in which these regulatory proteins control gene expression remains incompletely understood and so it is presently difficult to understand which regulatory protein binds differently to a mutated regulatory region, or how that change in binding affects expression of the regulated genes. In fact, we still do not even know where the regulatory regions are in the tissues we think are dysfunctional in disease. This project aims to better understand how these mutations contribute to autoimmune disease by first increasing our understanding of how regulatory proteins and regulatory regions work to control when and where genes are expressed, and then applying this knowledge to understand genetic disease. First, regulatory regions will be identified in immune cells and their effects on gene expression measured so that mutations that are likely to contribute to disease (those in regulatory regions) can be identified. The relationship between regulatory proteins, regulatory sequence, and gene expression will be learned by creating millions of synthetic regulatory regions and measuring their effect on gene expression, providing many examples of binding sites for each regulatory protein from which to learn. Finally, our new understanding of gene regulation will be applied to determine which genetic mutations change regulatory protein binding and cause disease. This will help us better understand the underlying causes of disease so that new treatments can be developed that target the mutations within each person. The candidate's long term career goals are to better understand how gene regulation works in humans so that we can better understand how the sequence of the genome controls the expression of our genes. The candidate currently works at the Broad Institute, a leading institute in human genetics and genomics with the resources and personnel required of this project. In order to continue to develop as a scientist, the candidate will gain more experience teaching, publish and present his existing findings, gain the necessary skills to work with human cells, and secure a faculty position and funding so that he can continue to make a positive impact on our knowledge of the genome. Project Narrative Certain genetic diseases are thought to be caused by mutations in the DNA that alter the expression of nearby genes. This project will help us to understand how DNA sequence regulates the expression of genes, and aims to apply this knowledge to predict how and why mutations change gene expression and contribute to disease. By better understanding the fundamental causes of disease, we can better design therapeutic interventions.",Learning the rules of enhancer activity to understand non-coding genetic variation in autoimmune disease,9695242,K99HG009920,"['ATAC-seq', 'Affect', 'Alleles', 'Autoimmune Diseases', 'Binding', 'Binding Proteins', 'Binding Sites', 'Biochemical', 'Biochemistry', 'Biological Assay', 'Cell Line', 'Cell Separation', 'Cell physiology', 'Cells', 'Chromatin', 'Communities', 'Complex', 'Computer Simulation', 'DNA', 'DNA Sequence', 'DNA Sequence Alteration', 'Data', 'Data Set', 'Development', 'Diagnosis', 'Disease', 'Educational process of instructing', 'Enhancers', 'Faculty', 'Funding', 'Gene Expression', 'Gene Expression Regulation', 'Genes', 'Genetic Diseases', 'Genetic Polymorphism', 'Genetic Variation', 'Genome', 'Goals', 'Growth', 'Haplotypes', 'Health', 'Human', 'Human Activities', 'Human Cell Line', 'Human Genetics', 'Human Genome', 'Human Resources', 'Immune', 'Institutes', 'Knowledge', 'Learning', 'Libraries', 'Link', 'Logic', 'Lupus', 'Machine Learning', 'Maps', 'Measurement', 'Measures', 'Methodology', 'Modeling', 'Mutate', 'Mutation', 'Nucleic Acid Regulatory Sequences', 'Persons', 'Phase', 'Plasmids', 'Positioning Attribute', 'Predisposition', 'Protein Region', 'Proteins', 'Publishing', 'Regulation', 'Reporter', 'Research', 'Resolution', 'Resources', 'Rheumatoid Arthritis', 'Scientist', 'Secure', 'Specificity', 'System', 'Testing', 'Therapeutic Intervention', 'Time', 'Tissues', 'Training', 'Untranslated RNA', 'Work', 'Yeasts', 'biochemical model', 'career', 'cell type', 'design', 'disorder risk', 'experience', 'genetic predictors', 'genetic regulatory protein', 'genome wide association study', 'genome-wide', 'human genomics', 'improved', 'in vivo', 'personalized medicine', 'promoter', 'rare variant', 'skills', 'transcription factor']",NHGRI,"BROAD INSTITUTE, INC.",K99,2019,90935,0.10716838212732621
"Learning the rules of enhancer activity to understand non-coding genetic variation in autoimmune disease Project Summary/Abstract Genome-wide association studies have given us many clues about the mutations that cause common genetic diseases, including autoimmune diseases like lupus and rheumatoid arthritis. However, many of the mutations implicated in disease lie outside of the genes themselves and instead lie in the regions controlling expression of the genes, and so probably contribute to disease by producing the wrong amount of the gene in the wrong tissue or at the wrong time. Mutations in regulatory regions are thought to cause disease by altering the binding of regulatory proteins to the DNA, changing the DNA sequence from one that the protein can bind to one that it cannot (or vice versa). However, the ways in which these regulatory proteins control gene expression remains incompletely understood and so it is presently difficult to understand which regulatory protein binds differently to a mutated regulatory region, or how that change in binding affects expression of the regulated genes. In fact, we still do not even know where the regulatory regions are in the tissues we think are dysfunctional in disease. This project aims to better understand how these mutations contribute to autoimmune disease by first increasing our understanding of how regulatory proteins and regulatory regions work to control when and where genes are expressed, and then applying this knowledge to understand genetic disease. First, regulatory regions will be identified in immune cells and their effects on gene expression measured so that mutations that are likely to contribute to disease (those in regulatory regions) can be identified. The relationship between regulatory proteins, regulatory sequence, and gene expression will be learned by creating millions of synthetic regulatory regions and measuring their effect on gene expression, providing many examples of binding sites for each regulatory protein from which to learn. Finally, our new understanding of gene regulation will be applied to determine which genetic mutations change regulatory protein binding and cause disease. This will help us better understand the underlying causes of disease so that new treatments can be developed that target the mutations within each person. The candidate's long term career goals are to better understand how gene regulation works in humans so that we can better understand how the sequence of the genome controls the expression of our genes. The candidate currently works at the Broad Institute, a leading institute in human genetics and genomics with the resources and personnel required of this project. In order to continue to develop as a scientist, the candidate will gain more experience teaching, publish and present his existing findings, gain the necessary skills to work with human cells, and secure a faculty position and funding so that he can continue to make a positive impact on our knowledge of the genome. Project Narrative Certain genetic diseases are thought to be caused by mutations in the DNA that alter the expression of nearby genes. This project will help us to understand how DNA sequence regulates the expression of genes, and aims to apply this knowledge to predict how and why mutations change gene expression and contribute to disease. By better understanding the fundamental causes of disease, we can better design therapeutic interventions.",Learning the rules of enhancer activity to understand non-coding genetic variation in autoimmune disease,9431485,K99HG009920,"['ATAC-seq', 'Affect', 'Alleles', 'Autoimmune Diseases', 'Binding', 'Binding Proteins', 'Binding Sites', 'Biochemical', 'Biochemistry', 'Biological Assay', 'Cell Line', 'Cell Separation', 'Cell physiology', 'Cells', 'Chromatin', 'Communities', 'Complex', 'Computer Simulation', 'DNA', 'DNA Sequence', 'DNA Sequence Alteration', 'Data', 'Data Set', 'Development', 'Diagnosis', 'Disease', 'Educational process of instructing', 'Enhancers', 'Faculty', 'Funding', 'Gene Expression', 'Gene Expression Regulation', 'Genes', 'Genetic Diseases', 'Genetic Polymorphism', 'Genetic Variation', 'Genome', 'Goals', 'Growth', 'Haplotypes', 'Health', 'Human', 'Human Activities', 'Human Cell Line', 'Human Genetics', 'Human Genome', 'Human Resources', 'Immune', 'Institutes', 'Knowledge', 'Learning', 'Libraries', 'Link', 'Logic', 'Machine Learning', 'Maps', 'Measurement', 'Measures', 'Methodology', 'Modeling', 'Mutate', 'Mutation', 'Nucleic Acid Regulatory Sequences', 'Persons', 'Phase', 'Plasmids', 'Positioning Attribute', 'Predisposition', 'Protein Region', 'Proteins', 'Publishing', 'Regulation', 'Reporter', 'Research', 'Resolution', 'Resources', 'Rheumatoid Arthritis', 'Scientist', 'Secure', 'Specificity', 'System', 'Testing', 'Therapeutic Intervention', 'Time', 'Tissues', 'Training', 'Untranslated RNA', 'Work', 'Yeasts', 'biochemical model', 'career', 'cell type', 'design', 'disorder risk', 'experience', 'genetic predictors', 'genetic regulatory protein', 'genome wide association study', 'genome-wide', 'human genomics', 'improved', 'in vivo', 'lupus-like', 'personalized medicine', 'promoter', 'rare variant', 'skills', 'transcription factor']",NHGRI,"BROAD INSTITUTE, INC.",K99,2018,120204,0.10716838212732621
"Interrogating regulatory variants by multiplexed genome editing A major result from recent genome wide association studies (GWAS) is that the majority of genetic variants driving common human diseases lie in regulatory, rather than protein-coding, regions. Massive efforts to map epigenomic features such as localization of histone modifications (HMs) and transcription factors (TFs) have paved the way toward understanding the regulatory genome. However, dissecting the impact of an individual non-coding variant remains an unsolved challenge.  A variety of computational methods have been proposed, such as quantitative trait loci (QTL) studies and machine learning techniques. However, these methods still do not provide conclusive information about causality of any specific non-coding mutation and lack gold-standard experimental results for evaluation. Several techniques are used to experimentally test the impact of individual regulatory variants. For example, massively parallel reporter assays (MPRA) synthesize thousands of oligonucleotides encoding mutated versions of putative regulatory elements placed in plasmids upstream of reporter genes. However, a major limitation is that tested sequences are outside of their endogenous chromosomal locus, and hence do not necessarily provide physiological relevance.  CRISPR enables targeted editing of genomic DNA. Indeed, CRISPR is widely used, but studies of individual point mutations have been primarily on a small scale and are usually limited to a handful of variants or to a single gene. The major throughput challenge in studying a specific variant using genome editing is in tying genotype to phenotype. Introducing individual mutations exhibits low efficiency, and thus there is a need for enrichment of the genotype or phenotype of interest prior to assessing the impact of a mutation on a phenotype, such as gene expression. Current enrichment methods either disrupt the physiological context or are low throughput. Recent efforts overcame these challenges using pooled editing to analyze thousands of mutations simultaneously, but were limited to variants in protein coding regions.  This proposal aims to develop a novel technique merging multiplexed genome editing of putative regulatory variants followed by chromatin immunoprecipitation sequencing (ChIP-seq) to simultaneously measure the impact of hundreds of non-coding variants on regulatory potential in their native genomic context. The key insight of the proposed approach is that mutations impacting epigenomic features can be measured both in genomic DNA and in phenotypic readouts such as ChIP-seq of TFs or HMs, avoiding the need for a selection step to connect genotypes with phenotypes. Aim 1 develops the pooled editing technique on a pilot set of previously validated regulatory variants. Aim 2 scales this approach to interrogate thousands of mutations at once. Aim 3 integrates experimental predictions with state of the art machine learning methods to evaluate and optimize computational methods for regulatory variant effect prediction. Recent studies have demonstrated that the majority of genetic changes in the population contributing to common human diseases, such as schizophrenia, heart disease, and diabetes, lie in regions of the genome that do not code for proteins, but rather regulate the expression of genes. Despite massive efforts to map regulatory regions across dozens of human cell types, it is still difficult to predict the effect of an individual non-coding mutation. This project develops a high-throughput genome editing technique to simultaneously measure the impact of hundreds of non-coding mutations on regulatory potential in their native genomic context, with the ultimate goal of interpreting genetic changes leading to human disease.",Interrogating regulatory variants by multiplexed genome editing,9509167,R21HG010070,"['Address', 'Affect', 'Allelic Imbalance', 'Automobile Driving', 'Binding', 'Biological Assay', 'CRISPR/Cas technology', 'Cell Fraction', 'Cells', 'ChIP-seq', 'Code', 'Computing Methodologies', 'DNA', 'Data Set', 'Diabetes Mellitus', 'Enhancers', 'Etiology', 'Evaluation', 'Exhibits', 'Frequencies', 'Gene Expression', 'Genes', 'Genome', 'Genomic DNA', 'Genomics', 'Genotype', 'Goals', 'Gold', 'HNF4A gene', 'Heart Diseases', 'HepG2', 'Hepatocyte', 'Human', 'Individual', 'Machine Learning', 'Malignant Epithelial Cell', 'Maps', 'Measures', 'Messenger RNA', 'Methods', 'Molecular', 'Mutate', 'Mutation', 'Nucleic Acid Regulatory Sequences', 'Oligonucleotides', 'Open Reading Frames', 'Phenotype', 'Physiological', 'Plasmids', 'Point Mutation', 'Population', 'Primary carcinoma of the liver cells', 'Proteins', 'Quantitative Trait Loci', 'Regulatory Element', 'Reporter', 'Reporter Genes', 'Resources', 'Schizophrenia', 'Sorting - Cell Movement', 'Techniques', 'Testing', 'Untranslated RNA', 'Variant', 'cell type', 'epigenomics', 'genetic variant', 'genome editing', 'genome wide association study', 'histone modification', 'human disease', 'improved', 'innovation', 'insight', 'interest', 'learning strategy', 'mRNA Expression', 'molecular phenotype', 'novel', 'transcription factor']",NHGRI,"UNIVERSITY OF CALIFORNIA, SAN DIEGO",R21,2018,196302,0.033153328298620686
"Interrogating regulatory variants by multiplexed genome editing A major result from recent genome wide association studies (GWAS) is that the majority of genetic variants driving common human diseases lie in regulatory, rather than protein-coding, regions. Massive efforts to map epigenomic features such as localization of histone modifications (HMs) and transcription factors (TFs) have paved the way toward understanding the regulatory genome. However, dissecting the impact of an individual non-coding variant remains an unsolved challenge.  A variety of computational methods have been proposed, such as quantitative trait loci (QTL) studies and machine learning techniques. However, these methods still do not provide conclusive information about causality of any specific non-coding mutation and lack gold-standard experimental results for evaluation. Several techniques are used to experimentally test the impact of individual regulatory variants. For example, massively parallel reporter assays (MPRA) synthesize thousands of oligonucleotides encoding mutated versions of putative regulatory elements placed in plasmids upstream of reporter genes. However, a major limitation is that tested sequences are outside of their endogenous chromosomal locus, and hence do not necessarily provide physiological relevance.  CRISPR enables targeted editing of genomic DNA. Indeed, CRISPR is widely used, but studies of individual point mutations have been primarily on a small scale and are usually limited to a handful of variants or to a single gene. The major throughput challenge in studying a specific variant using genome editing is in tying genotype to phenotype. Introducing individual mutations exhibits low efficiency, and thus there is a need for enrichment of the genotype or phenotype of interest prior to assessing the impact of a mutation on a phenotype, such as gene expression. Current enrichment methods either disrupt the physiological context or are low throughput. Recent efforts overcame these challenges using pooled editing to analyze thousands of mutations simultaneously, but were limited to variants in protein coding regions.  This proposal aims to develop a novel technique merging multiplexed genome editing of putative regulatory variants followed by chromatin immunoprecipitation sequencing (ChIP-seq) to simultaneously measure the impact of hundreds of non-coding variants on regulatory potential in their native genomic context. The key insight of the proposed approach is that mutations impacting epigenomic features can be measured both in genomic DNA and in phenotypic readouts such as ChIP-seq of TFs or HMs, avoiding the need for a selection step to connect genotypes with phenotypes. Aim 1 develops the pooled editing technique on a pilot set of previously validated regulatory variants. Aim 2 scales this approach to interrogate thousands of mutations at once. Aim 3 integrates experimental predictions with state of the art machine learning methods to evaluate and optimize computational methods for regulatory variant effect prediction. Recent studies have demonstrated that the majority of genetic changes in the population contributing to common human diseases, such as schizophrenia, heart disease, and diabetes, lie in regions of the genome that do not code for proteins, but rather regulate the expression of genes. Despite massive efforts to map regulatory regions across dozens of human cell types, it is still difficult to predict the effect of an individual non-coding mutation. This project develops a high-throughput genome editing technique to simultaneously measure the impact of hundreds of non-coding mutations on regulatory potential in their native genomic context, with the ultimate goal of interpreting genetic changes leading to human disease.",Interrogating regulatory variants by multiplexed genome editing,9761568,R21HG010070,"['Address', 'Affect', 'Allelic Imbalance', 'Automobile Driving', 'Binding', 'Biological Assay', 'CRISPR/Cas technology', 'Cell Fraction', 'Cells', 'ChIP-seq', 'Code', 'Computing Methodologies', 'DNA', 'Data Set', 'Diabetes Mellitus', 'Enhancers', 'Etiology', 'Evaluation', 'Exhibits', 'Frequencies', 'Gene Expression', 'Genes', 'Genome', 'Genomic DNA', 'Genomics', 'Genotype', 'Goals', 'Gold', 'HNF4A gene', 'Heart Diseases', 'HepG2', 'Hepatocyte', 'Human', 'Individual', 'Machine Learning', 'Malignant Epithelial Cell', 'Maps', 'Measures', 'Messenger RNA', 'Methods', 'Molecular', 'Mutate', 'Mutation', 'Nucleic Acid Regulatory Sequences', 'Oligonucleotides', 'Open Reading Frames', 'Phenotype', 'Physiological', 'Plasmids', 'Point Mutation', 'Population', 'Primary carcinoma of the liver cells', 'Proteins', 'Quantitative Trait Loci', 'Regulatory Element', 'Reporter', 'Reporter Genes', 'Resources', 'Schizophrenia', 'Sorting - Cell Movement', 'Techniques', 'Testing', 'Untranslated RNA', 'Variant', 'cell type', 'epigenomics', 'genetic variant', 'genome editing', 'genome wide association study', 'histone modification', 'human disease', 'improved', 'innovation', 'insight', 'interest', 'learning strategy', 'mRNA Expression', 'molecular phenotype', 'novel', 'transcription factor']",NHGRI,"UNIVERSITY OF CALIFORNIA, SAN DIEGO",R21,2019,236250,0.033153328298620686
"Investigating the clinical ontologies of loss-of-function and gain-of-function human gene variants PROJECT SUMMARY/ABSTRACT This proposal is for an MD/PhD students individual pre-doctoral fellowship application. Joseph Park, the applicant under consideration, proposes a research training plan with the long-term goal of developing into an independent physician-scientist studying the genetic mechanisms underlying cardiometabolic and other complex diseases using computational, experimental, and translational approaches. Genome-wide association studies (GWAS) have successfully described the roles of common genetic variation on human diseases by analyzing large populations with shared disease traits, but the clinical ontologies of numerous genes remain incompletely described through these phenotype-based methodologies. Additionally, a fundamental problem of genetic association studies remains to be the difficulty of describing the functional consequences of disease- associated variants to their respective gene products (i.e. loss- vs. gain-of-function). The Penn Medicine Biobank, a healthcare system-based database of genotype, whole-exome sequencing, and electronic health record (EHR) data, allows for an unbiased, genotype-first approach to describing the relationships between dysfunctional genes and human disease traits captured in the clinical setting through phenome-wide association studies (PheWAS). Through gene-burden PheWAS tests, the proposed study aims to characterize the clinical manifestations of disease caused by rare, loss-of-function mutations in each gene on a genome- wide scale. Our analyses will enable clinicians to more effectively identify genetic diseases among their patients in the clinical setting. Furthermore, in addition to our interrogation of loss-of-function mutations, our proposed project has the potential to define the roles of known gain-of-function mutations in human disease and identify novel gain-of-function variants relevant to disease, offering a direction for investigators to design follow-up experimental studies in the basic sciences as well as a platform promoting more efficient therapeutic discoveries. And importantly, while conducting the proposed study, Joseph will receive rigorous training in computational biology and statistical genetics during the funding period, promoting his maturation into a successful, independent physician-scientist thoroughly prepared for a clinical career involving the analysis of omics and big data. These goals will be accomplished through the extensive fellowship training plan jointly developed by him and his sponsor, Daniel Rader. Through the mentorship of numerous senior investigators, regular attendance at seminars, conferences, and other opportunities for presentation and interaction with renowned scientists at the University of Pennsylvania, and the collaborative research environment that the Rader laboratory and its physically surrounding organizations promote, Joseph is well-equipped to achieve his career goals through his guaranteed development during the proposed training. PROJECT NARRATIVE Genome-wide association studies (GWAS) have successfully described the roles of many human genes by analyzing large populations with shared traits, but these phenotype-based methodologies have incompletely described the clinical implications of numerous genes. I propose to address this knowledge gap by taking an unbiased, genotype-first approach to describing the relationships between dysfunctional genes and human disease traits through gene-burden phenome-wide association studies (PheWAS), essentially intersecting data from our healthcare system-based biobank database comprised of genotype data, whole-exome sequencing, and electronic health records (EHR). In addition to capturing the disease implications of rare, loss-of-function mutations on a genome-wide scale, my proposed project has the potential to define the roles of known and novel gain-of-function mutations in human disease, offering a direction for follow-up functional studies as well as a platform for more efficient therapeutic discoveries.",Investigating the clinical ontologies of loss-of-function and gain-of-function human gene variants,9916631,F30HG010442,"['Address', 'African American', 'Animal Model', 'Authorization documentation', 'Basic Science', 'Big Data', 'Clinical', 'Clinical Data', 'Code', 'Complex', 'Computational Biology', 'Computing Methodologies', 'Data', 'Data Set', 'Databases', 'Development', 'Disease', 'Electronic Health Record', 'Environment', 'Fellowship', 'Frequencies', 'Funding', 'Genes', 'Genetic', 'Genetic Diseases', 'Genetic Models', 'Genetic Variation', 'Genetic study', 'Genome', 'Genotype', 'Goals', 'Grant', 'Health system', 'Healthcare', 'Healthcare Systems', 'Human', 'Human Genetics', 'Individual', 'Knowledge', 'Laboratories', 'Literature', 'Measurement', 'Medicine', 'Mentorship', 'Methodology', 'Methods', 'Mutation', 'Natural Language Processing', 'Ontology', 'Participant', 'Patients', 'Pennsylvania', 'Phenotype', 'Physicians', 'Play', 'Population', 'Population Analysis', 'Privatization', 'Recontacts', 'Records', 'Regression Analysis', 'Research', 'Research Personnel', 'Research Training', 'Resources', 'Role', 'Scientist', 'Serum', 'Structure', 'Suggestion', 'Testing', 'Therapeutic', 'Tissue Model', 'Training', 'Universities', 'Variant', 'Veterans', 'Work', 'base', 'biobank', 'cardiometabolism', 'career', 'design', 'disease phenotype', 'doctoral student', 'exome sequencing', 'experimental study', 'follow-up', 'gain of function', 'gain of function mutation', 'gene discovery', 'gene product', 'genetic association', 'genetic variant', 'genome wide association study', 'genome-wide', 'human disease', 'human tissue', 'loss of function', 'loss of function mutation', 'medical schools', 'novel', 'phenome', 'pre-doctoral', 'precision medicine', 'programs', 'quantitative imaging', 'rare variant', 'recruit', 'symposium', 'text searching', 'tool', 'trait', 'translational approach']",NHGRI,UNIVERSITY OF PENNSYLVANIA,F30,2020,50520,0.06179235695035027
"Genetic and Morphometric Analysis of Facial Clefts DESCRIPTION (provided by applicant): Cleft lip (CL) or Cleft lip/palate (CL/P) occurs in about 1 in 700 live births, and while they are treatable, many individuals with these types of deformities will require lifelong care. Both of these conditions are the result of failures of the facial prominences to fuse during embryogenesis. CL and CL/P can occur as a single deformity or as part of a syndrome. Branchio-Occulo-Facial Syndrome (BOFS), for example, presents with facial clefting, ear and eye deformities and has been linked to mutations in the gene TFAP2A, encoding transcription factor AP-2. One mouse model of this disease employs a null allele in combination with a hypomorphic or ""weak"" allele of AP-2, creating a partial loss of AP-2 function. These mice develop a fully penetrant bilateral CL/P and our preliminary data suggest that it is small changes in growth and/or morphogenesis of the facial prominences that are responsible for failed fusion. Molecular analysis of this model shows increased expression of genes involved in Fgf signaling. Further, the loss of a single fgf8 allele in these mice is able to  partially rescue the bilateral CL/P seen in the AP-2 hypomorphic mice to a unilateral CL/P. I, therefore hypothesize that AP-2 and FGF8 are elements of the same pathway during normal facial development and loss or mutation of AP-2 can affect the signaling interactions required for facial development. We will test this hypothesis by examining shape, gene expression and function in a mouse model that overexpresses FGF8 in the facial ectoderm and comparing this model to our AP-2 model. This proposal will generate shape data using 3D imaging and morphometrics. With this data we will be able to compare shape between the FGF8 overexpression model to the AP-2 hypomorphic mutation model and determine if these two genes are affecting development in the same manner during development. The gene expression data will allow us to 1) correlate shape change with gene expression, cell proliferation and death changes, allowing identification of pathways and mechanisms that may be causative of the growth changes. 2) The expression data will allow comparison of the two models on a molecular level to determine if they are affecting the same downstream targets, and thus, acting within the same pathway. Based on this data, we hope be able to build out how this pathway is interacting with other established facial development pathways to determine the overall facial gene regulatory network for facial development. Cleft lip (CL) or Cleft lip/palate (CL/P) occurs in about 1 in 700 live births, and while they are treatable, many individuals with these types of deformities will require lifelong care. This proposal aims to increase our understanding of the underlying genetic and molecular causes of cleft lip and cleft palate and how different genes interact during the process of facial development. A more thorough understanding of the etiology of these disorders will help lead to better diagnostics and possibly treatments.",Genetic and Morphometric Analysis of Facial Clefts,8598809,F31DE022214,"['Affect', 'Alleles', 'Beryllium', 'Bilateral', 'Caring', 'Cell Death', 'Cell Proliferation', 'Cells', 'Cleaved cell', 'Cleft Lip', 'Cleft Palate', 'Complement', 'Data', 'Data Set', 'Deformity', 'Development', 'Diagnostic', 'Disease', 'Ear', 'Ectoderm', 'Embryo', 'Embryonic Development', 'Etiology', 'Exhibits', 'Eye', 'FGF8 gene', 'Face', 'Failure', 'Gene Dosage', 'Gene Expression', 'Genes', 'Genetic', 'Growth', 'In Situ Hybridization', 'Individual', 'Knock-out', 'Lead', 'Link', 'Live Birth', 'Maps', 'Modeling', 'Molecular', 'Molecular Analysis', 'Molecular Genetics', 'Morphogenesis', 'Mus', 'Mutation', 'Neural Crest', 'Paper', 'Pathway interactions', 'Pattern', 'Phenotype', 'Principal Component Analysis', 'Process', 'Regulator Genes', 'Relative (related person)', 'Shapes', 'Signal Transduction', 'Specificity', 'Statistical Methods', 'Syndrome', 'TFAP2A gene', 'Testing', 'Three-Dimensional Imaging', 'TimeLine', 'Tissues', 'Transgenes', 'Variant', 'Wild Type Mouse', 'Writing', 'base', 'cleft lip and palate', 'gene function', 'mouse model', 'orofacial', 'overexpression', 'recombinase', 'response', 'transcription factor', 'transcriptome sequencing']",NIDCR,UNIVERSITY OF COLORADO DENVER,F31,2014,27962,0.08702415756586686
"Genetic and Morphometric Analysis of Facial Clefts DESCRIPTION (provided by applicant): Cleft lip (CL) or Cleft lip/palate (CL/P) occurs in about 1 in 700 live births, and while they are treatable, many individuals with these types of deformities will require lifelong care. Both of these conditions are the result of failures of the facial prominences to fuse during embryogenesis. CL and CL/P can occur as a single deformity or as part of a syndrome. Branchio-Occulo-Facial Syndrome (BOFS), for example, presents with facial clefting, ear and eye deformities and has been linked to mutations in the gene TFAP2A, encoding transcription factor AP-2. One mouse model of this disease employs a null allele in combination with a hypomorphic or ""weak"" allele of AP-2, creating a partial loss of AP-2 function. These mice develop a fully penetrant bilateral CL/P and our preliminary data suggest that it is small changes in growth and/or morphogenesis of the facial prominences that are responsible for failed fusion. Molecular analysis of this model shows increased expression of genes involved in Fgf signaling. Further, the loss of a single fgf8 allele in these mice is able to  partially rescue the bilateral CL/P seen in the AP-2 hypomorphic mice to a unilateral CL/P. I, therefore hypothesize that AP-2 and FGF8 are elements of the same pathway during normal facial development and loss or mutation of AP-2 can affect the signaling interactions required for facial development. We will test this hypothesis by examining shape, gene expression and function in a mouse model that overexpresses FGF8 in the facial ectoderm and comparing this model to our AP-2 model. This proposal will generate shape data using 3D imaging and morphometrics. With this data we will be able to compare shape between the FGF8 overexpression model to the AP-2 hypomorphic mutation model and determine if these two genes are affecting development in the same manner during development. The gene expression data will allow us to 1) correlate shape change with gene expression, cell proliferation and death changes, allowing identification of pathways and mechanisms that may be causative of the growth changes. 2) The expression data will allow comparison of the two models on a molecular level to determine if they are affecting the same downstream targets, and thus, acting within the same pathway. Based on this data, we hope be able to build out how this pathway is interacting with other established facial development pathways to determine the overall facial gene regulatory network for facial development. Cleft lip (CL) or Cleft lip/palate (CL/P) occurs in about 1 in 700 live births, and while they are treatable, many individuals with these types of deformities will require lifelong care. This proposal aims to increase our understanding of the underlying genetic and molecular causes of cleft lip and cleft palate and how different genes interact during the process of facial development. A more thorough understanding of the etiology of these disorders will help lead to better diagnostics and possibly treatments.",Genetic and Morphometric Analysis of Facial Clefts,8429534,F31DE022214,"['Affect', 'Alleles', 'Beryllium', 'Bilateral', 'Caring', 'Cell Death', 'Cell Proliferation', 'Cells', 'Cleaved cell', 'Cleft Lip', 'Cleft Palate', 'Complement', 'Data', 'Data Set', 'Deformity', 'Development', 'Diagnostic', 'Disease', 'Ear', 'Ectoderm', 'Embryo', 'Embryonic Development', 'Etiology', 'Exhibits', 'Eye', 'FGF8 gene', 'Face', 'Failure', 'Gene Dosage', 'Gene Expression', 'Genes', 'Genetic', 'Growth', 'In Situ Hybridization', 'Individual', 'Knock-out', 'Lead', 'Link', 'Live Birth', 'Maps', 'Modeling', 'Molecular', 'Molecular Analysis', 'Molecular Genetics', 'Morphogenesis', 'Mus', 'Mutation', 'Neural Crest', 'Paper', 'Pathway interactions', 'Pattern', 'Phenotype', 'Principal Component Analysis', 'Process', 'Regulator Genes', 'Relative (related person)', 'Shapes', 'Signal Transduction', 'Specificity', 'Statistical Methods', 'Syndrome', 'TFAP2A gene', 'Testing', 'Three-Dimensional Imaging', 'TimeLine', 'Tissues', 'Transgenes', 'Variant', 'Wild Type Mouse', 'Writing', 'base', 'cleft lip and palate', 'gene function', 'mouse model', 'orofacial', 'overexpression', 'recombinase', 'response', 'transcription factor', 'transcriptome sequencing']",NIDCR,UNIVERSITY OF COLORADO DENVER,F31,2013,29741,0.08702415756586686
"Genetic and Morphometric Analysis of Facial Clefts     DESCRIPTION (provided by applicant): Cleft lip (CL) or Cleft lip/palate (CL/P) occurs in about 1 in 700 live births, and while they are treatable, many individuals with these types of deformities will require lifelong care. Both of these conditions are the result of failures of the facial prominences to fuse during embryogenesis. CL and CL/P can occur as a single deformity or as part of a syndrome. Branchio-Occulo-Facial Syndrome (BOFS), for example, presents with facial clefting, ear and eye deformities and has been linked to mutations in the gene TFAP2A, encoding transcription factor AP-2. One mouse model of this disease employs a null allele in combination with a hypomorphic or ""weak"" allele of AP-2, creating a partial loss of AP-2 function. These mice develop a fully penetrant bilateral CL/P and our preliminary data suggest that it is small changes in growth and/or morphogenesis of the facial prominences that are responsible for failed fusion. Molecular analysis of this model shows increased expression of genes involved in Fgf signaling. Further, the loss of a single fgf8 allele in these mice is able to partially rescue the bilateral CL/P seen in the AP-2 hypomorphic mice to a unilateral CL/P. I, therefore hypothesize that AP-2 and FGF8 are elements of the same pathway during normal facial development and loss or mutation of AP-2 can affect the signaling interactions required for facial development. We will test this hypothesis by examining shape, gene expression and function in a mouse model that overexpresses FGF8 in the facial ectoderm and comparing this model to our AP-2 model. This proposal will generate shape data using 3D imaging and morphometrics. With this data we will be able to compare shape between the FGF8 overexpression model to the AP-2 hypomorphic mutation model and determine if these two genes are affecting development in the same manner during development. The gene expression data will allow us to 1) correlate shape change with gene expression, cell proliferation and death changes, allowing identification of pathways and mechanisms that may be causative of the growth changes. 2) The expression data will allow comparison of the two models on a molecular level to determine if they are affecting the same downstream targets, and thus, acting within the same pathway. Based on this data, we hope be able to build out how this pathway is interacting with other established facial development pathways to determine the overall facial gene regulatory network for facial development.        PUBLIC HEALTH RELEVANCE: Cleft lip (CL) or Cleft lip/palate (CL/P) occurs in about 1 in 700 live births, and while they are treatable, many individuals with these types of deformities will require lifelong care. This proposal aims to increase our understanding of the underlying genetic and molecular causes of cleft lip and cleft palate and how different genes interact during the process of facial development. A more thorough understanding of the etiology of these disorders will help lead to better diagnostics and possibly treatments.                  Cleft lip (CL) or Cleft lip/palate (CL/P) occurs in about 1 in 700 live births, and while they are treatable, many individuals with these types of deformities will require lifelong care. This proposal aims to increase our understanding of the underlying genetic and molecular causes of cleft lip and cleft palate and how different genes interact during the process of facial development. A more thorough understanding of the etiology of these disorders will help lead to better diagnostics and possibly treatments.                ",Genetic and Morphometric Analysis of Facial Clefts,8314431,F31DE022214,"['Affect', 'Alleles', 'Beryllium', 'Bilateral', 'Caring', 'Cell Death', 'Cell Proliferation', 'Cells', 'Cleaved cell', 'Cleft Lip', 'Cleft Palate', 'Complement', 'Data', 'Data Set', 'Deformity', 'Development', 'Diagnostic', 'Disease', 'Ear', 'Ectoderm', 'Embryo', 'Embryonic Development', 'Etiology', 'Exhibits', 'Eye', 'FGF8 gene', 'Face', 'Failure', 'Gene Dosage', 'Gene Expression', 'Genes', 'Genetic', 'Growth', 'In Situ Hybridization', 'Individual', 'Knock-out', 'Lead', 'Link', 'Live Birth', 'Maps', 'Modeling', 'Molecular', 'Molecular Analysis', 'Molecular Genetics', 'Morphogenesis', 'Mus', 'Mutation', 'Neural Crest', 'Paper', 'Pathway interactions', 'Pattern', 'Phenotype', 'Principal Component Analysis', 'Process', 'RNA', 'Regulator Genes', 'Relative (related person)', 'Shapes', 'Signal Transduction', 'Specificity', 'Statistical Methods', 'Syndrome', 'TFAP2A gene', 'Testing', 'Three-Dimensional Imaging', 'TimeLine', 'Tissues', 'Transgenes', 'Variant', 'Wild Type Mouse', 'Writing', 'base', 'cleft lip and palate', 'gene function', 'mouse model', 'orofacial', 'overexpression', 'recombinase', 'response', 'transcription factor']",NIDCR,UNIVERSITY OF COLORADO DENVER,F31,2012,29741,0.08463477941251973
"Imaging Brain Function/Structure in Presymptomatic FTD    DESCRIPTION (provided by applicant): Frontotemporal dementia (FTD) represents only 10-20% of all dementias, but remains important clinically because of its earlier age of onset compared to Alzheimer's disease (AD), and its characteristic attack on core human qualities ,e.g..compassion, insight and verbal communication. Treatment of FTD, as in AD, is more likely to succeed when applied in the early stages of the underlying pathology than in later stages, when symptoms appear and worsen. Detection of brain pathology is needed prior to these symptoms in order to develop and evaluate such treatments. We propose to use functional and structural magnetic resonance imaging (MRI) to detect brain network functional alterations, and subtle changes in cortical density in the frontal and anterior temporal lobes, in persons without dementia symptoms, but who are destined to develop FTD. The high likelihood of developing FTD is well-defined in identified subjects with mutations in the valosin-containing protein (VCP) gene on chromosome 9 associated with FTD, Paget's disease of bone, and inclusion-body myopathy. These persons will be tested to insure the absence of symptoms and typical cognitive impairments in FTD. Mutation carriers will be compared to non-carrier members of the same families. The first specific aim is to perform functional MRI studies to measure frontal and parietal activation during standard working memory and letter fluency tasks typically performed poorly in persons with early symptoms of FTD. We will also perform a control confrontation naming task, shown in preliminary studies to activate regions of the posterior temporal and occipital regions equally in VCP mutation carriers and in non-carriers. These data will be analyzed using advanced analytical and statisitical techniques, discriminant analysis and hierarchical clustering, to identify carriers most likely to develop future dementia. The second specific aim is to compare regional cortical density measured from three-dimensional structural images between VCP mutation carriers and non-carriers. We will combine the functional and structural measures with cognitive test results to refine our predictive model for dementia. These fundamental studies are expected to demonstrate brain network functional alterations and regionally decreased cortical density in rigorously-defined presymptomatic FTD.           n/a",Imaging Brain Function/Structure in Presymptomatic FTD,7457725,R01AG025159,"['3-Dimensional', 'Adult', 'Affect', 'Age', 'Age of Onset', 'Alzheimer&apos', 's Disease', 'Anatomy', 'Anterior', 'Area', 'Back', 'Behavioral', 'Behavioral Symptoms', 'Bone Diseases', 'Brain', 'Brain Diseases', 'Brain Pathology', 'Brain imaging', 'Brodmann&apos', 's area', 'Central Nervous System Diseases', 'Cessation of life', 'Characteristics', 'Chromosomes, Human, Pair 17', 'Chromosomes, Human, Pair 9', 'Clinical', 'Cluster Analysis', 'Cognitive', 'Communication', 'Compassion', 'Data', 'Data Set', 'Dementia', 'Depression screen', 'Detection', 'Discriminant Analysis', 'Disease', 'Education', 'Equipment and supply inventories', 'Family', 'Frequencies', 'Frontotemporal Dementia', 'Functional Magnetic Resonance Imaging', 'Future', 'Gender', 'Genes', 'Genetic', 'Genetic Risk', 'High Risk Woman', 'Human', 'Image', 'Impaired cognition', 'Inclusion Bodies', 'Individual', 'Inferior', 'Internet', 'Laboratories', 'Language', 'Lead', 'Left', 'Letters', 'Link', 'Literature', 'Magnetic Resonance Imaging', 'Maps', 'Measures', 'Mental Depression', 'Methods', 'Muscle', 'Mutation', 'Myopathy', 'Names', 'Numbers', 'Osteitis Deformans', 'Parietal', 'Pathology', 'Pathway interactions', 'Pattern', 'Performance', 'Personal Satisfaction', 'Persons', 'Phenotype', 'Population', 'Preventive', 'Process', 'Purpose', 'Qualifying', 'Relative (related person)', 'Research', 'Research Personnel', 'Resolution', 'Respiratory Failure', 'Risk', 'Short-Term Memory', 'Site', 'Staging', 'Standards of Weights and Measures', 'Stimulus', 'Structure', 'Surrogate Markers', 'Symptoms', 'Techniques', 'Temporal Lobe', 'Test Result', 'Testing', 'Time', 'Tissues', 'Visual', 'Woman', 'Work', 'base', 'brain tissue', 'density', 'disorder risk', 'executive function', 'follow-up', 'frontal lobe', 'frontal lobe cortex', 'gray matter', 'improved', 'insight', 'member', 'middle age', 'morphometry', 'mutation carrier', 'neurocognitive test', 'performance tests', 'predictive modeling', 'programs', 'response', 'tau Proteins', 'treatment trial', 'valosin-containing protein', 'white matter']",NIA,UNIVERSITY OF KENTUCKY,R01,2008,285904,-0.017424208403539847
"Imaging Brain Function/Structure in Presymptomatic FTD    DESCRIPTION (provided by applicant): Frontotemporal dementia (FTD) represents only 10-20% of all dementias, but remains important clinically because of its earlier age of onset compared to Alzheimer's disease (AD), and its characteristic attack on core human qualities ,e.g..compassion, insight and verbal communication. Treatment of FTD, as in AD, is more likely to succeed when applied in the early stages of the underlying pathology than in later stages, when symptoms appear and worsen. Detection of brain pathology is needed prior to these symptoms in order to develop and evaluate such treatments. We propose to use functional and structural magnetic resonance imaging (MRI) to detect brain network functional alterations, and subtle changes in cortical density in the frontal and anterior temporal lobes, in persons without dementia symptoms, but who are destined to develop FTD. The high likelihood of developing FTD is well-defined in identified subjects with mutations in the valosin-containing protein (VCP) gene on chromosome 9 associated with FTD, Paget's disease of bone, and inclusion-body myopathy. These persons will be tested to insure the absence of symptoms and typical cognitive impairments in FTD. Mutation carriers will be compared to non-carrier members of the same families. The first specific aim is to perform functional MRI studies to measure frontal and parietal activation during standard working memory and letter fluency tasks typically performed poorly in persons with early symptoms of FTD. We will also perform a control confrontation naming task, shown in preliminary studies to activate regions of the posterior temporal and occipital regions equally in VCP mutation carriers and in non-carriers. These data will be analyzed using advanced analytical and statisitical techniques, discriminant analysis and hierarchical clustering, to identify carriers most likely to develop future dementia. The second specific aim is to compare regional cortical density measured from three-dimensional structural images between VCP mutation carriers and non-carriers. We will combine the functional and structural measures with cognitive test results to refine our predictive model for dementia. These fundamental studies are expected to demonstrate brain network functional alterations and regionally decreased cortical density in rigorously-defined presymptomatic FTD.           n/a",Imaging Brain Function/Structure in Presymptomatic FTD,7284260,R01AG025159,"['3-Dimensional', 'Adult', 'Affect', 'Age', 'Age of Onset', 'Alzheimer&apos', 's Disease', 'Anatomy', 'Anterior', 'Area', 'Back', 'Behavioral', 'Behavioral Symptoms', 'Bone Diseases', 'Brain', 'Brain Diseases', 'Brain Pathology', 'Brain imaging', 'Brodmann&apos', 's area', 'Central Nervous System Diseases', 'Cessation of life', 'Characteristics', 'Chromosomes, Human, Pair 17', 'Chromosomes, Human, Pair 9', 'Clinical', 'Cluster Analysis', 'Cognitive', 'Communication', 'Compassion', 'Data', 'Data Set', 'Dementia', 'Depression screen', 'Detection', 'Discriminant Analysis', 'Disease', 'Education', 'Equipment and supply inventories', 'Family', 'Frequencies', 'Frontotemporal Dementia', 'Functional Magnetic Resonance Imaging', 'Future', 'Gender', 'Genes', 'Genetic', 'Genetic Risk', 'High Risk Woman', 'Human', 'Image', 'Impaired cognition', 'Inclusion Bodies', 'Individual', 'Inferior', 'Internet', 'Laboratories', 'Language', 'Lead', 'Left', 'Letters', 'Link', 'Literature', 'Magnetic Resonance Imaging', 'Maps', 'Measures', 'Mental Depression', 'Methods', 'Muscle', 'Mutation', 'Myopathy', 'Names', 'Numbers', 'Osteitis Deformans', 'Parietal', 'Pathology', 'Pathway interactions', 'Pattern', 'Performance', 'Personal Satisfaction', 'Persons', 'Phenotype', 'Population', 'Preventive', 'Process', 'Purpose', 'Qualifying', 'Relative (related person)', 'Research', 'Research Personnel', 'Resolution', 'Respiratory Failure', 'Risk', 'Short-Term Memory', 'Site', 'Staging', 'Standards of Weights and Measures', 'Stimulus', 'Structure', 'Surrogate Markers', 'Symptoms', 'Techniques', 'Temporal Lobe', 'Test Result', 'Testing', 'Time', 'Tissues', 'Visual', 'Woman', 'Work', 'base', 'brain tissue', 'density', 'disorder risk', 'executive function', 'follow-up', 'frontal lobe', 'frontal lobe cortex', 'gray matter', 'improved', 'insight', 'member', 'middle age', 'morphometry', 'mutation carrier', 'neurocognitive test', 'performance tests', 'predictive modeling', 'programs', 'response', 'tau Proteins', 'treatment trial', 'valosin-containing protein', 'white matter']",NIA,UNIVERSITY OF KENTUCKY,R01,2007,291979,-0.017424208403539847
"Imaging Brain Function/Structure in Presymptomatic FTD    DESCRIPTION (provided by applicant): Frontotemporal dementia (FTD) represents only 10-20% of all dementias, but remains important clinically because of its earlier age of onset compared to Alzheimer's disease (AD), and its characteristic attack on core human qualities ,e.g..compassion, insight and verbal communication. Treatment of FTD, as in AD, is more likely to succeed when applied in the early stages of the underlying pathology than in later stages, when symptoms appear and worsen. Detection of brain pathology is needed prior to these symptoms in order to develop and evaluate such treatments. We propose to use functional and structural magnetic resonance imaging (MRI) to detect brain network functional alterations, and subtle changes in cortical density in the frontal and anterior temporal lobes, in persons without dementia symptoms, but who are destined to develop FTD. The high likelihood of developing FTD is well-defined in identified subjects with mutations in the valosin-containing protein (VCP) gene on chromosome 9 associated with FTD, Paget's disease of bone, and inclusion-body myopathy. These persons will be tested to insure the absence of symptoms and typical cognitive impairments in FTD. Mutation carriers will be compared to non-carrier members of the same families. The first specific aim is to perform functional MRI studies to measure frontal and parietal activation during standard working memory and letter fluency tasks typically performed poorly in persons with early symptoms of FTD. We will also perform a control confrontation naming task, shown in preliminary studies to activate regions of the posterior temporal and occipital regions equally in VCP mutation carriers and in non-carriers. These data will be analyzed using advanced analytical and statisitical techniques, discriminant analysis and hierarchical clustering, to identify carriers most likely to develop future dementia. The second specific aim is to compare regional cortical density measured from three-dimensional structural images between VCP mutation carriers and non-carriers. We will combine the functional and structural measures with cognitive test results to refine our predictive model for dementia. These fundamental studies are expected to demonstrate brain network functional alterations and regionally decreased cortical density in rigorously-defined presymptomatic FTD.           n/a",Imaging Brain Function/Structure in Presymptomatic FTD,7094778,R01AG025159,"['aging', 'behavioral /social science research tag', 'bioimaging /biomedical imaging', 'brain disorder diagnosis', 'brain imaging /visualization /scanning', 'brain mapping', 'clinical research', 'cognition', 'dementia', 'disease /disorder onset', 'early diagnosis', 'executive function', 'family genetics', 'functional magnetic resonance imaging', 'gene mutation', 'genetic carriers', 'human subject', 'language', 'magnetic resonance imaging', 'mathematical model', 'neurogenetics', 'neuropsychological tests', 'short term memory']",NIA,UNIVERSITY OF KENTUCKY,R01,2006,310747,-0.017424208403539847
"Population Genetics Theory    DESCRIPTION (provided by applicant): Four areas of theoretical population genetics will be studied. In the first, we will develop mathematical and statistical framework for studying the evolution of genes that affect how other sets of genes interact with one another. This theory helps in understanding conditions under which the genome can be expected to become modular in its production of phenotypes, as well as when synergy between mutations in different genes should be produced by evolution. We shall study how the pattern of interaction between deleterious mutations evolves as a function of the mutation rate, the recombination rate, and the degree of fitness loss of each mutation. We shall also study buildup of statistical association between genes that influence culturally transmitted traits that are associated either through transmission or through fitness. The second area of study concerns the evolution of pathogens such as influenza. Here we build models to predict the accumulation of mutations during epidemics and pandemics in a way that can assist in guiding vaccination strategies. We will develop algorithms that search for potential recombinants and reassortants among a collection of up to 1000 viral sequences. Here we aim to devise a statistical test to indicate whether identified recombinants or reassortants are spurious or statistically significant. Our recent theory of niche construction will form the basis of studies of how pathogens might evolve in response to human actions that they induce, such as use of antibiotics. The final research area will develop multiple-gene models for sex-linked control of genomic imprinting. These will include cis and trans modifiers of imprinting. Fertility selection as well as sex- specific viabilities will be studied in order to clarify the role of multiple paternities, which has been proposed as a driving force in the evolution of genomic imprinting. Genomic data from mammalian species will be analyzed using tools from statistical learning in order to predict which genes are likely to be imprinted. Correlations between DMA sequence properties and predicted imprinting status based on life history characteristics will also be sought.           n/a",Population Genetics Theory,7869395,R01GM028016,"['Affect', 'Algorithms', 'Alleles', 'Antibiotics', 'Antigens', 'Area', 'Bacteria', 'Bacteriophages', 'Characteristics', 'Collection', 'Complex', 'Computers', 'DNA Sequence', 'Data', 'Development', 'Drug Formulations', 'Epidemic', 'Evolution', 'Fertility', 'Genes', 'Genetic', 'Genetic Epistasis', 'Genetic Models', 'Genetic Recombination', 'Genome', 'Genomic Imprinting', 'Genomics', 'Haploidy', 'Human', 'Influenza', 'Laboratories', 'Link', 'Machine Learning', 'Mammals', 'Modeling', 'Modification', 'Mutation', 'Organism', 'Pattern', 'Phenotype', 'Population Genetics', 'Production', 'Property', 'Recombinants', 'Research', 'Role', 'Specific qualifier value', 'Taxon', 'Testing', 'Time', 'Tweens', 'Vaccination', 'Variant', 'Viral', 'Virus', 'base', 'driving force', 'father role', 'fitness', 'gene function', 'genome sequencing', 'imprint', 'influenza epidemic', 'life history', 'pandemic disease', 'pathogen', 'research study', 'response', 'sex', 'social', 'theories', 'tool', 'trait', 'transmission process', 'vaccination strategy']",NIGMS,STANFORD UNIVERSITY,R01,2010,261556,0.2517045731598981
"Population Genetics Theory    DESCRIPTION (provided by applicant): Four areas of theoretical population genetics will be studied. In the first, we will develop mathematical and statistical framework for studying the evolution of genes that affect how other sets of genes interact with one another. This theory helps in understanding conditions under which the genome can be expected to become modular in its production of phenotypes, as well as when synergy between mutations in different genes should be produced by evolution. We shall study how the pattern of interaction between deleterious mutations evolves as a function of the mutation rate, the recombination rate, and the degree of fitness loss of each mutation. We shall also study buildup of statistical association between genes that influence culturally transmitted traits that are associated either through transmission or through fitness. The second area of study concerns the evolution of pathogens such as influenza. Here we build models to predict the accumulation of mutations during epidemics and pandemics in a way that can assist in guiding vaccination strategies. We will develop algorithms that search for potential recombinants and reassortants among a collection of up to 1000 viral sequences. Here we aim to devise a statistical test to indicate whether identified recombinants or reassortants are spurious or statistically significant. Our recent theory of niche construction will form the basis of studies of how pathogens might evolve in response to human actions that they induce, such as use of antibiotics. The final research area will develop multiple-gene models for sex-linked control of genomic imprinting. These will include cis and trans modifiers of imprinting. Fertility selection as well as sex- specific viabilities will be studied in order to clarify the role of multiple paternities, which has been proposed as a driving force in the evolution of genomic imprinting. Genomic data from mammalian species will be analyzed using tools from statistical learning in order to predict which genes are likely to be imprinted. Correlations between DMA sequence properties and predicted imprinting status based on life history characteristics will also be sought.           n/a",Population Genetics Theory,7986659,R01GM028016,"['Affect', 'Algorithms', 'Alleles', 'Antibiotics', 'Antigens', 'Area', 'Bacteria', 'Bacteriophages', 'Characteristics', 'Collection', 'Complex', 'Computers', 'DNA Sequence', 'Data', 'Development', 'Drug Formulations', 'Epidemic', 'Evolution', 'Fertility', 'Genes', 'Genetic', 'Genetic Epistasis', 'Genetic Models', 'Genetic Recombination', 'Genome', 'Genomic Imprinting', 'Genomics', 'Haploidy', 'Human', 'Influenza', 'Laboratories', 'Link', 'Machine Learning', 'Mammals', 'Modeling', 'Modification', 'Mutation', 'Organism', 'Pattern', 'Phenotype', 'Population Genetics', 'Production', 'Property', 'Recombinants', 'Research', 'Role', 'Specific qualifier value', 'Taxon', 'Testing', 'Time', 'Tweens', 'Vaccination', 'Variant', 'Viral', 'Virus', 'base', 'driving force', 'father role', 'fitness', 'gene function', 'genome sequencing', 'imprint', 'influenza epidemic', 'life history', 'pandemic disease', 'pathogen', 'research study', 'response', 'sex', 'social', 'theories', 'tool', 'trait', 'transmission process', 'vaccination strategy']",NIGMS,STANFORD UNIVERSITY,R01,2010,142237,0.2517045731598981
"Population Genetics Theory    DESCRIPTION (provided by applicant): Four areas of theoretical population genetics will be studied. In the first, we will develop mathematical and statistical framework for studying the evolution of genes that affect how other sets of genes interact with one another. This theory helps in understanding conditions under which the genome can be expected to become modular in its production of phenotypes, as well as when synergy between mutations in different genes should be produced by evolution. We shall study how the pattern of interaction between deleterious mutations evolves as a function of the mutation rate, the recombination rate, and the degree of fitness loss of each mutation. We shall also study buildup of statistical association between genes that influence culturally transmitted traits that are associated either through transmission or through fitness. The second area of study concerns the evolution of pathogens such as influenza. Here we build models to predict the accumulation of mutations during epidemics and pandemics in a way that can assist in guiding vaccination strategies. We will develop algorithms that search for potential recombinants and reassortants among a collection of up to 1000 viral sequences. Here we aim to devise a statistical test to indicate whether identified recombinants or reassortants are spurious or statistically significant. Our recent theory of niche construction will form the basis of studies of how pathogens might evolve in response to human actions that they induce, such as use of antibiotics. The final research area will develop multiple-gene models for sex-linked control of genomic imprinting. These will include cis and trans modifiers of imprinting. Fertility selection as well as sex- specific viabilities will be studied in order to clarify the role of multiple paternities, which has been proposed as a driving force in the evolution of genomic imprinting. Genomic data from mammalian species will be analyzed using tools from statistical learning in order to predict which genes are likely to be imprinted. Correlations between DMA sequence properties and predicted imprinting status based on life history characteristics will also be sought.           n/a",Population Genetics Theory,7631265,R01GM028016,"['Affect', 'Algorithms', 'Alleles', 'Antibiotics', 'Antigens', 'Area', 'Bacteria', 'Bacteriophages', 'Characteristics', 'Collection', 'Complex', 'Computers', 'DNA Sequence', 'Data', 'Development', 'Drug Formulations', 'Epidemic', 'Evolution', 'Fertility', 'Genes', 'Genetic', 'Genetic Epistasis', 'Genetic Models', 'Genetic Recombination', 'Genome', 'Genomic Imprinting', 'Genomics', 'Haploidy', 'Human', 'Influenza', 'Laboratories', 'Link', 'Machine Learning', 'Mammals', 'Modeling', 'Modification', 'Mutation', 'Organism', 'Pan Genus', 'Pattern', 'Phenotype', 'Population Genetics', 'Production', 'Property', 'Recombinants', 'Research', 'Role', 'Specific qualifier value', 'Taxon', 'Testing', 'Time', 'Tweens', 'Vaccination', 'Variant', 'Viral', 'Virus', 'base', 'driving force', 'father role', 'fitness', 'gene function', 'genome sequencing', 'imprint', 'influenza epidemic', 'life history', 'pandemic disease', 'pathogen', 'research study', 'response', 'sex', 'social', 'theories', 'tool', 'trait', 'transmission process', 'vaccination strategy']",NIGMS,STANFORD UNIVERSITY,R01,2009,259841,0.2517045731598981
"Population Genetics Theory    DESCRIPTION (provided by applicant): Four areas of theoretical population genetics will be studied. In the first, we will develop mathematical and statistical framework for studying the evolution of genes that affect how other sets of genes interact with one another. This theory helps in understanding conditions under which the genome can be expected to become modular in its production of phenotypes, as well as when synergy between mutations in different genes should be produced by evolution. We shall study how the pattern of interaction between deleterious mutations evolves as a function of the mutation rate, the recombination rate, and the degree of fitness loss of each mutation. We shall also study buildup of statistical association between genes that influence culturally transmitted traits that are associated either through transmission or through fitness. The second area of study concerns the evolution of pathogens such as influenza. Here we build models to predict the accumulation of mutations during epidemics and pandemics in a way that can assist in guiding vaccination strategies. We will develop algorithms that search for potential recombinants and reassortants among a collection of up to 1000 viral sequences. Here we aim to devise a statistical test to indicate whether identified recombinants or reassortants are spurious or statistically significant. Our recent theory of niche construction will form the basis of studies of how pathogens might evolve in response to human actions that they induce, such as use of antibiotics. The final research area will develop multiple-gene models for sex-linked control of genomic imprinting. These will include cis and trans modifiers of imprinting. Fertility selection as well as sex- specific viabilities will be studied in order to clarify the role of multiple paternities, which has been proposed as a driving force in the evolution of genomic imprinting. Genomic data from mammalian species will be analyzed using tools from statistical learning in order to predict which genes are likely to be imprinted. Correlations between DMA sequence properties and predicted imprinting status based on life history characteristics will also be sought.           n/a",Population Genetics Theory,7457930,R01GM028016,"['Affect', 'Algorithms', 'Alleles', 'Antibiotics', 'Antigens', 'Area', 'Bacteria', 'Bacteriophages', 'Characteristics', 'Class', 'Collection', 'Complex', 'Computers', 'Condition', 'DNA Sequence', 'Data', 'Development', 'Drug Formulations', 'Epidemic', 'Evolution', 'Facility Construction Funding Category', 'Fertility', 'Genes', 'Genetic', 'Genetic Epistasis', 'Genetic Models', 'Genetic Recombination', 'Genome', 'Genomic Imprinting', 'Genomics', 'Haploidy', 'Human', 'Influenza', 'Laboratories', 'Link', 'Machine Learning', 'Mammals', 'Modeling', 'Modification', 'Mutation', 'Numbers', 'Organism', 'Pan Genus', 'Pattern', 'Personal Satisfaction', 'Phenotype', 'Population Genetics', 'Production', 'Property', 'Purpose', 'Rate', 'Recombinants', 'Research', 'Role', 'Specific qualifier value', 'Standards of Weights and Measures', 'Statistically Significant', 'Taxon', 'Testing', 'Time', 'Tweens', 'Vaccination', 'Variant', 'Viral', 'Virus', 'base', 'driving force', 'father role', 'fitness', 'gene function', 'genome sequencing', 'imprint', 'influenza epidemic', 'life history', 'pandemic disease', 'pathogen', 'research study', 'response', 'sex', 'social', 'theories', 'tool', 'trait', 'transmission process', 'vaccination strategy']",NIGMS,STANFORD UNIVERSITY,R01,2008,254996,0.2517045731598981
"Population Genetics Theory    DESCRIPTION (provided by applicant): Four areas of theoretical population genetics will be studied. In the first, we will develop mathematical and statistical framework for studying the evolution of genes that affect how other sets of genes interact with one another. This theory helps in understanding conditions under which the genome can be expected to become modular in its production of phenotypes, as well as when synergy between mutations in different genes should be produced by evolution. We shall study how the pattern of interaction between deleterious mutations evolves as a function of the mutation rate, the recombination rate, and the degree of fitness loss of each mutation. We shall also study buildup of statistical association between genes that influence culturally transmitted traits that are associated either through transmission or through fitness. The second area of study concerns the evolution of pathogens such as influenza. Here we build models to predict the accumulation of mutations during epidemics and pandemics in a way that can assist in guiding vaccination strategies. We will develop algorithms that search for potential recombinants and reassortants among a collection of up to 1000 viral sequences. Here we aim to devise a statistical test to indicate whether identified recombinants or reassortants are spurious or statistically significant. Our recent theory of niche construction will form the basis of studies of how pathogens might evolve in response to human actions that they induce, such as use of antibiotics. The final research area will develop multiple-gene models for sex-linked control of genomic imprinting. These will include cis and trans modifiers of imprinting. Fertility selection as well as sex- specific viabilities will be studied in order to clarify the role of multiple paternities, which has been proposed as a driving force in the evolution of genomic imprinting. Genomic data from mammalian species will be analyzed using tools from statistical learning in order to predict which genes are likely to be imprinted. Correlations between DMA sequence properties and predicted imprinting status based on life history characteristics will also be sought.           n/a",Population Genetics Theory,7313297,R01GM028016,"['Affect', 'Algorithms', 'Alleles', 'Antibiotics', 'Antigens', 'Area', 'Bacteria', 'Bacteriophages', 'Characteristics', 'Class', 'Collection', 'Complex', 'Computers', 'Condition', 'DNA Sequence', 'Data', 'Development', 'Drug Formulations', 'Epidemic', 'Evolution', 'Facility Construction Funding Category', 'Fertility', 'Genes', 'Genetic', 'Genetic Epistasis', 'Genetic Models', 'Genetic Recombination', 'Genome', 'Genomic Imprinting', 'Genomics', 'Haploidy', 'Human', 'Influenza', 'Laboratories', 'Link', 'Machine Learning', 'Mammals', 'Modeling', 'Modification', 'Mutation', 'Numbers', 'Organism', 'Pan Genus', 'Pattern', 'Personal Satisfaction', 'Phenotype', 'Population Genetics', 'Production', 'Property', 'Purpose', 'Rate', 'Recombinants', 'Research', 'Role', 'Specific qualifier value', 'Standards of Weights and Measures', 'Statistically Significant', 'Taxon', 'Testing', 'Time', 'Tweens', 'Vaccination', 'Variant', 'Viral', 'Virus', 'base', 'driving force', 'father role', 'fitness', 'gene function', 'genome sequencing', 'imprint', 'influenza epidemic', 'life history', 'pandemic disease', 'pathogen', 'research study', 'response', 'sex', 'social', 'theories', 'tool', 'trait', 'transmission process', 'vaccination strategy']",NIGMS,STANFORD UNIVERSITY,R01,2007,258957,0.2517045731598981
"Integrating transcriptomic, proteomic and pharmacogenomic data to inform individualized therapy in cancers PROJECT SUMMARY As a computational biologist, my long-term goal is to develop methods and tools to discover new or better therapeutics for cancers. In the past few years, I have identified drug-repositioning candidates for a number of primary cancers using Big Data approaches. These candidates have been validated successfully in preclinical mouse models. To maximize the utility of Big Data, I plan to translate the findings into therapeutics; therefore, I propose to develop methods to utilize transcriptomic, proteomic and pharmacogenomic data to inform individualized therapy in cancers. Current preclinical and clinical approaches including the NCI MATCH trial select therapies primarily based on actionable mutations, yet patients may have no actionable mutations or multiple actionable mutations that are hard to prioritize, suggesting the need for other different types of molecular biomarkers. The recent efforts have enabled the large-scale identification of various types of molecular biomarkers through correlating drug sensitivity with molecular profiles of pre-treatment cancer cell lines. Computational methods to match these biomarkers to individual patients to inform therapy in the clinic are thus in high demand. The objective of this award is therefore to develop computational approaches to identify therapeutics for individual patients by leveraging large-scale biomarkers identified from cancer cell lines. Through conducing this research, I expect to expand my knowledge in cancer clinical trials, cancer genomics, cancer biology, and statistics. To achieve the goal, I have gathered seven renowned experts from different fields related to Big Data Science as mentors/advisors/collaborators: Primary Mentor Dr. Atul Butte in translational bioinformatics from UCSF, Co-mentor Dr. Samuel So in cancer biology from Stanford University, Co-mentor Dr. Mark Segal in statistics from UCSF, Advisor Dr. Andrei Goga in cancer biology from UCSF, Advisor Dr. Laura Esserman in breast cancer trials from UCSF, Collaborator Dr. John Gordan in liver cancer trials from UCSF and Collaborator Dr. Xin Chen in cancer biology from UCSF. With the support from my world- class mentors, advisors and collaborators, this award will prepare me to be a leader in developing big data methods that are broadly impactful. PROJECT NARRATIVE One goal of the precision medicine initiative is to select optimal therapies for individual cancer patients based on their molecular and clinical profiles. Current preclinical and clinical approaches select therapies primarily based on actionable mutations. This work is expected to employ the protein/gene expression based biomarkers computed from public databases to inform individualized cancer therapy.","Integrating transcriptomic, proteomic and pharmacogenomic data to inform individualized therapy in cancers",9925076,K01ES028047,"['Address', 'Adopted', 'Antineoplastic Agents', 'Award', 'Basal cell carcinoma', 'Big Data', 'Big Data Methods', 'Bioinformatics', 'Biological Markers', 'Cancer Biology', 'Cancer Patient', 'Cancer cell line', 'Cell Line', 'Clinic', 'Clinical', 'Clinical Trials', 'Code', 'Communities', 'Computing Methodologies', 'Consumption', 'Data', 'Data Set', 'Databases', 'Disease', 'Ewings sarcoma', 'Expression Profiling', 'Gene Expression', 'Gene Proteins', 'Genomic Data Commons', 'Goals', 'Individual', 'Knowledge', 'Machine Learning', 'Malignant - descriptor', 'Malignant Neoplasms', 'Malignant neoplasm of liver', 'Mentors', 'Meta-Analysis', 'Methods', 'Molecular', 'Molecular Profiling', 'Mus', 'Mutation', 'Non-Malignant', 'Normal tissue morphology', 'Patients', 'Pattern', 'Pharmaceutical Preparations', 'Pharmacogenomics', 'Precision Medicine Initiative', 'Primary carcinoma of the liver cells', 'Probability', 'Proteomics', 'Research', 'Resources', 'Sampling', 'Scientist', 'Source', 'System', 'Therapeutic', 'Time', 'Tissue Sample', 'Translating', 'Treatment outcome', 'Tumor Tissue', 'Universities', 'Validation', 'Work', 'Xenograft procedure', 'actionable mutation', 'base', 'big-data science', 'c-myc Genes', 'cancer cell', 'cancer clinical trial', 'cancer genomics', 'cancer therapy', 'data sharing', 'drug candidate', 'drug efficacy', 'drug sensitivity', 'efficacy testing', 'genetic signature', 'individual patient', 'individualized medicine', 'learning classifier', 'malignant breast neoplasm', 'molecular marker', 'mouse model', 'novel', 'oncotype', 'optimal treatments', 'personalized cancer therapy', 'personalized medicine', 'pre-clinical', 'predictive marker', 'protein expression', 'response', 'statistics', 'tool', 'transcriptomics', 'triple-negative invasive breast carcinoma', 'tumor']",NIEHS,MICHIGAN STATE UNIVERSITY,K01,2020,169087,0.10200515815059787
"Integrating transcriptomic, proteomic and pharmacogenomic data to inform individualized therapy in cancers PROJECT SUMMARY As a computational biologist, my long-term goal is to develop methods and tools to discover new or better therapeutics for cancers. In the past few years, I have identified drug-repositioning candidates for a number of primary cancers using Big Data approaches. These candidates have been validated successfully in preclinical mouse models. To maximize the utility of Big Data, I plan to translate the findings into therapeutics; therefore, I propose to develop methods to utilize transcriptomic, proteomic and pharmacogenomic data to inform individualized therapy in cancers. Current preclinical and clinical approaches including the NCI MATCH trial select therapies primarily based on actionable mutations, yet patients may have no actionable mutations or multiple actionable mutations that are hard to prioritize, suggesting the need for other different types of molecular biomarkers. The recent efforts have enabled the large-scale identification of various types of molecular biomarkers through correlating drug sensitivity with molecular profiles of pre-treatment cancer cell lines. Computational methods to match these biomarkers to individual patients to inform therapy in the clinic are thus in high demand. The objective of this award is therefore to develop computational approaches to identify therapeutics for individual patients by leveraging large-scale biomarkers identified from cancer cell lines. Through conducing this research, I expect to expand my knowledge in cancer clinical trials, cancer genomics, cancer biology, and statistics. To achieve the goal, I have gathered seven renowned experts from different fields related to Big Data Science as mentors/advisors/collaborators: Primary Mentor Dr. Atul Butte in translational bioinformatics from UCSF, Co-mentor Dr. Samuel So in cancer biology from Stanford University, Co-mentor Dr. Mark Segal in statistics from UCSF, Advisor Dr. Andrei Goga in cancer biology from UCSF, Advisor Dr. Laura Esserman in breast cancer trials from UCSF, Collaborator Dr. John Gordan in liver cancer trials from UCSF and Collaborator Dr. Xin Chen in cancer biology from UCSF. With the support from my world- class mentors, advisors and collaborators, this award will prepare me to be a leader in developing big data methods that are broadly impactful. PROJECT NARRATIVE One goal of the precision medicine initiative is to select optimal therapies for individual cancer patients based on their molecular and clinical profiles. Current preclinical and clinical approaches select therapies primarily based on actionable mutations. This work is expected to employ the protein/gene expression based biomarkers computed from public databases to inform individualized cancer therapy.","Integrating transcriptomic, proteomic and pharmacogenomic data to inform individualized therapy in cancers",9741127,K01ES028047,"['Address', 'Adopted', 'Antineoplastic Agents', 'Award', 'Basal cell carcinoma', 'Big Data', 'Big Data Methods', 'Bioinformatics', 'Biological Markers', 'Cancer Biology', 'Cancer Patient', 'Cancer cell line', 'Cell Line', 'Clinic', 'Clinical', 'Clinical Trials', 'Code', 'Communities', 'Computing Methodologies', 'Consumption', 'Data', 'Data Science', 'Data Set', 'Databases', 'Disease', 'Ewings sarcoma', 'Expression Profiling', 'Gene Expression', 'Gene Proteins', 'Genomic Data Commons', 'Goals', 'Individual', 'Knowledge', 'Machine Learning', 'Malignant - descriptor', 'Malignant Neoplasms', 'Malignant neoplasm of liver', 'Mentors', 'Meta-Analysis', 'Methods', 'Molecular', 'Molecular Profiling', 'Mus', 'Mutation', 'Non-Malignant', 'Normal tissue morphology', 'Patients', 'Pattern', 'Pharmaceutical Preparations', 'Pharmacogenomics', 'Precision Medicine Initiative', 'Primary carcinoma of the liver cells', 'Probability', 'Proteomics', 'Research', 'Resources', 'Sampling', 'Scientist', 'Source', 'System', 'Therapeutic', 'Time', 'Tissue Sample', 'Translating', 'Treatment outcome', 'Tumor Tissue', 'Universities', 'Validation', 'Work', 'Xenograft procedure', 'actionable mutation', 'base', 'c-myc Genes', 'cancer cell', 'cancer clinical trial', 'cancer genomics', 'cancer therapy', 'data sharing', 'drug candidate', 'drug efficacy', 'drug sensitivity', 'efficacy testing', 'genetic signature', 'individual patient', 'individualized medicine', 'malignant breast neoplasm', 'molecular marker', 'mouse model', 'novel', 'optimal treatments', 'personalized cancer therapy', 'personalized medicine', 'pre-clinical', 'predictive marker', 'protein expression', 'response', 'statistics', 'tool', 'transcriptomics', 'triple-negative invasive breast carcinoma', 'tumor']",NIEHS,MICHIGAN STATE UNIVERSITY,K01,2019,170187,0.10200515815059787
"Integrating transcriptomic, proteomic and pharmacogenomic data to inform individualized therapy in cancers PROJECT SUMMARY As a computational biologist, my long-term goal is to develop methods and tools to discover new or better therapeutics for cancers. In the past few years, I have identified drug-repositioning candidates for a number of primary cancers using Big Data approaches. These candidates have been validated successfully in preclinical mouse models. To maximize the utility of Big Data, I plan to translate the findings into therapeutics; therefore, I propose to develop methods to utilize transcriptomic, proteomic and pharmacogenomic data to inform individualized therapy in cancers. Current preclinical and clinical approaches including the NCI MATCH trial select therapies primarily based on actionable mutations, yet patients may have no actionable mutations or multiple actionable mutations that are hard to prioritize, suggesting the need for other different types of molecular biomarkers. The recent efforts have enabled the large-scale identification of various types of molecular biomarkers through correlating drug sensitivity with molecular profiles of pre-treatment cancer cell lines. Computational methods to match these biomarkers to individual patients to inform therapy in the clinic are thus in high demand. The objective of this award is therefore to develop computational approaches to identify therapeutics for individual patients by leveraging large-scale biomarkers identified from cancer cell lines. Through conducing this research, I expect to expand my knowledge in cancer clinical trials, cancer genomics, cancer biology, and statistics. To achieve the goal, I have gathered seven renowned experts from different fields related to Big Data Science as mentors/advisors/collaborators: Primary Mentor Dr. Atul Butte in translational bioinformatics from UCSF, Co-mentor Dr. Samuel So in cancer biology from Stanford University, Co-mentor Dr. Mark Segal in statistics from UCSF, Advisor Dr. Andrei Goga in cancer biology from UCSF, Advisor Dr. Laura Esserman in breast cancer trials from UCSF, Collaborator Dr. John Gordan in liver cancer trials from UCSF and Collaborator Dr. Xin Chen in cancer biology from UCSF. With the support from my world- class mentors, advisors and collaborators, this award will prepare me to be a leader in developing big data methods that are broadly impactful. PROJECT NARRATIVE One goal of the precision medicine initiative is to select optimal therapies for individual cancer patients based on their molecular and clinical profiles. Current preclinical and clinical approaches select therapies primarily based on actionable mutations. This work is expected to employ the protein/gene expression based biomarkers computed from public databases to inform individualized cancer therapy.","Integrating transcriptomic, proteomic and pharmacogenomic data to inform individualized therapy in cancers",9324471,K01ES028047,"['Address', 'Adopted', 'Alpha Cell', 'Antineoplastic Agents', 'Award', 'Basal cell carcinoma', 'Big Data', 'Bioinformatics', 'Biological Markers', 'Cancer Biology', 'Cancer Patient', 'Cancer cell line', 'Cell Line', 'Clinic', 'Clinical', 'Clinical Trials', 'Code', 'Communities', 'Computing Methodologies', 'Data', 'Data Science', 'Data Set', 'Databases', 'Disease', 'Ewings sarcoma', 'Gene Expression', 'Gene Proteins', 'Genomic Data Commons', 'Goals', 'Individual', 'Knowledge', 'Machine Learning', 'Malignant - descriptor', 'Malignant Neoplasms', 'Malignant neoplasm of liver', 'Mentors', 'Meta-Analysis', 'Methods', 'Molecular', 'Molecular Profiling', 'Mus', 'Mutation', 'Non-Malignant', 'Normal tissue morphology', 'Patients', 'Pattern', 'Pharmaceutical Preparations', 'Pharmacogenomics', 'Precision Medicine Initiative', 'Primary carcinoma of the liver cells', 'Probability', 'Proteomics', 'Research', 'Resources', 'Sampling', 'Scientist', 'Source', 'System', 'Therapeutic', 'Time', 'Tissue Sample', 'Translating', 'Treatment outcome', 'Tumor Tissue', 'Universities', 'Validation', 'Work', 'Xenograft procedure', 'actionable mutation', 'base', 'c-myc Genes', 'cancer cell', 'cancer clinical trial', 'cancer genomics', 'cancer therapy', 'data sharing', 'drug candidate', 'drug efficacy', 'drug sensitivity', 'efficacy testing', 'genetic signature', 'individual patient', 'malignant breast neoplasm', 'molecular marker', 'mouse model', 'novel', 'personalized cancer therapy', 'personalized medicine', 'pre-clinical', 'predictive marker', 'protein expression', 'response', 'statistics', 'tool', 'transcriptomics', 'triple-negative invasive breast carcinoma', 'tumor']",NIEHS,"UNIVERSITY OF CALIFORNIA, SAN FRANCISCO",K01,2017,171216,0.10200515815059787
"Integrating transcriptomic, proteomic and pharmacogenomic data to inform individualized therapy in cancers PROJECT SUMMARY As a computational biologist, my long-term goal is to develop methods and tools to discover new or better therapeutics for cancers. In the past few years, I have identified drug-repositioning candidates for a number of primary cancers using Big Data approaches. These candidates have been validated successfully in preclinical mouse models. To maximize the utility of Big Data, I plan to translate the findings into therapeutics; therefore, I propose to develop methods to utilize transcriptomic, proteomic and pharmacogenomic data to inform individualized therapy in cancers. Current preclinical and clinical approaches including the NCI MATCH trial select therapies primarily based on actionable mutations, yet patients may have no actionable mutations or multiple actionable mutations that are hard to prioritize, suggesting the need for other different types of molecular biomarkers. The recent efforts have enabled the large-scale identification of various types of molecular biomarkers through correlating drug sensitivity with molecular profiles of pre-treatment cancer cell lines. Computational methods to match these biomarkers to individual patients to inform therapy in the clinic are thus in high demand. The objective of this award is therefore to develop computational approaches to identify therapeutics for individual patients by leveraging large-scale biomarkers identified from cancer cell lines. Through conducing this research, I expect to expand my knowledge in cancer clinical trials, cancer genomics, cancer biology, and statistics. To achieve the goal, I have gathered seven renowned experts from different fields related to Big Data Science as mentors/advisors/collaborators: Primary Mentor Dr. Atul Butte in translational bioinformatics from UCSF, Co-mentor Dr. Samuel So in cancer biology from Stanford University, Co-mentor Dr. Mark Segal in statistics from UCSF, Advisor Dr. Andrei Goga in cancer biology from UCSF, Advisor Dr. Laura Esserman in breast cancer trials from UCSF, Collaborator Dr. John Gordan in liver cancer trials from UCSF and Collaborator Dr. Xin Chen in cancer biology from UCSF. With the support from my world- class mentors, advisors and collaborators, this award will prepare me to be a leader in developing big data methods that are broadly impactful. PROJECT NARRATIVE One goal of the precision medicine initiative is to select optimal therapies for individual cancer patients based on their molecular and clinical profiles. Current preclinical and clinical approaches select therapies primarily based on actionable mutations. This work is expected to employ the protein/gene expression based biomarkers computed from public databases to inform individualized cancer therapy.","Integrating transcriptomic, proteomic and pharmacogenomic data to inform individualized therapy in cancers",9675371,K01ES028047,"['Address', 'Adopted', 'Antineoplastic Agents', 'Award', 'Basal cell carcinoma', 'Big Data', 'Bioinformatics', 'Biological Markers', 'Cancer Biology', 'Cancer Patient', 'Cancer cell line', 'Cell Line', 'Clinic', 'Clinical', 'Clinical Trials', 'Code', 'Communities', 'Computing Methodologies', 'Data', 'Data Science', 'Data Set', 'Databases', 'Disease', 'Ewings sarcoma', 'Expression Profiling', 'Gene Expression', 'Gene Proteins', 'Genomic Data Commons', 'Goals', 'Individual', 'Knowledge', 'Machine Learning', 'Malignant - descriptor', 'Malignant Neoplasms', 'Malignant neoplasm of liver', 'Mentors', 'Meta-Analysis', 'Methods', 'Molecular', 'Molecular Profiling', 'Mus', 'Mutation', 'Non-Malignant', 'Normal tissue morphology', 'Patients', 'Pattern', 'Pharmaceutical Preparations', 'Pharmacogenomics', 'Precision Medicine Initiative', 'Primary carcinoma of the liver cells', 'Probability', 'Proteomics', 'Research', 'Resources', 'Sampling', 'Scientist', 'Source', 'System', 'Therapeutic', 'Time', 'Tissue Sample', 'Translating', 'Treatment outcome', 'Tumor Tissue', 'Universities', 'Validation', 'Work', 'Xenograft procedure', 'actionable mutation', 'base', 'c-myc Genes', 'cancer cell', 'cancer clinical trial', 'cancer genomics', 'cancer therapy', 'data sharing', 'drug candidate', 'drug efficacy', 'drug sensitivity', 'efficacy testing', 'genetic signature', 'individual patient', 'individualized medicine', 'malignant breast neoplasm', 'molecular marker', 'mouse model', 'novel', 'optimal treatments', 'personalized cancer therapy', 'personalized medicine', 'pre-clinical', 'predictive marker', 'protein expression', 'response', 'statistics', 'tool', 'transcriptomics', 'triple-negative invasive breast carcinoma', 'tumor']",NIEHS,MICHIGAN STATE UNIVERSITY,K01,2018,171217,0.10200515815059787
"A novel human T-cell platform to define biological effects of genome editing PROJECT SUMMARY Genome editing technologies have extraordinary potential as new genomic medicines that address underlying genetic causes of human disease; however, it remains challenging to predict their long-term safety, because we do not know the consequences of potential side effects of genome editing such as off-target mutations or immunogenicity. Our long-term goal is to understand and predict such unintended biological effects to advance the development of safe and effective therapies. T-cells are an ideal cellular model because: 1) they are highly relevant as the most widely used cells for development of therapeutic genome editing strategies (such as cell-based treatments for HIV and cancer) and 2) mature T-cells encode a diverse T-cell receptor repertoire that can be exploited as built-in cellular barcodes for quantifying clonal expansion or depletion in response to specific treatments. We, therefore, propose the following specific aims: 1) to predict which unintended editing sites have biological effects on human T-cells by integrating large-scale genome-wide activity and epigenomic profiles with state-of-the-art deep learning models and 2) to develop a human primary T-cell platform to detect functional effects of genome editing by measuring clonal representation, off-target mutation frequencies, immunogenicity, or gene expression. If successful, our experimental and predictive framework will profoundly increase confidence in the safety of the next generation of promising genome editing therapies. PROJECT NARRATIVE Genome editing technologies have extraordinary potential as the basis of new genomic medicines that address the underlying genetic causes of human disease; however, it is challenging to predict their long-term safety, because we do not know the consequences of potential unintended side effects of genome editing such as off-target mutations or immunogenicity. To define the biological effects of genome editing strategies, we will develop a human primary T-cell platform to sensitively detect functional effects coupled with an empirically-trained artificial intelligence models to predict them. Together, our platform will significantly improve confidence in safety assessments of promising genome editing therapeutics.",A novel human T-cell platform to define biological effects of genome editing,9783881,U01EB029373,"['Address', 'Advanced Development', 'Adverse effects', 'Affect', 'Artificial Intelligence', 'Benign', 'Biochemical', 'Bioinformatics', 'Biological', 'Biological Assay', 'Cell model', 'Cell physiology', 'Cells', 'Chromatin', 'Clonal Expansion', 'Complex', 'Coupled', 'DNA Methylation', 'Detection', 'Engineering', 'Epitopes', 'Frequencies', 'Gene Expression', 'Genes', 'Genetic', 'Genetic Diseases', 'Genetic Transcription', 'Genetic Variation', 'Genomic medicine', 'Genomics', 'Goals', 'HIV', 'Human', 'Human Genetics', 'Human Genome', 'Immunologic Deficiency Syndromes', 'In Vitro', 'Inherited', 'Machine Learning', 'Malignant Neoplasms', 'Maps', 'Mature T-Lymphocyte', 'Measures', 'Methods', 'Modeling', 'Mutation', 'Oncogenic', 'Organizational Change', 'Outcome', 'Peptide Library', 'Peripheral Blood Mononuclear Cell', 'Phenotype', 'Population', 'Proto-Oncogenes', 'Regulatory Element', 'Retroviral Vector', 'Ribonucleoproteins', 'Safety', 'Site', 'Site-Directed Mutagenesis', 'Standardization', 'Streptococcus pyogenes', 'T cell response', 'T-Cell Proliferation', 'T-Cell Receptor', 'T-Lymphocyte', 'T-cell receptor repertoire', 'Technology', 'Testing', 'Therapeutic', 'Training', 'Variant', 'adaptive immune response', 'adverse outcome', 'base', 'comparative genomics', 'cytokine', 'deep learning', 'effective therapy', 'epigenomics', 'functional genomics', 'gene therapy', 'genome editing', 'genome-wide', 'genotoxicity', 'histone modification', 'human disease', 'immunogenic', 'immunogenicity', 'improved', 'in vivo', 'learning strategy', 'next generation', 'novel', 'novel therapeutics', 'response', 'safety assessment', 'safety testing', 'side effect', 'therapeutic development', 'therapeutic gene', 'therapeutic genome editing', 'transcriptome sequencing']",NIBIB,ST. JUDE CHILDREN'S RESEARCH HOSPITAL,U01,2019,611358,0.12325170204758766
"Imaging signatures of genetic mutations in glioblastoma using machine learning Glioblastoma (GB) is the most common and aggressive malignant adult brain tumor, with grim prognosis and heterogeneous molecular and imaging profiles. Although the currently applicable treatment options (i.e., surgery, radiotherapy, chemotherapy) have expanded during the last 20 years, there is no substantial improvement in the OS rates. The major obstacle in treating GBM patients is the heterogeneity of their molecular landscape. Determination of molecular targets requires ex vivo postoperative tissue analyses, which are limited in assessing the tumor's spatial heterogeneity (sampling error due to single sample histopathological and molecular analysis) and temporal heterogeneity (not possible to continuously assess the molecular transformation of the tumor during treatment). Herein we propose to develop quantitative imaging phenomic (QIP) markers of a range of mutations of interest in GB. We will build on prior work on EGFR, IDH1 mutations and MGMT methylation QIP signatures, and develop an extensive panel of imaging signatures of 10 gene mutations, as well as MGMT promoter methylation, using machine learning methods applied to relatively routine clinical mpMRI (standard plus diffusion tensor and perfusion protocols). Availability of such biomarkers can contribute to non-invasive i) patient stratification into appropriate treatments, ii) measurement of individual molecular characteristics. In particular, we propose to carry out the following specific aims: Specific Aim 1 (SA1): To develop the enabling methodologies for constructing Quantitative Imaging Phenomic signatures of GB mutations Specific Aim 2 (SA2): Establish QIP signatures of 10 mutations of interest in gliomas, plus MGMT promoter status, using next generation sequencing (NGS). We will use 709 datasets. Specific Aim 3 (SA3): Characterize the molecular heterogeneity of GB using QIP signatures, leveraging the NGS samples of SA1, as well as a new sample that we will genotype, adding to a total of 600 tumor samples obtained from 4 different locations per patient from 150 patients. The first 150 tissue samples are already analyzed as part of ongoing work. Specific Aim 4 (SA4): Integrate our methods into the Cancer Imaging Phenomics Toolkit (CaPTk), in order to allow easy access to them by users This project will investigate the relationship between imaging characteristics of glioblastoma and its underlying genetic mutations/variants. As such, it aims to develop a number of imaging signatures of mutations that are important in GBM, using 1,159 (709 patients plus an additional 450 tissue samples of 150 of these patients obtained from different locations in the tumor) analyzed via next generation sequencing. The primary motivation of this work is to develop the imaging analytics methodologies and associated biomarkers that will allow us to evaluate the spatial, temporal and molecular heterogeneity of glioblastoma, thereby assisting in patient stratification and treatment.",Imaging signatures of genetic mutations in glioblastoma using machine learning,9893291,R01NS042645,"['Adult', 'Atlases', 'Biological Markers', 'Biophysics', 'Biopsy', 'Brain Neoplasms', 'Characteristics', 'Clinical', 'Complex', 'DNA Sequence Alteration', 'Data', 'Data Set', 'Descriptor', 'Diagnosis', 'Diffusion', 'Epidermal Growth Factor Receptor', 'Evaluation', 'Gene Mutation', 'Genes', 'Genotype', 'Glioblastoma', 'Glioma', 'Growth', 'Heterogeneity', 'Image', 'Image Analysis', 'Individual', 'Infiltration', 'Ligand Binding', 'Location', 'MGMT gene', 'Machine Learning', 'Magnetic Resonance Imaging', 'Malignant - descriptor', 'Malignant Neoplasms', 'Measurement', 'Measures', 'Methodology', 'Methods', 'Methylation', 'Modeling', 'Molecular', 'Molecular Analysis', 'Molecular Profiling', 'Molecular Target', 'Morphology', 'Motivation', 'Mutation', 'Operative Surgical Procedures', 'Pathway interactions', 'Patients', 'Pattern', 'Perfusion', 'Phenotype', 'Postoperative Period', 'Protocols documentation', 'Radiation therapy', 'Radiogenomics', 'Sampling', 'Sampling Errors', 'Signal Transduction', 'Spatial Distribution', 'Stratification', 'Subgroup', 'Survival Rate', 'Testing', 'Texture', 'Therapeutic Clinical Trial', 'Tissue Sample', 'Tissues', 'Variant', 'Work', 'base', 'cancer imaging', 'chemotherapy', 'clinical imaging', 'clinical phenotype', 'clinically actionable', 'clinically relevant', 'deep learning', 'design', 'genetic signature', 'in vivo', 'individual patient', 'interest', 'machine learning method', 'molecular imaging', 'next generation sequencing', 'outcome forecast', 'patient stratification', 'personalized diagnostics', 'personalized predictions', 'phenomics', 'predictive signature', 'programs', 'promoter', 'quantitative imaging', 'radiomics', 'rapid growth', 'receptor', 'routine imaging', 'standard of care', 'tumor', 'tumor growth', 'tumor heterogeneity']",NINDS,UNIVERSITY OF PENNSYLVANIA,R01,2020,670422,0.0564666025773513
"Molecular Characterization of Joubert Syndrome Project Summary Congenital ataxia presents in early childhood with non-progressive hypotonia, gross motor, fine motor and cognitive delays. These disorders are distinct from the progressive ataxias because of the presence of congenital cerebellar malformations and because they are typically inherited recessively. Joubert Syndrome and Related Disorders (JSRD) constitute a major subset of these conditions, consisting of a cerebellar midline (vermis) malformation, a nearly pathognomonic Molar Tooth sign on brain Imaging (MTI) and co-existent oculomotor apraxia and episodic breathing dysrhythmias. In our published data, we have: 1] Identified ten unique genetic causes of JSRD (nearly half of the published causes), 2] Generated genotype-phenotype correlations involving cerebellar, retinal, renal, hepatic, digit, and cerebral manifestations. 3] Identified common founder mutations that allow for population-based screening. 4] Discovered that JSRD encoded proteins frequently localize to the cilium. 5] Identified ciliary transition zone (TZ) defects in cells with JSRD mutations. 6] Performed siRNA cell-based screens for defective ciliogenesis to prioritize candidate JSRD genes. 7] Generated and characterized multiple zebrafish, mouse and human cell culture models for JSRD. 8] Defined the concept of Ciliary localization model, in which one JSRD gene is required for ciliary localization of other JSRD proteins. In our unpublished data we have: 1] Recruited an additional 200 JSRD patients without molecular diagnosis. 2] Performed whole exome (WES) and whole genome sequencing (WGS) on an additional 100 JSRD families. 3] Identified an additional 12 novel likely JSRD candidate genes. 4] Generated IPSCs and cerebellar organoids from mutation-positive and negative families to aid in functional analysis and gene discovery using RNAseq. 5] Begun functional validation of the putative mutations. 6] Developed methods to interrogate ciliary structure in a high-throughput fashion with electron microscopy (EM). The goal of this competing renewal is to identify the remaining discoverable genes that lead to JSRD when lost, functionally validate mutations within the pathogenetic framework, and test the hypothesis that mutations in JSRD genes lead to collapse of the ciliary TZ. Because the majority of patients still have unknown cause of disease, this renewal aims to advance knowledge through molecular characterization of new genes, using newly evolving high-throughput techniques, integrated bioinformatics, and a unique resource of consanguineous families recruited world-wide. We further aim to validate these mutations in patient cells, within a mechanistic framework that JSRD genes are required for essential ciliary structural components during cerebellar development. Project Narrative Joubert syndrome is a genetically and phenotypically heterogeneous neurodevelopmental disorder unified by defects of the cellular primary cilium. This work will identify new genetic causes and dissect ciliary defects associated with genetic mutations.",Molecular Characterization of Joubert Syndrome,9988508,R01NS048453,"['Apraxias', 'Ataxia', 'Bioinformatics', 'Brain imaging', 'Breathing', 'Candidate Disease Gene', 'Cell Culture Techniques', 'Cells', 'Cerebellar malformation', 'Cerebellar vermis structure', 'Cerebrum', 'Cilia', 'Clinical', 'Clustered Regularly Interspaced Short Palindromic Repeats', 'Cognitive', 'Congenital cerebellar hypoplasia', 'Cultured Cells', 'Cytoplasmic Granules', 'DNA Sequence Alteration', 'Data', 'Databases', 'Defect', 'Development', 'Digit structure', 'Disease', 'Electron Microscopy', 'Electrons', 'Embryo', 'Enrollment', 'Face', 'Family', 'Gene Mutation', 'Genes', 'Genetic', 'Genotype', 'Goals', 'Gold', 'Hepatic', 'Human', 'Individual', 'Inherited', 'Joubert syndrome', 'Kidney', 'Knock-out', 'Knowledge', 'Lead', 'Length', 'Machine Learning', 'Mass Spectrum Analysis', 'Methods', 'Microscopic', 'Middle East', 'Modeling', 'Molar tooth', 'Molecular', 'Molecular Diagnosis', 'Morphogenesis', 'Morphology', 'Motor', 'Mus', 'Muscle hypotonia', 'Mutation', 'Neurodevelopmental Disorder', 'Organoids', 'Pathogenicity', 'Patients', 'Phenotype', 'Probability', 'Protein Analysis', 'Proteins', 'Publishing', 'Resources', 'Retina', 'Risk', 'Scanning Electron Microscopy', 'Series', 'Severities', 'Signal Transduction', 'Small Interfering RNA', 'Sonication', 'Structure', 'Syndrome', 'Techniques', 'Termination of pregnancy', 'Testing', 'Three-dimensional analysis', 'Training', 'Transmission Electron Microscopy', 'Validation', 'Variant', 'WNT Signaling Pathway', 'Work', 'Zebrafish', 'accurate diagnosis', 'affection', 'base', 'cell type', 'cilium biogenesis', 'cohort', 'consanguineous family', 'disorder subtype', 'early childhood', 'exome', 'exome sequencing', 'fetal', 'founder mutation', 'gene discovery', 'genetic testing', 'genome sequencing', 'genome-wide', 'insight', 'knock-down', 'loss of function mutation', 'malformation', 'mutant', 'novel', 'oculomotor', 'population based', 'reconstruction', 'recruit', 'screening', 'stem cell biology', 'transcriptome sequencing', 'whole genome']",NINDS,"UNIVERSITY OF CALIFORNIA, SAN DIEGO",R01,2020,510012,0.21695242775957127
"Molecular Characterization of Joubert Syndrome Project Summary Congenital ataxia presents in early childhood with non-progressive hypotonia, gross motor, fine motor and cognitive delays. These disorders are distinct from the progressive ataxias because of the presence of congenital cerebellar malformations and because they are typically inherited recessively. Joubert Syndrome and Related Disorders (JSRD) constitute a major subset of these conditions, consisting of a cerebellar midline (vermis) malformation, a nearly pathognomonic Molar Tooth sign on brain Imaging (MTI) and co-existent oculomotor apraxia and episodic breathing dysrhythmias. In our published data, we have: 1] Identified ten unique genetic causes of JSRD (nearly half of the published causes), 2] Generated genotype-phenotype correlations involving cerebellar, retinal, renal, hepatic, digit, and cerebral manifestations. 3] Identified common founder mutations that allow for population-based screening. 4] Discovered that JSRD encoded proteins frequently localize to the cilium. 5] Identified ciliary transition zone (TZ) defects in cells with JSRD mutations. 6] Performed siRNA cell-based screens for defective ciliogenesis to prioritize candidate JSRD genes. 7] Generated and characterized multiple zebrafish, mouse and human cell culture models for JSRD. 8] Defined the concept of Ciliary localization model, in which one JSRD gene is required for ciliary localization of other JSRD proteins. In our unpublished data we have: 1] Recruited an additional 200 JSRD patients without molecular diagnosis. 2] Performed whole exome (WES) and whole genome sequencing (WGS) on an additional 100 JSRD families. 3] Identified an additional 12 novel likely JSRD candidate genes. 4] Generated IPSCs and cerebellar organoids from mutation-positive and negative families to aid in functional analysis and gene discovery using RNAseq. 5] Begun functional validation of the putative mutations. 6] Developed methods to interrogate ciliary structure in a high-throughput fashion with electron microscopy (EM). The goal of this competing renewal is to identify the remaining discoverable genes that lead to JSRD when lost, functionally validate mutations within the pathogenetic framework, and test the hypothesis that mutations in JSRD genes lead to collapse of the ciliary TZ. Because the majority of patients still have unknown cause of disease, this renewal aims to advance knowledge through molecular characterization of new genes, using newly evolving high-throughput techniques, integrated bioinformatics, and a unique resource of consanguineous families recruited world-wide. We further aim to validate these mutations in patient cells, within a mechanistic framework that JSRD genes are required for essential ciliary structural components during cerebellar development. Project Narrative Joubert syndrome is a genetically and phenotypically heterogeneous neurodevelopmental disorder unified by defects of the cellular primary cilium. This work will identify new genetic causes and dissect ciliary defects associated with genetic mutations.",Molecular Characterization of Joubert Syndrome,9749889,R01NS048453,"['Apraxias', 'Ataxia', 'Bioinformatics', 'Brain imaging', 'Breathing', 'Candidate Disease Gene', 'Cell Culture Techniques', 'Cells', 'Cerebellar malformation', 'Cerebellar vermis structure', 'Cerebrum', 'Cilia', 'Clinical', 'Clustered Regularly Interspaced Short Palindromic Repeats', 'Cognitive', 'Congenital cerebellar hypoplasia', 'Cultured Cells', 'Cytoplasmic Granules', 'DNA Sequence Alteration', 'Data', 'Databases', 'Defect', 'Development', 'Digit structure', 'Disease', 'Electron Microscopy', 'Electrons', 'Embryo', 'Enrollment', 'Face', 'Family', 'Gene Mutation', 'Genes', 'Genetic', 'Genetic screening method', 'Genotype', 'Goals', 'Gold', 'Hepatic', 'Human', 'Individual', 'Inherited', 'Joubert syndrome', 'Kidney', 'Knock-out', 'Knowledge', 'Lead', 'Length', 'Machine Learning', 'Mass Spectrum Analysis', 'Methods', 'Microscopic', 'Middle East', 'Modeling', 'Molar tooth', 'Molecular', 'Molecular Diagnosis', 'Morphogenesis', 'Morphology', 'Motor', 'Mus', 'Muscle hypotonia', 'Mutation', 'Neurodevelopmental Disorder', 'Organoids', 'Pathogenicity', 'Patients', 'Phenotype', 'Probability', 'Protein Analysis', 'Proteins', 'Publishing', 'Resources', 'Retinal', 'Risk', 'Scanning Electron Microscopy', 'Series', 'Severities', 'Signal Transduction', 'Small Interfering RNA', 'Sonication', 'Structure', 'Syndrome', 'Techniques', 'Termination of pregnancy', 'Testing', 'Three-dimensional analysis', 'Training', 'Transmission Electron Microscopy', 'Validation', 'Variant', 'WNT Signaling Pathway', 'Work', 'Zebrafish', 'accurate diagnosis', 'affection', 'base', 'cell type', 'cilium biogenesis', 'cohort', 'consanguineous family', 'disorder subtype', 'early childhood', 'exome', 'exome sequencing', 'fetal', 'founder mutation', 'gene discovery', 'genome sequencing', 'genome-wide', 'insight', 'knock-down', 'loss of function mutation', 'malformation', 'mutant', 'novel', 'oculomotor', 'population based', 'reconstruction', 'recruit', 'screening', 'stem cell biology', 'transcriptome sequencing', 'whole genome']",NINDS,"UNIVERSITY OF CALIFORNIA, SAN DIEGO",R01,2019,510012,0.21695242775957127
"Molecular Characterization of Joubert Syndrome Project Summary Congenital ataxia presents in early childhood with non-progressive hypotonia, gross motor, fine motor and cognitive delays. These disorders are distinct from the progressive ataxias because of the presence of congenital cerebellar malformations and because they are typically inherited recessively. Joubert Syndrome and Related Disorders (JSRD) constitute a major subset of these conditions, consisting of a cerebellar midline (vermis) malformation, a nearly pathognomonic Molar Tooth sign on brain Imaging (MTI) and co-existent oculomotor apraxia and episodic breathing dysrhythmias. In our published data, we have: 1] Identified ten unique genetic causes of JSRD (nearly half of the published causes), 2] Generated genotype-phenotype correlations involving cerebellar, retinal, renal, hepatic, digit, and cerebral manifestations. 3] Identified common founder mutations that allow for population-based screening. 4] Discovered that JSRD encoded proteins frequently localize to the cilium. 5] Identified ciliary transition zone (TZ) defects in cells with JSRD mutations. 6] Performed siRNA cell-based screens for defective ciliogenesis to prioritize candidate JSRD genes. 7] Generated and characterized multiple zebrafish, mouse and human cell culture models for JSRD. 8] Defined the concept of Ciliary localization model, in which one JSRD gene is required for ciliary localization of other JSRD proteins. In our unpublished data we have: 1] Recruited an additional 200 JSRD patients without molecular diagnosis. 2] Performed whole exome (WES) and whole genome sequencing (WGS) on an additional 100 JSRD families. 3] Identified an additional 12 novel likely JSRD candidate genes. 4] Generated IPSCs and cerebellar organoids from mutation-positive and negative families to aid in functional analysis and gene discovery using RNAseq. 5] Begun functional validation of the putative mutations. 6] Developed methods to interrogate ciliary structure in a high-throughput fashion with electron microscopy (EM). The goal of this competing renewal is to identify the remaining discoverable genes that lead to JSRD when lost, functionally validate mutations within the pathogenetic framework, and test the hypothesis that mutations in JSRD genes lead to collapse of the ciliary TZ. Because the majority of patients still have unknown cause of disease, this renewal aims to advance knowledge through molecular characterization of new genes, using newly evolving high-throughput techniques, integrated bioinformatics, and a unique resource of consanguineous families recruited world-wide. We further aim to validate these mutations in patient cells, within a mechanistic framework that JSRD genes are required for essential ciliary structural components during cerebellar development. Project Narrative Joubert syndrome is a genetically and phenotypically heterogeneous neurodevelopmental disorder unified by defects of the cellular primary cilium. This work will identify new genetic causes and dissect ciliary defects associated with genetic mutations.",Molecular Characterization of Joubert Syndrome,9359994,R01NS048453,"['Apraxias', 'Ataxia', 'Bioinformatics', 'Brain imaging', 'Breathing', 'Candidate Disease Gene', 'Cell Culture Techniques', 'Cells', 'Cerebellar malformation', 'Cerebellar vermis structure', 'Cerebrum', 'Cilia', 'Clinical', 'Clustered Regularly Interspaced Short Palindromic Repeats', 'Cognitive', 'Congenital cerebellar hypoplasia', 'Cultured Cells', 'Cytoplasmic Granules', 'DNA Sequence Alteration', 'Data', 'Databases', 'Defect', 'Development', 'Digit structure', 'Disease', 'Electron Microscopy', 'Electrons', 'Embryo', 'Enrollment', 'Face', 'Family', 'Gene Mutation', 'Genes', 'Genetic', 'Genetic screening method', 'Genotype', 'Goals', 'Gold', 'Hepatic', 'Human', 'Individual', 'Inherited', 'Joubert syndrome', 'Kidney', 'Knock-out', 'Knowledge', 'Lead', 'Length', 'Machine Learning', 'Mass Spectrum Analysis', 'Methods', 'Microscopic', 'Middle East', 'Modeling', 'Molar tooth', 'Molecular', 'Molecular Diagnosis', 'Morphogenesis', 'Morphology', 'Motor', 'Mus', 'Muscle hypotonia', 'Mutation', 'Neurodevelopmental Disorder', 'Organoids', 'Pathogenicity', 'Patients', 'Phenotype', 'Probability', 'Protein Analysis', 'Proteins', 'Publishing', 'Resources', 'Retinal', 'Risk', 'Scanning Electron Microscopy', 'Series', 'Severities', 'Signal Transduction', 'Small Interfering RNA', 'Sonication', 'Structure', 'Syndrome', 'Techniques', 'Termination of pregnancy', 'Testing', 'Three-dimensional analysis', 'Training', 'Transmission Electron Microscopy', 'Validation', 'Variant', 'WNT Signaling Pathway', 'Work', 'Zebrafish', 'accurate diagnosis', 'affection', 'base', 'cell type', 'cilium biogenesis', 'cohort', 'consanguineous family', 'disorder subtype', 'early childhood', 'exome', 'exome sequencing', 'fetal', 'founder mutation', 'gene discovery', 'genome sequencing', 'genome-wide', 'insight', 'knock-down', 'loss of function mutation', 'malformation', 'mutant', 'novel', 'oculomotor', 'population based', 'reconstruction', 'recruit', 'screening', 'stem cell biology', 'transcriptome sequencing', 'whole genome']",NINDS,"UNIVERSITY OF CALIFORNIA, SAN DIEGO",R01,2018,510012,0.21695242775957127
"Molecular Characterization of Joubert Syndrome     DESCRIPTION (provided by applicant): Congenital ataxia presents in early childhood with non-progressive hypotonia, gross and fine motor delay and cognitive delays. These disorders are distinct from the progressive ataxias because of the presence of congenital cerebellar malformations and because they are typically inherited recessively. Joubert Syndrome and Related Disorders (JSRD) constitute a major subset of these conditions, consisting of a cerebellar midline (vermis) malformation, a nearly pathognomonic Molar Tooth sign on brain Imaging (MTI) and co-existent oculomotor apraxia and episodic breathing dysrhythmias. In our published data, we have: 1] Identified ten unique genetic causes of JSRD (nearly half of the published causes), 2] Generated genotype-phenotype correlations involving cerebellar, retinal, renal, hepatic, digit, and cerebral manifestations. 3] Identified common founder mutations that allow for population-based screening. 4] Discovered that JSRD encoded proteins localize to the cilium. 5] Identified ciliary defects in cells with JSRD mutations. 6] Performed siRNA cell-based screens for defective ciliogenesis to prioritize candidate JSRD genes. 7] Generated and characterized multiple zebrafish, mouse and human cell culture models for JSRD. 8] Defined the concept of `Ciliary localization' model, in which one JSRD gene is required for ciliary localization of other JSRD proteins. In our unpublished work we have: 1] Recruited an additional 200 JSRD patients without molecular diagnosis. 2] Performed whole exome sequencing (WES) and genetic mapping on an additional 100 JSRD families. 3] Identified an additional 12 novel likely JSRD candidate genes. 4] Begun functional validation of the putative mutations. 5] Developed methods to ultrastructurally interrogate ciliary structure in a high-throughput fashion. The goal of this competing renewal is to identify the remaining `discoverable' genes that when mutated lead to JSRD, functionally validate mutations within the pathogenetic framework, and test the hypothesis that mutations in any proven JSRD gene lead to collapse of the ciliary transition zone by correlating genetic mutations with ultrastructural ciliary defects. Because the majority of patients still have unknown cause of disease, this renewal aims to advance knowledge through molecular characterization of new genes, using newly evolving high-throughput techniques, integrated bioinformatics, and a unique resource of consanguineous families recruited world-wide. We further aim to validate these mutations within a mechanistic framework, and a model that JSRD genes are required for essential ciliary structural components during cerebellar development. PUBLIC HEALTH RELEVANCE: Joubert syndrome is a genetically and phenotypically heterogeneous neurodevelopmental disorder unified by defects of the cellular primary cilium. This work will identify new genetic causes and dissect ciliary defects associated with genetic mutations",Molecular Characterization of Joubert Syndrome,9450748,R01NS048453,"['Apraxias', 'Ataxia', 'Attention', 'Autistic Disorder', 'Bioinformatics', 'Brain Diseases', 'Brain imaging', 'Breathing', 'Candidate Disease Gene', 'Cell Culture Techniques', 'Cells', 'Cerebellar malformation', 'Cerebellar vermis structure', 'Cerebrum', 'Childhood', 'Chromosome Mapping', 'Cilia', 'Clinical', 'Clustered Regularly Interspaced Short Palindromic Repeats', 'Cognitive', 'Complex', 'Congenital cerebellar hypoplasia', 'Cultured Cells', 'DNA Sequence Alteration', 'Data', 'Databases', 'Defect', 'Development', 'Diagnosis', 'Diagnostic radiologic examination', 'Digit structure', 'Disease', 'Electrons', 'Embryo', 'Enrollment', 'Face', 'Family', 'Gene Mutation', 'Genes', 'Genetic', 'Genetic screening method', 'Genotype', 'Goals', 'Gold', 'Hepatic', 'Human', 'Individual', 'Inherited', 'Joubert syndrome', 'Kidney', 'Knock-out', 'Knowledge', 'Lead', 'Learning', 'Length', 'Machine Learning', 'Mental Retardation', 'Methods', 'Microscopic', 'Middle East', 'Modeling', 'Molar tooth', 'Molecular', 'Molecular Diagnosis', 'Morphogenesis', 'Motor', 'Mus', 'Muscle hypotonia', 'Mutate', 'Mutation', 'Neurodevelopmental Disorder', 'Pathogenicity', 'Patients', 'Phenotype', 'Pregnancy Tests', 'Probability', 'Protein Analysis', 'Proteins', 'Publishing', 'Recruitment Activity', 'Resources', 'Retinal', 'Risk', 'Scanning Electron Microscopy', 'Series', 'Small Interfering RNA', 'Sonication', 'Structure', 'Syndrome', 'Techniques', 'Termination of pregnancy', 'Testing', 'Training', 'Transmission Electron Microscopy', 'Validation', 'Variant', 'WNT Signaling Pathway', 'Work', 'Zebrafish', 'affection', 'base', 'cilium biogenesis', 'cohort', 'consanguineous family', 'disorder subtype', 'early childhood', 'exome sequencing', 'founder mutation', 'gene discovery', 'genome sequencing', 'genome-wide', 'knock-down', 'loss of function mutation', 'malformation', 'mutant', 'novel', 'oculomotor', 'population based', 'public health relevance', 'reconstruction', 'screening', 'unpublished works']",NINDS,"UNIVERSITY OF CALIFORNIA, SAN DIEGO",R01,2017,510012,0.26919350506848994
"Molecular Characterization of Joubert Syndrome Project Summary Congenital ataxia presents in early childhood with non-progressive hypotonia, gross motor, fine motor and cognitive delays. These disorders are distinct from the progressive ataxias because of the presence of congenital cerebellar malformations and because they are typically inherited recessively. Joubert Syndrome and Related Disorders (JSRD) constitute a major subset of these conditions, consisting of a cerebellar midline (vermis) malformation, a nearly pathognomonic Molar Tooth sign on brain Imaging (MTI) and co-existent oculomotor apraxia and episodic breathing dysrhythmias. In our published data, we have: 1] Identified ten unique genetic causes of JSRD (nearly half of the published causes), 2] Generated genotype-phenotype correlations involving cerebellar, retinal, renal, hepatic, digit, and cerebral manifestations. 3] Identified common founder mutations that allow for population-based screening. 4] Discovered that JSRD encoded proteins frequently localize to the cilium. 5] Identified ciliary transition zone (TZ) defects in cells with JSRD mutations. 6] Performed siRNA cell-based screens for defective ciliogenesis to prioritize candidate JSRD genes. 7] Generated and characterized multiple zebrafish, mouse and human cell culture models for JSRD. 8] Defined the concept of Ciliary localization model, in which one JSRD gene is required for ciliary localization of other JSRD proteins. In our unpublished data we have: 1] Recruited an additional 200 JSRD patients without molecular diagnosis. 2] Performed whole exome (WES) and whole genome sequencing (WGS) on an additional 100 JSRD families. 3] Identified an additional 12 novel likely JSRD candidate genes. 4] Generated IPSCs and cerebellar organoids from mutation-positive and negative families to aid in functional analysis and gene discovery using RNAseq. 5] Begun functional validation of the putative mutations. 6] Developed methods to interrogate ciliary structure in a high-throughput fashion with electron microscopy (EM). The goal of this competing renewal is to identify the remaining discoverable genes that lead to JSRD when lost, functionally validate mutations within the pathogenetic framework, and test the hypothesis that mutations in JSRD genes lead to collapse of the ciliary TZ. Because the majority of patients still have unknown cause of disease, this renewal aims to advance knowledge through molecular characterization of new genes, using newly evolving high-throughput techniques, integrated bioinformatics, and a unique resource of consanguineous families recruited world-wide. We further aim to validate these mutations in patient cells, within a mechanistic framework that JSRD genes are required for essential ciliary structural components during cerebellar development. Project Narrative Joubert syndrome is a genetically and phenotypically heterogeneous neurodevelopmental disorder unified by defects of the cellular primary cilium. This work will identify new genetic causes and dissect ciliary defects associated with genetic mutations.",Molecular Characterization of Joubert Syndrome,9239923,R01NS048453,"['Apraxias', 'Ataxia', 'Bioinformatics', 'Brain imaging', 'Breathing', 'Candidate Disease Gene', 'Cell Culture Techniques', 'Cells', 'Cerebellar malformation', 'Cerebellar vermis structure', 'Cerebrum', 'Cilia', 'Clinical', 'Clustered Regularly Interspaced Short Palindromic Repeats', 'Cognitive', 'Congenital cerebellar hypoplasia', 'Cultured Cells', 'Cytoplasmic Granules', 'DNA Sequence Alteration', 'Data', 'Databases', 'Defect', 'Development', 'Digit structure', 'Disease', 'Electron Microscopy', 'Electrons', 'Embryo', 'Enrollment', 'Face', 'Family', 'Gene Mutation', 'Genes', 'Genetic', 'Genetic screening method', 'Genotype', 'Goals', 'Gold', 'Hepatic', 'Human', 'Individual', 'Inherited', 'Joubert syndrome', 'Kidney', 'Knock-out', 'Knowledge', 'Lead', 'Length', 'Machine Learning', 'Mass Spectrum Analysis', 'Methods', 'Microscopic', 'Middle East', 'Modeling', 'Molar tooth', 'Molecular', 'Molecular Diagnosis', 'Morphogenesis', 'Morphology', 'Motor', 'Mus', 'Muscle hypotonia', 'Mutation', 'Neurodevelopmental Disorder', 'Organoids', 'Pathogenicity', 'Patients', 'Phenotype', 'Probability', 'Protein Analysis', 'Proteins', 'Publishing', 'Recruitment Activity', 'Resources', 'Retinal', 'Risk', 'Scanning Electron Microscopy', 'Series', 'Severities', 'Signal Transduction', 'Small Interfering RNA', 'Structure', 'Syndrome', 'Techniques', 'Termination of pregnancy', 'Testing', 'Three-dimensional analysis', 'Training', 'Transmission Electron Microscopy', 'Validation', 'Variant', 'Work', 'Zebrafish', 'accurate diagnosis', 'affection', 'base', 'cell type', 'cilium biogenesis', 'cohort', 'consanguineous family', 'disorder subtype', 'early childhood', 'exome', 'exome sequencing', 'fetal', 'founder mutation', 'gene discovery', 'genome sequencing', 'genome-wide', 'induced pluripotent stem cell', 'insight', 'knock-down', 'loss of function mutation', 'malformation', 'mutant', 'novel', 'oculomotor', 'population based', 'reconstruction', 'screening', 'stem cell biology', 'transcriptome sequencing', 'whole genome']",NINDS,ROCKEFELLER UNIVERSITY,R01,2016,557723,0.21695242775957127
"Computational evaluation of the causal role of somatic mutations in human aging Project Abstract Although genome instability has long been considered as one of the major causal factors of aging, little is known about the actual number of genome alterations per cell and their effects on aging organisms, most notably humans. In the research proposed here I will take a single cell approach to identify the most common types of somatic mutations, i.e., base substitutions, small INDELS, copy number variation, genome structural variation and retrotranspositions, in human B lymphocytes as a function of age. The overarching goal is then to estimate functional effects of these DNA mutations accumulated during human aging in this particular cell type, which will also serve as a model for studying somatic mutations and their consequences in other cell types. This could never be tested before, because it was never possible to analyze random somatic mutations in a tissue by sequencing bulk DNA from that tissue (mutations are low- abundant), I will achieve this goal by utilizing a new, single-cell, whole genome sequencing (SCWGS) protocol that we developed. In this project I will focus on human B lymphocytes from individuals varying in age from about 30 to over 100 years and determine the genome-wide frequency and location of the different types of mutations in multiple cells from each individual (Aim 1). Preliminary results already show a significant increase of both base substitution mutations and CNVs with age, with a substantial number of these mutations in B cell genomic regions that are potentially functional. Hence, in Aim 2 I will predict the actual functional effects of these potentially functional, age-related mutations using machine learning approaches and integrative network analysis. Finally, in Aim 3 I will empirically test these predictions as to whether the mutation loads observed affect B cell's ability of response to stimulus. Hence, to test the long-standing hypothesis of genome instability as a causal factor in aging ,I will determine age-related mutations in single cells at four levels: (1) number of mutations, mutation spectra and genome distribution in individual cells; (2) potential functional effects of individual mutations, i.e., non-synonymous mutations in exons and mutations in gene regulatory regions; (3) mutations collectively affecting the gene regulatory network; and (4) relationship between mutation load and B cell activation status. In summary, the results of the proposed project will, for the first time uncover possible direct functional effects of somatic mutations on cellular function. Project Narrative Genome instability is considered as one of the major factors of aging and age-related diseases. This research aims to study somatic DNA mutations in normal blood cells (B lymphocytes) of humans of different ages and evaluate the functional effect of these mutations. It will dramatically improve the knowledge of DNA mutations in aging and deepen the understanding of genome instability as a basic aging mechanism in human.",Computational evaluation of the causal role of somatic mutations in human aging,9785353,K99AG056656,"['3&apos', ' Untranslated Regions', '5&apos', ' Untranslated Regions', 'Affect', 'Age', 'Aging', 'B-Cell Activation', 'B-Lymphocytes', 'Binding Sites', 'Blood Cells', 'CRISPR/Cas technology', 'Cancer Etiology', 'Cell physiology', 'Cells', 'Centenarian', 'Code', 'Collecting Cell', 'Copy Number Polymorphism', 'DNA', 'DNA Damage', 'DNA Repair', 'DNA Replication Damage', 'DNA Sequence Alteration', 'DNA Transposable Elements', 'DNA amplification', 'Data', 'Defect', 'Deoxyribonuclease I', 'Disease', 'Elderly', 'Enhancers', 'Evaluation', 'Exons', 'Frequencies', 'Functional disorder', 'Genes', 'Genome', 'Genomic Instability', 'Genomic Segment', 'Goals', 'Human', 'Hypersensitivity', 'Immunization', 'Individual', 'Knowledge', 'Laboratories', 'Lead', 'Learning', 'Location', 'Locus Control Region', 'Machine Learning', 'Mentors', 'Methods', 'Mutation', 'Mutation Analysis', 'Mutation Spectra', 'Nucleic Acid Regulatory Sequences', 'Nucleotides', 'Organism', 'Pathway Analysis', 'Process', 'Proteins', 'Protocols documentation', 'RNA', 'RNA amplification', 'Regulator Genes', 'Research', 'Retrotransposition', 'Role', 'Site', 'Software Tools', 'Somatic Cell', 'Somatic Mutation', 'Source', 'Stimulus', 'Structure', 'Study models', 'Testing', 'Time', 'Tissues', 'Variant', 'age related', 'base', 'cell type', 'crosslink', 'dietary restriction', 'genome sequencing', 'genome-wide', 'improved', 'insertion/deletion mutation', 'nonsynonymous mutation', 'promoter', 'repair enzyme', 'repaired', 'response', 'single cell sequencing', 'single cell technology', 'theories', 'transcription factor', 'whole genome']",NIA,ALBERT EINSTEIN COLLEGE OF MEDICINE,K99,2019,135945,0.3210419255106178
"Computational evaluation of the causal role of somatic mutations in human aging Project Abstract Although genome instability has long been considered as one of the major causal factors of aging, little is known about the actual number of genome alterations per cell and their effects on aging organisms, most notably humans. In the research proposed here I will take a single cell approach to identify the most common types of somatic mutations, i.e., base substitutions, small INDELS, copy number variation, genome structural variation and retrotranspositions, in human B lymphocytes as a function of age. The overarching goal is then to estimate functional effects of these DNA mutations accumulated during human aging in this particular cell type, which will also serve as a model for studying somatic mutations and their consequences in other cell types. This could never be tested before, because it was never possible to analyze random somatic mutations in a tissue by sequencing bulk DNA from that tissue (mutations are low- abundant), I will achieve this goal by utilizing a new, single-cell, whole genome sequencing (SCWGS) protocol that we developed. In this project I will focus on human B lymphocytes from individuals varying in age from about 30 to over 100 years and determine the genome-wide frequency and location of the different types of mutations in multiple cells from each individual (Aim 1). Preliminary results already show a significant increase of both base substitution mutations and CNVs with age, with a substantial number of these mutations in B cell genomic regions that are potentially functional. Hence, in Aim 2 I will predict the actual functional effects of these potentially functional, age-related mutations using machine learning approaches and integrative network analysis. Finally, in Aim 3 I will empirically test these predictions as to whether the mutation loads observed affect B cell's ability of response to stimulus. Hence, to test the long-standing hypothesis of genome instability as a causal factor in aging ,I will determine age-related mutations in single cells at four levels: (1) number of mutations, mutation spectra and genome distribution in individual cells; (2) potential functional effects of individual mutations, i.e., non-synonymous mutations in exons and mutations in gene regulatory regions; (3) mutations collectively affecting the gene regulatory network; and (4) relationship between mutation load and B cell activation status. In summary, the results of the proposed project will, for the first time uncover possible direct functional effects of somatic mutations on cellular function. Project Narrative Genome instability is considered as one of the major factors of aging and age-related diseases. This research aims to study somatic DNA mutations in normal blood cells (B lymphocytes) of humans of different ages and evaluate the functional effect of these mutations. It will dramatically improve the knowledge of DNA mutations in aging and deepen the understanding of genome instability as a basic aging mechanism in human.",Computational evaluation of the causal role of somatic mutations in human aging,9527264,K99AG056656,"['3&apos', ' Untranslated Regions', '5&apos', ' Untranslated Regions', 'Affect', 'Age', 'Aging', 'B-Cell Activation', 'B-Lymphocytes', 'Binding Sites', 'Blood Cells', 'CRISPR/Cas technology', 'Cancer Etiology', 'Cell Count', 'Cell physiology', 'Cells', 'Centenarian', 'Code', 'Collecting Cell', 'Copy Number Polymorphism', 'DNA', 'DNA Damage', 'DNA Repair', 'DNA Replication Damage', 'DNA Sequence Alteration', 'DNA Transposable Elements', 'DNA amplification', 'Data', 'Defect', 'Deoxyribonuclease I', 'Disease', 'Elderly', 'Enhancers', 'Evaluation', 'Exons', 'Frequencies', 'Functional disorder', 'Genes', 'Genome', 'Genomic Instability', 'Genomic Segment', 'Goals', 'Human', 'Hypersensitivity', 'Immunization', 'Individual', 'Knowledge', 'Laboratories', 'Lead', 'Learning', 'Location', 'Locus Control Region', 'Machine Learning', 'Mentors', 'Methods', 'Mutation', 'Mutation Analysis', 'Mutation Spectra', 'Nucleic Acid Regulatory Sequences', 'Nucleotides', 'Organism', 'Pathway Analysis', 'Process', 'Proteins', 'Protocols documentation', 'RNA', 'RNA amplification', 'Regulator Genes', 'Research', 'Retrotransposition', 'Role', 'Site', 'Software Tools', 'Somatic Cell', 'Somatic Mutation', 'Source', 'Stimulus', 'Study models', 'Testing', 'Time', 'Tissues', 'Variant', 'age related', 'base', 'cell type', 'crosslink', 'dietary restriction', 'genome sequencing', 'genome-wide', 'improved', 'insertion/deletion mutation', 'promoter', 'repair enzyme', 'repaired', 'response', 'single cell sequencing', 'single cell technology', 'theories', 'transcription factor', 'whole genome']",NIA,"ALBERT EINSTEIN COLLEGE OF MEDICINE, INC",K99,2018,40760,0.3210419255106178
"ADPKD: Disease Spectrum & Genotype-Phenotype Correlations Autosomal dominant polycystic kidney disease (ADPKD) is a common monoallelic disorder associated with progressive cyst development and resulting in end stage renal failure (ESRD) in 50% of patients by 60y. However, there is considerable phenotypic variability, extending from in utero onset to patients with adequate renal function into old age. Autosomal dominant polycystic liver disease (ADPLD), as traditionally defined, results in PLD with minimal renal cysts. Classically there have been considered two ADPKD genes, PKD1 and PKD2, encoding PC1 and PC2, and two ADPLD genes, PRKCSH and SEC63, but in the past few years greater genetic heterogeneity has been described, with nine genes now implicated overall. Recent data also indicates an overlap in etiology and pathogenesis associated with ADPKD and ADPLD, with the efficient biogenesis and localization of the PC-complex central to both disorders. During the last funding period we identified a novel gene, GANAB, which is associated with both disorders, where the encoded protein, GII is involved in the maturation and trafficking of PC1.  In this proposal we will take advantage of advances in next generation sequencing (NGS) methodologies, and large populations of ADPKD and ADPLD patients that have been assembled and screened for the classic genes, to hunt for novel genes for these disorders (Aim 1). The phenotype associated with these genes will be characterized (Aim 3) along with their mechanism of action (Aim 2). NGS methods will be perfected to screen the segmentally duplicated locus, PKD1, and to identify missed mutations at the known loci, including those present in just some cells due to mosaicism (Aim 1). The significance of many PKD1 nontruncating variants has been difficult to evaluate (classed as variants of unknown significance; VUS), but recently evidence that some are incompletely penetrant alleles partially explains phenotypic variability in PKD1 populations. In Aim 2 improved in silico predictions, in combination with machine learning, will improve the understanding of the pathogenicity and penetrance of VUS. A cellular assay of the biogenesis and trafficking of this PC-complex will also be employed to quantify the penetrance of VUS. The mechanism of pathogenesis will be explored in animal models with ultralow penetrant (ULP) Pkd1 or Pkd2 alleles. Employing the large clinically, imaging, and genetically well-defined populations phenotypic groupings of patients will be defined that will then be compared to the genic and PKD1 allelic groups (Aim 3). This iterative process will allow the Variant Score (VS) associated with each PKD1 VUS to be refined. In a separate population the revised VS, alone and in combination with clinical, functional, and imaging data, will be employed to generate a comprehensive, predictive algorithm for ADPKD (Aim 3). Disease modifiers to severe disease, via biallelic ADPKD, and due to alleles at other loci will also be identified and characterized in the cellular assay and in vivo in combination with the Pkd1 hypomorphic, RC model. The final aim will exploit the newly identified information that some PKD1 and PKD2 VUS are rescuable, folding mutations that in a maturation-fostering environment can traffic and function appropriately. A screening scheme based on the level of cell surface PC1 will be improved and new chaperone drugs specific for the PC complex will be sought in collaboration with Sanford Burnham Prebys. A second mutation group that will be explored therapeutically are nonsense mutations. A cellular assay for readthrough efficiency is being developed and will be used for screening. Identified chaperone or readthrough drugs will be tested in available mouse models. Overall this proposal will better explain the etiology and the genetic causes of phenotypic variability in ADPKD/ADPLD, develop better prognostic tools for individual selection of patients for treatment that are now becoming available, and explore allele based treatments for ADPKD. ADPKD and ADPLD are genetic diseases associated with cyst development and loss of function in the kidney and liver cysts, where the disease severity varies greatly between patients. Here we will identify new genes that cause these disorders and evaluate mutations in silico, in a cellular assay, and in whole animals to better predict the disease course in each patient. Treatment options associated with the type of individual patient mutations will also be explored, bringing individualized medicine to these diseases.",ADPKD: Disease Spectrum & Genotype-Phenotype Correlations,10148997,R01DK058816,"['Age', 'Alleles', 'Animal Model', 'Animals', 'Autosomal Dominant Polycystic Kidney', 'Biochemical', 'Biogenesis', 'Biological', 'Budgets', 'Cell surface', 'Cells', 'Cellular Assay', 'Clinical', 'Collaborations', 'Complex', 'Cyst', 'Cystic kidney', 'Data', 'Defect', 'Development', 'Diagnostic', 'Disease', 'End stage renal failure', 'Environment', 'Etiology', 'Event', 'Family', 'Fostering', 'Functional Imaging', 'Funding', 'Genes', 'Genetic', 'Genetic Diseases', 'Genetic Heterogeneity', 'Genotype', 'Germ-Line Mutation', 'Goals', 'Grouping', 'Hepatic', 'Hepatic Cyst', 'Image', 'Individual', 'Kidney', 'Knowledge', 'Machine Learning', 'Methodology', 'Methods', 'Modeling', 'Molecular Chaperones', 'Mosaicism', 'Mutation', 'Nonsense Mutation', 'Other Genetics', 'PRKCSH protein', 'Pathogenesis', 'Pathogenicity', 'Patient Selection', 'Patients', 'Penetrance', 'Pharmaceutical Preparations', 'Phenotype', 'Population', 'Process', 'Proprotein Convertase 1', 'Proprotein Convertase 2', 'Proteins', 'Renal function', 'Role', 'Scheme', 'Severities', 'Severity of illness', 'Signal Transduction', 'Testing', 'Therapeutic', 'Variant', 'base', 'disease phenotype', 'dosage', 'early onset', 'exome sequencing', 'improved', 'in silico', 'in utero', 'in vitro Assay', 'in vivo', 'individual patient', 'individualized medicine', 'insight', 'large datasets', 'loss of function', 'molecular diagnostics', 'mouse model', 'mutant', 'mutation screening', 'next generation sequencing', 'novel', 'polycystic liver disease', 'prediction algorithm', 'prognostic', 'prognostic tool', 'protein folding', 'screening', 'therapy development', 'trafficking', 'variant of unknown significance']",NIDDK,MAYO CLINIC ROCHESTER,R01,2020,15035,0.14854288641414423
"ADPKD: Disease Spectrum & Genotype-Phenotype Correlations Autosomal dominant polycystic kidney disease (ADPKD) is a common monoallelic disorder associated with progressive cyst development and resulting in end stage renal failure (ESRD) in 50% of patients by 60y. However, there is considerable phenotypic variability, extending from in utero onset to patients with adequate renal function into old age. Autosomal dominant polycystic liver disease (ADPLD), as traditionally defined, results in PLD with minimal renal cysts. Classically there have been considered two ADPKD genes, PKD1 and PKD2, encoding PC1 and PC2, and two ADPLD genes, PRKCSH and SEC63, but in the past few years greater genetic heterogeneity has been described, with nine genes now implicated overall. Recent data also indicates an overlap in etiology and pathogenesis associated with ADPKD and ADPLD, with the efficient biogenesis and localization of the PC-complex central to both disorders. During the last funding period we identified a novel gene, GANAB, which is associated with both disorders, where the encoded protein, GII is involved in the maturation and trafficking of PC1.  In this proposal we will take advantage of advances in next generation sequencing (NGS) methodologies, and large populations of ADPKD and ADPLD patients that have been assembled and screened for the classic genes, to hunt for novel genes for these disorders (Aim 1). The phenotype associated with these genes will be characterized (Aim 3) along with their mechanism of action (Aim 2). NGS methods will be perfected to screen the segmentally duplicated locus, PKD1, and to identify missed mutations at the known loci, including those present in just some cells due to mosaicism (Aim 1). The significance of many PKD1 nontruncating variants has been difficult to evaluate (classed as variants of unknown significance; VUS), but recently evidence that some are incompletely penetrant alleles partially explains phenotypic variability in PKD1 populations. In Aim 2 improved in silico predictions, in combination with machine learning, will improve the understanding of the pathogenicity and penetrance of VUS. A cellular assay of the biogenesis and trafficking of this PC-complex will also be employed to quantify the penetrance of VUS. The mechanism of pathogenesis will be explored in animal models with ultralow penetrant (ULP) Pkd1 or Pkd2 alleles. Employing the large clinically, imaging, and genetically well-defined populations phenotypic groupings of patients will be defined that will then be compared to the genic and PKD1 allelic groups (Aim 3). This iterative process will allow the Variant Score (VS) associated with each PKD1 VUS to be refined. In a separate population the revised VS, alone and in combination with clinical, functional, and imaging data, will be employed to generate a comprehensive, predictive algorithm for ADPKD (Aim 3). Disease modifiers to severe disease, via biallelic ADPKD, and due to alleles at other loci will also be identified and characterized in the cellular assay and in vivo in combination with the Pkd1 hypomorphic, RC model. The final aim will exploit the newly identified information that some PKD1 and PKD2 VUS are rescuable, folding mutations that in a maturation-fostering environment can traffic and function appropriately. A screening scheme based on the level of cell surface PC1 will be improved and new chaperone drugs specific for the PC complex will be sought in collaboration with Sanford Burnham Prebys. A second mutation group that will be explored therapeutically are nonsense mutations. A cellular assay for readthrough efficiency is being developed and will be used for screening. Identified chaperone or readthrough drugs will be tested in available mouse models. Overall this proposal will better explain the etiology and the genetic causes of phenotypic variability in ADPKD/ADPLD, develop better prognostic tools for individual selection of patients for treatment that are now becoming available, and explore allele based treatments for ADPKD. ADPKD and ADPLD are genetic diseases associated with cyst development and loss of function in the kidney and liver cysts, where the disease severity varies greatly between patients. Here we will identify new genes that cause these disorders and evaluate mutations in silico, in a cellular assay, and in whole animals to better predict the disease course in each patient. Treatment options associated with the type of individual patient mutations will also be explored, bringing individualized medicine to these diseases.",ADPKD: Disease Spectrum & Genotype-Phenotype Correlations,9976498,R01DK058816,"['Age', 'Alleles', 'Animal Model', 'Animals', 'Autosomal Dominant Polycystic Kidney', 'Biochemical', 'Biogenesis', 'Biological', 'Budgets', 'Cell surface', 'Cells', 'Cellular Assay', 'Clinical', 'Collaborations', 'Complex', 'Cyst', 'Cystic kidney', 'Data', 'Defect', 'Development', 'Diagnostic', 'Disease', 'End stage renal failure', 'Environment', 'Etiology', 'Event', 'Family', 'Fostering', 'Functional Imaging', 'Funding', 'Genes', 'Genetic', 'Genetic Diseases', 'Genetic Heterogeneity', 'Genotype', 'Germ-Line Mutation', 'Goals', 'Grouping', 'Hepatic', 'Hepatic Cyst', 'Image', 'Individual', 'Kidney', 'Knowledge', 'Machine Learning', 'Methodology', 'Methods', 'Modeling', 'Molecular Chaperones', 'Mosaicism', 'Mutation', 'Nonsense Mutation', 'Other Genetics', 'PRKCSH protein', 'Pathogenesis', 'Pathogenicity', 'Patient Selection', 'Patients', 'Penetrance', 'Pharmaceutical Preparations', 'Phenotype', 'Population', 'Process', 'Proprotein Convertase 1', 'Proprotein Convertase 2', 'Proteins', 'Renal function', 'Role', 'Scheme', 'Severities', 'Severity of illness', 'Signal Transduction', 'Testing', 'Therapeutic', 'Variant', 'base', 'disease phenotype', 'dosage', 'early onset', 'exome sequencing', 'improved', 'in silico', 'in utero', 'in vitro Assay', 'in vivo', 'individual patient', 'individualized medicine', 'insight', 'large datasets', 'loss of function', 'molecular diagnostics', 'mouse model', 'mutant', 'mutation screening', 'next generation sequencing', 'novel', 'polycystic liver disease', 'prediction algorithm', 'prognostic', 'prognostic tool', 'protein folding', 'screening', 'therapy development', 'trafficking', 'variant of unknown significance']",NIDDK,MAYO CLINIC ROCHESTER,R01,2020,510292,0.14854288641414423
"ADPKD: Disease Spectrum & Genotype-Phenotype Correlations Autosomal dominant polycystic kidney disease (ADPKD) is a common monoallelic disorder associated with progressive cyst development and resulting in end stage renal failure (ESRD) in 50% of patients by 60y. However, there is considerable phenotypic variability, extending from in utero onset to patients with adequate renal function into old age. Autosomal dominant polycystic liver disease (ADPLD), as traditionally defined, results in PLD with minimal renal cysts. Classically there have been considered two ADPKD genes, PKD1 and PKD2, encoding PC1 and PC2, and two ADPLD genes, PRKCSH and SEC63, but in the past few years greater genetic heterogeneity has been described, with nine genes now implicated overall. Recent data also indicates an overlap in etiology and pathogenesis associated with ADPKD and ADPLD, with the efficient biogenesis and localization of the PC-complex central to both disorders. During the last funding period we identified a novel gene, GANAB, which is associated with both disorders, where the encoded protein, GII is involved in the maturation and trafficking of PC1.  In this proposal we will take advantage of advances in next generation sequencing (NGS) methodologies, and large populations of ADPKD and ADPLD patients that have been assembled and screened for the classic genes, to hunt for novel genes for these disorders (Aim 1). The phenotype associated with these genes will be characterized (Aim 3) along with their mechanism of action (Aim 2). NGS methods will be perfected to screen the segmentally duplicated locus, PKD1, and to identify missed mutations at the known loci, including those present in just some cells due to mosaicism (Aim 1). The significance of many PKD1 nontruncating variants has been difficult to evaluate (classed as variants of unknown significance; VUS), but recently evidence that some are incompletely penetrant alleles partially explains phenotypic variability in PKD1 populations. In Aim 2 improved in silico predictions, in combination with machine learning, will improve the understanding of the pathogenicity and penetrance of VUS. A cellular assay of the biogenesis and trafficking of this PC-complex will also be employed to quantify the penetrance of VUS. The mechanism of pathogenesis will be explored in animal models with ultralow penetrant (ULP) Pkd1 or Pkd2 alleles. Employing the large clinically, imaging, and genetically well-defined populations phenotypic groupings of patients will be defined that will then be compared to the genic and PKD1 allelic groups (Aim 3). This iterative process will allow the Variant Score (VS) associated with each PKD1 VUS to be refined. In a separate population the revised VS, alone and in combination with clinical, functional, and imaging data, will be employed to generate a comprehensive, predictive algorithm for ADPKD (Aim 3). Disease modifiers to severe disease, via biallelic ADPKD, and due to alleles at other loci will also be identified and characterized in the cellular assay and in vivo in combination with the Pkd1 hypomorphic, RC model. The final aim will exploit the newly identified information that some PKD1 and PKD2 VUS are rescuable, folding mutations that in a maturation-fostering environment can traffic and function appropriately. A screening scheme based on the level of cell surface PC1 will be improved and new chaperone drugs specific for the PC complex will be sought in collaboration with Sanford Burnham Prebys. A second mutation group that will be explored therapeutically are nonsense mutations. A cellular assay for readthrough efficiency is being developed and will be used for screening. Identified chaperone or readthrough drugs will be tested in available mouse models. Overall this proposal will better explain the etiology and the genetic causes of phenotypic variability in ADPKD/ADPLD, develop better prognostic tools for individual selection of patients for treatment that are now becoming available, and explore allele based treatments for ADPKD. ADPKD and ADPLD are genetic diseases associated with cyst development and loss of function in the kidney and liver cysts, where the disease severity varies greatly between patients. Here we will identify new genes that cause these disorders and evaluate mutations in silico, in a cellular assay, and in whole animals to better predict the disease course in each patient. Treatment options associated with the type of individual patient mutations will also be explored, bringing individualized medicine to these diseases.",ADPKD: Disease Spectrum & Genotype-Phenotype Correlations,9778816,R01DK058816,"['Age', 'Alleles', 'Animal Model', 'Animals', 'Autosomal Dominant Polycystic Kidney', 'Biochemical', 'Biogenesis', 'Biological', 'Budgets', 'Cell surface', 'Cells', 'Cellular Assay', 'Clinical', 'Collaborations', 'Complex', 'Computer Simulation', 'Cyst', 'Cystic kidney', 'Data', 'Data Set', 'Defect', 'Development', 'Diagnostic', 'Disease', 'End stage renal failure', 'Environment', 'Etiology', 'Event', 'Family', 'Fostering', 'Functional Imaging', 'Funding', 'Genes', 'Genetic', 'Genetic Diseases', 'Genetic Heterogeneity', 'Genotype', 'Germ-Line Mutation', 'Goals', 'Grouping', 'Hepatic', 'Hepatic Cyst', 'Image', 'Individual', 'Kidney', 'Knowledge', 'Machine Learning', 'Methodology', 'Methods', 'Modeling', 'Molecular Chaperones', 'Mosaicism', 'Mutation', 'Nonsense Mutation', 'Other Genetics', 'PRKCSH protein', 'Pathogenesis', 'Pathogenicity', 'Patient Selection', 'Patients', 'Penetrance', 'Pharmaceutical Preparations', 'Phenotype', 'Population', 'Process', 'Proprotein Convertase 1', 'Proprotein Convertase 2', 'Proteins', 'Renal function', 'Role', 'Scheme', 'Severities', 'Severity of illness', 'Signal Transduction', 'Testing', 'Therapeutic', 'Variant', 'base', 'disease phenotype', 'dosage', 'early onset', 'exome sequencing', 'improved', 'in utero', 'in vitro Assay', 'in vivo', 'individual patient', 'individualized medicine', 'insight', 'loss of function', 'molecular diagnostics', 'mouse model', 'mutant', 'mutation screening', 'next generation sequencing', 'novel', 'polycystic liver disease', 'prediction algorithm', 'prognostic', 'prognostic tool', 'protein folding', 'screening', 'therapy development', 'trafficking', 'variant of unknown significance']",NIDDK,MAYO CLINIC ROCHESTER,R01,2019,510292,0.14854288641414423
"ADPKD: Disease Spectrum & Genotype-Phenotype Correlations Autosomal dominant polycystic kidney disease (ADPKD) is a common monoallelic disorder associated with progressive cyst development and resulting in end stage renal failure (ESRD) in 50% of patients by 60y. However, there is considerable phenotypic variability, extending from in utero onset to patients with adequate renal function into old age. Autosomal dominant polycystic liver disease (ADPLD), as traditionally defined, results in PLD with minimal renal cysts. Classically there have been considered two ADPKD genes, PKD1 and PKD2, encoding PC1 and PC2, and two ADPLD genes, PRKCSH and SEC63, but in the past few years greater genetic heterogeneity has been described, with nine genes now implicated overall. Recent data also indicates an overlap in etiology and pathogenesis associated with ADPKD and ADPLD, with the efficient biogenesis and localization of the PC-complex central to both disorders. During the last funding period we identified a novel gene, GANAB, which is associated with both disorders, where the encoded protein, GII is involved in the maturation and trafficking of PC1.  In this proposal we will take advantage of advances in next generation sequencing (NGS) methodologies, and large populations of ADPKD and ADPLD patients that have been assembled and screened for the classic genes, to hunt for novel genes for these disorders (Aim 1). The phenotype associated with these genes will be characterized (Aim 3) along with their mechanism of action (Aim 2). NGS methods will be perfected to screen the segmentally duplicated locus, PKD1, and to identify missed mutations at the known loci, including those present in just some cells due to mosaicism (Aim 1). The significance of many PKD1 nontruncating variants has been difficult to evaluate (classed as variants of unknown significance; VUS), but recently evidence that some are incompletely penetrant alleles partially explains phenotypic variability in PKD1 populations. In Aim 2 improved in silico predictions, in combination with machine learning, will improve the understanding of the pathogenicity and penetrance of VUS. A cellular assay of the biogenesis and trafficking of this PC-complex will also be employed to quantify the penetrance of VUS. The mechanism of pathogenesis will be explored in animal models with ultralow penetrant (ULP) Pkd1 or Pkd2 alleles. Employing the large clinically, imaging, and genetically well-defined populations phenotypic groupings of patients will be defined that will then be compared to the genic and PKD1 allelic groups (Aim 3). This iterative process will allow the Variant Score (VS) associated with each PKD1 VUS to be refined. In a separate population the revised VS, alone and in combination with clinical, functional, and imaging data, will be employed to generate a comprehensive, predictive algorithm for ADPKD (Aim 3). Disease modifiers to severe disease, via biallelic ADPKD, and due to alleles at other loci will also be identified and characterized in the cellular assay and in vivo in combination with the Pkd1 hypomorphic, RC model. The final aim will exploit the newly identified information that some PKD1 and PKD2 VUS are rescuable, folding mutations that in a maturation-fostering environment can traffic and function appropriately. A screening scheme based on the level of cell surface PC1 will be improved and new chaperone drugs specific for the PC complex will be sought in collaboration with Sanford Burnham Prebys. A second mutation group that will be explored therapeutically are nonsense mutations. A cellular assay for readthrough efficiency is being developed and will be used for screening. Identified chaperone or readthrough drugs will be tested in available mouse models. Overall this proposal will better explain the etiology and the genetic causes of phenotypic variability in ADPKD/ADPLD, develop better prognostic tools for individual selection of patients for treatment that are now becoming available, and explore allele based treatments for ADPKD. ADPKD and ADPLD are genetic diseases associated with cyst development and loss of function in the kidney and liver cysts, where the disease severity varies greatly between patients. Here we will identify new genes that cause these disorders and evaluate mutations in silico, in a cellular assay, and in whole animals to better predict the disease course in each patient. Treatment options associated with the type of individual patient mutations will also be explored, bringing individualized medicine to these diseases.",ADPKD: Disease Spectrum & Genotype-Phenotype Correlations,9522439,R01DK058816,"['Age', 'Alleles', 'Animal Model', 'Animals', 'Autosomal Dominant Polycystic Kidney', 'Biochemical', 'Biogenesis', 'Biological', 'Budgets', 'Cell surface', 'Cells', 'Cellular Assay', 'Clinical', 'Collaborations', 'Complex', 'Computer Simulation', 'Cyst', 'Cystic kidney', 'Data', 'Data Set', 'Defect', 'Development', 'Diagnostic', 'Disease', 'End stage renal failure', 'Environment', 'Etiology', 'Event', 'Family', 'Fostering', 'Functional Imaging', 'Funding', 'Genes', 'Genetic', 'Genetic Diseases', 'Genetic Heterogeneity', 'Genotype', 'Germ-Line Mutation', 'Goals', 'Grouping', 'Hepatic', 'Hepatic Cyst', 'Image', 'Individual', 'Kidney', 'Knowledge', 'Machine Learning', 'Methodology', 'Methods', 'Modeling', 'Molecular Chaperones', 'Mosaicism', 'Mutation', 'Nonsense Mutation', 'Other Genetics', 'PRKCSH protein', 'Pathogenesis', 'Pathogenicity', 'Patient Selection', 'Patients', 'Penetrance', 'Pharmaceutical Preparations', 'Phenotype', 'Population', 'Process', 'Proprotein Convertase 1', 'Proprotein Convertase 2', 'Proteins', 'Renal function', 'Role', 'Scheme', 'Severities', 'Severity of illness', 'Signal Transduction', 'Testing', 'Therapeutic', 'Variant', 'base', 'disease phenotype', 'dosage', 'early onset', 'exome sequencing', 'improved', 'in utero', 'in vitro Assay', 'in vivo', 'individual patient', 'individualized medicine', 'insight', 'loss of function', 'molecular diagnostics', 'mouse model', 'mutant', 'mutation screening', 'next generation sequencing', 'novel', 'polycystic liver disease', 'prediction algorithm', 'prognostic', 'prognostic tool', 'protein folding', 'screening', 'therapy development', 'trafficking', 'variant of unknown significance']",NIDDK,MAYO CLINIC ROCHESTER,R01,2018,510292,0.14854288641414423
"Blood mitochondrial DNA biomarkers of midlife cognitive decline and adverse brain imaging changes - A longitudinal investigation in the CARDIA populationbased cohort study SUMMARY Alzheimers disease and related dementias (ADRDs) are typically the result of neurodegenerative processes that begin 15-20 years before clinical diagnosis. Despite this lengthy subclinical phase and advances in early diagnostic technologies including cerebrospinal fluid (CSF) biomarkers, brain MRIs, and positron emission tomography (PET) measures there are no scalable biomarkers to identify individuals with preclinical disease, which may offer the best time window for intervention. Specifically, because brain MRI and PET tests are resource-intensive and CSF sampling is invasive, there is urgent need for biomarkers based on blood samples, which can be non-invasively collected even in centers lacking highly specialized technology. The mitochondrial genome (mtDNA), unlike the stable nuclear genome, is dynamic and accumulates somatic mutations over the lifespan. Mutations in the mtDNA can be induced by oxidative stress and lead to declining mitochondrial function as we age; in turn, less functional mitochondria generate higher levels of oxidative stress, which induces chronic inflammation and tissue injury in specific organs including the brain. Yet, no study has investigated mtDNA mutations as early predictors of ADRD. We hypothesize that individuals with higher levels and faster accumulation of blood mtDNA mutations have greater cognitive decline and preclinical ADRD brain imaging changes during midlife, and that these mtDNA biomarkers will predict ADRD diagnosis in older adults. We will test our hypotheses by leveraging the NHLBI-funded Coronary Artery Risk Development In young Adults (CARDIA) study. CARDIA is a multicenter, community-based, longitudinal cohort that recruited 5,115 black and white young adults (mean age 25 years), followed them up at least every five years, and is preparing to conduct its examination Year 35 (Y35) visit in 2020/21 (mean age 60 years) when over 3,000 participants are expected to return. We will use state-of-the-art deep sequencing technology to measure mtDNA mutations in CARDIA blood samples collected at Y15, Y25, and Y35. In Aim 1, we will determine whether higher levels of mtDNA mutations and their accumulation over time are associated with greater cognitive decline in midlife. In Aim 2, we will determine whether mtDNA mutations are associated with structural, physiological, and functional MRI phenotypes of preclinical ADRD as well as with sensitive MRI-based markers of accelerated brain aging and preclinical ADRD constructed by our team using contemporary machine learning techniques. Finally, in Aim 3, we will test the clinical utility of these mtDNA mutation biomarkers in identifying individuals at risk of future ADRD in four older cohorts that have large numbers of longitudinally identified, clinically-diagnosed ADRD. Our focus on longitudinal measures of blood mtDNA, cognitive function, and MRI changes over a 10- year period during midlife, combined with characterization of their clinical utility in older populations, is highly innovative. If successful, our study may help initiate possible future interventions in early midlife and reduce the public health and medical burden of AD and dementia. PUBLIC HEALTH STATEMENT This study has high potential for characterizing novel blood-based biomarkers to identify preclinical ADRD and test their utility in predicting clinical ADRD. No other study has a similar design with repeated blood mtDNA mutations, cognitive assessments, and brain imaging data during midlife, a critical time window for interventions to prevent clinical ADRD development. By also using data from four large cohorts of older adults, we can determine the clinical utility of these mtDNA biomarkers to predict clinical ADRD and move the field closer toward the NIHs goal of personalized health interventions.",Blood mitochondrial DNA biomarkers of midlife cognitive decline and adverse brain imaging changes - A longitudinal investigation in the CARDIA populationbased cohort study,10055446,R01AG069120,"['Address', 'Age', 'Aging', 'Alzheimer&apos', 's Disease', 'Alzheimer&apos', 's disease related dementia', 'Alzheimer&apos', 's disease risk', 'Biological Markers', 'Blood', 'Blood specimen', 'Brain', 'Brain imaging', 'Cerebrospinal Fluid', 'Chronic', 'Clinical', 'Clinical Markers', 'Cognitive', 'Cohort Studies', 'Communities', 'Coronary Artery Risk Development in Young Adults Study', 'Data', 'Development', 'Diagnosis', 'Diagnostic', 'Disease', 'Elderly', 'Environmental Risk Factor', 'Framingham Heart Study', 'Functional Magnetic Resonance Imaging', 'Funding', 'Future', 'Genome', 'Goals', 'Health', 'Impaired cognition', 'Individual', 'Inflammation', 'Intervention', 'Investigation', 'Lead', 'Link', 'Longevity', 'Longitudinal cohort', 'Machine Learning', 'Magnetic Resonance Imaging', 'Measures', 'Medical', 'Mitochondria', 'Mitochondrial DNA', 'Mutation', 'National Heart, Lung, and Blood Institute', 'Nerve Degeneration', 'Nuclear', 'Older Population', 'Organ', 'Oxidative Stress', 'Participant', 'Patients', 'Pattern', 'Phase', 'Phenotype', 'Physiological', 'Positron-Emission Tomography', 'Process', 'Public Health', 'Research', 'Research Design', 'Research Personnel', 'Resources', 'Risk', 'Role', 'Sampling', 'Solid', 'Somatic Mutation', 'Structure', 'Techniques', 'Technology', 'Testing', 'Time', 'Trans-Omics for Precision Medicine', 'United States National Institutes of Health', 'Visit', 'Work', 'age related', 'aged', 'aging brain', 'base', 'blood-based biomarker', 'cerebral atrophy', 'clinical Diagnosis', 'clinical predictors', 'clinical risk', 'cognitive function', 'cognitive testing', 'cohort', 'critical period', 'deep sequencing', 'dementia risk', 'design', 'epigenome', 'experience', 'follow-up', 'genome sequencing', 'innovation', 'insight', 'middle age', 'mitochondrial DNA mutation', 'mitochondrial genome', 'novel', 'population based', 'pre-clinical', 'predictive marker', 'prevent', 'programs', 'prospective', 'recruit', 'tissue injury', 'tool', 'whole genome', 'young adult']",NIA,COLUMBIA UNIVERSITY HEALTH SCIENCES,R01,2020,852784,0.09315648122494152
"Computational Methods for Fine Mapping    DESCRIPTION (provided by applicant): We propose to continue work on the use of computationally intensive methods to fine-map genes involved in complex traits. This work was previously supported under our grant ""'Computational methods in genetic epidemiology"" (GM58897, PI: D. Thomas). The present incarnation is a more focused version of this earlier grant. Our particular emphasis is on methods that exploit the underlying genealogy (ancestry) of a sample of interest. The pattern of haplotype diversity, D, one sees in a sample of individuals is the result of a complex interaction between the unobserved genealogy, G, of the sample (which itself is a function of recombination) and the forces of mutation acting upon that genealogy. This is further influenced by the shared ancestry induced by the presence of the functional mutation(s) related to the trait of interest. This results in linkage disequilibrium in regions close to functional mutations. In principle, one wishes to explore the space of possible genealogies that might give rise to a particular data set and use this as a basis for an approach to mapping. Such an approach is likely to be impossible, or prohibitively expensive computationally.       We therefore propose to adopt the following two approximations to this desired goal:   - Genealogical methods in which we explicitly include the unobserved genealogy of the sample of interest, but use hybrid rejection/MCMC methods to avoid calculating P (DIG), (this quantity can only be calculated for a family of simplistic, unrealistic mutation models).   - Bayes methods, which abstract out the effects of the genealogy using hierarchical clustering   techniques.         n/a",Computational Methods for Fine Mapping,7278157,R01GM069890,"['Adopted', 'Bayesian Method', 'Chromosome Mapping', 'Complex', 'Computing Methodologies', 'Data Set', 'Family', 'Genealogy', 'Genetic Recombination', 'Goals', 'Grant', 'Haplotypes', 'Hybrids', 'Individual', 'Linkage Disequilibrium', 'Maps', 'Methods', 'Modeling', 'Mutation', 'Pattern', 'Sampling', 'Techniques', 'Work', 'abstracting', 'base', 'desire', 'genetic epidemiology', 'interest', 'trait']",NIGMS,UNIVERSITY OF SOUTHERN CALIFORNIA,R01,2007,467230,0.2108409810214905
"Computational Methods for Fine Mapping    DESCRIPTION (provided by applicant): We propose to continue work on the use of computationally intensive methods to fine-map genes involved in complex traits. This work was previously supported under our grant ""'Computational methods in genetic epidemiology"" (GM58897, PI: D. Thomas). The present incarnation is a more focused version of this earlier grant. Our particular emphasis is on methods that exploit the underlying genealogy (ancestry) of a sample of interest. The pattern of haplotype diversity, D, one sees in a sample of individuals is the result of a complex interaction between the unobserved genealogy, G, of the sample (which itself is a function of recombination) and the forces of mutation acting upon that genealogy. This is further influenced by the shared ancestry induced by the presence of the functional mutation(s) related to the trait of interest. This results in linkage disequilibrium in regions close to functional mutations. In principle, one wishes to explore the space of possible genealogies that might give rise to a particular data set and use this as a basis for an approach to mapping. Such an approach is likely to be impossible, or prohibitively expensive computationally.       We therefore propose to adopt the following two approximations to this desired goal:   - Genealogical methods in which we explicitly include the unobserved genealogy of the sample of interest, but use hybrid rejection/MCMC methods to avoid calculating P (DIG), (this quantity can only be calculated for a family of simplistic, unrealistic mutation models).   - Bayes methods, which abstract out the effects of the genealogy using hierarchical clustering   techniques.         n/a",Computational Methods for Fine Mapping,7103429,R01GM069890,"['bioinformatics', 'clinical research', 'computational biology', 'computer assisted sequence analysis', 'epidemiology', 'family genetics', 'genetic mapping', 'human data', 'human population genetics', 'method development', 'statistics /biometry']",NIGMS,UNIVERSITY OF SOUTHERN CALIFORNIA,R01,2006,503752,0.2108409810214905
"Computational Methods for Fine Mapping    DESCRIPTION (provided by applicant): We propose to continue work on the use of computationally intensive methods to fine-map genes involved in complex traits. This work was previously supported under our grant ""'Computational methods in genetic epidemiology"" (GM58897, PI: D. Thomas). The present incarnation is a more focused version of this earlier grant. Our particular emphasis is on methods that exploit the underlying genealogy (ancestry) of a sample of interest. The pattern of haplotype diversity, D, one sees in a sample of individuals is the result of a complex interaction between the unobserved genealogy, G, of the sample (which itself is a function of recombination) and the forces of mutation acting upon that genealogy. This is further influenced by the shared ancestry induced by the presence of the functional mutation(s) related to the trait of interest. This results in linkage disequilibrium in regions close to functional mutations. In principle, one wishes to explore the space of possible genealogies that might give rise to a particular data set and use this as a basis for an approach to mapping. Such an approach is likely to be impossible, or prohibitively expensive computationally.       We therefore propose to adopt the following two approximations to this desired goal:   - Genealogical methods in which we explicitly include the unobserved genealogy of the sample of interest, but use hybrid rejection/MCMC methods to avoid calculating P (DIG), (this quantity can only be calculated for a family of simplistic, unrealistic mutation models).   - Bayes methods, which abstract out the effects of the genealogy using hierarchical clustering   techniques.         n/a",Computational Methods for Fine Mapping,6938538,R01GM069890,"['bioinformatics', 'clinical research', 'computational biology', 'computer assisted sequence analysis', 'epidemiology', 'family genetics', 'genetic mapping', 'human data', 'human population genetics', 'method development', 'statistics /biometry']",NIGMS,UNIVERSITY OF SOUTHERN CALIFORNIA,R01,2005,468867,0.2108409810214905
"Computational Methods for Fine Mapping    DESCRIPTION (provided by applicant): We propose to continue work on the use of computationally intensive methods to fine-map genes involved in complex traits. This work was previously supported under our grant ""'Computational methods in genetic epidemiology"" (GM58897, PI: D. Thomas). The present incarnation is a more focused version of this earlier grant. Our particular emphasis is on methods that exploit the underlying genealogy (ancestry) of a sample of interest. The pattern of haplotype diversity, D, one sees in a sample of individuals is the result of a complex interaction between the unobserved genealogy, G, of the sample (which itself is a function of recombination) and the forces of mutation acting upon that genealogy. This is further influenced by the shared ancestry induced by the presence of the functional mutation(s) related to the trait of interest. This results in linkage disequilibrium in regions close to functional mutations. In principle, one wishes to explore the space of possible genealogies that might give rise to a particular data set and use this as a basis for an approach to mapping. Such an approach is likely to be impossible, or prohibitively expensive computationally.       We therefore propose to adopt the following two approximations to this desired goal:   - Genealogical methods in which we explicitly include the unobserved genealogy of the sample of interest, but use hybrid rejection/MCMC methods to avoid calculating P (DIG), (this quantity can only be calculated for a family of simplistic, unrealistic mutation models).   - Bayes methods, which abstract out the effects of the genealogy using hierarchical clustering   techniques.         n/a",Computational Methods for Fine Mapping,6821190,R01GM069890,"['bioinformatics', 'clinical research', 'computational biology', 'computer assisted sequence analysis', 'epidemiology', 'family genetics', 'genetic mapping', 'human data', 'human population genetics', 'method development', 'statistics /biometry']",NIGMS,UNIVERSITY OF SOUTHERN CALIFORNIA,R01,2004,487500,0.2108409810214905
"Novel Inhibitors to DHPS to Probe Catalytic Mechanism & Therapeutic Potential    DESCRIPTION (provided by applicant): Folate biosynthesis is an essential bacterial pathway that is absent in higher animals, and it has been an effective target of antibacterial agents for over 70 years. The sulfonamide drugs inhibit a key enzyme in the pathway, dihydropteroate synthase (DHPS), by acting as non-productive substrate analogs of paminobenzoic acid (pABA). However, the flexible pABA binding site is structurally susceptible to resistance mutations, and the sulfonamides are rapidly becoming therapeutically ineffective. In contrast, the binding site of the second DHPS substrate, pterin-pyrophosphate, is buried in a conserved pocket that is less likely to tolerate mutations. We propose to generate new classes of potent DHPS inhibitors that specifically engage this pocket. These inhibitors have the potential of being developed into novel therapeutic agents that still target folate synthesis but which avoid the problems of resistance. To generate effective inhibitors of any enzyme, it is crucial to understand the structure and mechanism of its active site. This information is largely absent for DHPS, and understanding how DHPS performs catalysis at the molecular level will be a central goal of the application.      This comprehensive project will encompass biochemistry, structural biology, medicinal chemistry, computational biology, and microbiology, and will be performed in two laboratories at neighboring institutions in Memphis. The central focus of the project is the design and synthesis of novel small molecules that can be used to probe the DHPS mechanism and also be evaluated as DHPS inhibitors. Promising inhibitor scaffolds will then be tested for their potential as anti-microbials by direct screening of select organisms. The more potent inhibitors will be used to create derivative libraries for further screening and evaluation. The use of state-of-the-art drug discovery software, library synthesis, high-throughput screening and X-ray crystallography are central features of the research. Our goal is to provide a solid platform for the development of new, desperately-needed, broad-spectrum anti-infectives agents. However, we are also focused on developing specific therapies for the category A biowarfare agents B. anthracis, Y. pestis and F. tularensis, as well as for pathogenic protozoa and fungi.          n/a",Novel Inhibitors to DHPS to Probe Catalytic Mechanism & Therapeutic Potential,7617662,R01AI070721,"['4-Aminobenzoic Acid', 'Acids', 'Active Sites', 'Affinity', 'Amino Acids', 'Animals', 'Anti-Bacterial Agents', 'Anti-Infective Agents', 'Antibiotics', 'Arts', 'Bacillus anthracis', 'Binding', 'Binding Sites', 'Biochemistry', 'Biological Warfare', 'Candida albicans', 'Catalysis', 'Categories', 'Collaborations', 'Computational Biology', 'Computer software', 'Data', 'Development', 'Dihydropteroate Synthase', 'Diphosphates', 'Disease', 'Drug Design', 'Drug resistance', 'Enzymes', 'Escherichia coli', 'Evaluation', 'Folate', 'Folate Biosynthesis Pathway', 'Folic Acid Antagonists', 'Francisella tularensis', 'Funding', 'Genes', 'Genomics', 'Goals', 'Immunocompromised Host', 'Individual', 'Infection', 'Institution', 'Laboratories', 'Libraries', 'Ligands', 'Locales', 'Methods', 'Microbiology', 'Modeling', 'Molecular', 'Molecular Conformation', 'Mutation', 'Mycobacterium tuberculosis', 'Organism', 'Orthologous Gene', 'Pathway interactions', 'Pharmaceutical Chemistry', 'Pharmaceutical Preparations', 'Proteins', 'Protozoa', 'Protozoan Infections', 'Pseudomonas aeruginosa', 'Pterins', 'Quantitative Structure-Activity Relationship', 'Research', 'Research Personnel', 'Resistance', 'Role', 'Salmonella', 'Screening procedure', 'Serum', 'Site', 'Site-Directed Mutagenesis', 'Solid', 'Specificity', 'Staphylococcus aureus', 'Streptococcus pneumoniae', 'Structure', 'Sulfonamides', 'Techniques', 'Testing', 'Therapeutic', 'Therapeutic Agents', 'X-Ray Crystallography', 'Yersinia pestis', 'analog', 'antimicrobial', 'bacterial resistance', 'base', 'biodefense', 'chemical synthesis', 'cytotoxicity', 'design', 'dihydropteroate', 'drug discovery', 'enzyme mechanism', 'flexibility', 'fungus', 'high throughput screening', 'in vivo', 'inhibitor/antagonist', 'insight', 'interest', 'methicillin resistant Staphylococcus aureus', 'microorganism', 'molecular dynamics', 'novel', 'novel therapeutics', 'programs', 'resistance mutation', 'resistant strain', 'scaffold', 'small molecule', 'structural biology', 'text searching', 'virtual']",NIAID,ST. JUDE CHILDREN'S RESEARCH HOSPITAL,R01,2009,614066,0.08039194872558002
"Novel Inhibitors to DHPS to Probe Catalytic Mechanism & Therapeutic Potential    DESCRIPTION (provided by applicant): Folate biosynthesis is an essential bacterial pathway that is absent in higher animals, and it has been an effective target of antibacterial agents for over 70 years. The sulfonamide drugs inhibit a key enzyme in the pathway, dihydropteroate synthase (DHPS), by acting as non-productive substrate analogs of paminobenzoic acid (pABA). However, the flexible pABA binding site is structurally susceptible to resistance mutations, and the sulfonamides are rapidly becoming therapeutically ineffective. In contrast, the binding site of the second DHPS substrate, pterin-pyrophosphate, is buried in a conserved pocket that is less likely to tolerate mutations. We propose to generate new classes of potent DHPS inhibitors that specifically engage this pocket. These inhibitors have the potential of being developed into novel therapeutic agents that still target folate synthesis but which avoid the problems of resistance. To generate effective inhibitors of any enzyme, it is crucial to understand the structure and mechanism of its active site. This information is largely absent for DHPS, and understanding how DHPS performs catalysis at the molecular level will be a central goal of the application.      This comprehensive project will encompass biochemistry, structural biology, medicinal chemistry, computational biology, and microbiology, and will be performed in two laboratories at neighboring institutions in Memphis. The central focus of the project is the design and synthesis of novel small molecules that can be used to probe the DHPS mechanism and also be evaluated as DHPS inhibitors. Promising inhibitor scaffolds will then be tested for their potential as anti-microbials by direct screening of select organisms. The more potent inhibitors will be used to create derivative libraries for further screening and evaluation. The use of state-of-the-art drug discovery software, library synthesis, high-throughput screening and X-ray crystallography are central features of the research. Our goal is to provide a solid platform for the development of new, desperately-needed, broad-spectrum anti-infectives agents. However, we are also focused on developing specific therapies for the category A biowarfare agents B. anthracis, Y. pestis and F. tularensis, as well as for pathogenic protozoa and fungi.          n/a",Novel Inhibitors to DHPS to Probe Catalytic Mechanism & Therapeutic Potential,7422359,R01AI070721,"['4-Aminobenzoic Acid', 'Acids', 'Active Sites', 'Affinity', 'Amino Acids', 'Animals', 'Anti-Bacterial Agents', 'Anti-Infective Agents', 'Antibiotics', 'Arts', 'Bacillus anthracis', 'Binding', 'Binding Sites', 'Biochemistry', 'Biological Warfare', 'Candida albicans', 'Catalysis', 'Categories', 'Class', 'Collaborations', 'Computational Biology', 'Computer software', 'Data', 'Development', 'Dihydropteroate Synthase', 'Diphosphates', 'Disease', 'Drug Design', 'Drug resistance', 'Enzymes', 'Escherichia coli', 'Evaluation', 'Folate', 'Folate Biosynthesis Pathway', 'Folic Acid Antagonists', 'Francisella tularensis', 'Funding', 'Genes', 'Genomics', 'Goals', 'Immunocompromised Host', 'Individual', 'Infection', 'Institution', 'Laboratories', 'Libraries', 'Ligands', 'Locales', 'Methods', 'Microbiology', 'Modeling', 'Molecular', 'Molecular Conformation', 'Mutation', 'Mycobacterium tuberculosis', 'Numbers', 'Organism', 'Orthologous Gene', 'Pathway interactions', 'Pharmaceutical Chemistry', 'Pharmaceutical Preparations', 'Proteins', 'Protozoa', 'Protozoan Infections', 'Pseudomonas aeruginosa', 'Pterins', 'Quantitative Structure-Activity Relationship', 'Rate', 'Research', 'Research Personnel', 'Resistance', 'Role', 'Salmonella', 'Screening procedure', 'Serum', 'Site', 'Site-Directed Mutagenesis', 'Solid', 'Specificity', 'Staphylococcus aureus', 'Streptococcus pneumoniae', 'Structure', 'Sulfonamides', 'Techniques', 'Testing', 'Therapeutic', 'Therapeutic Agents', 'X-Ray Crystallography', 'Yersinia pestis', 'analog', 'antimicrobial', 'bacterial resistance', 'base', 'biodefense', 'chemical synthesis', 'cytotoxicity', 'design', 'dihydropteroate', 'drug discovery', 'enzyme mechanism', 'fungus', 'high throughput screening', 'in vivo', 'inhibitor/antagonist', 'insight', 'interest', 'mecarzole', 'methicillin resistant Staphylococcus aureus', 'microorganism', 'molecular dynamics', 'novel', 'novel therapeutics', 'programs', 'scaffold', 'small molecule', 'structural biology', 'text searching', 'virtual']",NIAID,ST. JUDE CHILDREN'S RESEARCH HOSPITAL,R01,2008,598667,0.08039194872558002
"Novel Inhibitors to DHPS to Probe Catalytic Mechanism & Therapeutic Potential    DESCRIPTION (provided by applicant): Folate biosynthesis is an essential bacterial pathway that is absent in higher animals, and it has been an effective target of antibacterial agents for over 70 years. The sulfonamide drugs inhibit a key enzyme in the pathway, dihydropteroate synthase (DHPS), by acting as non-productive substrate analogs of paminobenzoic acid (pABA). However, the flexible pABA binding site is structurally susceptible to resistance mutations, and the sulfonamides are rapidly becoming therapeutically ineffective. In contrast, the binding site of the second DHPS substrate, pterin-pyrophosphate, is buried in a conserved pocket that is less likely to tolerate mutations. We propose to generate new classes of potent DHPS inhibitors that specifically engage this pocket. These inhibitors have the potential of being developed into novel therapeutic agents that still target folate synthesis but which avoid the problems of resistance. To generate effective inhibitors of any enzyme, it is crucial to understand the structure and mechanism of its active site. This information is largely absent for DHPS, and understanding how DHPS performs catalysis at the molecular level will be a central goal of the application.      This comprehensive project will encompass biochemistry, structural biology, medicinal chemistry, computational biology, and microbiology, and will be performed in two laboratories at neighboring institutions in Memphis. The central focus of the project is the design and synthesis of novel small molecules that can be used to probe the DHPS mechanism and also be evaluated as DHPS inhibitors. Promising inhibitor scaffolds will then be tested for their potential as anti-microbials by direct screening of select organisms. The more potent inhibitors will be used to create derivative libraries for further screening and evaluation. The use of state-of-the-art drug discovery software, library synthesis, high-throughput screening and X-ray crystallography are central features of the research. Our goal is to provide a solid platform for the development of new, desperately-needed, broad-spectrum anti-infectives agents. However, we are also focused on developing specific therapies for the category A biowarfare agents B. anthracis, Y. pestis and F. tularensis, as well as for pathogenic protozoa and fungi.          n/a",Novel Inhibitors to DHPS to Probe Catalytic Mechanism & Therapeutic Potential,7848340,R01AI070721,"['4-Aminobenzoic Acid', 'Acids', 'Active Sites', 'Affinity', 'Amino Acids', 'Animals', 'Anti-Bacterial Agents', 'Anti-Infective Agents', 'Antibiotics', 'Arts', 'Bacillus anthracis', 'Binding', 'Binding Sites', 'Biochemistry', 'Biological Warfare', 'Candida albicans', 'Catalysis', 'Categories', 'Collaborations', 'Computational Biology', 'Computer software', 'Data', 'Development', 'Dihydropteroate Synthase', 'Diphosphates', 'Disease', 'Drug Design', 'Drug resistance', 'Enzymes', 'Escherichia coli', 'Evaluation', 'Folate', 'Folate Biosynthesis Pathway', 'Folic Acid Antagonists', 'Francisella tularensis', 'Funding', 'Genes', 'Genomics', 'Goals', 'Immunocompromised Host', 'Individual', 'Infection', 'Institution', 'Laboratories', 'Libraries', 'Ligands', 'Locales', 'Methods', 'Microbiology', 'Modeling', 'Molecular', 'Molecular Conformation', 'Mutation', 'Mycobacterium tuberculosis', 'Organism', 'Orthologous Gene', 'Pathway interactions', 'Pharmaceutical Chemistry', 'Pharmaceutical Preparations', 'Proteins', 'Protozoa', 'Protozoan Infections', 'Pseudomonas aeruginosa', 'Pterins', 'Quantitative Structure-Activity Relationship', 'Research', 'Research Personnel', 'Resistance', 'Role', 'Salmonella', 'Screening procedure', 'Serum', 'Site', 'Site-Directed Mutagenesis', 'Solid', 'Specificity', 'Staphylococcus aureus', 'Streptococcus pneumoniae', 'Structure', 'Sulfonamides', 'Techniques', 'Testing', 'Therapeutic', 'Therapeutic Agents', 'X-Ray Crystallography', 'Yersinia pestis', 'analog', 'antimicrobial', 'bacterial resistance', 'base', 'biodefense', 'chemical synthesis', 'cytotoxicity', 'design', 'dihydropteroate', 'drug discovery', 'enzyme mechanism', 'flexibility', 'fungus', 'high throughput screening', 'in vivo', 'inhibitor/antagonist', 'insight', 'interest', 'methicillin resistant Staphylococcus aureus', 'microorganism', 'molecular dynamics', 'novel', 'novel therapeutics', 'programs', 'resistance mutation', 'resistant strain', 'scaffold', 'small molecule', 'structural biology', 'text searching', 'virtual']",NIAID,ST. JUDE CHILDREN'S RESEARCH HOSPITAL,R01,2010,623075,0.08039194872558002
"Novel Inhibitors to DHPS to Probe Catalytic Mechanism & Therapeutic Potential    DESCRIPTION (provided by applicant): Folate biosynthesis is an essential bacterial pathway that is absent in higher animals, and it has been an effective target of antibacterial agents for over 70 years. The sulfonamide drugs inhibit a key enzyme in the pathway, dihydropteroate synthase (DHPS), by acting as non-productive substrate analogs of paminobenzoic acid (pABA). However, the flexible pABA binding site is structurally susceptible to resistance mutations, and the sulfonamides are rapidly becoming therapeutically ineffective. In contrast, the binding site of the second DHPS substrate, pterin-pyrophosphate, is buried in a conserved pocket that is less likely to tolerate mutations. We propose to generate new classes of potent DHPS inhibitors that specifically engage this pocket. These inhibitors have the potential of being developed into novel therapeutic agents that still target folate synthesis but which avoid the problems of resistance. To generate effective inhibitors of any enzyme, it is crucial to understand the structure and mechanism of its active site. This information is largely absent for DHPS, and understanding how DHPS performs catalysis at the molecular level will be a central goal of the application.      This comprehensive project will encompass biochemistry, structural biology, medicinal chemistry, computational biology, and microbiology, and will be performed in two laboratories at neighboring institutions in Memphis. The central focus of the project is the design and synthesis of novel small molecules that can be used to probe the DHPS mechanism and also be evaluated as DHPS inhibitors. Promising inhibitor scaffolds will then be tested for their potential as anti-microbials by direct screening of select organisms. The more potent inhibitors will be used to create derivative libraries for further screening and evaluation. The use of state-of-the-art drug discovery software, library synthesis, high-throughput screening and X-ray crystallography are central features of the research. Our goal is to provide a solid platform for the development of new, desperately-needed, broad-spectrum anti-infectives agents. However, we are also focused on developing specific therapies for the category A biowarfare agents B. anthracis, Y. pestis and F. tularensis, as well as for pathogenic protozoa and fungi.          n/a",Novel Inhibitors to DHPS to Probe Catalytic Mechanism & Therapeutic Potential,7236066,R01AI070721,"['4-Aminobenzoic Acid', 'Acids', 'Active Sites', 'Affinity', 'Amino Acids', 'Animals', 'Anti-Bacterial Agents', 'Anti-Infective Agents', 'Antibiotics', 'Arts', 'Bacillus anthracis', 'Binding', 'Binding Sites', 'Biochemistry', 'Biological Warfare', 'Candida albicans', 'Catalysis', 'Categories', 'Class', 'Collaborations', 'Computational Biology', 'Computer software', 'Data', 'Development', 'Dihydropteroate Synthase', 'Diphosphates', 'Disease', 'Drug Design', 'Drug resistance', 'Enzymes', 'Escherichia coli', 'Evaluation', 'Folate', 'Folate Biosynthesis Pathway', 'Folic Acid Antagonists', 'Francisella tularensis', 'Funding', 'Genes', 'Genomics', 'Goals', 'Immunocompromised Host', 'Individual', 'Infection', 'Institution', 'Laboratories', 'Libraries', 'Ligands', 'Locales', 'Methods', 'Microbiology', 'Modeling', 'Molecular', 'Molecular Conformation', 'Mutation', 'Mycobacterium tuberculosis', 'Numbers', 'Organism', 'Orthologous Gene', 'Pathway interactions', 'Pharmaceutical Chemistry', 'Pharmaceutical Preparations', 'Proteins', 'Protozoa', 'Protozoan Infections', 'Pseudomonas aeruginosa', 'Pterins', 'Quantitative Structure-Activity Relationship', 'Rate', 'Research', 'Research Personnel', 'Resistance', 'Role', 'Salmonella', 'Screening procedure', 'Serum', 'Site', 'Site-Directed Mutagenesis', 'Solid', 'Specificity', 'Staphylococcus aureus', 'Streptococcus pneumoniae', 'Structure', 'Sulfonamides', 'Techniques', 'Testing', 'Therapeutic', 'Therapeutic Agents', 'X-Ray Crystallography', 'Yersinia pestis', 'analog', 'antimicrobial', 'bacterial resistance', 'base', 'biodefense', 'chemical synthesis', 'cytotoxicity', 'design', 'dihydropteroate', 'drug discovery', 'enzyme mechanism', 'fungus', 'high throughput screening', 'in vivo', 'inhibitor/antagonist', 'insight', 'interest', 'mecarzole', 'methicillin resistant Staphylococcus aureus', 'microorganism', 'molecular dynamics', 'novel', 'novel therapeutics', 'programs', 'scaffold', 'small molecule', 'structural biology', 'text searching', 'virtual']",NIAID,ST. JUDE CHILDREN'S RESEARCH HOSPITAL,R01,2007,589007,0.08039194872558002
"Modeling of Protein Complexes and Missense Mutations Amino acid mutations in human proteins are often associated with inherited predispositions to specific diseases. Yet most observed missense polymorphisms, those involving a single nucleotide change leading to a changed amino acid, have not been characterized in terms of their effects on protein structure and function. We hypothesize that many of the most deleterious missense mutations affect protein function in one of two ways: 1) by altering interaction of proteins with other molecules, including other proteins, DMA, and small ligands; or 2) by altering stability of the protein. Both of these mechanisms depend primarily on the location of the mutation and its physical properties: changes in protein interactions are usually caused by mutations in or very near to a binding site; changes in stability are usually caused by mutations of buried hydrophobic residues. The aim of this proposal is to develop a computational system for predicting the functional effects of missense mutations through homology modeling of protein complexes. New functional data on 1000 random mutations in two dimeric enzyme systems will be obtained to train and test the model. The primary application of this computational system will be to genes associated with the development of cancer. Cancer is usually linked to a number of genetic changes, some inherited and others somatic. These include loss of DNA-damage repair, breakdown of cell-cycle checkpoints, and resistance to apoptosis. Each of these processes requires many protein interactions, often in large protein complexes. These interactions may be compromised by missense mutations that alter individual interactions between molecules or mutations that lower protein stability. n/a",Modeling of Protein Complexes and Missense Mutations,7582317,R01GM073784,"['Affect', 'Amino Acid Sequence', 'Amino Acids', 'Apoptosis', 'Bayesian Method', 'Binding Sites', 'Biological Assay', 'Biological Models', 'Biological Neural Networks', 'Cancer Genome Anatomy Project', 'Cell Cycle Checkpoint', 'Complex', 'Computer software', 'Computing Methodologies', 'Cystathionine beta-Synthase', 'DNA Repair', 'Data', 'Data Set', 'Databases', 'Development', 'Disease', 'Disease Association', 'Enzymes', 'Gene Mutation', 'Genes', 'Genetic Polymorphism', 'Genetic Predisposition to Disease', 'Goals', 'HIV Protease', 'Homologous Gene', 'Homology Modeling', 'Human', 'Individual', 'Inherited', 'Ions', 'Lac Repressors', 'Ligands', 'Link', 'Literature', 'Location', 'Machine Learning', 'Malignant Neoplasms', 'Maps', 'Membrane Proteins', 'Methods', 'Methylenetetrahydrofolate reductase (NADPH)', 'Missense Mutation', 'Modeling', 'Muramidase', 'Mutagenesis', 'Mutation', 'Nucleotides', 'Online Mendelian Inheritance In Man', 'Peptide Sequence Determination', 'Peptides', 'Phenotype', 'Positioning Attribute', 'Potential Energy', 'Procedures', 'Process', 'Proteins', 'Research Personnel', 'Resistance', 'Rest', 'Scheme', 'Scientist', 'Side', 'Statistical Models', 'Structure', 'Surface', 'System', 'Tertiary Protein Structure', 'Testing', 'Time', 'Training', 'Validation', 'base', 'dimer', 'graphical user interface', 'insertion/deletion mutation', 'interest', 'loss of function', 'monomer', 'open source', 'physical property', 'programs', 'protein complex', 'protein folding', 'protein function', 'protein protein interaction', 'protein structure function']",NIGMS,RESEARCH INST OF FOX CHASE CAN CTR,R01,2009,307176,0.34561421349194144
"Modeling of Protein Complexes and Missense Mutations Amino acid mutations in human proteins are often associated with inherited predispositions to specific diseases. Yet most observed missense polymorphisms, those involving a single nucleotide change leading to a changed amino acid, have not been characterized in terms of their effects on protein structure and function. We hypothesize that many of the most deleterious missense mutations affect protein function in one of two ways: 1) by altering interaction of proteins with other molecules, including other proteins, DMA, and small ligands; or 2) by altering stability of the protein. Both of these mechanisms depend primarily on the location of the mutation and its physical properties: changes in protein interactions are usually caused by mutations in or very near to a binding site; changes in stability are usually caused by mutations of buried hydrophobic residues. The aim of this proposal is to develop a computational system for predicting the functional effects of missense mutations through homology modeling of protein complexes. New functional data on 1000 random mutations in two dimeric enzyme systems will be obtained to train and test the model. The primary application of this computational system will be to genes associated with the development of cancer. Cancer is usually linked to a number of genetic changes, some inherited and others somatic. These include loss of DNA-damage repair, breakdown of cell-cycle checkpoints, and resistance to apoptosis. Each of these processes requires many protein interactions, often in large protein complexes. These interactions may be compromised by missense mutations that alter individual interactions between molecules or mutations that lower protein stability. n/a",Modeling of Protein Complexes and Missense Mutations,7369808,R01GM073784,"['Affect', 'Amino Acid Sequence', 'Amino Acids', 'Apoptosis', 'Bayesian Method', 'Binding Sites', 'Biological Assay', 'Biological Models', 'Biological Neural Networks', 'Cancer Genome Anatomy Project', 'Cell Cycle Checkpoint', 'Complex', 'Computer software', 'Computing Methodologies', 'Cystathionine beta-Synthase', 'DNA Repair', 'Data', 'Data Set', 'Databases', 'Development', 'Disease', 'Disease Association', 'Enzymes', 'Gene Mutation', 'Genes', 'Genetic Polymorphism', 'Genetic Predisposition to Disease', 'Goals', 'HIV Protease', 'Homologous Gene', 'Homology Modeling', 'Human', 'Individual', 'Inherited', 'Ions', 'Lac Repressors', 'Ligands', 'Link', 'Literature', 'Location', 'Machine Learning', 'Malignant Neoplasms', 'Maps', 'Membrane Proteins', 'Methods', 'Methylenetetrahydrofolate reductase (NADPH)', 'Missense Mutation', 'Modeling', 'Muramidase', 'Mutagenesis', 'Mutation', 'Nucleotides', 'Numbers', 'Online Mendelian Inheritance In Man', 'Peptide Sequence Determination', 'Peptides', 'Phenotype', 'Positioning Attribute', 'Potential Energy', 'Procedures', 'Process', 'Proteins', 'Research Personnel', 'Resistance', 'Rest', 'Scheme', 'Scientist', 'Side', 'Statistical Models', 'Structure', 'Surface', 'System', 'Tertiary Protein Structure', 'Testing', 'Time', 'Training', 'Validation', 'base', 'dimer', 'graphical user interface', 'insertion/deletion mutation', 'interest', 'loss of function', 'monomer', 'open source', 'physical property', 'programs', 'protein folding', 'protein function', 'protein protein interaction', 'protein structure', 'protein structure function']",NIGMS,RESEARCH INST OF FOX CHASE CAN CTR,R01,2008,307176,0.34561421349194144
"Modeling of Protein Complexes and Missense Mutations    DESCRIPTION (provided by applicant): Amino acid mutations in human proteins are often associated with inherited predispositions to specific diseases. Yet most observed missense polymorphisms, those involving a single nucleotide change leading to a changed amino acid, have not been characterized in terms of their effects on protein structure and function. We hypothesize that many of the most deleterious missense mutations affect protein function in one of two ways: 1) by altering interaction of proteins with other molecules, including other proteins, DMA, and small ligands; or 2) by altering stability of the protein. Both of these mechanisms depend primarily on the location of the mutation and its physical properties: changes in protein interactions are usually caused by mutations in or very near to a binding site; changes in stability are usually caused by mutations of buried hydrophobic residues. The aim of this proposal is to develop a computational system for predicting the functional effects of missense mutations through homology modeling of protein complexes. New functional data on 1000 random mutations in two dimeric enzyme systems will be obtained to train and test the model. The primary application of this computational system will be to genes associated with the development of   cancer. Cancer is usually linked to a number of genetic changes, some inherited and others somatic. These include loss of DNA-damage repair, breakdown of cell-cycle checkpoints, and resistance to apoptosis. Each of these processes requires many protein interactions, often in large protein complexes. These interactions may be compromised by missense mutations that alter individual interactions between molecules or mutations that lower protein stability.    n/a",Modeling of Protein Complexes and Missense Mutations,7189836,R01GM073784,"['Affect', 'Amino Acid Sequence', 'Amino Acids', 'Apoptosis', 'Bayesian Method', 'Binding Sites', 'Biological Assay', 'Biological Models', 'Biological Neural Networks', 'Cancer Genome Anatomy Project', 'Cell Cycle Checkpoint', 'Complex', 'Computer software', 'Computing Methodologies', 'Cystathionine beta-Synthase', 'DNA Repair', 'Data', 'Data Set', 'Databases', 'Development', 'Disease', 'Disease Association', 'Enzymes', 'Gene Mutation', 'Genes', 'Genetic Polymorphism', 'Genetic Predisposition to Disease', 'Goals', 'HIV Protease', 'Homologous Gene', 'Homology Modeling', 'Human', 'Individual', 'Inherited', 'Ions', 'Lac Repressors', 'Ligands', 'Link', 'Literature', 'Location', 'Machine Learning', 'Malignant Neoplasms', 'Maps', 'Membrane Proteins', 'Methods', 'Methylenetetrahydrofolate reductase (NADPH)', 'Missense Mutation', 'Modeling', 'Muramidase', 'Mutagenesis', 'Mutation', 'Nucleotides', 'Numbers', 'Online Mendelian Inheritance In Man', 'Peptide Sequence Determination', 'Peptides', 'Phenotype', 'Positioning Attribute', 'Potential Energy', 'Procedures', 'Process', 'Proteins', 'Research Personnel', 'Resistance', 'Rest', 'Scheme', 'Scientist', 'Side', 'Statistical Models', 'Structure', 'Surface', 'System', 'Tertiary Protein Structure', 'Testing', 'Time', 'Training', 'Validation', 'base', 'dimer', 'graphical user interface', 'insertion/deletion mutation', 'interest', 'loss of function', 'monomer', 'open source', 'physical property', 'programs', 'protein folding', 'protein function', 'protein protein interaction', 'protein structure', 'protein structure function']",NIGMS,RESEARCH INST OF FOX CHASE CAN CTR,R01,2007,307176,0.34561421349194144
"Predicting and analyzing variation in cellular interactomes Project Summary Over the last two decades, significant experimental efforts have determined large sets of reference interactions for humans and other model organisms, along with substantial knowledge about the binding specificities of proteins, including for a large fraction of human transcription factors (TFs). The resulting data have proven to be an incredibly useful resource for understanding how cells function; nevertheless, they do not capture how molecular interactions and networks are different from the reference across individuals. Indeed, while human genomes in both healthy and disease populations are rapidly being sequenced, the corresponding individual-specific interaction networks remain largely unexamined; this represents a major gap in our knowledge, as mutations that alter molecular interactions underlie a wide range of human diseases. Further, the substantial amount of genetic variation across populations makes it infeasible in the near term to experimentally determine per-individual interaction networks. Thus our long-term goal is to develop computational methods to uncover whether and how mutations within coding and non-coding portions of the genome perturb cellular interactions and networks. Our specific aims are: (1) We will develop computational structure-based approaches to identify and catalog, at proteome-scale, variations within proteins that are likely to impact their ability to bind with DNA, RNA, small molecules, peptides or ions, thereby providing a comprehensive resource for analyzing protein interaction variation. (2) We will develop novel structure-based and probabilistic methods to predict how DNA-binding specificities are altered when a TF is mutated; since mutated TFs have been linked to numerous diseases, this will be a great aid in understanding disease networks and pathology. (3) We will develop new methods to uncover non-coding somatic mutations that alter human regulatory networks in cancer; this is a critical step towards ultimately uncovering patient-specific cancer networks. Overall by pursuing these aimswhich integrate mutational information with existing knowledge about reference interactions, interfaces and specificitieswe will develop novel computational methods that will significantly advance our understanding of molecular interactions perturbed in disease and healthy contexts. Narrative The proposed research will yield new software tools that predict whether specific genetic mutations alter molecular interactions and networks. Since many human diseases are caused by mutations that affect molecular interactions, this research will expand our understanding of the underlying basis of disease and will provide new avenues for diagnosis and treatment.",Predicting and analyzing variation in cellular interactomes,9896829,R01GM076275,"['Affect', 'Alleles', 'Amino Acid Sequence', 'Animal Model', 'Binding', 'Binding Proteins', 'Binding Sites', 'Bioinformatics', 'Biological', 'Biological Process', 'Catalogs', 'Cell physiology', 'Code', 'Complex', 'Computing Methodologies', 'DNA', 'DNA Binding', 'DNA Sequence Alteration', 'DNA-Protein Interaction', 'Data', 'Data Set', 'Diagnosis', 'Disease', 'Gene Expression', 'Genes', 'Genetic Variation', 'Genome', 'Goals', 'Human', 'Human Genome', 'Individual', 'Infrastructure', 'Internet', 'Ions', 'Knowledge', 'Ligand Binding', 'Link', 'Malignant Neoplasms', 'Mediating', 'Methods', 'Mutagenesis', 'Mutate', 'Mutation', 'Nucleic Acid Regulatory Sequences', 'Organism', 'Pathology', 'Patients', 'Pattern', 'Peptides', 'Play', 'Population', 'Property', 'Protein Analysis', 'Proteins', 'Proteome', 'RNA', 'Regulator Genes', 'Research', 'Resources', 'Sampling', 'Site', 'Software Tools', 'Somatic Mutation', 'Specificity', 'Structure', 'Untranslated RNA', 'Variant', 'Work', 'Zinc Fingers', 'base', 'cancer genome', 'disease-causing mutation', 'experimental study', 'human disease', 'improved', 'interest', 'knowledge base', 'machine learning method', 'novel', 'predictive tools', 'preference', 'small molecule', 'software development', 'transcription factor', 'tumor', 'virtual']",NIGMS,PRINCETON UNIVERSITY,R01,2020,312660,0.1741815828151572
"Predicting and analyzing variation in cellular interactomes Project Summary Over the last two decades, significant experimental efforts have determined large sets of reference interactions for humans and other model organisms, along with substantial knowledge about the binding specificities of proteins, including for a large fraction of human transcription factors (TFs). The resulting data have proven to be an incredibly useful resource for understanding how cells function; nevertheless, they do not capture how molecular interactions and networks are different from the reference across individuals. Indeed, while human genomes in both healthy and disease populations are rapidly being sequenced, the corresponding individual-specific interaction networks remain largely unexamined; this represents a major gap in our knowledge, as mutations that alter molecular interactions underlie a wide range of human diseases. Further, the substantial amount of genetic variation across populations makes it infeasible in the near term to experimentally determine per-individual interaction networks. Thus our long-term goal is to develop computational methods to uncover whether and how mutations within coding and non-coding portions of the genome perturb cellular interactions and networks. Our specific aims are: (1) We will develop computational structure-based approaches to identify and catalog, at proteome-scale, variations within proteins that are likely to impact their ability to bind with DNA, RNA, small molecules, peptides or ions, thereby providing a comprehensive resource for analyzing protein interaction variation. (2) We will develop novel structure-based and probabilistic methods to predict how DNA-binding specificities are altered when a TF is mutated; since mutated TFs have been linked to numerous diseases, this will be a great aid in understanding disease networks and pathology. (3) We will develop new methods to uncover non-coding somatic mutations that alter human regulatory networks in cancer; this is a critical step towards ultimately uncovering patient-specific cancer networks. Overall by pursuing these aimswhich integrate mutational information with existing knowledge about reference interactions, interfaces and specificitieswe will develop novel computational methods that will significantly advance our understanding of molecular interactions perturbed in disease and healthy contexts. Narrative The proposed research will yield new software tools that predict whether specific genetic mutations alter molecular interactions and networks. Since many human diseases are caused by mutations that affect molecular interactions, this research will expand our understanding of the underlying basis of disease and will provide new avenues for diagnosis and treatment.",Predicting and analyzing variation in cellular interactomes,9740714,R01GM076275,"['Affect', 'Alleles', 'Amino Acid Sequence', 'Animal Model', 'Binding', 'Binding Proteins', 'Binding Sites', 'Bioinformatics', 'Biological', 'Biological Process', 'Catalogs', 'Cell physiology', 'Code', 'Complex', 'Computing Methodologies', 'DNA', 'DNA Binding', 'DNA Sequence Alteration', 'DNA-Protein Interaction', 'Data', 'Data Set', 'Diagnosis', 'Disease', 'Gene Expression', 'Genes', 'Genetic Variation', 'Genome', 'Goals', 'Human', 'Human Genome', 'Individual', 'Infrastructure', 'Internet', 'Ions', 'Knowledge', 'Ligand Binding', 'Link', 'Machine Learning', 'Malignant Neoplasms', 'Mediating', 'Methods', 'Mutagenesis', 'Mutate', 'Mutation', 'Nucleic Acid Regulatory Sequences', 'Organism', 'Pathology', 'Patients', 'Pattern', 'Peptides', 'Play', 'Population', 'Property', 'Protein Analysis', 'Proteins', 'Proteome', 'RNA', 'Regulator Genes', 'Research', 'Resources', 'Sampling', 'Site', 'Software Tools', 'Somatic Mutation', 'Specificity', 'Structure', 'Untranslated RNA', 'Variant', 'Work', 'Zinc Fingers', 'base', 'cancer genome', 'disease-causing mutation', 'experimental study', 'human disease', 'improved', 'interest', 'knowledge base', 'learning strategy', 'novel', 'predictive tools', 'preference', 'small molecule', 'software development', 'transcription factor', 'tumor', 'virtual']",NIGMS,PRINCETON UNIVERSITY,R01,2019,312660,0.1741815828151572
"Genotype/Phenotype Correlations in Lysosomal Storage Diseases    DESCRIPTION (provided by applicant): Our long-term goal is to understand the detailed molecular mechanisms that connect genotype, phenotype and response to therapy in lysosomal storage diseases (LSDs). LSDs are a family of genetic metabolic diseases caused by lysosomal enzyme deficiencies. In this project we use Fabry disease as a model system to develop a bioinformatics-based paradigm to address two fundamental issues: 1) The relationship between genotype and phenotype in LSDs. This task is challenging because in LSDs different mutations in the same enzyme often lead to different disease phenotypes. 2) The relationship between genotype and response to ""pharmacological chaperone"" therapy. Pharmacological chaperones are small-molecule ligands that are used to rescue mutants, resulting in increased enzymatic activity; several Fabry mutations have been shown to be rescueable in this way. The same therapy is likely to be useful for other LSDs, particularly those with neurological involvement, for which enzyme replacement therapy is not viable. The two aims of this application address, at different levels, both issues described above. The first aim, tests the hypothesis that knowing the change that occurs in the protein sequence, together with the structural environment in which it occurs, is sufficient to predict the resulting disease phenotype and response to pharmacological chaperone therapy. This is tested through the rigorous training of classification methods using sequence and structure-derived descriptors for a large set of Fabry mutants of known phenotype. The resulting classification provides a large- scale quantitative description of the correlation between genotype and phenotype. The accuracy of predictions based on this approach is a measure of how much information about the genotype the descriptors contain. The same approach will be used to establish a quantitative correlation between genotype and response to pharmacological chaperone therapy. Finally, applying the classification methods to mutations in other LSDs will test the generality of the approach. The second aim of this application addresses the issue of genotype/phenotype correlation from a biophysical point of view. We test the hypothesis that a combination of factors, mainly folding free energy, ligand binding affinity, and relative pH stability of the mutants determines the disease phenotype and response to pharmacological chaperone therapy. This is done analyzing selected mutants using molecular modeling and molecular dynamics simulations of the enzyme/ligand and enzyme/receptor interactions, as well as, pH stability, and other calculations. The methods used in the second aim are very detailed, but are not applicable at a large scale. Thus, both aims provide complementary views of genotype/phenotype correlation in LSDs. The successful completion of this project will, for the first time, provide a quantitative connection between genotype and phenotype in LSDs and a detailed biophysical description of the molecular mechanisms underlying genotype/phenotype correlations and response to pharmacological chaperone therapy in Fabry disease. Relevance of this research to public health. Lysosomal storage diseases (LSDs) are a group of more than 40 genetic metabolic disorders. Worldwide, the incidence of patients with LSDs is estimated to be ~ 1 in 8,000 live births. Understanding the correlation between genotype, phenotype, and response to treatment in these diseases will help in their diagnosis and treatment, particularly for LSDs that affect the brain, for which no effective treatment is available to date.          n/a",Genotype/Phenotype Correlations in Lysosomal Storage Diseases,7388981,R21DK078345,"['Address', 'Affect', 'Affinity', 'Amino Acid Sequence', 'Amino Acids', 'Binding', 'Bioinformatics', 'Biological Models', 'Brain', 'Characteristics', 'Chemicals', 'Classification', 'Complex', 'Data', 'Descriptor', 'Development', 'Diagnosis', 'Disease', 'Endoplasmic Reticulum', 'Environment', 'Enzymes', 'Fabry Disease', 'Feedback', 'Free Energy', 'Galactosidase', 'Genetic', 'Genotype', 'Goals', 'Incidence', 'Lead', 'Ligand Binding', 'Ligands', 'Live Birth', 'Lysosomal Storage Diseases', 'Lysosomes', 'Machine Learning', 'Measures', 'Metabolic Diseases', 'Methods', 'Molecular', 'Molecular Chaperones', 'Molecular Conformation', 'Molecular Models', 'Mutate', 'Mutation', 'Neurologic', 'None or Not Applicable', 'Numbers', 'Output', 'Patients', 'Peptide Sequence Determination', 'Pharmacogenomics', 'Phenotype', 'Principal Investigator', 'Public Health', 'Relative (related person)', 'Research', 'Residual state', 'Structure', 'Testing', 'Time', 'Training', 'base', 'design', 'disease phenotype', 'enzyme deficiency', 'enzyme replacement therapy', 'enzyme structure', 'enzyme substrate', 'family genetics', 'improved', 'insight', 'molecular dynamics', 'molecular modeling', 'mutant', 'prevent', 'programs', 'protein degradation', 'receptor', 'receptor binding', 'response', 'simulation', 'small molecule', 'three dimensional structure']",NIDDK,ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI,R21,2008,124583,0.10249621411452053
"Genotype/Phenotype Correlations in Lysosomal Storage Diseases    DESCRIPTION (provided by applicant): Our long-term goal is to understand the detailed molecular mechanisms that connect genotype, phenotype and response to therapy in lysosomal storage diseases (LSDs). LSDs are a family of genetic metabolic diseases caused by lysosomal enzyme deficiencies. In this project we use Fabry disease as a model system to develop a bioinformatics-based paradigm to address two fundamental issues: 1) The relationship between genotype and phenotype in LSDs. This task is challenging because in LSDs different mutations in the same enzyme often lead to different disease phenotypes. 2) The relationship between genotype and response to ""pharmacological chaperone"" therapy. Pharmacological chaperones are small-molecule ligands that are used to rescue mutants, resulting in increased enzymatic activity; several Fabry mutations have been shown to be rescueable in this way. The same therapy is likely to be useful for other LSDs, particularly those with neurological involvement, for which enzyme replacement therapy is not viable. The two aims of this application address, at different levels, both issues described above. The first aim, tests the hypothesis that knowing the change that occurs in the protein sequence, together with the structural environment in which it occurs, is sufficient to predict the resulting disease phenotype and response to pharmacological chaperone therapy. This is tested through the rigorous training of classification methods using sequence and structure-derived descriptors for a large set of Fabry mutants of known phenotype. The resulting classification provides a large- scale quantitative description of the correlation between genotype and phenotype. The accuracy of predictions based on this approach is a measure of how much information about the genotype the descriptors contain. The same approach will be used to establish a quantitative correlation between genotype and response to pharmacological chaperone therapy. Finally, applying the classification methods to mutations in other LSDs will test the generality of the approach. The second aim of this application addresses the issue of genotype/phenotype correlation from a biophysical point of view. We test the hypothesis that a combination of factors, mainly folding free energy, ligand binding affinity, and relative pH stability of the mutants determines the disease phenotype and response to pharmacological chaperone therapy. This is done analyzing selected mutants using molecular modeling and molecular dynamics simulations of the enzyme/ligand and enzyme/receptor interactions, as well as, pH stability, and other calculations. The methods used in the second aim are very detailed, but are not applicable at a large scale. Thus, both aims provide complementary views of genotype/phenotype correlation in LSDs. The successful completion of this project will, for the first time, provide a quantitative connection between genotype and phenotype in LSDs and a detailed biophysical description of the molecular mechanisms underlying genotype/phenotype correlations and response to pharmacological chaperone therapy in Fabry disease. Relevance of this research to public health. Lysosomal storage diseases (LSDs) are a group of more than 40 genetic metabolic disorders. Worldwide, the incidence of patients with LSDs is estimated to be ~ 1 in 8,000 live births. Understanding the correlation between genotype, phenotype, and response to treatment in these diseases will help in their diagnosis and treatment, particularly for LSDs that affect the brain, for which no effective treatment is available to date.          n/a",Genotype/Phenotype Correlations in Lysosomal Storage Diseases,7239204,R21DK078345,"['Address', 'Affect', 'Affinity', 'Amino Acid Sequence', 'Amino Acids', 'Binding', 'Bioinformatics', 'Biological Models', 'Brain', 'Characteristics', 'Chemicals', 'Classification', 'Complex', 'Data', 'Descriptor', 'Development', 'Diagnosis', 'Disease', 'Endoplasmic Reticulum', 'Environment', 'Enzymes', 'Fabry Disease', 'Feedback', 'Free Energy', 'Galactosidase', 'Genetic', 'Genotype', 'Goals', 'Incidence', 'Lead', 'Ligand Binding', 'Ligands', 'Live Birth', 'Lysosomal Storage Diseases', 'Lysosomes', 'Machine Learning', 'Measures', 'Metabolic Diseases', 'Methods', 'Molecular', 'Molecular Chaperones', 'Molecular Conformation', 'Molecular Models', 'Mutate', 'Mutation', 'Neurologic', 'None or Not Applicable', 'Numbers', 'Output', 'Patients', 'Peptide Sequence Determination', 'Pharmacogenomics', 'Phenotype', 'Principal Investigator', 'Public Health', 'Relative (related person)', 'Research', 'Residual state', 'Structure', 'Testing', 'Time', 'Training', 'base', 'design', 'disease phenotype', 'enzyme deficiency', 'enzyme replacement therapy', 'enzyme structure', 'enzyme substrate', 'family genetics', 'improved', 'insight', 'molecular dynamics', 'molecular modeling', 'mutant', 'prevent', 'programs', 'protein degradation', 'receptor', 'receptor binding', 'response', 'simulation', 'small molecule', 'three dimensional structure']",NIDDK,MOUNT SINAI SCHOOL OF MEDICINE,R21,2007,127125,0.10249621411452053
"Molecular & Cellular Effects of Human Mutations in Cytochrome P450 Reductase DESCRIPTION (provided by applicant):  The cytochrome P450s comprise a large family of enzymes responsible for such diverse reactions as drug and xenobiotic metabolism, steroid and bile acid biosynthesis, and fatty acid and eicosanoid hydroxylation. NADPH-cytochrome P450 oxidoreductase (POR) is the sole provider of electrons to the microsomal cytochromes P450 and to heme oxygenase, which catabolizes heme degradation. Because there is no redundancy for POR in mammalian systems, sequence variants might be expected to exhibit varied and pleiotropic effects depending on the sequence location and severity of the mutation, particularly if it impacts POR interactions with some CYPs, but not others. Indeed, patients with Antley-Bixler-like syndrome, which is characterized by craniofacial dysmorphism, premature synostoses, and disordered steroidogenesis, were shown to have such variants. This proposal will investigate the question of how disruption of the redox enzyme POR affects development and function of various tissues, particularly liver and bone. It is hypothesized that these effects are mediated in part by loss of CYP metabolites that regulate downstream signaling pathways directly or indirectly, and that perturbation of the interaction between POR and particular CYPs may vary, producing different phenotypes dependent upon the affected CYPs. To address these questions, three Specific Aims are proposed as follows: Specific Aim I. Molecular Characterization. This aim will characterize the purified forms of naturally occurring POR variants in humans. A variety of biochemical and biophysical techniques will be employed to determine the physical properties and protein-protein interaction capabilities of POR and its variants, including spectral, kinetic, surface plasmon resonance, analytical ultracentrifugation, ELDOR and isothermal titration calorimetry. These studies will elucidate the molecular properties of the enzymes that cause these phenotypic changes. Specific Aim II. Effect of POR Deficiency and Mutations in Downstream Cellular Events. In this experimental aim, we will examine the effects of POR mutations on downstream cellular events. These will be determined in bone- and liver-derived cells and tissues in which POR expression has been diminished or deleted, for example, by shRNA or from tissue- specific knockout mice. These cellular events, dependent on bone or liver metabolites, may affect bone development and hepatocyte function. Specific Aim III. Liver- and Bone-Specific Effects of POR Variants and POR Knock-down. Bone development and defects will be examined in liver-specific cytochrome P450 reductase knockout mice and a newly developed (in the PI's laboratory) bone-specific knockout mouse model using micro CT, differential staining and determination of vitamin D, retinoic acid, cholesterol, steroid, and lipid serum levels in these mice. Identification of new human polymorphisms will continue to determine possible downstream biomarkers of POR deficiency is a potential outcome. PUBLIC HEALTH RELEVANCE:: The multifaceted approach taken by this proposal addresses the consequences of human cytochrome P450 reductase (POR) deficiency in human drug metabolism and bone development. Understanding these processes is crucial for tailoring drug regimens and other possible therapeutic interventions. By searching for new genetic mutations in this enzyme, identification of relevant biomarkers for POR deficiency is also a goal.",Molecular & Cellular Effects of Human Mutations in Cytochrome P450 Reductase,9000154,R01GM081568,"['Address', 'Affect', 'Amino Acids', 'Animals', 'Bile Acid Biosynthesis Pathway', 'Biochemical', 'Biological Assay', 'Biological Markers', 'Bone Development', 'Calorimetry', 'Cell Culture Techniques', 'Cell Line', 'Cell Survival', 'Cells', 'Cholesterol', 'Complement', 'Complex', 'Congenital abnormal Synostosis', 'Connexin 43', 'Connexins', 'Cytochrome P450', 'Cytochromes', 'DNA Sequence Alteration', 'Data', 'Databases', 'Defect', 'Development', 'Disease', 'Eicosanoids', 'Electrons', 'Environment', 'Enzymes', 'Event', 'Exhibits', 'Family', 'Fatty Acids', 'Flavins', 'Gap Junctions', 'Genetic Polymorphism', 'Goals', 'Health', 'Heme', 'Hepatocyte', 'Histocompatibility Testing', 'Human', 'Hydroxylation', 'Injection of therapeutic agent', 'Kinetics', 'Knockout Mice', 'Laboratories', 'Life', 'Lipids', 'Liposomes', 'Liver', 'Location', 'Mediating', 'Metabolic Biotransformation', 'Microsomes', 'Molecular', 'Mus', 'Mutation', 'NADPH-Ferrihemoprotein Reductase', 'Osteoblasts', 'Osteogenesis', 'Outcome', 'Oxidation-Reduction', 'Oxidative Stress', 'Oxidoreductase', 'Oxygenases', 'Patients', 'Pharmaceutical Preparations', 'Phenotype', 'Process', 'Property', 'Proteins', 'Provider', 'Reaction', 'Regimen', 'Reporting', 'Role', 'Serum', 'Severities', 'Signal Pathway', 'Small Interfering RNA', 'Spectrum Analysis', 'Stable Isotope Labeling', 'Staining method', 'Stains', 'Steroid biosynthesis', 'Steroids', 'Surface Plasmon Resonance', 'Syndrome', 'System', 'Tail', 'Techniques', 'Therapeutic Intervention', 'Tissues', 'Titrations', 'Tretinoin', 'Variant', 'Veins', 'Vitamin D', 'Xenobiotic Metabolism', 'Xenobiotics', 'analytical ultracentrifugation', 'biophysical properties', 'biophysical techniques', 'bone', 'bone cell', 'craniofacial', 'drug metabolism', 'follower of religion Jewish', 'knock-down', 'knockout animal', 'metabolic abnormality assessment', 'microCT', 'mouse model', 'mutant', 'physical property', 'pleiotropism', 'premature', 'protein protein interaction', 'reconstitution', 'small hairpin RNA', 'text searching', 'trafficking']",NIGMS,UNIVERSITY OF TEXAS HLTH SCIENCE CENTER,R01,2016,507344,0.0866282448005046
"Molecular & Cellular Effects of Human Mutations in Cytochrome P450 Reductase DESCRIPTION (provided by applicant):  The cytochrome P450s comprise a large family of enzymes responsible for such diverse reactions as drug and xenobiotic metabolism, steroid and bile acid biosynthesis, and fatty acid and eicosanoid hydroxylation. NADPH-cytochrome P450 oxidoreductase (POR) is the sole provider of electrons to the microsomal cytochromes P450 and to heme oxygenase, which catabolizes heme degradation. Because there is no redundancy for POR in mammalian systems, sequence variants might be expected to exhibit varied and pleiotropic effects depending on the sequence location and severity of the mutation, particularly if it impacts POR interactions with some CYPs, but not others. Indeed, patients with Antley-Bixler-like syndrome, which is characterized by craniofacial dysmorphism, premature synostoses, and disordered steroidogenesis, were shown to have such variants. This proposal will investigate the question of how disruption of the redox enzyme POR affects development and function of various tissues, particularly liver and bone. It is hypothesized that these effects are mediated in part by loss of CYP metabolites that regulate downstream signaling pathways directly or indirectly, and that perturbation of the interaction between POR and particular CYPs may vary, producing different phenotypes dependent upon the affected CYPs. To address these questions, three Specific Aims are proposed as follows: Specific Aim I. Molecular Characterization. This aim will characterize the purified forms of naturally occurring POR variants in humans. A variety of biochemical and biophysical techniques will be employed to determine the physical properties and protein-protein interaction capabilities of POR and its variants, including spectral, kinetic, surface plasmon resonance, analytical ultracentrifugation, ELDOR and isothermal titration calorimetry. These studies will elucidate the molecular properties of the enzymes that cause these phenotypic changes. Specific Aim II. Effect of POR Deficiency and Mutations in Downstream Cellular Events. In this experimental aim, we will examine the effects of POR mutations on downstream cellular events. These will be determined in bone- and liver-derived cells and tissues in which POR expression has been diminished or deleted, for example, by shRNA or from tissue- specific knockout mice. These cellular events, dependent on bone or liver metabolites, may affect bone development and hepatocyte function. Specific Aim III. Liver- and Bone-Specific Effects of POR Variants and POR Knock-down. Bone development and defects will be examined in liver-specific cytochrome P450 reductase knockout mice and a newly developed (in the PI's laboratory) bone-specific knockout mouse model using micro CT, differential staining and determination of vitamin D, retinoic acid, cholesterol, steroid, and lipid serum levels in these mice. Identification of new human polymorphisms will continue to determine possible downstream biomarkers of POR deficiency is a potential outcome. PUBLIC HEALTH RELEVANCE:: The multifaceted approach taken by this proposal addresses the consequences of human cytochrome P450 reductase (POR) deficiency in human drug metabolism and bone development. Understanding these processes is crucial for tailoring drug regimens and other possible therapeutic interventions. By searching for new genetic mutations in this enzyme, identification of relevant biomarkers for POR deficiency is also a goal.",Molecular & Cellular Effects of Human Mutations in Cytochrome P450 Reductase,8811971,R01GM081568,"['Address', 'Affect', 'Amino Acids', 'Animals', 'Bile Acid Biosynthesis Pathway', 'Biochemical', 'Biological Assay', 'Biological Markers', 'Bone Development', 'Calorimetry', 'Cell Culture Techniques', 'Cell Line', 'Cell Survival', 'Cells', 'Cholesterol', 'Complement', 'Complex', 'Congenital abnormal Synostosis', 'Connexin 43', 'Connexins', 'Cytochrome P450', 'Cytochromes', 'DNA Sequence Alteration', 'Data', 'Databases', 'Defect', 'Development', 'Disease', 'Eicosanoids', 'Electrons', 'Environment', 'Enzymes', 'Event', 'Exhibits', 'Family', 'Fatty Acids', 'Flavins', 'Gap Junctions', 'Genetic Polymorphism', 'Goals', 'Health', 'Heme', 'Hepatocyte', 'Histocompatibility Testing', 'Human', 'Hydroxylation', 'Injection of therapeutic agent', 'Kinetics', 'Knock-out', 'Knockout Mice', 'Laboratories', 'Life', 'Lipids', 'Liposomes', 'Liver', 'Location', 'Mediating', 'Metabolic Biotransformation', 'Microsomes', 'Molecular', 'Mus', 'Mutation', 'NADPH-Ferrihemoprotein Reductase', 'Osteoblasts', 'Osteogenesis', 'Outcome', 'Oxidation-Reduction', 'Oxidative Stress', 'Oxidoreductase', 'Oxygenases', 'Patients', 'Pharmaceutical Preparations', 'Phenotype', 'Process', 'Property', 'Proteins', 'Provider', 'Reaction', 'Regimen', 'Reporting', 'Role', 'Serum', 'Severities', 'Signal Pathway', 'Small Interfering RNA', 'Spectrum Analysis', 'Stable Isotope Labeling', 'Staining method', 'Stains', 'Steroid biosynthesis', 'Steroids', 'Surface Plasmon Resonance', 'Syndrome', 'System', 'Tail', 'Techniques', 'Therapeutic Intervention', 'Tissues', 'Titrations', 'Tretinoin', 'Variant', 'Veins', 'Vitamin D', 'Xenobiotic Metabolism', 'Xenobiotics', 'analytical ultracentrifugation', 'biophysical properties', 'biophysical techniques', 'bone', 'bone cell', 'craniofacial', 'drug metabolism', 'follower of religion Jewish', 'knock-down', 'metabolic abnormality assessment', 'microCT', 'mouse model', 'mutant', 'physical property', 'pleiotropism', 'premature', 'protein protein interaction', 'reconstitution', 'small hairpin RNA', 'text searching', 'trafficking']",NIGMS,UNIVERSITY OF TEXAS HLTH SCIENCE CENTER,R01,2015,507344,0.0866282448005046
"Molecular & Cellular Effects of Human Mutations in Cytochrome P450 Reductase DESCRIPTION (provided by applicant):  The cytochrome P450s comprise a large family of enzymes responsible for such diverse reactions as drug and xenobiotic metabolism, steroid and bile acid biosynthesis, and fatty acid and eicosanoid hydroxylation. NADPH-cytochrome P450 oxidoreductase (POR) is the sole provider of electrons to the microsomal cytochromes P450 and to heme oxygenase, which catabolizes heme degradation. Because there is no redundancy for POR in mammalian systems, sequence variants might be expected to exhibit varied and pleiotropic effects depending on the sequence location and severity of the mutation, particularly if it impacts POR interactions with some CYPs, but not others. Indeed, patients with Antley-Bixler-like syndrome, which is characterized by craniofacial dysmorphism, premature synostoses, and disordered steroidogenesis, were shown to have such variants. This proposal will investigate the question of how disruption of the redox enzyme POR affects development and function of various tissues, particularly liver and bone. It is hypothesized that these effects are mediated in part by loss of CYP metabolites that regulate downstream signaling pathways directly or indirectly, and that perturbation of the interaction between POR and particular CYPs may vary, producing different phenotypes dependent upon the affected CYPs. To address these questions, three Specific Aims are proposed as follows: Specific Aim I. Molecular Characterization. This aim will characterize the purified forms of naturally occurring POR variants in humans. A variety of biochemical and biophysical techniques will be employed to determine the physical properties and protein-protein interaction capabilities of POR and its variants, including spectral, kinetic, surface plasmon resonance, analytical ultracentrifugation, ELDOR and isothermal titration calorimetry. These studies will elucidate the molecular properties of the enzymes that cause these phenotypic changes. Specific Aim II. Effect of POR Deficiency and Mutations in Downstream Cellular Events. In this experimental aim, we will examine the effects of POR mutations on downstream cellular events. These will be determined in bone- and liver-derived cells and tissues in which POR expression has been diminished or deleted, for example, by shRNA or from tissue- specific knockout mice. These cellular events, dependent on bone or liver metabolites, may affect bone development and hepatocyte function. Specific Aim III. Liver- and Bone-Specific Effects of POR Variants and POR Knock-down. Bone development and defects will be examined in liver-specific cytochrome P450 reductase knockout mice and a newly developed (in the PI's laboratory) bone-specific knockout mouse model using micro CT, differential staining and determination of vitamin D, retinoic acid, cholesterol, steroid, and lipid serum levels in these mice. Identification of new human polymorphisms will continue to determine possible downstream biomarkers of POR deficiency is a potential outcome. PUBLIC HEALTH RELEVANCE:: The multifaceted approach taken by this proposal addresses the consequences of human cytochrome P450 reductase (POR) deficiency in human drug metabolism and bone development. Understanding these processes is crucial for tailoring drug regimens and other possible therapeutic interventions. By searching for new genetic mutations in this enzyme, identification of relevant biomarkers for POR deficiency is also a goal.",Molecular & Cellular Effects of Human Mutations in Cytochrome P450 Reductase,8914817,R01GM081568,"['Address', 'Affect', 'Amino Acids', 'Animals', 'Bile Acid Biosynthesis Pathway', 'Biochemical', 'Biological Assay', 'Biological Markers', 'Bone Development', 'Calorimetry', 'Cell Culture Techniques', 'Cell Line', 'Cell Survival', 'Cells', 'Cholesterol', 'Complement', 'Complex', 'Congenital abnormal Synostosis', 'Connexin 43', 'Connexins', 'Cytochrome P450', 'Cytochromes', 'Data', 'Databases', 'Defect', 'Development', 'Disease', 'Eicosanoids', 'Electrons', 'Environment', 'Enzymes', 'Event', 'Exhibits', 'Family', 'Fatty Acids', 'Flavins', 'Gap Junctions', 'Gene Mutation', 'Genetic Polymorphism', 'Goals', 'Health', 'Heme', 'Hepatocyte', 'Histocompatibility Testing', 'Human', 'Hydroxylation', 'Injection of therapeutic agent', 'Kinetics', 'Knock-out', 'Knockout Mice', 'Laboratories', 'Life', 'Lipids', 'Liposomes', 'Liver', 'Location', 'Mediating', 'Metabolic Biotransformation', 'Microsomes', 'Molecular', 'Mus', 'Mutation', 'NADPH-Ferrihemoprotein Reductase', 'Osteoblasts', 'Osteogenesis', 'Outcome', 'Oxidation-Reduction', 'Oxidative Stress', 'Oxidoreductase', 'Oxygenases', 'Patients', 'Pharmaceutical Preparations', 'Phenotype', 'Process', 'Property', 'Proteins', 'Provider', 'Reaction', 'Regimen', 'Reporting', 'Role', 'Serum', 'Severities', 'Signal Pathway', 'Small Interfering RNA', 'Spectrum Analysis', 'Stable Isotope Labeling', 'Staining method', 'Stains', 'Steroid biosynthesis', 'Steroids', 'Surface Plasmon Resonance', 'Syndrome', 'System', 'Tail', 'Techniques', 'Therapeutic Intervention', 'Tissues', 'Titrations', 'Tretinoin', 'Variant', 'Veins', 'Vitamin D', 'Xenobiotic Metabolism', 'Xenobiotics', 'analytical ultracentrifugation', 'biophysical properties', 'biophysical techniques', 'bone', 'bone cell', 'craniofacial', 'drug metabolism', 'follower of religion Jewish', 'knock-down', 'metabolic abnormality assessment', 'mouse model', 'mutant', 'physical property', 'premature', 'protein protein interaction', 'reconstitution', 'small hairpin RNA', 'text searching', 'trafficking']",NIGMS,UNIVERSITY OF TEXAS HLTH SCIENCE CENTER,R01,2014,31904,0.0866282448005046
"Molecular & Cellular Effects of Human Mutations in Cytochrome P450 Reductase     DESCRIPTION (provided by applicant):  The cytochrome P450s comprise a large family of enzymes responsible for such diverse reactions as drug and xenobiotic metabolism, steroid and bile acid biosynthesis, and fatty acid and eicosanoid hydroxylation. NADPH-cytochrome P450 oxidoreductase (POR) is the sole provider of electrons to the microsomal cytochromes P450 and to heme oxygenase, which catabolizes heme degradation. Because there is no redundancy for POR in mammalian systems, sequence variants might be expected to exhibit varied and pleiotropic effects depending on the sequence location and severity of the mutation, particularly if it impacts POR interactions with some CYPs, but not others. Indeed, patients with Antley-Bixler-like syndrome, which is characterized by craniofacial dysmorphism, premature synostoses, and disordered steroidogenesis, were shown to have such variants. This proposal will investigate the question of how disruption of the redox enzyme POR affects development and function of various tissues, particularly liver and bone. It is hypothesized that these effects are mediated in part by loss of CYP metabolites that regulate downstream signaling pathways directly or indirectly, and that perturbation of the interaction between POR and particular CYPs may vary, producing different phenotypes dependent upon the affected CYPs. To address these questions, three Specific Aims are proposed as follows: Specific Aim I. Molecular Characterization. This aim will characterize the purified forms of naturally occurring POR variants in humans. A variety of biochemical and biophysical techniques will be employed to determine the physical properties and protein-protein interaction capabilities of POR and its variants, including spectral, kinetic, surface plasmon resonance, analytical ultracentrifugation, ELDOR and isothermal titration calorimetry. These studies will elucidate the molecular properties of the enzymes that cause these phenotypic changes. Specific Aim II. Effect of POR Deficiency and Mutations in Downstream Cellular Events. In this experimental aim, we will examine the effects of POR mutations on downstream cellular events. These will be determined in bone- and liver-derived cells and tissues in which POR expression has been diminished or deleted, for example, by shRNA or from tissue- specific knockout mice. These cellular events, dependent on bone or liver metabolites, may affect bone development and hepatocyte function. Specific Aim III. Liver- and Bone-Specific Effects of POR Variants and POR Knock-down. Bone development and defects will be examined in liver-specific cytochrome P450 reductase knockout mice and a newly developed (in the PI's laboratory) bone-specific knockout mouse model using micro CT, differential staining and determination of vitamin D, retinoic acid, cholesterol, steroid, and lipid serum levels in these mice. Identification of new human polymorphisms will continue to determine possible downstream biomarkers of POR deficiency is a potential outcome.         PUBLIC HEALTH RELEVANCE:: The multifaceted approach taken by this proposal addresses the consequences of human cytochrome P450 reductase (POR) deficiency in human drug metabolism and bone development. Understanding these processes is crucial for tailoring drug regimens and other possible therapeutic interventions. By searching for new genetic mutations in this enzyme, identification of relevant biomarkers for POR deficiency is also a goal.            ",Molecular & Cellular Effects of Human Mutations in Cytochrome P450 Reductase,8603859,R01GM081568,"['Address', 'Affect', 'Amino Acids', 'Animals', 'Bile Acid Biosynthesis Pathway', 'Biochemical', 'Biological Assay', 'Biological Markers', 'Bone Development', 'Calorimetry', 'Cell Culture Techniques', 'Cell Line', 'Cell Survival', 'Cells', 'Cholesterol', 'Complement', 'Complex', 'Congenital abnormal Synostosis', 'Connexin 43', 'Connexins', 'Cytochrome P450', 'Cytochromes', 'Data', 'Databases', 'Defect', 'Development', 'Disease', 'Eicosanoids', 'Electrons', 'Environment', 'Enzymes', 'Event', 'Exhibits', 'Family', 'Fatty Acids', 'Flavins', 'Gap Junctions', 'Gene Mutation', 'Genetic Polymorphism', 'Goals', 'Heme', 'Hepatocyte', 'Histocompatibility Testing', 'Human', 'Hydroxylation', 'Injection of therapeutic agent', 'Kinetics', 'Knock-out', 'Knockout Mice', 'Laboratories', 'Life', 'Lipids', 'Liposomes', 'Liver', 'Location', 'Mediating', 'Metabolic Biotransformation', 'Microsomes', 'Molecular', 'Mus', 'Mutation', 'NADPH-Ferrihemoprotein Reductase', 'Osteoblasts', 'Osteogenesis', 'Outcome', 'Oxidation-Reduction', 'Oxidative Stress', 'Oxidoreductase', 'Oxygenases', 'Patients', 'Pharmaceutical Preparations', 'Phenotype', 'Process', 'Property', 'Proteins', 'Provider', 'Reaction', 'Regimen', 'Reporting', 'Role', 'Serum', 'Severities', 'Signal Pathway', 'Small Interfering RNA', 'Spectrum Analysis', 'Stable Isotope Labeling', 'Staining method', 'Stains', 'Steroid biosynthesis', 'Steroids', 'Surface Plasmon Resonance', 'Syndrome', 'System', 'Tail', 'Techniques', 'Therapeutic Intervention', 'Tissues', 'Titrations', 'Tretinoin', 'Variant', 'Veins', 'Vitamin D', 'Xenobiotic Metabolism', 'Xenobiotics', 'analytical ultracentrifugation', 'biophysical properties', 'biophysical techniques', 'bone', 'bone cell', 'craniofacial', 'drug metabolism', 'follower of religion Jewish', 'knock-down', 'metabolic abnormality assessment', 'mouse model', 'mutant', 'physical property', 'premature', 'protein protein interaction', 'public health relevance', 'reconstitution', 'small hairpin RNA', 'text searching', 'trafficking']",NIGMS,UNIVERSITY OF TEXAS HLTH SCIENCE CENTER,R01,2014,543161,0.0866282448005046
"Molecular & Cellular Effects of Human Mutations in Cytochrome P450 Reductase     DESCRIPTION (provided by applicant):  The cytochrome P450s comprise a large family of enzymes responsible for such diverse reactions as drug and xenobiotic metabolism, steroid and bile acid biosynthesis, and fatty acid and eicosanoid hydroxylation. NADPH-cytochrome P450 oxidoreductase (POR) is the sole provider of electrons to the microsomal cytochromes P450 and to heme oxygenase, which catabolizes heme degradation. Because there is no redundancy for POR in mammalian systems, sequence variants might be expected to exhibit varied and pleiotropic effects depending on the sequence location and severity of the mutation, particularly if it impacts POR interactions with some CYPs, but not others. Indeed, patients with Antley-Bixler-like syndrome, which is characterized by craniofacial dysmorphism, premature synostoses, and disordered steroidogenesis, were shown to have such variants. This proposal will investigate the question of how disruption of the redox enzyme POR affects development and function of various tissues, particularly liver and bone. It is hypothesized that these effects are mediated in part by loss of CYP metabolites that regulate downstream signaling pathways directly or indirectly, and that perturbation of the interaction between POR and particular CYPs may vary, producing different phenotypes dependent upon the affected CYPs. To address these questions, three Specific Aims are proposed as follows: Specific Aim I. Molecular Characterization. This aim will characterize the purified forms of naturally occurring POR variants in humans. A variety of biochemical and biophysical techniques will be employed to determine the physical properties and protein-protein interaction capabilities of POR and its variants, including spectral, kinetic, surface plasmon resonance, analytical ultracentrifugation, ELDOR and isothermal titration calorimetry. These studies will elucidate the molecular properties of the enzymes that cause these phenotypic changes. Specific Aim II. Effect of POR Deficiency and Mutations in Downstream Cellular Events. In this experimental aim, we will examine the effects of POR mutations on downstream cellular events. These will be determined in bone- and liver-derived cells and tissues in which POR expression has been diminished or deleted, for example, by shRNA or from tissue- specific knockout mice. These cellular events, dependent on bone or liver metabolites, may affect bone development and hepatocyte function. Specific Aim III. Liver- and Bone-Specific Effects of POR Variants and POR Knock-down. Bone development and defects will be examined in liver-specific cytochrome P450 reductase knockout mice and a newly developed (in the PI's laboratory) bone-specific knockout mouse model using micro CT, differential staining and determination of vitamin D, retinoic acid, cholesterol, steroid, and lipid serum levels in these mice. Identification of new human polymorphisms will continue to determine possible downstream biomarkers of POR deficiency is a potential outcome.         PUBLIC HEALTH RELEVANCE:: The multifaceted approach taken by this proposal addresses the consequences of human cytochrome P450 reductase (POR) deficiency in human drug metabolism and bone development. Understanding these processes is crucial for tailoring drug regimens and other possible therapeutic interventions. By searching for new genetic mutations in this enzyme, identification of relevant biomarkers for POR deficiency is also a goal.            ",Molecular & Cellular Effects of Human Mutations in Cytochrome P450 Reductase,8439401,R01GM081568,"['Address', 'Affect', 'Amino Acids', 'Animals', 'Bile Acid Biosynthesis Pathway', 'Biochemical', 'Biological Assay', 'Biological Markers', 'Bone Development', 'Calorimetry', 'Cell Culture Techniques', 'Cell Line', 'Cell Survival', 'Cells', 'Cholesterol', 'Complement', 'Complex', 'Congenital abnormal Synostosis', 'Connexin 43', 'Connexins', 'Cytochrome P450', 'Cytochromes', 'Data', 'Databases', 'Defect', 'Development', 'Disease', 'Eicosanoids', 'Electrons', 'Environment', 'Enzymes', 'Event', 'Exhibits', 'Family', 'Fatty Acids', 'Flavins', 'Gap Junctions', 'Gene Mutation', 'Genetic Polymorphism', 'Goals', 'Heme', 'Hepatocyte', 'Histocompatibility Testing', 'Human', 'Hydroxylation', 'Injection of therapeutic agent', 'Kinetics', 'Knock-out', 'Knockout Mice', 'Laboratories', 'Life', 'Lipids', 'Liposomes', 'Liver', 'Location', 'Mediating', 'Metabolic Biotransformation', 'Microsomes', 'Molecular', 'Mus', 'Mutation', 'NADPH-Ferrihemoprotein Reductase', 'Osteoblasts', 'Osteogenesis', 'Outcome', 'Oxidation-Reduction', 'Oxidative Stress', 'Oxidoreductase', 'Oxygenases', 'Patients', 'Pharmaceutical Preparations', 'Phenotype', 'Process', 'Property', 'Proteins', 'Provider', 'Reaction', 'Regimen', 'Reporting', 'Role', 'Serum', 'Severities', 'Signal Pathway', 'Small Interfering RNA', 'Spectrum Analysis', 'Stable Isotope Labeling', 'Staining method', 'Stains', 'Steroid biosynthesis', 'Steroids', 'Surface Plasmon Resonance', 'Syndrome', 'System', 'Tail', 'Techniques', 'Therapeutic Intervention', 'Tissues', 'Titrations', 'Tretinoin', 'Variant', 'Veins', 'Vitamin D', 'Xenobiotic Metabolism', 'Xenobiotics', 'analytical ultracentrifugation', 'bone', 'bone cell', 'craniofacial', 'drug metabolism', 'follower of religion Jewish', 'knock-down', 'metabolic abnormality assessment', 'mouse model', 'mutant', 'physical property', 'premature', 'protein protein interaction', 'public health relevance', 'reconstitution', 'small hairpin RNA', 'text searching', 'trafficking']",NIGMS,UNIVERSITY OF TEXAS HLTH SCIENCE CENTER,R01,2013,553804,0.0866282448005046
"Gene signatures linked to the cell biological phenotypes of familial PD     DESCRIPTION (provided by applicant): High throughput sequencing of the genome-wide transcriptome will generate many new hypotheses regarding the genetic interactions underlying neurodegenerative mechanisms. We expect that marker genes of biologically relevant pathways are needed to efficiently interrogate the large sets of raw data produced by the experiments. The goal of this new R21 proposal is to help validate the neuronal transcriptome as a tool for the study of Parkinson's disease. Cells from well-defined familial cases of Parkinson's disease, although rare, provide an excellent starting point for such analyses. We and others have shown that cells from Parkinson's disease patients carrying LRRK2 or PINK1 mutations demonstrate mitochondrial deficits. Importantly, the molecular mechanisms that connect LRRK2 or PINK1 mutations to the mitochondrial deficits remain unclear. Using an innovative approach to interpreting the neuronal transcriptome, we aim to generate new hypotheses regarding the molecular mechanisms of LRRK2 or PINK1 associated mitochondrial deficits. We will link the functional mitochondrial deficits of human neurons carrying Parkinson's disease associated LRRK2 and PINK1 mutations that we have observed to the RNA sequences expressed by the neurons. By combining high- throughput transcriptome sequencing with new quantitative PCR arrays, we propose to determine the expression level and sequence signatures of mitochondrial DNA (SA1) and nuclear DNA (SA2) encoded genes that mark the mitochondrial deficits of patient-derived neurons. Multiple clones of age-matched, sibling and isogenic control iPSCs will be used to minimize the influence of genomic variation across neuronal samples. In a first step towards our goal, RNA molecules from induced pluripotent stem cell (iPSC)-derived neurons carrying LRRK2, PINK1 mutations and showing mitochondrial deficits or healthy subjects were sequenced. Preliminary analyses of the RNAseq data confirmed the presence of the LRRK2 and PINK1 mutations in the neuronal transcriptome. Furthermore, our analysis suggests that the functional mitochondrial deficits are associated with aberrant processing of mitochondrial DNA-encoded transcripts. These data from human neurons can be used to establish a reasonable and coherent framework of cell biological responses to interpret a patient's transcriptome. Our results will be instructive and critical to future attempts to effectively analyze human cell biological phenotypes with the multiple underlying genetic interactions of sporadic forms of Parkinson's disease.         PUBLIC HEALTH RELEVANCE: Biomedical research can benefit from tractable informatic approaches to determine the underlying genetic interactions and molecular mechanisms of neurodegenerative disease. We propose to use phenotypic functional mitochondrial deficits to instruct genome-wide transcriptomic analysis of human neurons derived from Parkinson's disease patients carrying LRRK2 or PINK1 mutations. We will validate the innovative analytic methods of transcriptome-genome alignments and expression levels to generate new hypotheses relating to the molecular functions of LRRK2 and PINK1 in Parkinson's disease.             ",Gene signatures linked to the cell biological phenotypes of familial PD,8670043,R21NS084149,"['Age', 'Binding', 'Biogenesis', 'Bioinformatics', 'Biological', 'Biomedical Research', 'Candidate Disease Gene', 'Cell Line', 'Cells', 'Cellular biology', 'DNA', 'DNA Damage', 'DNA Repair', 'DNA Sequence', 'Data', 'Databases', 'Future', 'Gene Expression', 'Gene Expression Profile', 'Gene Mutation', 'Genes', 'Genetic', 'Genome', 'Genomics', 'Goals', 'High-Throughput Nucleotide Sequencing', 'Human', 'Individual', 'Informatics', 'LRRK2 gene', 'Link', 'Methods', 'Mitochondria', 'Mitochondrial DNA', 'Molecular', 'Movement', 'Mutation', 'Nerve Degeneration', 'Neurodegenerative Disorders', 'Neurons', 'Nuclear', 'Nucleotides', 'PINK1 gene', 'Parkinson Disease', 'Pathway interactions', 'Patients', 'Pattern', 'Phenotype', 'Principal Component Analysis', 'Process', 'RNA', 'RNA Sequences', 'Reactive Oxygen Species', 'Resolution', 'Sampling', 'Siblings', 'Solutions', 'Testing', 'Transcript', 'Variant', 'genome-wide', 'human data', 'induced pluripotent stem cell', 'innovation', 'mitochondrial dysfunction', 'novel strategies', 'public health relevance', 'research study', 'response', 'tool', 'transcriptome sequencing', 'transcriptomics']",NINDS,MCLEAN HOSPITAL,R21,2014,195525,0.10047633116546073
"Gene signatures linked to the cell biological phenotypes of familial PD     DESCRIPTION (provided by applicant): High throughput sequencing of the genome-wide transcriptome will generate many new hypotheses regarding the genetic interactions underlying neurodegenerative mechanisms. We expect that marker genes of biologically relevant pathways are needed to efficiently interrogate the large sets of raw data produced by the experiments. The goal of this new R21 proposal is to help validate the neuronal transcriptome as a tool for the study of Parkinson's disease. Cells from well-defined familial cases of Parkinson's disease, although rare, provide an excellent starting point for such analyses. We and others have shown that cells from Parkinson's disease patients carrying LRRK2 or PINK1 mutations demonstrate mitochondrial deficits. Importantly, the molecular mechanisms that connect LRRK2 or PINK1 mutations to the mitochondrial deficits remain unclear. Using an innovative approach to interpreting the neuronal transcriptome, we aim to generate new hypotheses regarding the molecular mechanisms of LRRK2 or PINK1 associated mitochondrial deficits. We will link the functional mitochondrial deficits of human neurons carrying Parkinson's disease associated LRRK2 and PINK1 mutations that we have observed to the RNA sequences expressed by the neurons. By combining high- throughput transcriptome sequencing with new quantitative PCR arrays, we propose to determine the expression level and sequence signatures of mitochondrial DNA (SA1) and nuclear DNA (SA2) encoded genes that mark the mitochondrial deficits of patient-derived neurons. Multiple clones of age-matched, sibling and isogenic control iPSCs will be used to minimize the influence of genomic variation across neuronal samples. In a first step towards our goal, RNA molecules from induced pluripotent stem cell (iPSC)-derived neurons carrying LRRK2, PINK1 mutations and showing mitochondrial deficits or healthy subjects were sequenced. Preliminary analyses of the RNAseq data confirmed the presence of the LRRK2 and PINK1 mutations in the neuronal transcriptome. Furthermore, our analysis suggests that the functional mitochondrial deficits are associated with aberrant processing of mitochondrial DNA-encoded transcripts. These data from human neurons can be used to establish a reasonable and coherent framework of cell biological responses to interpret a patient's transcriptome. Our results will be instructive and critical to future attempts to effectively analyze human cell biological phenotypes with the multiple underlying genetic interactions of sporadic forms of Parkinson's disease.         PUBLIC HEALTH RELEVANCE: Biomedical research can benefit from tractable informatic approaches to determine the underlying genetic interactions and molecular mechanisms of neurodegenerative disease. We propose to use phenotypic functional mitochondrial deficits to instruct genome-wide transcriptomic analysis of human neurons derived from Parkinson's disease patients carrying LRRK2 or PINK1 mutations. We will validate the innovative analytic methods of transcriptome-genome alignments and expression levels to generate new hypotheses relating to the molecular functions of LRRK2 and PINK1 in Parkinson's disease.             ",Gene signatures linked to the cell biological phenotypes of familial PD,8566838,R21NS084149,"['Age', 'Binding', 'Biogenesis', 'Bioinformatics', 'Biological', 'Biomedical Research', 'Candidate Disease Gene', 'Cell Line', 'Cells', 'Cellular biology', 'DNA', 'DNA Damage', 'DNA Repair', 'DNA Sequence', 'Data', 'Databases', 'Future', 'Gene Expression', 'Gene Expression Profile', 'Gene Mutation', 'Genes', 'Genetic', 'Genome', 'Genomics', 'Goals', 'Human', 'Individual', 'Informatics', 'LRRK2 gene', 'Link', 'Methods', 'Mitochondria', 'Mitochondrial DNA', 'Molecular', 'Movement', 'Mutation', 'Nerve Degeneration', 'Neurodegenerative Disorders', 'Neurons', 'Nuclear', 'Nucleotides', 'PINK1 gene', 'Parkinson Disease', 'Pathway interactions', 'Patients', 'Pattern', 'Phenotype', 'Principal Component Analysis', 'Process', 'RNA', 'RNA Sequences', 'Reactive Oxygen Species', 'Resolution', 'Sampling', 'Siblings', 'Solutions', 'Testing', 'Transcript', 'Variant', 'genome-wide', 'human data', 'induced pluripotent stem cell', 'innovation', 'mitochondrial dysfunction', 'novel strategies', 'public health relevance', 'research study', 'response', 'tool', 'transcriptome sequencing', 'transcriptomics']",NINDS,MCLEAN HOSPITAL,R21,2013,237000,0.10047633116546073
"Protein recognition for modular domains    DESCRIPTION (provided by applicant): Protein is essential for almost every biological process and the interaction between proteins and their interacting partners play critical roles in the functioning cells. Since mutations that disrupt the protein-protein interactions result in many diseases, it is important to understand the biochemical mechanisms of protein recognition, which is important for deciphering protein interaction network and designing potent drugs with high specificity against protein targets. Our long term goal is to develop theoretical models for describing protein binding specificity and reliably predict protein-protein interactions. In the proposed project, we have the following specific aims. Aim 1, we will develop a computational method that combines computer modeling and bioinformatics analysis to characterize the interaction interface between modular domains and their peptide ligands. We will test this method on several modular domains including SH3, SH2 and PDZ domains that bind to specific peptide sequences. Aim 2, we will systematically predict interacting peptides in the yeast genome of all yeast SH3 domains. Aim 3, we will experimentally validate the predictions in vitro to assess the performance of the computational method. We will also conduct in vivo experiments to examine the biological significance of a set of selected domain-peptide interactions.      PUBLIC HEALTH RELEVANCE: Protein-protein interactions play critical roles in the cell and mutations that disrupt these interactions result in many diseases. It is therefore important to understand the biochemical mechanisms of protein recognition.           Protein-protein interactions play critical roles in the cell and mutations that disrupt these interactions result in many diseases. It is therefore important to understand the biochemical mechanisms of protein recognition.",Protein recognition for modular domains,8197508,R01GM085188,"['Amino Acids', 'Binding', 'Biochemical', 'Bioinformatics', 'Biological', 'Biological Assay', 'Biological Process', 'Cell physiology', 'Cells', 'Classification', 'Code', 'Complex', 'Computer Simulation', 'Computing Methodologies', 'Data', 'Databases', 'Disease', 'Electrostatics', 'Evaluation', 'Free Energy', 'Fungal Genome', 'Goals', 'In Vitro', 'Left', 'Ligands', 'Machine Learning', 'Methods', 'Modeling', 'Mutation', 'PXXP Motif', 'Peptides', 'Performance', 'Pharmaceutical Preparations', 'Play', 'Proline', 'Protein Binding', 'Proteins', 'Proteome', 'Research', 'Role', 'SH3 Domains', 'Specificity', 'Structure', 'Techniques', 'Tertiary Protein Structure', 'Testing', 'Theoretical model', 'Training Support', 'Validation', 'Yeasts', 'base', 'design', 'enzyme activity', 'improved', 'in vivo', 'novel strategies', 'peptide I', 'protein aminoacid sequence', 'protein complex', 'protein protein interaction', 'public health relevance', 'research study', 'src Homology Region 2 Domain', 'success', 'web site']",NIGMS,"UNIVERSITY OF CALIFORNIA, SAN DIEGO",R01,2012,289290,0.11920255187845868
"Protein recognition for modular domains    DESCRIPTION (provided by applicant): Protein is essential for almost every biological process and the interaction between proteins and their interacting partners play critical roles in the functioning cells. Since mutations that disrupt the protein-protein interactions result in many diseases, it is important to understand the biochemical mechanisms of protein recognition, which is important for deciphering protein interaction network and designing potent drugs with high specificity against protein targets. Our long term goal is to develop theoretical models for describing protein binding specificity and reliably predict protein-protein interactions. In the proposed project, we have the following specific aims. Aim 1, we will develop a computational method that combines computer modeling and bioinformatics analysis to characterize the interaction interface between modular domains and their peptide ligands. We will test this method on several modular domains including SH3, SH2 and PDZ domains that bind to specific peptide sequences. Aim 2, we will systematically predict interacting peptides in the yeast genome of all yeast SH3 domains. Aim 3, we will experimentally validate the predictions in vitro to assess the performance of the computational method. We will also conduct in vivo experiments to examine the biological significance of a set of selected domain-peptide interactions.      PUBLIC HEALTH RELEVANCE: Protein-protein interactions play critical roles in the cell and mutations that disrupt these interactions result in many diseases. It is therefore important to understand the biochemical mechanisms of protein recognition.           Protein-protein interactions play critical roles in the cell and mutations that disrupt these interactions result in many diseases. It is therefore important to understand the biochemical mechanisms of protein recognition.",Protein recognition for modular domains,7997221,R01GM085188,"['Amino Acids', 'Binding', 'Biochemical', 'Bioinformatics', 'Biological', 'Biological Assay', 'Biological Process', 'Cell physiology', 'Cells', 'Classification', 'Code', 'Complex', 'Computer Simulation', 'Computing Methodologies', 'Data', 'Databases', 'Disease', 'Electrostatics', 'Evaluation', 'Free Energy', 'Fungal Genome', 'Goals', 'In Vitro', 'Left', 'Ligands', 'Machine Learning', 'Methods', 'Modeling', 'Mutation', 'PXXP Motif', 'Peptides', 'Performance', 'Pharmaceutical Preparations', 'Play', 'Proline', 'Protein Binding', 'Proteins', 'Proteome', 'Research', 'Role', 'SH3 Domains', 'Specificity', 'Structure', 'Techniques', 'Tertiary Protein Structure', 'Testing', 'Theoretical model', 'Training Support', 'Validation', 'Yeasts', 'base', 'design', 'enzyme activity', 'improved', 'in vivo', 'novel strategies', 'peptide I', 'protein aminoacid sequence', 'protein complex', 'protein protein interaction', 'public health relevance', 'research study', 'src Homology Region 2 Domain', 'success', 'web site']",NIGMS,"UNIVERSITY OF CALIFORNIA, SAN DIEGO",R01,2011,289681,0.11920255187845868
"Protein recognition for modular domains    DESCRIPTION (provided by applicant): Protein is essential for almost every biological process and the interaction between proteins and their interacting partners play critical roles in the functioning cells. Since mutations that disrupt the protein-protein interactions result in many diseases, it is important to understand the biochemical mechanisms of protein recognition, which is important for deciphering protein interaction network and designing potent drugs with high specificity against protein targets. Our long term goal is to develop theoretical models for describing protein binding specificity and reliably predict protein-protein interactions. In the proposed project, we have the following specific aims. Aim 1, we will develop a computational method that combines computer modeling and bioinformatics analysis to characterize the interaction interface between modular domains and their peptide ligands. We will test this method on several modular domains including SH3, SH2 and PDZ domains that bind to specific peptide sequences. Aim 2, we will systematically predict interacting peptides in the yeast genome of all yeast SH3 domains. Aim 3, we will experimentally validate the predictions in vitro to assess the performance of the computational method. We will also conduct in vivo experiments to examine the biological significance of a set of selected domain-peptide interactions.      PUBLIC HEALTH RELEVANCE: Protein-protein interactions play critical roles in the cell and mutations that disrupt these interactions result in many diseases. It is therefore important to understand the biochemical mechanisms of protein recognition.           Protein-protein interactions play critical roles in the cell and mutations that disrupt these interactions result in many diseases. It is therefore important to understand the biochemical mechanisms of protein recognition.",Protein recognition for modular domains,7741672,R01GM085188,"['Amino Acids', 'Binding', 'Biochemical', 'Bioinformatics', 'Biological', 'Biological Assay', 'Biological Process', 'Cell physiology', 'Cells', 'Classification', 'Code', 'Complex', 'Computer Simulation', 'Computing Methodologies', 'Data', 'Databases', 'Disease', 'Electrostatics', 'Evaluation', 'Free Energy', 'Fungal Genome', 'Goals', 'In Vitro', 'Left', 'Ligands', 'Machine Learning', 'Methods', 'Modeling', 'Mutation', 'PXXP Motif', 'Peptides', 'Performance', 'Pharmaceutical Preparations', 'Play', 'Proline', 'Protein Binding', 'Proteins', 'Proteome', 'Research', 'Role', 'SH3 Domains', 'Specificity', 'Structure', 'Techniques', 'Tertiary Protein Structure', 'Testing', 'Theoretical model', 'Training Support', 'Validation', 'Yeasts', 'base', 'design', 'enzyme activity', 'improved', 'in vivo', 'novel strategies', 'peptide I', 'protein aminoacid sequence', 'protein complex', 'protein protein interaction', 'public health relevance', 'research study', 'src Homology Region 2 Domain', 'success', 'web site']",NIGMS,"UNIVERSITY OF CALIFORNIA, SAN DIEGO",R01,2010,292978,0.11920255187845868
"Protein recognition for modular domains    DESCRIPTION (provided by applicant): Protein is essential for almost every biological process and the interaction between proteins and their interacting partners play critical roles in the functioning cells. Since mutations that disrupt the protein-protein interactions result in many diseases, it is important to understand the biochemical mechanisms of protein recognition, which is important for deciphering protein interaction network and designing potent drugs with high specificity against protein targets. Our long term goal is to develop theoretical models for describing protein binding specificity and reliably predict protein-protein interactions. In the proposed project, we have the following specific aims. Aim 1, we will develop a computational method that combines computer modeling and bioinformatics analysis to characterize the interaction interface between modular domains and their peptide ligands. We will test this method on several modular domains including SH3, SH2 and PDZ domains that bind to specific peptide sequences. Aim 2, we will systematically predict interacting peptides in the yeast genome of all yeast SH3 domains. Aim 3, we will experimentally validate the predictions in vitro to assess the performance of the computational method. We will also conduct in vivo experiments to examine the biological significance of a set of selected domain-peptide interactions.      PUBLIC HEALTH RELEVANCE: Protein-protein interactions play critical roles in the cell and mutations that disrupt these interactions result in many diseases. It is therefore important to understand the biochemical mechanisms of protein recognition.           Protein-protein interactions play critical roles in the cell and mutations that disrupt these interactions result in many diseases. It is therefore important to understand the biochemical mechanisms of protein recognition.",Protein recognition for modular domains,7584631,R01GM085188,"['Amino Acids', 'Binding', 'Biochemical', 'Bioinformatics', 'Biological', 'Biological Assay', 'Biological Process', 'Cell physiology', 'Cells', 'Classification', 'Code', 'Complex', 'Computer Simulation', 'Computing Methodologies', 'Data', 'Databases', 'Disease', 'Electrostatics', 'Evaluation', 'Free Energy', 'Fungal Genome', 'Goals', 'In Vitro', 'Left', 'Ligands', 'Machine Learning', 'Methods', 'Modeling', 'Mutation', 'PXXP Motif', 'Peptides', 'Performance', 'Pharmaceutical Preparations', 'Play', 'Proline', 'Protein Binding', 'Proteins', 'Proteome', 'Research', 'Role', 'SH3 Domains', 'Specificity', 'Structure', 'Techniques', 'Tertiary Protein Structure', 'Testing', 'Theoretical model', 'Training Support', 'Validation', 'Yeasts', 'base', 'design', 'enzyme activity', 'improved', 'in vivo', 'novel strategies', 'peptide I', 'protein aminoacid sequence', 'protein complex', 'protein protein interaction', 'public health relevance', 'research study', 'src Homology Region 2 Domain', 'success', 'web site']",NIGMS,"UNIVERSITY OF CALIFORNIA, SAN DIEGO",R01,2009,296287,0.11920255187845868
"CIPER--A NOVEL APOPTOSIS REGULATOR INVOLVED IN CANCER Dysfunction of apoptotic pathways plays a critical role in the development of cancer, and the identification and characterization of genes encoding regulators of apoptosis is therefore critical for understanding the pathophysiology of cancer and for developing novel therapeutic approaches. The laboratory has identified CIPER, a gene that regulates both apoptosis and the NF-kB signal transduction pathway, one which is associated with cell survival. Because of this dual function, CIPER appears to play an important role as the control point of a molecular decision-tree; under some circumstances, CIPER may promote apoptosis, while at other times CIPER may favor cell survival. Importantly, the CIPER gene has been found to be located at the chromosomal breakpoint region of t(1;14), a recurrent translocation associated with MALT B-cell lymphoma, and is frequently mutated in lymphomas of various other histologic types as well as some non-lymphoid neoplasms. Our hypothesis is that CIPER promotes tumor development through a combination of dysregulated apoptosis and NF-kB signaling which result from chromosomal mutations affecting the CIPER gene. We are proposing a series of aims to further define the molecular mechanisms by which CIPER controls these signaling pathways, to understand the cellular stimulae which influence CIPER function, and to explore how natural mutations in the CIPER gene affect its important role as a regulator of cell survival.  n/a",CIPER--A NOVEL APOPTOSIS REGULATOR INVOLVED IN CANCER,6463554,F32CA088470,"['B cell lymphoma', ' apoptosis', ' biological signal transduction', ' chromosome translocation', ' gene mutation', ' neoplasm /cancer genetics', ' neoplastic transformation', ' nuclear factor kappa beta', ' phosphoproteins', ' regulatory gene', ' tissue /cell culture']",NCI,UNIVERSITY OF MICHIGAN AT ANN ARBOR,F32,2002,33997,0.06484593947536754
"CIPER--A NOVEL APOPTOSIS REGULATOR INVOLVED IN CANCER Dysfunction of apoptotic pathways plays a critical role in the development of cancer, and the identification and characterization of genes encoding regulators of apoptosis is therefore critical for understanding the pathophysiology of cancer and for developing novel therapeutic approaches. The laboratory has identified CIPER, a gene that regulates both apoptosis and the NF-kB signal transduction pathway, one which is associated with cell survival. Because of this dual function, CIPER appears to play an important role as the control point of a molecular decision-tree; under some circumstances, CIPER may promote apoptosis, while at other times CIPER may favor cell survival. Importantly, the CIPER gene has been found to be located at the chromosomal breakpoint region of t(1;14), a recurrent translocation associated with MALT B-cell lymphoma, and is frequently mutated in lymphomas of various other histologic types as well as some non-lymphoid neoplasms. Our hypothesis is that CIPER promotes tumor development through a combination of dysregulated apoptosis and NF-kB signaling which result from chromosomal mutations affecting the CIPER gene. We are proposing a series of aims to further define the molecular mechanisms by which CIPER controls these signaling pathways, to understand the cellular stimulae which influence CIPER function, and to explore how natural mutations in the CIPER gene affect its important role as a regulator of cell survival.  n/a",CIPER--A NOVEL APOPTOSIS REGULATOR INVOLVED IN CANCER,6208105,F32CA088470,"['B cell lymphoma', ' apoptosis', ' biological signal transduction', ' chromosome translocation', ' gene mutation', ' neoplasm /cancer genetics', ' neoplastic transformation', ' nuclear factor kappa beta', ' phosphoproteins', ' regulatory gene', ' tissue /cell culture']",NCI,UNIVERSITY OF MICHIGAN AT ANN ARBOR,F32,2000,46300,0.06484593947536754
"EVOLUTIONARY DYNAMICS OF BARRETT'S ESOPHAGUS NEOPLASIA    DESCRIPTION  (Applicant's  Description):    The  cell  lineages  in neoplastic       tissues are evolving under the twin dynamics of mutation and clonal expansion.       This  is the basis for both its virulence and our difficulties in treating it.       We  hypothesize  that a subset of the mutations observed in the progression to       cancer  confer  beneficial  selective  effects  on  the cell.  Furthermore, we       hypothesize  that  the  interactions  between  these clonal populations in and       around  the neoplastic tissue determine the progression to cancer.  The aim of       this  project  is  to  identify  these  selective  mutations  and to infer the       interactions  between the mutant clones in Barrett's Esophagus that eventually       lead  to  the development of esophageal adenocarcinoma.  This analysis will be       based  on loss of heterozygosity data, promoter methylation, single nucleotide       polymorphisms,  and  gene  expression  data  for homogeneous subpopulations of       cells  sampled  from  neoplastic  tissue in patients with Barrett's Esophagus.       The  tissue  samples  come  from  biopsies of selected patients in the Seattle       Barrett's  Esophagus  Project  (N=285).   Data mining will be used to identify       mutations  that  are associated with clonal expansion as well as inhibition of       neighboring  clones.    The  order  of  genetic  events  in the progression to       esophageal adenocarcinoma will be determined by phylogenetic reconstruction of       the  cell lineages in the neoplastic tissue of each patient.  Machine learning       techniques,  such  as the EM algorithm, will be employed to infer missing data       and the effects of unsampled mutations. Computational modeling will be used to       generate   comparison  data  for  null  hypotheses  as  well  as  to  generate       experimental  predictions from our understanding of the progression to cancer.       This  is  the first step in my long-term career goal to contribute to medicine       through the use of computational and theoretical methods.  Working at the Fred       Hutchinson  Cancer  Research  Center  will  facilitate  the transition from my       background  in  computer  science  and  evolutionary theory, to an independent       research  program  based on the analysis of cellular and molecular dynamics of       cancer.  The challenge of this project is the integration of diverse molecular       and  epidemiological  data  into  a coherent and detailed understanding of the       progression to cancer in the neoplasm of a model system.                                                                                                                                                                                                       n/a",EVOLUTIONARY DYNAMICS OF BARRETT'S ESOPHAGUS NEOPLASIA,6886821,K01CA089267,"['Barretts esophagus', 'adenocarcinoma', 'cell cell interaction', 'clinical research', 'gene expression', 'gene mutation', 'human subject', 'loss of heterozygosity', 'mathematical model', 'microarray technology', 'model design /development', 'neoplasm /cancer genetics', 'neoplastic growth', 'neoplastic process', 'telomere']",NCI,WISTAR INSTITUTE,K01,2005,158490,0.22618543044399272
"EVOLUTIONARY DYNAMICS OF BARRETT'S ESOPHAGUS NEOPLASIA    DESCRIPTION  (Applicant's  Description):    The  cell  lineages  in neoplastic       tissues are evolving under the twin dynamics of mutation and clonal expansion.       This  is the basis for both its virulence and our difficulties in treating it.       We  hypothesize  that a subset of the mutations observed in the progression to       cancer  confer  beneficial  selective  effects  on  the cell.  Furthermore, we       hypothesize  that  the  interactions  between  these clonal populations in and       around  the neoplastic tissue determine the progression to cancer.  The aim of       this  project  is  to  identify  these  selective  mutations  and to infer the       interactions  between the mutant clones in Barrett's Esophagus that eventually       lead  to  the development of esophageal adenocarcinoma.  This analysis will be       based  on loss of heterozygosity data, promoter methylation, single nucleotide       polymorphisms,  and  gene  expression  data  for homogeneous subpopulations of       cells  sampled  from  neoplastic  tissue in patients with Barrett's Esophagus.       The  tissue  samples  come  from  biopsies of selected patients in the Seattle       Barrett's  Esophagus  Project  (N=285).   Data mining will be used to identify       mutations  that  are associated with clonal expansion as well as inhibition of       neighboring  clones.    The  order  of  genetic  events  in the progression to       esophageal adenocarcinoma will be determined by phylogenetic reconstruction of       the  cell lineages in the neoplastic tissue of each patient.  Machine learning       techniques,  such  as the EM algorithm, will be employed to infer missing data       and the effects of unsampled mutations. Computational modeling will be used to       generate   comparison  data  for  null  hypotheses  as  well  as  to  generate       experimental  predictions from our understanding of the progression to cancer.       This  is  the first step in my long-term career goal to contribute to medicine       through the use of computational and theoretical methods.  Working at the Fred       Hutchinson  Cancer  Research  Center  will  facilitate  the transition from my       background  in  computer  science  and  evolutionary theory, to an independent       research  program  based on the analysis of cellular and molecular dynamics of       cancer.  The challenge of this project is the integration of diverse molecular       and  epidemiological  data  into  a coherent and detailed understanding of the       progression to cancer in the neoplasm of a model system.                                                                                                                                                                                                       n/a",EVOLUTIONARY DYNAMICS OF BARRETT'S ESOPHAGUS NEOPLASIA,6751681,K01CA089267,"['Barretts esophagus', 'adenocarcinoma', 'cell cell interaction', 'clinical research', 'gene expression', 'gene mutation', 'human subject', 'loss of heterozygosity', 'mathematical model', 'microarray technology', 'model design /development', 'neoplasm /cancer genetics', 'neoplastic growth', 'neoplastic process', 'telomere']",NCI,FRED HUTCHINSON CANCER RESEARCH CENTER,K01,2004,126767,0.22618543044399272
"EVOLUTIONARY DYNAMICS OF BARRETT'S ESOPHAGUS NEOPLASIA    DESCRIPTION  (Applicant's  Description):    The  cell  lineages  in neoplastic       tissues are evolving under the twin dynamics of mutation and clonal expansion.       This  is the basis for both its virulence and our difficulties in treating it.       We  hypothesize  that a subset of the mutations observed in the progression to       cancer  confer  beneficial  selective  effects  on  the cell.  Furthermore, we       hypothesize  that  the  interactions  between  these clonal populations in and       around  the neoplastic tissue determine the progression to cancer.  The aim of       this  project  is  to  identify  these  selective  mutations  and to infer the       interactions  between the mutant clones in Barrett's Esophagus that eventually       lead  to  the development of esophageal adenocarcinoma.  This analysis will be       based  on loss of heterozygosity data, promoter methylation, single nucleotide       polymorphisms,  and  gene  expression  data  for homogeneous subpopulations of       cells  sampled  from  neoplastic  tissue in patients with Barrett's Esophagus.       The  tissue  samples  come  from  biopsies of selected patients in the Seattle       Barrett's  Esophagus  Project  (N=285).   Data mining will be used to identify       mutations  that  are associated with clonal expansion as well as inhibition of       neighboring  clones.    The  order  of  genetic  events  in the progression to       esophageal adenocarcinoma will be determined by phylogenetic reconstruction of       the  cell lineages in the neoplastic tissue of each patient.  Machine learning       techniques,  such  as the EM algorithm, will be employed to infer missing data       and the effects of unsampled mutations. Computational modeling will be used to       generate   comparison  data  for  null  hypotheses  as  well  as  to  generate       experimental  predictions from our understanding of the progression to cancer.       This  is  the first step in my long-term career goal to contribute to medicine       through the use of computational and theoretical methods.  Working at the Fred       Hutchinson  Cancer  Research  Center  will  facilitate  the transition from my       background  in  computer  science  and  evolutionary theory, to an independent       research  program  based on the analysis of cellular and molecular dynamics of       cancer.  The challenge of this project is the integration of diverse molecular       and  epidemiological  data  into  a coherent and detailed understanding of the       progression to cancer in the neoplasm of a model system.                                                                                                                                                                                                       n/a",EVOLUTIONARY DYNAMICS OF BARRETT'S ESOPHAGUS NEOPLASIA,6633897,K01CA089267,"['Barretts esophagus', ' adenocarcinoma', ' cell cell interaction', ' clinical research', ' gene expression', ' gene mutation', ' human subject', ' loss of heterozygosity', ' mathematical model', ' microarray technology', ' model design /development', ' neoplasm /cancer genetics', ' neoplastic growth', ' neoplastic process', ' telomere']",NCI,FRED HUTCHINSON CANCER RESEARCH CENTER,K01,2003,123974,0.22618543044399272
"EVOLUTIONARY DYNAMICS OF BARRETT'S ESOPHAGUS NEOPLASIA    DESCRIPTION  (Applicant's  Description):    The  cell  lineages  in neoplastic       tissues are evolving under the twin dynamics of mutation and clonal expansion.       This  is the basis for both its virulence and our difficulties in treating it.       We  hypothesize  that a subset of the mutations observed in the progression to       cancer  confer  beneficial  selective  effects  on  the cell.  Furthermore, we       hypothesize  that  the  interactions  between  these clonal populations in and       around  the neoplastic tissue determine the progression to cancer.  The aim of       this  project  is  to  identify  these  selective  mutations  and to infer the       interactions  between the mutant clones in Barrett's Esophagus that eventually       lead  to  the development of esophageal adenocarcinoma.  This analysis will be       based  on loss of heterozygosity data, promoter methylation, single nucleotide       polymorphisms,  and  gene  expression  data  for homogeneous subpopulations of       cells  sampled  from  neoplastic  tissue in patients with Barrett's Esophagus.       The  tissue  samples  come  from  biopsies of selected patients in the Seattle       Barrett's  Esophagus  Project  (N=285).   Data mining will be used to identify       mutations  that  are associated with clonal expansion as well as inhibition of       neighboring  clones.    The  order  of  genetic  events  in the progression to       esophageal adenocarcinoma will be determined by phylogenetic reconstruction of       the  cell lineages in the neoplastic tissue of each patient.  Machine learning       techniques,  such  as the EM algorithm, will be employed to infer missing data       and the effects of unsampled mutations. Computational modeling will be used to       generate   comparison  data  for  null  hypotheses  as  well  as  to  generate       experimental  predictions from our understanding of the progression to cancer.       This  is  the first step in my long-term career goal to contribute to medicine       through the use of computational and theoretical methods.  Working at the Fred       Hutchinson  Cancer  Research  Center  will  facilitate  the transition from my       background  in  computer  science  and  evolutionary theory, to an independent       research  program  based on the analysis of cellular and molecular dynamics of       cancer.  The challenge of this project is the integration of diverse molecular       and  epidemiological  data  into  a coherent and detailed understanding of the       progression to cancer in the neoplasm of a model system.                                                                                                                                                                                                       n/a",EVOLUTIONARY DYNAMICS OF BARRETT'S ESOPHAGUS NEOPLASIA,6514835,K01CA089267,"['Barretts esophagus', ' adenocarcinoma', ' cell cell interaction', ' clinical research', ' gene expression', ' gene mutation', ' human subject', ' loss of heterozygosity', ' mathematical model', ' microarray technology', ' model design /development', ' neoplasm /cancer genetics', ' neoplastic growth', ' neoplastic process', ' telomere']",NCI,FRED HUTCHINSON CANCER RESEARCH CENTER,K01,2002,121263,0.22618543044399272
"EVOLUTIONARY DYNAMICS OF BARRETT'S ESOPHAGUS NEOPLASIA    DESCRIPTION  (Applicant's  Description):    The  cell  lineages  in neoplastic       tissues are evolving under the twin dynamics of mutation and clonal expansion.       This  is the basis for both its virulence and our difficulties in treating it.       We  hypothesize  that a subset of the mutations observed in the progression to       cancer  confer  beneficial  selective  effects  on  the cell.  Furthermore, we       hypothesize  that  the  interactions  between  these clonal populations in and       around  the neoplastic tissue determine the progression to cancer.  The aim of       this  project  is  to  identify  these  selective  mutations  and to infer the       interactions  between the mutant clones in Barrett's Esophagus that eventually       lead  to  the development of esophageal adenocarcinoma.  This analysis will be       based  on loss of heterozygosity data, promoter methylation, single nucleotide       polymorphisms,  and  gene  expression  data  for homogeneous subpopulations of       cells  sampled  from  neoplastic  tissue in patients with Barrett's Esophagus.       The  tissue  samples  come  from  biopsies of selected patients in the Seattle       Barrett's  Esophagus  Project  (N=285).   Data mining will be used to identify       mutations  that  are associated with clonal expansion as well as inhibition of       neighboring  clones.    The  order  of  genetic  events  in the progression to       esophageal adenocarcinoma will be determined by phylogenetic reconstruction of       the  cell lineages in the neoplastic tissue of each patient.  Machine learning       techniques,  such  as the EM algorithm, will be employed to infer missing data       and the effects of unsampled mutations. Computational modeling will be used to       generate   comparison  data  for  null  hypotheses  as  well  as  to  generate       experimental  predictions from our understanding of the progression to cancer.       This  is  the first step in my long-term career goal to contribute to medicine       through the use of computational and theoretical methods.  Working at the Fred       Hutchinson  Cancer  Research  Center  will  facilitate  the transition from my       background  in  computer  science  and  evolutionary theory, to an independent       research  program  based on the analysis of cellular and molecular dynamics of       cancer.  The challenge of this project is the integration of diverse molecular       and  epidemiological  data  into  a coherent and detailed understanding of the       progression to cancer in the neoplasm of a model system.                                                                                                                                                                                                       n/a",EVOLUTIONARY DYNAMICS OF BARRETT'S ESOPHAGUS NEOPLASIA,6229855,K01CA089267,"['Barretts esophagus', ' adenocarcinoma', ' cell cell interaction', ' clinical research', ' gene expression', ' gene mutation', ' human subject', ' loss of heterozygosity', ' mathematical model', ' microarray technology', ' model design /development', ' neoplasm /cancer genetics', ' neoplastic growth', ' neoplastic process', ' telomere']",NCI,FRED HUTCHINSON CANCER RESEARCH CENTER,K01,2001,118630,0.22618543044399272
"HyPhy: Molecular Evolutionary Analyses    DESCRIPTION (provided by applicant): Project Description HyPhy (http://www.hyphy.org) is a scriptable software platform designed to enable flexible and powerful analyses of DNA, RNA, codon, amino acid and other types of sequence data in an evolutionary context. Such analyses have become an indispensable component of most research studies that make use of comparative genomic data. Biologists and bioinformaticians increasingly recognize the benefits of molecular evolutionary analyses. Since its initial release in 2001, HyPhy has become a relatively stable and mature product, and has been downloaded by more than 4,500 unique users, integrated into several popular web-based genomic data analysis servers, cited in over 400 peer-reviewed publications and described in three book chapters, in spite of the fact that the development of the package has never been directly funded. This proposal seeks support to improve the quality, performance, reliability, modularity, documentation and feature sets of the HyPhy system. Specific aims can be divided into four major areas: 1. Software engineering, testing, and documentation of the HyPhy codebase. 2. The development of a high-performance engine for phylogenetic maximum likelihood model fitting and inference. 3. Extension of a newly-initiated toolbox for machine learning applications in molecular evolution. 4. Creation and maintenance of a wiki-themed documentation resource.      PUBLIC HEALTH RELEVANCE: Project Narrative Molecular evolutionary analyses are central to many aspects of basic, translational, and applied biomedical research. Examples include identifying gene mutations that allow pathogens to evade the immune response; prediction of the structure and function of proteins; estimating the evolutionary relatedness of human or other populations; characterizing the magnitude of selective pressure, either natural or artificial, on genes or species.           Project Narrative Molecular evolutionary analyses are central to many aspects of basic, translational, and applied biomedical research. Examples include identifying gene mutations that allow pathogens to evade the immune response; prediction of the structure and function of proteins; estimating the evolutionary relatedness of human or other populations; characterizing the magnitude of selective pressure, either natural or artificial, on genes or species.",HyPhy: Molecular Evolutionary Analyses,7937611,R01GM093939,"['Amino Acids', 'Animal Model', 'Area', 'Biomedical Research', 'Book Chapters', 'Code', 'Codon Nucleotides', 'Collection', 'Computer software', 'DNA', 'Data', 'Data Analyses', 'Development', 'Documentation', 'Drug resistance', 'Evolution', 'Funding', 'Gene Mutation', 'Genes', 'Genetic Programming', 'Genome', 'Genomics', 'Goals', 'Human', 'Immune response', 'Internet', 'Language', 'Libraries', 'Machine Learning', 'Maintenance', 'Modeling', 'Molecular', 'Molecular Evolution', 'Molecular Sequence Data', 'Online Systems', 'Pathogenicity', 'Pattern', 'Peer Review', 'Performance', 'Phylogenetic Analysis', 'Phylogeny', 'Population', 'Procedures', 'Publications', 'Research Personnel', 'Resources', 'Software Engineering', 'Study models', 'System', 'Testing', 'Viral', 'Work', 'acronyms', 'base', 'combinatorial', 'comparative genomics', 'design', 'flexibility', 'improved', 'pathogen', 'pressure', 'programs', 'protein structure function', 'public health relevance', 'research study', 'tool', 'user-friendly', 'wiki']",NIGMS,NORTH CAROLINA STATE UNIVERSITY RALEIGH,R01,2010,296413,0.093547201744985
"HyPhy: Molecular Evolutionary Analyses    DESCRIPTION (provided by applicant): Project Description HyPhy (http://www.hyphy.org) is a scriptable software platform designed to enable flexible and powerful analyses of DNA, RNA, codon, amino acid and other types of sequence data in an evolutionary context. Such analyses have become an indispensable component of most research studies that make use of comparative genomic data. Biologists and bioinformaticians increasingly recognize the benefits of molecular evolutionary analyses. Since its initial release in 2001, HyPhy has become a relatively stable and mature product, and has been downloaded by more than 4,500 unique users, integrated into several popular web-based genomic data analysis servers, cited in over 400 peer-reviewed publications and described in three book chapters, in spite of the fact that the development of the package has never been directly funded. This proposal seeks support to improve the quality, performance, reliability, modularity, documentation and feature sets of the HyPhy system. Specific aims can be divided into four major areas: 1. Software engineering, testing, and documentation of the HyPhy codebase. 2. The development of a high-performance engine for phylogenetic maximum likelihood model fitting and inference. 3. Extension of a newly-initiated toolbox for machine learning applications in molecular evolution. 4. Creation and maintenance of a wiki-themed documentation resource.      PUBLIC HEALTH RELEVANCE: Project Narrative Molecular evolutionary analyses are central to many aspects of basic, translational, and applied biomedical research. Examples include identifying gene mutations that allow pathogens to evade the immune response; prediction of the structure and function of proteins; estimating the evolutionary relatedness of human or other populations; characterizing the magnitude of selective pressure, either natural or artificial, on genes or species.           Project Narrative Molecular evolutionary analyses are central to many aspects of basic, translational, and applied biomedical research. Examples include identifying gene mutations that allow pathogens to evade the immune response; prediction of the structure and function of proteins; estimating the evolutionary relatedness of human or other populations; characterizing the magnitude of selective pressure, either natural or artificial, on genes or species.",HyPhy: Molecular Evolutionary Analyses,8542870,R01GM093939,"['Amino Acids', 'Animal Model', 'Area', 'Biomedical Research', 'Book Chapters', 'Classification', 'Code', 'Codon Nucleotides', 'Collection', 'Computer software', 'DNA', 'Data', 'Data Analyses', 'Development', 'Documentation', 'Drug resistance', 'Evolution', 'Funding', 'Gene Mutation', 'Genes', 'Genetic Programming', 'Genome', 'Genomics', 'Goals', 'Human', 'Immune response', 'Internet', 'Language', 'Libraries', 'Likelihood Functions', 'Machine Learning', 'Maintenance', 'Modeling', 'Molecular', 'Molecular Evolution', 'Molecular Sequence Data', 'Online Systems', 'Pathogenicity', 'Pattern', 'Peer Review', 'Performance', 'Phylogenetic Analysis', 'Phylogeny', 'Population', 'Procedures', 'Publications', 'RNA', 'Research Personnel', 'Resources', 'Software Engineering', 'Study models', 'System', 'Testing', 'Viral', 'Work', 'acronyms', 'base', 'combinatorial', 'comparative genomics', 'design', 'flexibility', 'improved', 'pathogen', 'pressure', 'programs', 'protein structure function', 'public health relevance', 'research study', 'tool', 'user-friendly', 'wiki']",NIGMS,NORTH CAROLINA STATE UNIVERSITY RALEIGH,R01,2013,265099,0.093547201744985
"HyPhy: Molecular Evolutionary Analyses    DESCRIPTION (provided by applicant): Project Description HyPhy (http://www.hyphy.org) is a scriptable software platform designed to enable flexible and powerful analyses of DNA, RNA, codon, amino acid and other types of sequence data in an evolutionary context. Such analyses have become an indispensable component of most research studies that make use of comparative genomic data. Biologists and bioinformaticians increasingly recognize the benefits of molecular evolutionary analyses. Since its initial release in 2001, HyPhy has become a relatively stable and mature product, and has been downloaded by more than 4,500 unique users, integrated into several popular web-based genomic data analysis servers, cited in over 400 peer-reviewed publications and described in three book chapters, in spite of the fact that the development of the package has never been directly funded. This proposal seeks support to improve the quality, performance, reliability, modularity, documentation and feature sets of the HyPhy system. Specific aims can be divided into four major areas: 1. Software engineering, testing, and documentation of the HyPhy codebase. 2. The development of a high-performance engine for phylogenetic maximum likelihood model fitting and inference. 3. Extension of a newly-initiated toolbox for machine learning applications in molecular evolution. 4. Creation and maintenance of a wiki-themed documentation resource.      PUBLIC HEALTH RELEVANCE: Project Narrative Molecular evolutionary analyses are central to many aspects of basic, translational, and applied biomedical research. Examples include identifying gene mutations that allow pathogens to evade the immune response; prediction of the structure and function of proteins; estimating the evolutionary relatedness of human or other populations; characterizing the magnitude of selective pressure, either natural or artificial, on genes or species.           Project Narrative Molecular evolutionary analyses are central to many aspects of basic, translational, and applied biomedical research. Examples include identifying gene mutations that allow pathogens to evade the immune response; prediction of the structure and function of proteins; estimating the evolutionary relatedness of human or other populations; characterizing the magnitude of selective pressure, either natural or artificial, on genes or species.",HyPhy: Molecular Evolutionary Analyses,8322626,R01GM093939,"['Amino Acids', 'Animal Model', 'Area', 'Biomedical Research', 'Book Chapters', 'Classification', 'Code', 'Codon Nucleotides', 'Collection', 'Computer software', 'DNA', 'Data', 'Data Analyses', 'Development', 'Documentation', 'Drug resistance', 'Evolution', 'Funding', 'Gene Mutation', 'Genes', 'Genetic Programming', 'Genome', 'Genomics', 'Goals', 'Human', 'Immune response', 'Internet', 'Language', 'Libraries', 'Likelihood Functions', 'Machine Learning', 'Maintenance', 'Modeling', 'Molecular', 'Molecular Evolution', 'Molecular Sequence Data', 'Online Systems', 'Pathogenicity', 'Pattern', 'Peer Review', 'Performance', 'Phylogenetic Analysis', 'Phylogeny', 'Population', 'Procedures', 'Publications', 'RNA', 'Research Personnel', 'Resources', 'Software Engineering', 'Study models', 'System', 'Testing', 'Viral', 'Work', 'acronyms', 'base', 'combinatorial', 'comparative genomics', 'design', 'flexibility', 'improved', 'pathogen', 'pressure', 'programs', 'protein structure function', 'public health relevance', 'research study', 'tool', 'user-friendly', 'wiki']",NIGMS,NORTH CAROLINA STATE UNIVERSITY RALEIGH,R01,2012,274156,0.093547201744985
"HyPhy: Molecular Evolutionary Analyses    DESCRIPTION (provided by applicant): Project Description HyPhy (http://www.hyphy.org) is a scriptable software platform designed to enable flexible and powerful analyses of DNA, RNA, codon, amino acid and other types of sequence data in an evolutionary context. Such analyses have become an indispensable component of most research studies that make use of comparative genomic data. Biologists and bioinformaticians increasingly recognize the benefits of molecular evolutionary analyses. Since its initial release in 2001, HyPhy has become a relatively stable and mature product, and has been downloaded by more than 4,500 unique users, integrated into several popular web-based genomic data analysis servers, cited in over 400 peer-reviewed publications and described in three book chapters, in spite of the fact that the development of the package has never been directly funded. This proposal seeks support to improve the quality, performance, reliability, modularity, documentation and feature sets of the HyPhy system. Specific aims can be divided into four major areas: 1. Software engineering, testing, and documentation of the HyPhy codebase. 2. The development of a high-performance engine for phylogenetic maximum likelihood model fitting and inference. 3. Extension of a newly-initiated toolbox for machine learning applications in molecular evolution. 4. Creation and maintenance of a wiki-themed documentation resource.      PUBLIC HEALTH RELEVANCE: Project Narrative Molecular evolutionary analyses are central to many aspects of basic, translational, and applied biomedical research. Examples include identifying gene mutations that allow pathogens to evade the immune response; prediction of the structure and function of proteins; estimating the evolutionary relatedness of human or other populations; characterizing the magnitude of selective pressure, either natural or artificial, on genes or species.           Project Narrative Molecular evolutionary analyses are central to many aspects of basic, translational, and applied biomedical research. Examples include identifying gene mutations that allow pathogens to evade the immune response; prediction of the structure and function of proteins; estimating the evolutionary relatedness of human or other populations; characterizing the magnitude of selective pressure, either natural or artificial, on genes or species.",HyPhy: Molecular Evolutionary Analyses,8143338,R01GM093939,"['Amino Acids', 'Animal Model', 'Area', 'Biomedical Research', 'Book Chapters', 'Classification', 'Code', 'Codon Nucleotides', 'Collection', 'Computer software', 'DNA', 'Data', 'Data Analyses', 'Development', 'Documentation', 'Drug resistance', 'Evolution', 'Funding', 'Gene Mutation', 'Genes', 'Genetic Programming', 'Genome', 'Genomics', 'Goals', 'Human', 'Immune response', 'Internet', 'Language', 'Libraries', 'Likelihood Functions', 'Machine Learning', 'Maintenance', 'Modeling', 'Molecular', 'Molecular Evolution', 'Molecular Sequence Data', 'Online Systems', 'Pathogenicity', 'Pattern', 'Peer Review', 'Performance', 'Phylogenetic Analysis', 'Phylogeny', 'Population', 'Procedures', 'Publications', 'RNA', 'Research Personnel', 'Resources', 'Software Engineering', 'Study models', 'System', 'Testing', 'Viral', 'Work', 'acronyms', 'base', 'combinatorial', 'comparative genomics', 'design', 'flexibility', 'improved', 'pathogen', 'pressure', 'programs', 'protein structure function', 'public health relevance', 'research study', 'tool', 'user-friendly', 'wiki']",NIGMS,NORTH CAROLINA STATE UNIVERSITY RALEIGH,R01,2011,275732,0.093547201744985
"Massively parallel functional analyses of human PTEN variants Project Summary  We are now able to routinely sequence human genomes at single-base resolution. However, our ability to interpret the functional consequences of detected mutations has lagged behind. Computational approaches scale well but have poor accuracy, whereas retrospective analysis of detected variants has high accuracy but does not scale well. In order to solve this problem, a new experimental paradigm has emerged to empirically characterize the effects of mutations with high accuracy at scale. This approach takes advantage of recent and ongoing improvements in DNA synthesis and sequencing, and has the potential to offer unprecedented insight into protein biochemistry and human disease. We believe these insights will prove to be critical for unlocking the potential of genomic medicine.  In this project we seek to comprehensively assess multiple molecular effects of PTEN mutations on protein function, and assess the utility of this data as a predictor for human clinical phenotype. The PTEN protein is a tumor suppressor that is frequently mutated in diverse human cancers and in the germline of some individuals with overgrowth disorders, cancer predisposition syndromes, or autism. Currently, it is impossible to predict the effects of the vast majority of PTEN germline mutations. Since the phenotypic spectrum of PTEN mutation carriers is broad, it would be highly valuable to understand the ways in which phenotypic outcomes arise from PTEN mutation genotypes.  In Aim 1, we will first employ a yeast-based screen to assess the effects all PTEN single amino acid mutations on lipid phosphatase activity, the primary biochemical function of PTEN protein. It is known that several pathogenic variants are destabilized. Therefore, in Aim 2, we will perform a second, independent screen to assess the steady state protein stability of all PTEN single amino acid mutations. In Aim 3, we will use the data derived from this study as well as publically available biochemical information to train a classifier model to predict the relationship between the mutation genotypes and clinical phenotypes observed in humans. These data will increase our fundamental understanding of PTEN function and the role of mutations in diverse disorders, and could provide a valuable clinical tool that would increase the quality of life for PTEN mutation carriers. Project Narrative  Mutations in the gene PTEN are causal for a diverse set of clinical disorders ranging from cancer to autism spectrum disorder. Here, we seek to gain new fundamental insights into the functional relationships between PTEN mutations and clinical presentations by prospectively characterizing the effects of all single amino acid PTEN mutations in parallel. These data will allow the creation of new models that can predict risk of specific PTEN mutations for different clinical outcomes and potentially lead to personalized therapies, early interventions, and optimal outcomes for PTEN mutation carriers.",Massively parallel functional analyses of human PTEN variants,9539482,F31HD095571,"['Affect', 'Amino Acids', 'Autistic Disorder', 'Biochemical', 'Biochemistry', 'Biological Assay', 'Biology', 'Biophysics', 'Cataloging', 'Catalogs', 'Cell Separation', 'Cell Survival', 'Cells', 'Characteristics', 'Clinic', 'Clinical', 'Complex', 'Coupled', 'Coupling', 'DNA biosynthesis', 'DNA sequencing', 'Data', 'Data Set', 'Deletion Mutation', 'Development', 'Disease', 'Early Intervention', 'FRAP1 gene', 'Fluorescence', 'Genes', 'Genome', 'Genomic medicine', 'Genomics', 'Genotype', 'Germ-Line Mutation', 'Goals', 'Growth', 'Human', 'Human Genetics', 'Human Genome', 'Individual', 'Lead', 'Light', 'Lipids', 'Machine Learning', 'Malignant Neoplasms', 'Measures', 'Metabolism', 'Modeling', 'Molecular', 'Mutate', 'Mutation', 'Outcome', 'PTEN gene', 'PTEN protein', 'Pathogenicity', 'Pathway interactions', 'Patients', 'Phenotype', 'Phosphatidylinositols', 'Phosphoric Monoester Hydrolases', 'Play', 'Predisposition', 'Problem Solving', 'Process', 'Protein Biochemistry', 'Proteins', 'Pythons', 'Quality of life', 'Reaction', 'Resolution', 'Risk', 'Role', 'Signal Pathway', 'Signal Transduction', 'Site', 'Syndrome', 'Techniques', 'Temperature', 'Testing', 'Therapeutic Intervention', 'Time', 'Training', 'Tumor Suppressor Proteins', 'Ubiquitination', 'Variant', 'Yeast Model System', 'Yeasts', 'accurate diagnosis', 'autism spectrum disorder', 'base', 'clinical phenotype', 'experimental study', 'fitness', 'genomic signature', 'genomic variation', 'high throughput technology', 'human disease', 'improved', 'insight', 'mutation carrier', 'next generation', 'novel', 'open source', 'personalized medicine', 'prediction algorithm', 'predictive modeling', 'prospective', 'protein function', 'screening', 'synthetic biology', 'tool', 'tumorigenic']",NICHD,OREGON HEALTH & SCIENCE UNIVERSITY,F31,2018,44524,0.3168615497723371
"Massively parallel functional analyses of human PTEN variants Project Summary  We are now able to routinely sequence human genomes at single-base resolution. However, our ability to interpret the functional consequences of detected mutations has lagged behind. Computational approaches scale well but have poor accuracy, whereas retrospective analysis of detected variants has high accuracy but does not scale well. In order to solve this problem, a new experimental paradigm has emerged to empirically characterize the effects of mutations with high accuracy at scale. This approach takes advantage of recent and ongoing improvements in DNA synthesis and sequencing, and has the potential to offer unprecedented insight into protein biochemistry and human disease. We believe these insights will prove to be critical for unlocking the potential of genomic medicine.  In this project we seek to comprehensively assess multiple molecular effects of PTEN mutations on protein function, and assess the utility of this data as a predictor for human clinical phenotype. The PTEN protein is a tumor suppressor that is frequently mutated in diverse human cancers and in the germline of some individuals with overgrowth disorders, cancer predisposition syndromes, or autism. Currently, it is impossible to predict the effects of the vast majority of PTEN germline mutations. Since the phenotypic spectrum of PTEN mutation carriers is broad, it would be highly valuable to understand the ways in which phenotypic outcomes arise from PTEN mutation genotypes.  In Aim 1, we will first employ a yeast-based screen to assess the effects all PTEN single amino acid mutations on lipid phosphatase activity, the primary biochemical function of PTEN protein. It is known that several pathogenic variants are destabilized. Therefore, in Aim 2, we will perform a second, independent screen to assess the steady state protein stability of all PTEN single amino acid mutations. In Aim 3, we will use the data derived from this study as well as publically available biochemical information to train a classifier model to predict the relationship between the mutation genotypes and clinical phenotypes observed in humans. These data will increase our fundamental understanding of PTEN function and the role of mutations in diverse disorders, and could provide a valuable clinical tool that would increase the quality of life for PTEN mutation carriers. Project Narrative  Mutations in the gene PTEN are causal for a diverse set of clinical disorders ranging from cancer to autism spectrum disorder. Here, we seek to gain new fundamental insights into the functional relationships between PTEN mutations and clinical presentations by prospectively characterizing the effects of all single amino acid PTEN mutations in parallel. These data will allow the creation of new models that can predict risk of specific PTEN mutations for different clinical outcomes and potentially lead to personalized therapies, early interventions, and optimal outcomes for PTEN mutation carriers.",Massively parallel functional analyses of human PTEN variants,9794010,F31HD095571,"['Affect', 'Amino Acids', 'Biochemical', 'Biochemistry', 'Biological Assay', 'Biology', 'Biophysics', 'Cataloging', 'Catalogs', 'Cell Separation', 'Cell Survival', 'Cells', 'Characteristics', 'Clinic', 'Clinical', 'Complex', 'Coupled', 'Coupling', 'DNA biosynthesis', 'DNA sequencing', 'Data', 'Data Set', 'Deletion Mutation', 'Development', 'Disease', 'Early Intervention', 'FRAP1 gene', 'Fluorescence', 'Genes', 'Genome', 'Genomic medicine', 'Genomics', 'Genotype', 'Germ-Line Mutation', 'Goals', 'Growth', 'Human', 'Human Genetics', 'Human Genome', 'Individual', 'Lead', 'Light', 'Lipids', 'Machine Learning', 'Malignant Neoplasms', 'Measures', 'Metabolism', 'Modeling', 'Molecular', 'Mutate', 'Mutation', 'Outcome', 'PTEN gene', 'PTEN protein', 'Pathogenicity', 'Pathway interactions', 'Patients', 'Phenotype', 'Phosphatidylinositols', 'Phosphoric Monoester Hydrolases', 'Play', 'Predisposition', 'Problem Solving', 'Process', 'Protein Biochemistry', 'Proteins', 'Pythons', 'Quality of life', 'Reaction', 'Resolution', 'Risk', 'Role', 'Signal Pathway', 'Signal Transduction', 'Site', 'Syndrome', 'Techniques', 'Temperature', 'Testing', 'Therapeutic Intervention', 'Time', 'Training', 'Tumor Suppressor Proteins', 'Ubiquitination', 'Variant', 'Yeast Model System', 'Yeasts', 'accurate diagnosis', 'autism spectrum disorder', 'base', 'clinical phenotype', 'experimental study', 'fitness', 'genomic signature', 'genomic variation', 'high throughput technology', 'human disease', 'improved', 'insight', 'mutation carrier', 'next generation', 'novel', 'open source', 'personalized medicine', 'prediction algorithm', 'predictive modeling', 'prospective', 'protein function', 'screening', 'synthetic biology', 'tool', 'tumorigenic']",NICHD,OREGON HEALTH & SCIENCE UNIVERSITY,F31,2019,45016,0.3168615497723371
"Microsatellite instability and cancer gene expression DESCRIPTION (provided by applicant):  Genetic or epigenetic inactivation of DNA mismatch repair in tumor precursor cells causes a profound mutator phenotype. The microsatellite mutator phenotype (MMP) was discovered by the detection of deletion/insertion mutations in repeated sequences due to slippage by strand misalignment during DNA replication. The importance of microsatellite sequences for the development of cancer has been well illustrated through the MMP mechanism: cancerrelated genes that contain microsatellite repeats in their coding regions are specifically mutated in MMP-positive tumors. The role of non-coding microsatellites in MMP cancer pathogenesis has only been suggested by scarce experimental data and theoretical speculations. The working hypothesis of this proposal is that the MMP inevitably causes mutations in microsatellites located in non-coding regions of cancer-related genes, and that these mutations may affect their expression through modulation of gene transcription, translation, RNA splicing or mRNA stability. These changes in the levels of negative and positive cell growth regulators in turn, will contribute to awake and/or increase the cell neoplastic potential. The goal of the proposed research is to directly test this hypothesis. The unique feature of this hypothesis is that in the MMP cancer pathway these non-coding microsatellite mutations, despite their presumable modest oncogenic potency, may be equally important for tumorigenesis than other more potent coding mutations, because they occur well before. To test this hypothesis, we will: analyze EGFR CA repeat expansion in MMP-positive cancers; estimate the levels of EGFR expression in subclones of MMP cell lines with different repeat lengths, and their apoptotic response by transfection and small interference RNA assays; correlate EGFR repeat expansion with K-ras oncogene mutations and expression of apoptosis-related genes; examine tumor archeology regarding EGFR expression and repeat expansion; and test the oncogenic potential in vivo of EGFR CA repeat expansion by tumorigenicity assays (Specific aim 1). We will determine the effect of deletions in the 3'UTR of the fl-catenin gene in protein expression and in tumor phenotype by transfection and tumorigenicity assays. We will also test the effect in gene expression of deletions in the 3'UTR of the p53 and other identified candidate genes (Specific aim 2). We will also identify other cancer-related genes with regulatory microsatellite repeats and characterize the non-coding microsatellite expression modulation as outlined before for the EGFR and beta-catenin genes. (Specific aim 3). This proposal will provide insights on a novel pathway of cancer gene expression modulation in tumorigenesis. n/a",Microsatellite instability and cancer gene expression,7219945,R01CA098818,"['3&apos', ' Untranslated Regions', 'Affect', 'Apoptosis', 'Apoptotic', 'Archaeology', 'Biological Assay', 'Candidate Disease Gene', 'Cell Line', 'Cell Separation', 'Code', 'Correlation Studies', 'DNA', 'DNA biosynthesis', 'Data', 'Detection', 'Development', 'EGFR gene', 'Epidermal Growth Factor Receptor', 'Epigenetic Process', 'Functional RNA', 'Gene Bank', 'Gene Expression', 'Gene Mutation', 'Genes', 'Genetic', 'Genetic Transcription', 'Goals', 'Growth', 'Immunohistochemistry', 'K-ras Gene', 'K-ras Oncogene', 'Length', 'Link', 'Malignant Neoplasms', 'Measures', 'Messenger RNA', 'Microsatellite Instability', 'Microsatellite Mutator Phenotype', 'Microsatellite Repeats', 'Mismatch Repair', 'Mutate', 'Mutation', 'Nude Mice', 'Oncogenic', 'Pathogenesis', 'Pathway interactions', 'Personal Satisfaction', 'Phenotype', 'Polymerase Chain Reaction', 'Predisposition', 'Proteins', 'RNA Interference', 'RNA Splicing', 'Reporter', 'Research', 'Role', 'TP53 gene', 'Testing', 'Tissue Microarray', 'Transfection', 'Translations', 'Tumorigenicity', 'Variant', 'Work', 'awake', 'beta catenin', 'cancer gene expression', 'cell growth', 'in vivo', 'insertion/deletion mutation', 'insight', 'mRNA Stability', 'neoplastic cell', 'novel', 'precursor cell', 'protein expression', 'research study', 'response', 'text searching', 'tumor', 'tumorigenesis', 'vector']",NCI,SANFORD-BURNHAM MEDICAL RESEARCH INSTIT,R01,2007,405062,0.11893913277007154
"Pharmacogenomics of serotonin-specific reuptake inhibitors     DESCRIPTION (provided by applicant): Neuropsychiatric disorders, such as depression, have not shown conclusive linkage or association study results. Today, an enormous portion of heritability for depression remains unexplained. Rather than reiterating studies attempting to identify genetic variants underlying depression pathophysiology, I propose a different approach of evaluating genetic variation in the safety and efficacy of the major class of antidepressants. I will identify patients with the quantitative and discrete phenotypes of serotonin-specific reuptake inhibitor (SSRI) response (as measured through the Patient's Health Questionnaire-9 pre- and post-SSRI treatment), and SSRI-associated serious side effects, such as abnormal bleeding and serotonin syndrome. After identification of these phenotypes from the electronic Medical Records and Genetic Epidemiology (eMERGE) consortium, I will perform a genome-wide association study (GWAS) on 50,109 subjects to identify candidate genes involved in SSRI pharmacology and then leverage overlapping exome sequence data to identify rare, potentially causative mutations. As many GWAS and rare variant studies suffer from a lack of functional validation (i.e., that the identified variant truly causes the phenotype), I will functionally valiate these identified rare mutations in the model organism Saccharomyces cerevisiae using a yeast growth-based assay as a direct measure of protein function. The P450 enzyme CYP3A4, which has been implicated in SSRI metabolism, will be used as a proof of concept for the yeast assay. Finally, I will then use this yeast growth assay to perform deep mutational scanning to create a pharmacogenomic map of all possible mutations and their effect on enzyme hydrolysis, thereby linking DNA sequence to protein function. This work will provide a unique resource for understanding SSRI pharmacology. Through completion of a GWAS on the pharmacogenomic phenotypes of SSRI response and separately, risk of SSRI-associated bleeding and serotonin syndrome, I will likely identify numerous candidate genes that may further inform on the metabolism, transport, and mechanism of action of SSRIs, thereby furthering basic science. Moreover, through functional validation and creation of a pharmacogenomic map with deep mutational scanning, I will create an invaluable resource for clinicians to interpret the likely efect of their patient's rare mutation. Through this project, I hope to further the effort to bring personalized, genomic medicine into clinical practice, to decrease the morbidity and mortality of depression, which is estimated by the Center for Disease Control to affect 1 in 10 adults in the U.S.          PUBLIC HEALTH RELEVANCE: Depression is affects 1 in 10 adults in the United States and is one of the leading causes of disability. Depression is primarily treated with serotonin-specific reuptake inhibitors (SSRIs). Understanding how mutations in genes affect SSRI response and risk of side effects forwards the implementation of personalized, genomic medicine into evidence-based clinical practice. This integration of genomic information will likely greatly decrease the morbidity of depression in the United States and globally.            ",Pharmacogenomics of serotonin-specific reuptake inhibitors,8841610,F31MH101905,"['Address', 'Adult', 'Adverse effects', 'Affect', 'Algorithms', 'American', 'Amino Acid Sequence', 'Animal Model', 'Antidepressive Agents', 'Basic Science', 'Bioinformatics', 'Biological Assay', 'Biology', 'CYP3A4 gene', 'Candidate Disease Gene', 'Centers for Disease Control and Prevention (U.S.)', 'Code', 'Complementary DNA', 'Computerized Medical Record', 'Cytochrome P450', 'DNA Sequence', 'Data', 'Development', 'Disease', 'Environment', 'Enzymes', 'Fellowship', 'Functional disorder', 'Genes', 'Genetic', 'Genetic Variation', 'Genome', 'Genomics', 'Genotype', 'Goals', 'Growth', 'Health', 'Hemorrhage', 'Heritability', 'Human', 'Hydrolysis', 'ICD-9', 'Incidence', 'International', 'Knowledge', 'Laboratories', 'Link', 'Logistic Regressions', 'Maps', 'Measures', 'Medical', 'Medical Genetics', 'Medicine', 'Mental Depression', 'Metabolism', 'Methods', 'Modeling', 'Morbidity - disease rate', 'Mutation', 'Natural Language Processing', 'Patients', 'Peptide Sequence Determination', 'Pharmaceutical Preparations', 'Pharmacogenomics', 'Pharmacology', 'Pharmacotherapy', 'Phenotype', 'Physicians', 'Play', 'Population', 'Proteins', 'Questionnaires', 'Regression Analysis', 'Resources', 'Risk', 'Role', 'Saccharomyces cerevisiae', 'Safety', 'Scanning', 'Scientist', 'Selective Serotonin Reuptake Inhibitor', 'Serotonin', 'Serotonin Syndrome', 'Site-Directed Mutagenesis', 'Testing', 'Training', 'Translating', 'United States', 'United States National Institutes of Health', 'Validation', 'Variant', 'Visit', 'Work', 'Yeasts', 'absorption', 'base', 'clinical phenotype', 'clinical practice', 'disability', 'disease classification', 'evidence base', 'exome sequencing', 'genetic epidemiology', 'genetic variant', 'genome wide association study', 'inhibitor/antagonist', 'mortality', 'mutant', 'neuropsychiatry', 'novel', 'protein function', 'public health relevance', 'rare variant', 'response', 'reuptake', 'skills']",NIMH,UNIVERSITY OF WASHINGTON,F31,2014,35141,0.08008757807506094
"The interaction of myosin and the thin filament: how mutations cause allosteric dysfunction and their connection to genetic cardiomyopathy Project Summary: The long-term goal of this research program is to develop a rigorously experimentally validated all-atom computational model of the cardiac thin filament (CTF) bound to myosin S1 which provides a unique and accessible platform to identify novel, high resolution disease mechanisms linked to Hypertrophic Cardiomyopathy (HCM). In the prior funding period, we refined and extended our existing CTF computational model and successfully employed it to identify unique and clinically relevant allosteric disease mechanisms including HCM mutation-induced changes in myofilament Ca2+ kinetics, mutation-specific molecular causes of differential cardiac remodeling and disease progression. This included an in vivo validation via the development of a novel transgenic mouse model of cTnT-linked dilated cardiomyopathy and a predictive algorithm to determine the pathogenicity of cTnT mutations that out-performed existing computational approaches in a preliminary test. The key to these advances has been the ability of the current model to precisely identify and locate allosteric changes caused by mutations throughout all components of the CTF followed by closely coupled experimental validation and eventual in vivo model correlation. We now propose to significantly expand the biological complexity of the model to include myosin S1, the molecular motor that drives contraction and the second most common genetic cause of HCM. This important and challenging advance will facilitate a deeper understanding of disease pathogenesis by, for the first time, incorporating the role of molecular allosteric mechanisms between myosin S1 and thin filament. This new computational  experimental platform will be used for both mechanistic insight (for example used for the identification of novel myofilament disease targets,) and the development of a comprehensive deep-learning predictive algorithm to assign pathogenicity to both myosin and thin filament HCM mutations. The latter represents the first use of high-resolution structure, dynamics and function to predict HCM disease allele pathogenicity, a central challenge in the clinical management of these complex patients. Both the training and testing components of the deep learning development will utilize data from the highly annotated and curated SHaRe HCM registry thus greatly improving translational power. Two Specific Aims will be pursued: Aim 1 will utilize state of the art rare event simulation methods developed in one of our groups and refinement of existing unstructured domains of the CTF via FRET to establish the new model. Aim 2 will employ an extensive program of computational analysis and subsequent in vitro validation using pathogenic, variants of unknown significance and non- pathogenic HCM alleles derived from SHaRe to provide inputs to the machine learning environment for algorithm development. Novel disease mechanisms for myosin and thin filament HCM that include crosstalk between the two components will also be explored. Elucidation of these mechanisms can be the basis for robust molecular approaches to disease. Precision medicine and molecular medicine are concepts that aim to employ a patients genetic structure to discern the best medical treatments for disease. Hypertrophic cardiomyopathy is a genetic disease that afflicts 1/500 people. This application translates our knowledge of the molecular level effects of cardiac tissue mutation to disease and will aim to lead to eventual treatment.",The interaction of myosin and the thin filament: how mutations cause allosteric dysfunction and their connection to genetic cardiomyopathy,10071638,R01HL107046,"['Address', 'Alleles', 'Anisotropy', 'Artificial Intelligence', 'Biological', 'Biological Assay', 'Biology', 'Biophysics', 'Breath Tests', 'C-terminal', 'Cardiac', 'Chemistry', 'Clinical Management', 'Complex', 'Computer Analysis', 'Computer Models', 'Contracts', 'Coupled', 'Data', 'Data Set', 'Descriptor', 'Development', 'Differential Scanning Calorimetry', 'Dilated Cardiomyopathy', 'Disease', 'Disease Progression', 'Distant', 'Engineering', 'Enzymes', 'Event', 'Fluorescence Anisotropy', 'Fluorescence Resonance Energy Transfer', 'Functional disorder', 'Funding', 'Generations', 'Genetic', 'Genetic Diseases', 'Genetic Structures', 'Goals', 'Grant', 'Hand', 'Human', 'Hypertrophic Cardiomyopathy', 'In Vitro', 'Individual', 'Induced Mutation', 'Kinetics', 'Knowledge', 'Lead', 'Link', 'Machine Learning', 'Manuals', 'Medical', 'Methodology', 'Methods', 'Microfilaments', 'Modeling', 'Molecular', 'Molecular Conformation', 'Molecular Medicine', 'Molecular Motors', 'Motor', 'Mutation', 'Myosin ATPase', 'Pathogenesis', 'Pathogenicity', 'Patients', 'Perception', 'Physiological', 'Play', 'Protein Conformation', 'Protein Dynamics', 'Proteins', 'Registries', 'Research', 'Resolution', 'Resources', 'Role', 'Sampling', 'Sarcomeres', 'Site', 'Structure', 'System', 'Techniques', 'Technology', 'Testing', 'Thick Filament', 'Thin Filament', 'Thinness', 'Time', 'Tissues', 'Training', 'Transgenic Mice', 'Translating', 'Validation', 'Variant', 'Work', 'algorithm development', 'automated analysis', 'base', 'cell motility', 'clinically relevant', 'deep learning', 'educational atmosphere', 'experimental study', 'improved', 'in vivo', 'in vivo Model', 'inherited cardiomyopathy', 'insight', 'machine learning algorithm', 'mouse model', 'neural network', 'next generation', 'novel', 'phosphorescence', 'precision medicine', 'prediction algorithm', 'programs', 'quantum chemistry', 'response', 'simulation', 'stopped-flow fluorescence', 'success', 'variant of unknown significance']",NHLBI,UNIVERSITY OF ARIZONA,R01,2020,585711,0.14710525286397488
"Massively parallel dissection of psychiatric regulatory networks     DESCRIPTION (provided by applicant): Abnormal neuronal development can lead to a wide array of mental disorders. Genes important for neurodevelopment have been combed for coding mutations leading to psychiatric disease with limited success, suggesting that other regions in the genome could be causative. A variety of molecular and clinical data indicates that mutations associated with psychiatric disease can reside in gene regulatory sequences such as enhancers. However, only a few enhancers have been definitively linked with these disorders to date. This is primarily because regulatory mutations are challenging to functionally characterize and link to specific genes and phenotypes. To address this challenge, we will use functional genomics data, sequence motifs, and evolutionary signatures to train EnhancerFinder, software that we developed that predicts functional enhancers at high success rates, to now specifically identify active neurodevelopmental enhancers. Over 12,000 candidate neurodevelopmental enhancers will then be cloned and assayed en masse for their enhancer activity using massively parallel reporter assays (MPRAs) in three human embryonic stem cell (hESC) derived neuronal lines: early initiation, neural progenitor cell stage that produces only neurons upon further differentiation, and astrocytes. In addition, we will link enhancers to their target genes using a novel chromatin structure-based prediction approach, called TargetFinder, thereby establishing a network connecting regulatory regions to neurodevelopmental genes. By overlaying reproducible psychiatric disease associated loci with this network, we will identify and prioritize non-coding mutations that are likely to affect expression of neurodevelopmental genes with roles in psychiatric disease. These predictions will be validated using genome- editing techniques to knock out regulatory elements and then assay changes in chromatin interactions and gene expression in developing neurons. The key innovations of our approach are: (i) accurate, quantitative measurements of activity for thousands of psychiatric disease associated enhancer candidates in parallel, (ii) chromatin based inference of gene regulatory networks linking enhancer mutations to genes and pathways, and (iii) a well-characterized stem cell based system to apply these techniques in a high-throughput manner to developing human neurons. We will rapidly disseminate software, reagents, protocols, and datasets to enable follow-up functional studies in the labs of our mental health collaborators and many others. Our long-term aim is to pinpoint causative regulatory variants in the many genomic loci associated with psychiatric disease where an obvious coding mutation is lacking. This approach could easily be adapted to functionally characterize gene regulatory elements involved in other complex human diseases. PUBLIC HEALTH RELEVANCE Despite a wide variety of molecular and clinical data suggesting that psychiatric disease can be caused by mutations in gene regulatory elements such as enhancers that control when and where genes turn on and off during neuronal development, only a few such mutations have been identified thus far. In this project, we will use advanced computational tools to predict neurodevelopmental enhancers and their gene targets, plus a technique called massively parallel reporter assay (MPRA) to functionally test thousands of these predictions en masse in human embryonic stem cell derived neuronal cell lines. We will then identify and functionally characterize disease associated DNA variants in these validated enhancers that disrupt their normal gene regulatory functions in neuronal development.",Massively parallel dissection of psychiatric regulatory networks,9873080,R01MH109907,"['ATAC-seq', 'Address', 'Adult', 'Affect', 'Animal Model', 'Astrocytes', 'Bar Codes', 'Biological Assay', 'Brain', 'CRISPR/Cas technology', 'Catalogs', 'Cell Line', 'Cell model', 'Cells', 'ChIP-seq', 'Chromatin', 'Chromatin Interaction Analysis by Paired-End Tag Sequencing', 'Chromatin Structure', 'Clinical Data', 'Code', 'Collection', 'Colony-Forming Units Assay', 'Comb animal structure', 'Complex', 'Computer software', 'Coupled', 'DNA', 'DNase I hypersensitive sites sequencing', 'Data', 'Data Set', 'Databases', 'Development', 'Disease', 'Dissection', 'Embryo', 'Enhancers', 'Future', 'Gene Expression', 'Gene Expression Regulation', 'Gene Targeting', 'Genes', 'Genome', 'Genotype', 'Human', 'Human Genome', 'In Vitro', 'Knock-out', 'Lead', 'Letters', 'Link', 'Machine Learning', 'Measurement', 'Measures', 'Mental Health', 'Mental disorders', 'Modeling', 'Molecular', 'Mus', 'Mutation', 'National Human Genome Research Institute', 'Neurons', 'Nucleic Acid Regulatory Sequences', 'Nucleotides', 'Outcome', 'Pathway interactions', 'Phenotype', 'Prosencephalon', 'Protocols documentation', 'Reagent', 'Regulator Genes', 'Regulatory Element', 'Regulatory Pathway', 'Reporter', 'Reproducibility', 'Resources', 'Role', 'Scanning', 'Subfamily lentivirinae', 'System', 'Techniques', 'Technology', 'Testing', 'Time', 'Tissues', 'Training', 'Untranslated RNA', 'Validation', 'Variant', 'Work', 'base', 'brain cell', 'brain tissue', 'causal variant', 'cell type', 'computerized tools', 'disease phenotype', 'epigenomics', 'fetal', 'follow-up', 'functional genomics', 'functional/structural genomics', 'genetic association', 'genome editing', 'genome wide association study', 'genome-wide', 'genomic data', 'genomic locus', 'human disease', 'human embryonic stem cell', 'innovation', 'insertion/deletion mutation', 'nerve stem cell', 'neurodevelopment', 'neurogenesis', 'neuron development', 'novel', 'prediction algorithm', 'predictive test', 'promoter', 'psychiatric genomics', 'public health relevance', 'rare variant', 'relating to nervous system', 'screening', 'software development', 'stem cells', 'success', 'supervised learning', 'transcriptome sequencing', 'vector']",NIMH,J. DAVID GLADSTONE INSTITUTES,R01,2020,698941,0.1366798561756537
"Massively parallel dissection of psychiatric regulatory networks     DESCRIPTION (provided by applicant): Abnormal neuronal development can lead to a wide array of mental disorders. Genes important for neurodevelopment have been combed for coding mutations leading to psychiatric disease with limited success, suggesting that other regions in the genome could be causative. A variety of molecular and clinical data indicates that mutations associated with psychiatric disease can reside in gene regulatory sequences such as enhancers. However, only a few enhancers have been definitively linked with these disorders to date. This is primarily because regulatory mutations are challenging to functionally characterize and link to specific genes and phenotypes. To address this challenge, we will use functional genomics data, sequence motifs, and evolutionary signatures to train EnhancerFinder, software that we developed that predicts functional enhancers at high success rates, to now specifically identify active neurodevelopmental enhancers. Over 12,000 candidate neurodevelopmental enhancers will then be cloned and assayed en masse for their enhancer activity using massively parallel reporter assays (MPRAs) in three human embryonic stem cell (hESC) derived neuronal lines: early initiation, neural progenitor cell stage that produces only neurons upon further differentiation, and astrocytes. In addition, we will link enhancers to their target genes using a novel chromatin structure-based prediction approach, called TargetFinder, thereby establishing a network connecting regulatory regions to neurodevelopmental genes. By overlaying reproducible psychiatric disease associated loci with this network, we will identify and prioritize non-coding mutations that are likely to affect expression of neurodevelopmental genes with roles in psychiatric disease. These predictions will be validated using genome- editing techniques to knock out regulatory elements and then assay changes in chromatin interactions and gene expression in developing neurons. The key innovations of our approach are: (i) accurate, quantitative measurements of activity for thousands of psychiatric disease associated enhancer candidates in parallel, (ii) chromatin based inference of gene regulatory networks linking enhancer mutations to genes and pathways, and (iii) a well-characterized stem cell based system to apply these techniques in a high-throughput manner to developing human neurons. We will rapidly disseminate software, reagents, protocols, and datasets to enable follow-up functional studies in the labs of our mental health collaborators and many others. Our long-term aim is to pinpoint causative regulatory variants in the many genomic loci associated with psychiatric disease where an obvious coding mutation is lacking. This approach could easily be adapted to functionally characterize gene regulatory elements involved in other complex human diseases. PUBLIC HEALTH RELEVANCE Despite a wide variety of molecular and clinical data suggesting that psychiatric disease can be caused by mutations in gene regulatory elements such as enhancers that control when and where genes turn on and off during neuronal development, only a few such mutations have been identified thus far. In this project, we will use advanced computational tools to predict neurodevelopmental enhancers and their gene targets, plus a technique called massively parallel reporter assay (MPRA) to functionally test thousands of these predictions en masse in human embryonic stem cell derived neuronal cell lines. We will then identify and functionally characterize disease associated DNA variants in these validated enhancers that disrupt their normal gene regulatory functions in neuronal development.",Massively parallel dissection of psychiatric regulatory networks,9654772,R01MH109907,"['ATAC-seq', 'Address', 'Adult', 'Affect', 'Animal Model', 'Astrocytes', 'Biological Assay', 'Brain', 'CRISPR/Cas technology', 'Catalogs', 'Cell Line', 'Cell model', 'Cells', 'ChIP-seq', 'Chromatin', 'Chromatin Interaction Analysis by Paired-End Tag Sequencing', 'Chromatin Structure', 'Clinical Data', 'Code', 'Collection', 'Colony-Forming Units Assay', 'Comb animal structure', 'Complex', 'Computer software', 'Coupled', 'DNA', 'DNase I hypersensitive sites sequencing', 'Data', 'Data Set', 'Databases', 'Development', 'Disease', 'Dissection', 'Embryo', 'Enhancers', 'Future', 'Gene Expression', 'Gene Expression Regulation', 'Gene Targeting', 'Genes', 'Genome', 'Genomics', 'Genotype', 'Human', 'Human Genome', 'In Vitro', 'Knock-out', 'Lead', 'Letters', 'Link', 'Machine Learning', 'Measurement', 'Measures', 'Mental Health', 'Mental disorders', 'Modeling', 'Molecular', 'Mus', 'Mutation', 'National Human Genome Research Institute', 'Neurons', 'Nucleic Acid Regulatory Sequences', 'Nucleotides', 'Outcome', 'Pathway interactions', 'Phenotype', 'Prosencephalon', 'Protocols documentation', 'Reagent', 'Regulator Genes', 'Regulatory Element', 'Regulatory Pathway', 'Reporter', 'Reproducibility', 'Resources', 'Role', 'Scanning', 'Stem cells', 'Subfamily lentivirinae', 'System', 'Techniques', 'Technology', 'Testing', 'Time', 'Tissues', 'Training', 'Untranslated RNA', 'Validation', 'Variant', 'Work', 'base', 'brain cell', 'brain tissue', 'causal variant', 'cell type', 'computerized tools', 'disease phenotype', 'epigenomics', 'fetal', 'follow-up', 'functional genomics', 'functional/structural genomics', 'genetic association', 'genome editing', 'genome wide association study', 'genome-wide', 'genomic data', 'human disease', 'human embryonic stem cell', 'innovation', 'insertion/deletion mutation', 'nerve stem cell', 'neurodevelopment', 'neurogenesis', 'neuron development', 'novel', 'prediction algorithm', 'predictive test', 'promoter', 'public health relevance', 'rare variant', 'relating to nervous system', 'screening', 'software development', 'success', 'supervised learning', 'transcriptome sequencing', 'vector']",NIMH,J. DAVID GLADSTONE INSTITUTES,R01,2019,713214,0.1366798561756537
"Massively parallel dissection of psychiatric regulatory networks     DESCRIPTION (provided by applicant): Abnormal neuronal development can lead to a wide array of mental disorders. Genes important for neurodevelopment have been combed for coding mutations leading to psychiatric disease with limited success, suggesting that other regions in the genome could be causative. A variety of molecular and clinical data indicates that mutations associated with psychiatric disease can reside in gene regulatory sequences such as enhancers. However, only a few enhancers have been definitively linked with these disorders to date. This is primarily because regulatory mutations are challenging to functionally characterize and link to specific genes and phenotypes. To address this challenge, we will use functional genomics data, sequence motifs, and evolutionary signatures to train EnhancerFinder, software that we developed that predicts functional enhancers at high success rates, to now specifically identify active neurodevelopmental enhancers. Over 12,000 candidate neurodevelopmental enhancers will then be cloned and assayed en masse for their enhancer activity using massively parallel reporter assays (MPRAs) in three human embryonic stem cell (hESC) derived neuronal lines: early initiation, neural progenitor cell stage that produces only neurons upon further differentiation, and astrocytes. In addition, we will link enhancers to their target genes using a novel chromatin structure-based prediction approach, called TargetFinder, thereby establishing a network connecting regulatory regions to neurodevelopmental genes. By overlaying reproducible psychiatric disease associated loci with this network, we will identify and prioritize non-coding mutations that are likely to affect expression of neurodevelopmental genes with roles in psychiatric disease. These predictions will be validated using genome- editing techniques to knock out regulatory elements and then assay changes in chromatin interactions and gene expression in developing neurons. The key innovations of our approach are: (i) accurate, quantitative measurements of activity for thousands of psychiatric disease associated enhancer candidates in parallel, (ii) chromatin based inference of gene regulatory networks linking enhancer mutations to genes and pathways, and (iii) a well-characterized stem cell based system to apply these techniques in a high-throughput manner to developing human neurons. We will rapidly disseminate software, reagents, protocols, and datasets to enable follow-up functional studies in the labs of our mental health collaborators and many others. Our long-term aim is to pinpoint causative regulatory variants in the many genomic loci associated with psychiatric disease where an obvious coding mutation is lacking. This approach could easily be adapted to functionally characterize gene regulatory elements involved in other complex human diseases. PUBLIC HEALTH RELEVANCE Despite a wide variety of molecular and clinical data suggesting that psychiatric disease can be caused by mutations in gene regulatory elements such as enhancers that control when and where genes turn on and off during neuronal development, only a few such mutations have been identified thus far. In this project, we will use advanced computational tools to predict neurodevelopmental enhancers and their gene targets, plus a technique called massively parallel reporter assay (MPRA) to functionally test thousands of these predictions en masse in human embryonic stem cell derived neuronal cell lines. We will then identify and functionally characterize disease associated DNA variants in these validated enhancers that disrupt their normal gene regulatory functions in neuronal development.",Massively parallel dissection of psychiatric regulatory networks,9433692,R01MH109907,"['ATAC-seq', 'Address', 'Adult', 'Affect', 'Animal Model', 'Astrocytes', 'Biological Assay', 'Brain', 'CRISPR/Cas technology', 'Catalogs', 'Cell Line', 'Cell model', 'Cells', 'ChIP-seq', 'Chromatin', 'Chromatin Interaction Analysis by Paired-End Tag Sequencing', 'Chromatin Structure', 'Clinical Data', 'Code', 'Collection', 'Colony-Forming Units Assay', 'Comb animal structure', 'Complex', 'Computer software', 'Coupled', 'DNA', 'DNase I hypersensitive sites sequencing', 'Data', 'Data Set', 'Databases', 'Development', 'Disease', 'Dissection', 'Embryo', 'Enhancers', 'Future', 'Gene Expression', 'Gene Expression Regulation', 'Gene Targeting', 'Genes', 'Genome', 'Genomics', 'Genotype', 'Human', 'Human Genome', 'In Vitro', 'Knock-out', 'Lead', 'Letters', 'Link', 'Machine Learning', 'Measurement', 'Measures', 'Mental Health', 'Mental disorders', 'Modeling', 'Molecular', 'Mus', 'Mutation', 'National Human Genome Research Institute', 'Neurons', 'Nucleic Acid Regulatory Sequences', 'Nucleotides', 'Outcome', 'Pathway interactions', 'Phenotype', 'Prosencephalon', 'Protocols documentation', 'Reagent', 'Regulator Genes', 'Regulatory Element', 'Regulatory Pathway', 'Reporter', 'Reproducibility', 'Resources', 'Role', 'Scanning', 'Stem cells', 'Subfamily lentivirinae', 'Supervision', 'System', 'Techniques', 'Technology', 'Testing', 'Time', 'Tissues', 'Training', 'Untranslated RNA', 'Validation', 'Variant', 'Work', 'base', 'brain cell', 'brain tissue', 'cell type', 'computerized tools', 'disease phenotype', 'epigenomics', 'fetal', 'follow-up', 'functional genomics', 'genetic association', 'genome editing', 'genome wide association study', 'genome-wide', 'genomic data', 'human disease', 'human embryonic stem cell', 'innovation', 'insertion/deletion mutation', 'nerve stem cell', 'neurodevelopment', 'neurogenesis', 'neuron development', 'novel', 'prediction algorithm', 'predictive test', 'promoter', 'public health relevance', 'rare variant', 'relating to nervous system', 'screening', 'software development', 'success', 'transcriptome sequencing', 'vector']",NIMH,J. DAVID GLADSTONE INSTITUTES,R01,2018,635723,0.1366798561756537
"Massively parallel dissection of psychiatric regulatory networks     DESCRIPTION (provided by applicant): Abnormal neuronal development can lead to a wide array of mental disorders. Genes important for neurodevelopment have been combed for coding mutations leading to psychiatric disease with limited success, suggesting that other regions in the genome could be causative. A variety of molecular and clinical data indicates that mutations associated with psychiatric disease can reside in gene regulatory sequences such as enhancers. However, only a few enhancers have been definitively linked with these disorders to date. This is primarily because regulatory mutations are challenging to functionally characterize and link to specific genes and phenotypes. To address this challenge, we will use functional genomics data, sequence motifs, and evolutionary signatures to train EnhancerFinder, software that we developed that predicts functional enhancers at high success rates, to now specifically identify active neurodevelopmental enhancers. Over 12,000 candidate neurodevelopmental enhancers will then be cloned and assayed en masse for their enhancer activity using massively parallel reporter assays (MPRAs) in three human embryonic stem cell (hESC) derived neuronal lines: early initiation, neural progenitor cell stage that produces only neurons upon further differentiation, and astrocytes. In addition, we will link enhancers to their target genes using a novel chromatin structure-based prediction approach, called TargetFinder, thereby establishing a network connecting regulatory regions to neurodevelopmental genes. By overlaying reproducible psychiatric disease associated loci with this network, we will identify and prioritize non-coding mutations that are likely to affect expression of neurodevelopmental genes with roles in psychiatric disease. These predictions will be validated using genome- editing techniques to knock out regulatory elements and then assay changes in chromatin interactions and gene expression in developing neurons. The key innovations of our approach are: (i) accurate, quantitative measurements of activity for thousands of psychiatric disease associated enhancer candidates in parallel, (ii) chromatin based inference of gene regulatory networks linking enhancer mutations to genes and pathways, and (iii) a well-characterized stem cell based system to apply these techniques in a high-throughput manner to developing human neurons. We will rapidly disseminate software, reagents, protocols, and datasets to enable follow-up functional studies in the labs of our mental health collaborators and many others. Our long-term aim is to pinpoint causative regulatory variants in the many genomic loci associated with psychiatric disease where an obvious coding mutation is lacking. This approach could easily be adapted to functionally characterize gene regulatory elements involved in other complex human diseases. PUBLIC HEALTH RELEVANCE Despite a wide variety of molecular and clinical data suggesting that psychiatric disease can be caused by mutations in gene regulatory elements such as enhancers that control when and where genes turn on and off during neuronal development, only a few such mutations have been identified thus far. In this project, we will use advanced computational tools to predict neurodevelopmental enhancers and their gene targets, plus a technique called massively parallel reporter assay (MPRA) to functionally test thousands of these predictions en masse in human embryonic stem cell derived neuronal cell lines. We will then identify and functionally characterize disease associated DNA variants in these validated enhancers that disrupt their normal gene regulatory functions in neuronal development.",Massively parallel dissection of psychiatric regulatory networks,9265137,R01MH109907,"['ATAC-seq', 'Address', 'Adult', 'Affect', 'Animal Model', 'Astrocytes', 'Biological Assay', 'Brain', 'CRISPR/Cas technology', 'Catalogs', 'Cell Line', 'Cell model', 'Cells', 'ChIP-seq', 'Chromatin', 'Chromatin Interaction Analysis by Paired-End Tag Sequencing', 'Chromatin Structure', 'Clinical Data', 'Code', 'Collection', 'Comb animal structure', 'Complex', 'Computer software', 'Coupled', 'DNA', 'DNase I hypersensitive sites sequencing', 'Data', 'Data Set', 'Databases', 'Development', 'Disease', 'Dissection', 'Embryo', 'Enhancers', 'Future', 'Gene Expression', 'Gene Expression Regulation', 'Gene Targeting', 'Genes', 'Genome', 'Genomics', 'Genotype', 'Human', 'Human Genome', 'In Vitro', 'Knock-out', 'Lead', 'Letters', 'Link', 'Machine Learning', 'Measurement', 'Measures', 'Mental Health', 'Mental disorders', 'Modeling', 'Molecular', 'Mus', 'Mutation', 'National Human Genome Research Institute', 'Neurons', 'Nucleic Acid Regulatory Sequences', 'Nucleotides', 'Outcome', 'Pathway interactions', 'Phenotype', 'Prosencephalon', 'Protocols documentation', 'Reagent', 'Regulator Genes', 'Regulatory Element', 'Regulatory Pathway', 'Reporter', 'Reproducibility', 'Resources', 'Role', 'Scanning', 'Stem cells', 'Subfamily lentivirinae', 'Supervision', 'System', 'Techniques', 'Technology', 'Testing', 'Time', 'Tissues', 'Training', 'Untranslated RNA', 'Validation', 'Variant', 'Work', 'base', 'brain cell', 'brain tissue', 'cell type', 'computerized tools', 'disease phenotype', 'epigenomics', 'fetal', 'follow-up', 'functional genomics', 'genetic association', 'genome editing', 'genome wide association study', 'genome-wide', 'genomic data', 'human disease', 'human embryonic stem cell', 'innovation', 'insertion/deletion mutation', 'nerve stem cell', 'neurodevelopment', 'neurogenesis', 'neuron development', 'novel', 'prediction algorithm', 'promoter', 'public health relevance', 'rare variant', 'relating to nervous system', 'screening', 'software development', 'success', 'transcriptome sequencing', 'vector']",NIMH,J. DAVID GLADSTONE INSTITUTES,R01,2017,662230,0.1366798561756537
"Massively parallel dissection of psychiatric regulatory networks     DESCRIPTION (provided by applicant): Abnormal neuronal development can lead to a wide array of mental disorders. Genes important for neurodevelopment have been combed for coding mutations leading to psychiatric disease with limited success, suggesting that other regions in the genome could be causative. A variety of molecular and clinical data indicates that mutations associated with psychiatric disease can reside in gene regulatory sequences such as enhancers. However, only a few enhancers have been definitively linked with these disorders to date. This is primarily because regulatory mutations are challenging to functionally characterize and link to specific genes and phenotypes. To address this challenge, we will use functional genomics data, sequence motifs, and evolutionary signatures to train EnhancerFinder, software that we developed that predicts functional enhancers at high success rates, to now specifically identify active neurodevelopmental enhancers. Over 12,000 candidate neurodevelopmental enhancers will then be cloned and assayed en masse for their enhancer activity using massively parallel reporter assays (MPRAs) in three human embryonic stem cell (hESC) derived neuronal lines: early initiation, neural progenitor cell stage that produces only neurons upon further differentiation, and astrocytes. In addition, we will link enhancers to their target genes using a novel chromatin structure-based prediction approach, called TargetFinder, thereby establishing a network connecting regulatory regions to neurodevelopmental genes. By overlaying reproducible psychiatric disease associated loci with this network, we will identify and prioritize non-coding mutations that are likely to affect expression of neurodevelopmental genes with roles in psychiatric disease. These predictions will be validated using genome- editing techniques to knock out regulatory elements and then assay changes in chromatin interactions and gene expression in developing neurons. The key innovations of our approach are: (i) accurate, quantitative measurements of activity for thousands of psychiatric disease associated enhancer candidates in parallel, (ii) chromatin based inference of gene regulatory networks linking enhancer mutations to genes and pathways, and (iii) a well-characterized stem cell based system to apply these techniques in a high-throughput manner to developing human neurons. We will rapidly disseminate software, reagents, protocols, and datasets to enable follow-up functional studies in the labs of our mental health collaborators and many others. Our long-term aim is to pinpoint causative regulatory variants in the many genomic loci associated with psychiatric disease where an obvious coding mutation is lacking. This approach could easily be adapted to functionally characterize gene regulatory elements involved in other complex human diseases.         PUBLIC HEALTH RELEVANCE Despite a wide variety of molecular and clinical data suggesting that psychiatric disease can be caused by mutations in gene regulatory elements such as enhancers that control when and where genes turn on and off during neuronal development, only a few such mutations have been identified thus far. In this project, we will use advanced computational tools to predict neurodevelopmental enhancers and their gene targets, plus a technique called massively parallel reporter assay (MPRA) to functionally test thousands of these predictions en masse in human embryonic stem cell derived neuronal cell lines. We will then identify and functionally characterize disease associated DNA variants in these validated enhancers that disrupt their normal gene regulatory functions in neuronal development.            ",Massively parallel dissection of psychiatric regulatory networks,9101722,R01MH109907,"['ATAC-seq', 'Address', 'Adult', 'Affect', 'Animal Model', 'Astrocytes', 'Biological Assay', 'Brain', 'CRISPR/Cas technology', 'Cataloging', 'Catalogs', 'Cell Line', 'Cells', 'ChIP-seq', 'Chromatin', 'Chromatin Interaction Analysis by Paired-End Tag Sequencing', 'Chromatin Structure', 'Clinical Data', 'Code', 'Collection', 'Colony-Forming Units Assay', 'Comb animal structure', 'Complex', 'Computer software', 'Coupled', 'DNA', 'DNase I hypersensitive sites sequencing', 'Data', 'Databases', 'Development', 'Disease', 'Dissection', 'Embryo', 'Enhancers', 'Future', 'Gene Expression', 'Gene Expression Regulation', 'Gene Targeting', 'Genes', 'Genome', 'Genomics', 'Genotype', 'Human', 'Human Genome', 'In Vitro', 'Knock-out', 'Lead', 'Letters', 'Link', 'Machine Learning', 'Measurement', 'Measures', 'Mental Health', 'Mental disorders', 'Modeling', 'Molecular', 'Mus', 'Mutation', 'National Human Genome Research Institute', 'Neurons', 'Nucleic Acid Regulatory Sequences', 'Nucleotides', 'Outcome', 'Pathway interactions', 'Phenotype', 'Prosencephalon', 'Protocols documentation', 'Reagent', 'Regulator Genes', 'Regulatory Element', 'Regulatory Pathway', 'Reporter', 'Resources', 'Role', 'Scanning', 'Staging', 'Stem cells', 'Subfamily lentivirinae', 'System', 'Techniques', 'Technology', 'Testing', 'Time', 'Tissues', 'Training', 'Untranslated RNA', 'Validation', 'Variant', 'Work', 'base', 'brain cell', 'brain tissue', 'cell type', 'computerized tools', 'disease phenotype', 'epigenomics', 'fetal', 'follow-up', 'functional genomics', 'genetic association', 'genome editing', 'genome wide association study', 'genome-wide', 'genomic data', 'human disease', 'human embryonic stem cell', 'innovation', 'insertion/deletion mutation', 'nerve stem cell', 'neurodevelopment', 'neurogenesis', 'neuron development', 'novel', 'prediction algorithm', 'promoter', 'public health relevance', 'rare variant', 'relating to nervous system', 'screening', 'software development', 'success', 'transcriptome sequencing', 'vector']",NIMH,J. DAVID GLADSTONE INSTITUTES,R01,2016,643447,0.1366798561756537
"Transcriptional regulation, neuronal development, and function of the mushroom body in a Drosophila model of intellectual disability ABSTRACT Intellectual disability (ID) disorders affect 2% of the population and are characterized by an IQ score lower than 70 with deficits in adaptive functioning. Mutations in over 400 genes contribute to the pathogenesis of ID disorders, with patients presenting with learning and memory impairments and often syndromic features such as epilepsy, anxiety, short stature, and aggressive tendencies. Our research focusses on the KDM5 family of transcriptional regulators, mutations in which account for 1-3% of inherited ID ranging from mild to severe. The molecular mechanisms by which KDM5 proteins impact neuronal function remain largely unknown, leaving patients without effective treatment strategies. Thus, the overarching goal of this project will be to understand how mutations in KDM5 contribute to neuronal and transcriptional outputs that influence cognition. Here, we will utilize the genetically tractable Drosophila, which encodes a single ortholog of kdm5, to investigate neuronal morphology, transcriptional outputs, and behavioral phenotypes of flies bearing patient-derived KDM5 missense mutations. We have generated a set of ten fly strains, each of which harbors a conserved mutation in Drosophila kdm5 that is analogous to an ID-associated allele. Preliminary data have demonstrated that RNAi-mediated knockdown of kdm5 results in profound guidance and growth defects of the mushroom body (MB), a paired neuropil-rich structure required for the acquisition, consolidation, and retrieval of long- and short-term memory. Significantly, similar morphological MB defects are observed in flies bearing a mutation analogous to an ID- causing missense mutation in an A/T rich interacting domain (ARID) previously implicated in KDM5 DNA binding. Based on these and other data, our central hypothesis is that KDM5 is essential for MB development, and that conserved ID-associated missense mutations that disrupt KDM5s transcriptional activity lead to the misexpression of genes required for MB morphology and cognitive function. This hypothesis will be tested in three specific aims. The first will be to quantify the extent of MB defects in all kdm5 mutant strains harboring ID- associated missense mutations at both gross and single-cell resolution. The second aim will define the gene expression defects within MB neurons of kdm5 knockdown and ID mutant strains using combined genome-wide transcriptome (RNA-seq) and binding (ChIP-seq) assays. Our third aim will quantify analogous cognitive and behavioral phenotypes that are classically associated with ID. This work will thus be the first to utilize conserved ID-causing KDM5 missense alleles to link ID-associated behavioral phenotypes with neuronal and transcriptional regulatory programs, opening new avenues for the development of therapeutic strategies. Under the mentorship and guidance of Drs. Julie Secombe and Nicholas Baker, I will be able to accomplish these goals while acquiring new skills in developmental neuroscience and related fields. Additionally, I will gain valuable experience presenting, networking, and preparing manuscripts, skills that are essential as I train to become an independent investigator and physician-scientist in the neurosciences. PROJECT NARRATIVE Intellectual disability (ID) disorders are diagnosed during early childhood, leading to lifelong educational, social, and financial consequences for patients and their caregivers. However, despite these profound burdens, little is known regarding the pathogenesis of ID disorders, particularly how disruptions in genetic and neuronal regulatory programs contribute to cognitive and behavioral dysfunction. Using a combination of neuroanatomical, transcriptional, and behavioral analyses, we will investigate how mutations in one class of transcriptional regulatory proteins lead to such deficits, paving the way for the development of novel and effective therapeutic strategies.","Transcriptional regulation, neuronal development, and function of the mushroom body in a Drosophila model of intellectual disability",9815924,F31NS110278,"['Affect', 'Aggressive behavior', 'Alleles', 'Anxiety', 'Axon', 'Behavioral', 'Binding', 'Biological Assay', 'Brain', 'Caregivers', 'Cell Nucleus', 'Cells', 'Cellular Morphology', 'ChIP-seq', 'Cognition', 'Cognitive', 'Consumption', 'DNA Binding', 'DNA Binding Domain', 'Data', 'Data Set', 'Defect', 'Development', 'Diagnosis', 'Disease', 'Drosophila genus', 'Epilepsy', 'Family', 'Functional disorder', 'Gene Expression', 'Gene Expression Profiling', 'Genes', 'Genetic', 'Genetic Transcription', 'Goals', 'Growth', 'Image', 'Impairment', 'Inherited', 'Intellectual functioning disability', 'Knockout Mice', 'Lead', 'Learning', 'Link', 'Manuscripts', 'Mediating', 'Memory', 'Memory impairment', 'Mentorship', 'Missense Mutation', 'Modeling', 'Molecular', 'Morphogenesis', 'Morphology', 'Mosaicism', 'Mus', 'Mushroom Bodies', 'Mutation', 'Nature', 'Neuroglia', 'Neurons', 'Neuropil', 'Neurosciences', 'Orthologous Gene', 'Output', 'Pathogenesis', 'Pathway interactions', 'Patients', 'Pattern', 'Physicians', 'Population', 'Process', 'Proteins', 'RNA Interference', 'Reporting', 'Research', 'Research Personnel', 'Resolution', 'Retrieval', 'Scientist', 'Seizures', 'Social Behavior', 'Stereotyping', 'Structural defect', 'Structure', 'Syndrome', 'Techniques', 'Testing', 'Therapeutic', 'Time', 'Training', 'Transcription Regulatory Protein', 'Transcriptional Regulation', 'Treatment Efficacy', 'Vertebral column', 'Work', 'X-linked intellectual disability', 'base', 'behavioral phenotyping', 'cell type', 'cognitive function', 'differential expression', 'early childhood', 'effective therapy', 'experience', 'fly', 'genetic profiling', 'genome-wide', 'histone demethylase', 'in vivo', 'innovation', 'knock-down', 'long short term memory', 'mouse model', 'mutant', 'neuron development', 'neuronal guidance', 'novel', 'programs', 'relating to nervous system', 'skills', 'social', 'therapeutic development', 'tool', 'transcriptome', 'transcriptome sequencing', 'treatment strategy']",NINDS,ALBERT EINSTEIN COLLEGE OF MEDICINE,F31,2020,50520,0.21879814148953367
"A Functional Census of p53 Cancer and Suppressor Mutants DESCRIPTION (provided by applicant):  The broad, long-term objectives are (1) demonstrate computational and experimental methods cooperating to achieve a functional census of a large mutation sequence space of great medical importance; (2) contribute to our knowledge of p53 functional rescue mechanisms, and so facilitate the search for a small molecule cancer drug that effects an analogous functional rescue of p53; and (3) elucidate part of the systems biology of cancer by characterizing the spectrum of p53 cancer and suppressor mutants across known downstream p53 DNA binding sites. Mutations to the tumor suppressor protein p53 occur in approximately half of all human cancers, and restoring function to a mutationally defective p53 protein is a long-held medical goal. Biological precedence for rescuing p53 cancer mutations is found in second-site p53 cancer suppressor mutations. The analogous p53 pharmacological rescue would save hundreds of thousands of lives annually. Understanding and predicting p53 rescue is an important step toward that goal.      The specific aims are (1) computationally predict all single suppressor mutations for p53 cancer mutants and validate the results experimentally, (2) optimize the rescue effects of known and putative p53 suppressor regions through two or more coordinated mutation changes, and (3) predict and experimentally validate the DNA binding specificity of p53 cancer and suppressor mutants for known p53 DNA binding sites. Our broad strategy is a coordinated computational and experimental attack. We already have experimental p53 functional assays and computational predictors of p53 activity, developed as part of our Preliminary Studies. Computational predictors will be used to focus experimental work into the highest priority areas. Experimental validation of the predictions will lead to a larger training set for machine learning techniques. The larger training set will lead to even more accurate predictions, thus even more focused experimentation. Thus, the interplay between computation and experiment will become ever more efficient as the project progresses. Variations of this basic strategy apply to each of our Specific Aims, which all rely on closely coordinated experiment and computation. n/a",A Functional Census of p53 Cancer and Suppressor Mutants,7613343,R01CA112560,"['Affect', 'Amino Acids', 'Antineoplastic Agents', 'Apoptosis', 'Area', 'Binding Sites', 'Bioinformatics', 'Biological', 'Biological Assay', 'Cancerous', 'Cataloging', 'Catalogs', 'Cell Cycle Arrest', 'Cells', 'Censuses', 'Consensus', 'DNA Binding', 'Data Sources', 'Engineering', 'Gene Targeting', 'Genomics', 'Goals', 'Human', 'Knowledge', 'Lead', 'Letters', 'Life', 'Machine Learning', 'Malignant Neoplasms', 'Maps', 'Medical', 'Methodology', 'Methods', 'Missense Mutation', 'Modeling', 'Molecular Conformation', 'Mutation', 'Positioning Attribute', 'Proliferating', 'Protein p53', 'Research Personnel', 'Signal Transduction', 'Site', 'Source Code', 'Specificity', 'Stress', 'Suppressor Mutations', 'Surveys', 'Systems Biology', 'TP53 gene', 'Techniques', 'Training', 'Tumor Suppressor Proteins', 'Validation', 'Variant', 'Work', 'Yeasts', 'base', 'cancer therapy', 'computerized tools', 'design', 'functional restoration', 'interest', 'killings', 'mutant', 'programs', 'repaired', 'research study', 'small molecule', 'transcription factor', 'tumor', 'web site']",NCI,UNIVERSITY OF CALIFORNIA-IRVINE,R01,2009,342292,0.22052661247551547
"A Functional Census of p53 Cancer and Suppressor Mutants DESCRIPTION (provided by applicant):  The broad, long-term objectives are (1) demonstrate computational and experimental methods cooperating to achieve a functional census of a large mutation sequence space of great medical importance; (2) contribute to our knowledge of p53 functional rescue mechanisms, and so facilitate the search for a small molecule cancer drug that effects an analogous functional rescue of p53; and (3) elucidate part of the systems biology of cancer by characterizing the spectrum of p53 cancer and suppressor mutants across known downstream p53 DNA binding sites. Mutations to the tumor suppressor protein p53 occur in approximately half of all human cancers, and restoring function to a mutationally defective p53 protein is a long-held medical goal. Biological precedence for rescuing p53 cancer mutations is found in second-site p53 cancer suppressor mutations. The analogous p53 pharmacological rescue would save hundreds of thousands of lives annually. Understanding and predicting p53 rescue is an important step toward that goal.      The specific aims are (1) computationally predict all single suppressor mutations for p53 cancer mutants and validate the results experimentally, (2) optimize the rescue effects of known and putative p53 suppressor regions through two or more coordinated mutation changes, and (3) predict and experimentally validate the DNA binding specificity of p53 cancer and suppressor mutants for known p53 DNA binding sites. Our broad strategy is a coordinated computational and experimental attack. We already have experimental p53 functional assays and computational predictors of p53 activity, developed as part of our Preliminary Studies. Computational predictors will be used to focus experimental work into the highest priority areas. Experimental validation of the predictions will lead to a larger training set for machine learning techniques. The larger training set will lead to even more accurate predictions, thus even more focused experimentation. Thus, the interplay between computation and experiment will become ever more efficient as the project progresses. Variations of this basic strategy apply to each of our Specific Aims, which all rely on closely coordinated experiment and computation. n/a",A Functional Census of p53 Cancer and Suppressor Mutants,7426313,R01CA112560,"['Affect', 'Amino Acids', 'Antineoplastic Agents', 'Apoptosis', 'Area', 'Binding Sites', 'Bioinformatics', 'Biological', 'Biological Assay', 'Cancerous', 'Cataloging', 'Catalogs', 'Cell Cycle Arrest', 'Cells', 'Censuses', 'Consensus', 'DNA Binding', 'Data', 'Engineering', 'Gene Targeting', 'Genomics', 'Goals', 'Human', 'Knowledge', 'Lead', 'Letters', 'Life', 'Machine Learning', 'Malignant Neoplasms', 'Maps', 'Medical', 'Methodology', 'Methods', 'Missense Mutation', 'Modeling', 'Molecular Conformation', 'Mutation', 'Numbers', 'Positioning Attribute', 'Proliferating', 'Protein p53', 'Research Personnel', 'Signal Transduction', 'Site', 'Source Code', 'Specificity', 'Stress', 'Suppressor Mutations', 'Surveys', 'Systems Biology', 'TP53 gene', 'Techniques', 'Training', 'Tumor Suppressor Proteins', 'Validation', 'Variant', 'Work', 'Yeasts', 'base', 'cancer therapy', 'computerized tools', 'design', 'functional restoration', 'interest', 'killings', 'mutant', 'programs', 'repaired', 'research study', 'small molecule', 'transcription factor', 'tumor']",NCI,UNIVERSITY OF CALIFORNIA-IRVINE,R01,2008,335397,0.22052661247551547
"A Functional Census of p53 Cancer and Suppressor Mutants DESCRIPTION (provided by applicant):  The broad, long-term objectives are (1) demonstrate computational and experimental methods cooperating to achieve a functional census of a large mutation sequence space of great medical importance; (2) contribute to our knowledge of p53 functional rescue mechanisms, and so facilitate the search for a small molecule cancer drug that effects an analogous functional rescue of p53; and (3) elucidate part of the systems biology of cancer by characterizing the spectrum of p53 cancer and suppressor mutants across known downstream p53 DNA binding sites. Mutations to the tumor suppressor protein p53 occur in approximately half of all human cancers, and restoring function to a mutationally defective p53 protein is a long-held medical goal. Biological precedence for rescuing p53 cancer mutations is found in second-site p53 cancer suppressor mutations. The analogous p53 pharmacological rescue would save hundreds of thousands of lives annually. Understanding and predicting p53 rescue is an important step toward that goal.      The specific aims are (1) computationally predict all single suppressor mutations for p53 cancer mutants and validate the results experimentally, (2) optimize the rescue effects of known and putative p53 suppressor regions through two or more coordinated mutation changes, and (3) predict and experimentally validate the DNA binding specificity of p53 cancer and suppressor mutants for known p53 DNA binding sites. Our broad strategy is a coordinated computational and experimental attack. We already have experimental p53 functional assays and computational predictors of p53 activity, developed as part of our Preliminary Studies. Computational predictors will be used to focus experimental work into the highest priority areas. Experimental validation of the predictions will lead to a larger training set for machine learning techniques. The larger training set will lead to even more accurate predictions, thus even more focused experimentation. Thus, the interplay between computation and experiment will become ever more efficient as the project progresses. Variations of this basic strategy apply to each of our Specific Aims, which all rely on closely coordinated experiment and computation. n/a",A Functional Census of p53 Cancer and Suppressor Mutants,7253241,R01CA112560,"['Affect', 'Amino Acids', 'Antineoplastic Agents', 'Apoptosis', 'Area', 'Binding Sites', 'Bioinformatics', 'Biological', 'Biological Assay', 'Cancerous', 'Cataloging', 'Catalogs', 'Cell Cycle Arrest', 'Cells', 'Censuses', 'Consensus', 'DNA Binding', 'Data', 'Engineering', 'Gene Targeting', 'Genomics', 'Goals', 'Human', 'Knowledge', 'Lead', 'Letters', 'Life', 'Machine Learning', 'Malignant Neoplasms', 'Maps', 'Medical', 'Methodology', 'Methods', 'Missense Mutation', 'Modeling', 'Molecular Conformation', 'Mutation', 'Numbers', 'Positioning Attribute', 'Proliferating', 'Protein p53', 'Research Personnel', 'Signal Transduction', 'Site', 'Source Code', 'Specificity', 'Stress', 'Suppressor Mutations', 'Surveys', 'Systems Biology', 'TP53 gene', 'Techniques', 'Training', 'Tumor Suppressor Proteins', 'Validation', 'Variant', 'Work', 'Yeasts', 'base', 'cancer therapy', 'computerized tools', 'design', 'functional restoration', 'interest', 'killings', 'mutant', 'programs', 'repaired', 'research study', 'small molecule', 'transcription factor', 'tumor']",NCI,UNIVERSITY OF CALIFORNIA IRVINE,R01,2007,333814,0.22052661247551547
"A Functional Census of p53 Cancer and Suppressor Mutants DESCRIPTION (provided by applicant):  The broad, long-term objectives are (1) demonstrate computational and experimental methods cooperating to achieve a functional census of a large mutation sequence space of great medical importance; (2) contribute to our knowledge of p53 functional rescue mechanisms, and so facilitate the search for a small molecule cancer drug that effects an analogous functional rescue of p53; and (3) elucidate part of the systems biology of cancer by characterizing the spectrum of p53 cancer and suppressor mutants across known downstream p53 DNA binding sites. Mutations to the tumor suppressor protein p53 occur in approximately half of all human cancers, and restoring function to a mutationally defective p53 protein is a long-held medical goal. Biological precedence for rescuing p53 cancer mutations is found in second-site p53 cancer suppressor mutations. The analogous p53 pharmacological rescue would save hundreds of thousands of lives annually. Understanding and predicting p53 rescue is an important step toward that goal.      The specific aims are (1) computationally predict all single suppressor mutations for p53 cancer mutants and validate the results experimentally, (2) optimize the rescue effects of known and putative p53 suppressor regions through two or more coordinated mutation changes, and (3) predict and experimentally validate the DNA binding specificity of p53 cancer and suppressor mutants for known p53 DNA binding sites. Our broad strategy is a coordinated computational and experimental attack. We already have experimental p53 functional assays and computational predictors of p53 activity, developed as part of our Preliminary Studies. Computational predictors will be used to focus experimental work into the highest priority areas. Experimental validation of the predictions will lead to a larger training set for machine learning techniques. The larger training set will lead to even more accurate predictions, thus even more focused experimentation. Thus, the interplay between computation and experiment will become ever more efficient as the project progresses. Variations of this basic strategy apply to each of our Specific Aims, which all rely on closely coordinated experiment and computation. n/a",A Functional Census of p53 Cancer and Suppressor Mutants,7103691,R01CA112560,"['DNA binding protein', 'artificial intelligence', 'binding sites', 'computational biology', 'gene induction /repression', 'gene mutation', 'genetic screening', 'genetic transcription', 'mathematical model', 'model design /development', 'molecular biology information system', 'neoplasm /cancer genetics', 'neoplasm /cancer pharmacology', 'p53 gene /protein', 'protein sequence', 'recombinant proteins', 'small molecule', 'tumor suppressor genes', 'yeast two hybrid system']",NCI,UNIVERSITY OF CALIFORNIA IRVINE,R01,2006,356838,0.22052661247551547
"A Functional Census of p53 Cancer and Suppressor Mutants DESCRIPTION (provided by applicant):  The broad, long-term objectives are (1) demonstrate computational and experimental methods cooperating to achieve a functional census of a large mutation sequence space of great medical importance; (2) contribute to our knowledge of p53 functional rescue mechanisms, and so facilitate the search for a small molecule cancer drug that effects an analogous functional rescue of p53; and (3) elucidate part of the systems biology of cancer by characterizing the spectrum of p53 cancer and suppressor mutants across known downstream p53 DNA binding sites. Mutations to the tumor suppressor protein p53 occur in approximately half of all human cancers, and restoring function to a mutationally defective p53 protein is a long-held medical goal. Biological precedence for rescuing p53 cancer mutations is found in second-site p53 cancer suppressor mutations. The analogous p53 pharmacological rescue would save hundreds of thousands of lives annually. Understanding and predicting p53 rescue is an important step toward that goal.      The specific aims are (1) computationally predict all single suppressor mutations for p53 cancer mutants and validate the results experimentally, (2) optimize the rescue effects of known and putative p53 suppressor regions through two or more coordinated mutation changes, and (3) predict and experimentally validate the DNA binding specificity of p53 cancer and suppressor mutants for known p53 DNA binding sites. Our broad strategy is a coordinated computational and experimental attack. We already have experimental p53 functional assays and computational predictors of p53 activity, developed as part of our Preliminary Studies. Computational predictors will be used to focus experimental work into the highest priority areas. Experimental validation of the predictions will lead to a larger training set for machine learning techniques. The larger training set will lead to even more accurate predictions, thus even more focused experimentation. Thus, the interplay between computation and experiment will become ever more efficient as the project progresses. Variations of this basic strategy apply to each of our Specific Aims, which all rely on closely coordinated experiment and computation. n/a",A Functional Census of p53 Cancer and Suppressor Mutants,6989008,R01CA112560,"['DNA binding protein', 'artificial intelligence', 'binding sites', 'computational biology', 'gene induction /repression', 'gene mutation', 'genetic screening', 'genetic transcription', 'mathematical model', 'model design /development', 'molecular biology information system', 'neoplasm /cancer genetics', 'neoplasm /cancer pharmacology', 'p53 gene /protein', 'protein sequence', 'recombinant proteins', 'small molecule', 'tumor suppressor genes', 'yeast two hybrid system']",NCI,UNIVERSITY OF CALIFORNIA IRVINE,R01,2005,363175,0.22052661247551547
"Functional Annotation of Natural and Disease Variants in Tryosine Kinases     DESCRIPTION (provided by applicant): Protein tyrosine kinases are dynamic molecular switches that toggle between a catalytically ""on"" and ""off"" state to turn on and off signals responsible for cell growth and survival. While the tyrosine kinase switch is tightly regulated by  diverse array of structural mechanisms in normal states, in many disease states, the switch is permanently turned on or off due, in part, to mutations in the tyrosine kinase domain. Although genome sequencing studies have revealed the mutational patterns of tyrosine kinases from many different disease types, understanding the structural and functional impact of these mutations is a challenge because many recurrent mutations occur far from the active site (distal mutations) and the residue networks that contribute to the complex modes of tyrosine kinase allosteric regulation are not fully understood. Our long term goal is to understand the relationships connecting sequence, structure, function, regulation and disease in protein kinases using a combination of computational and experimental approaches. Our objective in this proposal, which is the next logical step toward attainment of our long-term goal, is to delineate the residue interaction networks that contribute to the unique modes of allosteric regulation in tyrosine kinases, and to develop a computational framework for predicting mutation impact using the evolutionary and allosteric properties encoded in three dimensional structures. The central hypothesis is that distal mutations alter evolutionarily conserved allosteric networks in tyrosine kinases, and delineating the allosteric networks unique to tyrosine kinases will provide context for predicting and testing disease mutation impact. The specific aims are: * To identify and characterize natural sequence and structural variants associated with tight  allosteric control of tyrosine kinase activity * To develop a computational framework for predicting mutation impact on kinase activation and to  experimentally validate computational predictions using selected receptor tyrosine kinases as  model systems Successful completion of these aims is expected to reveal novel activating mutations in putative allosteric sites in the tyrosine kinase domain, and pinpoint key residues and interactions for functional studies. These outcomes, in turn, are expected to have major biomedical impact by accelerating the functional characterization of the mutated tyrosine kinome, which is emerging as a major target for personalized medicine. Finally, by providing detailed mechanistic annotation of mutations identified in genome sequencing studies, this proposal will address a fundamental NIH roadmap problem in translational medicine of converting genomic discoveries into therapeutic strategies. PUBLIC HEALTH RELEVANCE: Protein tyrosine kinases are a biomedically important class of proteins that are abnormally regulated in many human diseases including cancer, diabetes, and inflammatory disorders, to name but a few. They have been the focus of many drug discovery efforts and genome sequencing studies because of the therapeutic potential of targeting mutated tyrosine kinases for personalized therapy. By providing functional annotation of natural and disease mutations in tyrosine kinases, the proposed studies will accelerate the targeting of mutated tyrosine kinases for drug discovery and personalized therapy.",Functional Annotation of Natural and Disease Variants in Tryosine Kinases,9301599,R01GM114409,"['Active Sites', 'Address', 'Allosteric Regulation', 'Allosteric Site', 'Antineoplastic Agents', 'Binding', 'Biological Assay', 'Biological Models', 'Cell Survival', 'Communities', 'Complex', 'Diabetes Mellitus', 'Disease', 'Distal', 'Drug Binding Site', 'Drug resistance', 'Foundations', 'Genes', 'Genomics', 'Goals', 'Human Genome', 'In Vitro', 'Inflammatory', 'Machine Learning', 'Malignant Neoplasms', 'Modeling', 'Molecular', 'Mutate', 'Mutation', 'Names', 'Ontology', 'Organism', 'Outcome', 'Pathogenicity', 'Pattern', 'Peptides', 'Pharmaceutical Preparations', 'Phosphotransferases', 'Property', 'Protein Kinase', 'Protein Tyrosine Kinase', 'Protein-Serine-Threonine Kinases', 'Proteins', 'Publishing', 'Receptor Protein-Tyrosine Kinases', 'Recurrence', 'Regulation', 'Signal Transduction', 'Site', 'Structure', 'System', 'Testing', 'Therapeutic', 'Tyrosine', 'Tyrosine Kinase Domain', 'United States National Institutes of Health', 'Variant', 'base', 'cell growth', 'computer framework', 'drug discovery', 'genome sequencing', 'human disease', 'improved', 'insight', 'molecular dynamics', 'mutant', 'novel', 'personalized medicine', 'public health relevance', 'three dimensional structure', 'translational medicine']",NIGMS,UNIVERSITY OF GEORGIA,R01,2017,300000,0.2635068026198381
"Functional Annotation of Natural and Disease Variants in Tryosine Kinases     DESCRIPTION (provided by applicant): Protein tyrosine kinases are dynamic molecular switches that toggle between a catalytically ""on"" and ""off"" state to turn on and off signals responsible for cell growth and survival. While the tyrosine kinase switch is tightly regulated by  diverse array of structural mechanisms in normal states, in many disease states, the switch is permanently turned on or off due, in part, to mutations in the tyrosine kinase domain. Although genome sequencing studies have revealed the mutational patterns of tyrosine kinases from many different disease types, understanding the structural and functional impact of these mutations is a challenge because many recurrent mutations occur far from the active site (distal mutations) and the residue networks that contribute to the complex modes of tyrosine kinase allosteric regulation are not fully understood. Our long term goal is to understand the relationships connecting sequence, structure, function, regulation and disease in protein kinases using a combination of computational and experimental approaches. Our objective in this proposal, which is the next logical step toward attainment of our long-term goal, is to delineate the residue interaction networks that contribute to the unique modes of allosteric regulation in tyrosine kinases, and to develop a computational framework for predicting mutation impact using the evolutionary and allosteric properties encoded in three dimensional structures. The central hypothesis is that distal mutations alter evolutionarily conserved allosteric networks in tyrosine kinases, and delineating the allosteric networks unique to tyrosine kinases will provide context for predicting and testing disease mutation impact. The specific aims are: * To identify and characterize natural sequence and structural variants associated with tight  allosteric control of tyrosine kinase activity * To develop a computational framework for predicting mutation impact on kinase activation and to  experimentally validate computational predictions using selected receptor tyrosine kinases as  model systems Successful completion of these aims is expected to reveal novel activating mutations in putative allosteric sites in the tyrosine kinase domain, and pinpoint key residues and interactions for functional studies. These outcomes, in turn, are expected to have major biomedical impact by accelerating the functional characterization of the mutated tyrosine kinome, which is emerging as a major target for personalized medicine. Finally, by providing detailed mechanistic annotation of mutations identified in genome sequencing studies, this proposal will address a fundamental NIH roadmap problem in translational medicine of converting genomic discoveries into therapeutic strategies. PUBLIC HEALTH RELEVANCE: Protein tyrosine kinases are a biomedically important class of proteins that are abnormally regulated in many human diseases including cancer, diabetes, and inflammatory disorders, to name but a few. They have been the focus of many drug discovery efforts and genome sequencing studies because of the therapeutic potential of targeting mutated tyrosine kinases for personalized therapy. By providing functional annotation of natural and disease mutations in tyrosine kinases, the proposed studies will accelerate the targeting of mutated tyrosine kinases for drug discovery and personalized therapy.",Functional Annotation of Natural and Disease Variants in Tryosine Kinases,9116916,R01GM114409,"['Active Sites', 'Address', 'Allosteric Regulation', 'Allosteric Site', 'Antineoplastic Agents', 'Binding', 'Biological Assay', 'Biological Models', 'Cell Survival', 'Communities', 'Complex', 'Diabetes Mellitus', 'Disease', 'Distal', 'Drug Binding Site', 'Drug Regulations', 'Drug resistance', 'Family', 'Foundations', 'Genes', 'Genomics', 'Goals', 'Health', 'Human Genome', 'In Vitro', 'Inflammatory', 'Machine Learning', 'Malignant Neoplasms', 'Modeling', 'Mutate', 'Mutation', 'Names', 'Ontology', 'Organism', 'Outcome', 'Pattern', 'Peptides', 'Pharmaceutical Preparations', 'Phosphotransferases', 'Property', 'Protein Kinase', 'Protein Tyrosine Kinase', 'Protein-Serine-Threonine Kinases', 'Proteins', 'Publishing', 'Receptor Protein-Tyrosine Kinases', 'Recurrence', 'Regulation', 'Signal Transduction', 'Site', 'Structure', 'System', 'Testing', 'Therapeutic', 'Tyrosine', 'Tyrosine Kinase Domain', 'United States National Institutes of Health', 'Variant', 'Work', 'base', 'cell growth', 'computer framework', 'drug discovery', 'genome sequencing', 'human disease', 'improved', 'insight', 'molecular dynamics', 'mutant', 'novel', 'personalized medicine', 'three dimensional structure', 'translational medicine']",NIGMS,UNIVERSITY OF GEORGIA,R01,2016,300000,0.2635068026198381
"Functional Annotation of Natural and Disease Variants in Tryosine Kinases     DESCRIPTION (provided by applicant): Protein tyrosine kinases are dynamic molecular switches that toggle between a catalytically ""on"" and ""off"" state to turn on and off signals responsible for cell growth and survival. While the tyrosine kinase switch is tightly regulated by  diverse array of structural mechanisms in normal states, in many disease states, the switch is permanently turned on or off due, in part, to mutations in the tyrosine kinase domain. Although genome sequencing studies have revealed the mutational patterns of tyrosine kinases from many different disease types, understanding the structural and functional impact of these mutations is a challenge because many recurrent mutations occur far from the active site (distal mutations) and the residue networks that contribute to the complex modes of tyrosine kinase allosteric regulation are not fully understood. Our long term goal is to understand the relationships connecting sequence, structure, function, regulation and disease in protein kinases using a combination of computational and experimental approaches. Our objective in this proposal, which is the next logical step toward attainment of our long-term goal, is to delineate the residue interaction networks that contribute to the unique modes of allosteric regulation in tyrosine kinases, and to develop a computational framework for predicting mutation impact using the evolutionary and allosteric properties encoded in three dimensional structures. The central hypothesis is that distal mutations alter evolutionarily conserved allosteric networks in tyrosine kinases, and delineating the allosteric networks unique to tyrosine kinases will provide context for predicting and testing disease mutation impact. The specific aims are: * To identify and characterize natural sequence and structural variants associated with tight  allosteric control of tyrosine kinase activity * To develop a computational framework for predicting mutation impact on kinase activation and to  experimentally validate computational predictions using selected receptor tyrosine kinases as  model systems Successful completion of these aims is expected to reveal novel activating mutations in putative allosteric sites in the tyrosine kinase domain, and pinpoint key residues and interactions for functional studies. These outcomes, in turn, are expected to have major biomedical impact by accelerating the functional characterization of the mutated tyrosine kinome, which is emerging as a major target for personalized medicine. Finally, by providing detailed mechanistic annotation of mutations identified in genome sequencing studies, this proposal will address a fundamental NIH roadmap problem in translational medicine of converting genomic discoveries into therapeutic strategies.         PUBLIC HEALTH RELEVANCE: Protein tyrosine kinases are a biomedically important class of proteins that are abnormally regulated in many human diseases including cancer, diabetes, and inflammatory disorders, to name but a few. They have been the focus of many drug discovery efforts and genome sequencing studies because of the therapeutic potential of targeting mutated tyrosine kinases for personalized therapy. By providing functional annotation of natural and disease mutations in tyrosine kinases, the proposed studies will accelerate the targeting of mutated tyrosine kinases for drug discovery and personalized therapy.            ",Functional Annotation of Natural and Disease Variants in Tryosine Kinases,8984471,R01GM114409,"['Active Sites', 'Address', 'Allosteric Regulation', 'Allosteric Site', 'Antineoplastic Agents', 'Binding', 'Biological Assay', 'Biological Models', 'Cell Survival', 'Communities', 'Complex', 'Diabetes Mellitus', 'Disease', 'Distal', 'Drug Binding Site', 'Drug Regulations', 'Drug resistance', 'Family', 'Foundations', 'Genes', 'Genomics', 'Goals', 'Human Genome', 'In Vitro', 'Inflammatory', 'Machine Learning', 'Malignant Neoplasms', 'Modeling', 'Mutate', 'Mutation', 'Names', 'Ontology', 'Organism', 'Outcome', 'Pattern', 'Peptides', 'Pharmaceutical Preparations', 'Phosphotransferases', 'Property', 'Protein Kinase', 'Protein Tyrosine Kinase', 'Protein-Serine-Threonine Kinases', 'Proteins', 'Publishing', 'Receptor Protein-Tyrosine Kinases', 'Recurrence', 'Regulation', 'Signal Transduction', 'Site', 'Structure', 'System', 'Testing', 'Therapeutic', 'Tyrosine', 'Tyrosine Kinase Domain', 'United States National Institutes of Health', 'Variant', 'Work', 'base', 'cell growth', 'computer framework', 'drug discovery', 'genome sequencing', 'human disease', 'improved', 'insight', 'molecular dynamics', 'mutant', 'novel', 'personalized medicine', 'public health relevance', 'three dimensional structure', 'translational medicine']",NIGMS,UNIVERSITY OF GEORGIA,R01,2015,300000,0.2635068026198381
"Developing integrative approaches for identifying disease-causing genes and dysfunctional networks     DESCRIPTION: Cancer is a consequence of the accumulation of genetic alterations. Large whole-genome scale resequencing projects such as The Cancer Genome Atlas (TCGA) have been launched in an effort to comprehensively catalog the genomic mutations and epigenetic modifications that are associated with cancer. It is essential to identify cancer-causing genes and pathways to gain insight into the disease mechanisms and hence facilitate early diagnosis and optimal treatment. However, identifying cancer-causing genes and their functional pathways remains challenging due to the complex biological interactions and the heterogeneity of diseases. Genetic mutations in disease-causing genes can disturb signaling pathways that impact the expression of a set of genes performing certain biological functions. We refer to a set of such genes as a functional module. We hypothesize that driver mutations, that is, mutations that lead to cancer progression, are likely to affect common disease-associated functional modules, and the causal relationship between the mutations and the perturbed signals of the modules can be reconstructed from gene expression data and protein interaction data. In this project, we will develop a novel approach to infer disease-causing genes and networks by integrating information from multiple types of data including genomic variations, gene expression and protein interactions. We first dynamically identify disease-associated modules that consist of a set of interacting genes, then develop a Bayesian-based approach to infer causative genes from the disease-associated modules. Then, by developing a stochastic search based method, we can determine the paths connecting causative genes and gene modules. As a result, disease- related pathways are inferred from the paths. Furthermore, we will integrate those pathways with the human interactome to discover higher-level disease-associated networks. In addition, we will develop machine learning based classifiers to predict disease types and clinical outcomes utilizing the molecular signatures identified in this project, such as differentially expressed gene modules and causative genes. Our computational framework and classifiers will be made available to the research community via a webserver. The PI serves as the university bioinformatics program director and has extensive teaching and research experience. A goal of this project is also to provide scientific research training to students and o help students to gain biological insight through their involvement with the project. Students will learn practical scientific computing skills from the PI and develop their own computational approaches to solving specific biomedical problems under the guidance of the PI. Thus the project will serve as an effective learning-research model in bioinformatics.         PUBLIC HEALTH RELEVANCE: In this project, we will develop and implement a novel framework to identify causative mutations and pathways and study cancer disease mechanisms by reconstructing signaling pathways. This will help to advance personalized medicine and lead to a greater understanding of cancer mechanisms, which can lay the foundation for improving early diagnosis and treatment planning, as well as the discovery of new therapeutic targets.            ",Developing integrative approaches for identifying disease-causing genes and dysfunctional networks,8880075,R15GM114739,"['Affect', 'Bioinformatics', 'Biological', 'Biological Process', 'Cancer Etiology', 'Cataloging', 'Catalogs', 'Clinical', 'Clinical Data', 'Communities', 'Complex', 'DNA', 'DNA Resequencing', 'DNA Sequence Alteration', 'DNA-Protein Interaction', 'Data', 'Disease', 'Drug Targeting', 'Early Diagnosis', 'Early treatment', 'Educational process of instructing', 'Epigenetic Process', 'Foundations', 'Gene Cluster', 'Gene Expression', 'Gene Mutation', 'Gene Proteins', 'Genes', 'Genome', 'Genomics', 'Goals', 'Heterogeneity', 'Human', 'Investigation', 'Lead', 'Learning', 'Machine Learning', 'Malignant Neoplasms', 'Malignant neoplasm of ovary', 'Methods', 'Modeling', 'Modification', 'Molecular', 'Molecular Profiling', 'Mutation', 'Outcome', 'Pathway interactions', 'Performance', 'Phosphorylation', 'Population', 'Proteins', 'Recurrent disease', 'Research', 'Research Training', 'Resources', 'Role', 'Sampling', 'Signal Pathway', 'Signal Transduction', 'Single Nucleotide Polymorphism', 'Statistical Models', 'Students', 'System', 'Technology', 'The Cancer Genome Atlas', 'Universities', 'base', 'computer based statistical methods', 'computer framework', 'differential expression', 'disease diagnosis', 'disorder risk', 'experience', 'genome wide association study', 'genome-wide', 'genomic variation', 'heuristics', 'improved', 'innovation', 'insight', 'knowledge base', 'new therapeutic target', 'next generation sequencing', 'novel', 'novel strategies', 'personalized medicine', 'predictive modeling', 'programs', 'promoter', 'prospective', 'protein protein interaction', 'public health relevance', 'scientific computing', 'skills', 'treatment planning', 'tumor progression']",NIGMS,UNIVERSITY OF ARKANSAS AT LITTLE ROCK,R15,2015,373520,0.2179925197543028
"Characterizing the Co-evolution of Protein-protein and Regulatory Interactions     DESCRIPTION (provided by applicant): Evolutionary processes are fundamentally shaped by the physico-chemical properties of proteins, DNA, and other biomolecules: many layers of biophysical and biochemical mechanisms connect a DNA mutation to a cell's ability to survive and reproduce. Little is known about how random mutations affect these molecular properties and ultimately shape the evolutionary fate of a population. This knowledge is particularly crucial for predicting or controlling the evolution of antibiotic resistance in bacteria. The complexity of binding interactions and gene regulation suggests that a mutation to a single protein may have far-reaching effects throughout the cell. The goal of this project is to determine how mutations affect these molecular interactions and the resulting consequences for evolution in bacteria. Using a combination of theoretical and experimental approaches, it tests the hypothesis that protein-protein and regulatory interactions evolve rapidly and predictably in response to a mutational perturbation, while specific compensatory mutations that target individual protein traits, such as folding stability, and evolve over longer times. The project will first develop a multi-scale model that combines the biochemical kinetics of protein folding, binding, and regulation with the evolutionary dynamics of selection, mutation, and genetic drift. Computational simulations of the model will make experimental predictions. The project will then test these predictions by experimentally evolving E. coli with mutant dihydrofolate reductase (DHFR), an essential metabolic enzyme. Whole-genome sequencing and phenotyping of the evolved populations will allow comparison of the experiments with the theoretical predictions. This project will substantially increase our understanding of how mutations affect molecular interactions in cells, and how this shapes evolutionary outcomes.         PUBLIC HEALTH RELEVANCE: Antibiotic resistance is a growing threat to public health worldwide, but currently we do not understand how bacteria evolve resistance at the molecular level. My research seeks to characterize the molecular effects of mutations in bacteria and their consequences for evolution. This may contribute to predicting and ultimately controlling the evolution of antibiotic resistance.            ",Characterizing the Co-evolution of Protein-protein and Regulatory Interactions,9118763,F32GM116217,"['Address', 'Affect', 'Antibiotic Resistance', 'Antibiotics', 'Bacteria', 'Binding', 'Biochemical', 'Cell Shape', 'Cells', 'Computer Simulation', 'DNA', 'DNA Sequence Alteration', 'Dihydrofolate Reductase', 'Entropy', 'Enzymes', 'Escherichia coli', 'Evolution', 'Fellowship', 'Gene Expression Regulation', 'Genetic Drift', 'Genetic Epistasis', 'Genomics', 'Goals', 'Individual', 'Kinetics', 'Knowledge', 'Measures', 'Metabolic', 'Modeling', 'Molecular', 'Mutation', 'National Research Service Awards', 'Outcome', 'Phenotype', 'Population', 'Portraits', 'Process', 'Property', 'Proteins', 'Proteome', 'Public Health', 'Regulation', 'Research', 'Resistance', 'Shapes', 'Testing', 'Time', 'Ursidae Family', 'Work', 'base', 'chemical property', 'cost', 'environmental stressor', 'genetic regulatory protein', 'genome sequencing', 'in vivo', 'interest', 'microbial', 'microorganism', 'multi-scale modeling', 'mutant', 'pleiotropism', 'promoter', 'protein folding', 'protein protein interaction', 'public health relevance', 'research study', 'response', 'text searching', 'trait', 'whole genome']",NIGMS,HARVARD UNIVERSITY,F32,2016,56118,0.23852201279118918
"Characterizing the Co-evolution of Protein-protein and Regulatory Interactions     DESCRIPTION (provided by applicant): Evolutionary processes are fundamentally shaped by the physico-chemical properties of proteins, DNA, and other biomolecules: many layers of biophysical and biochemical mechanisms connect a DNA mutation to a cell's ability to survive and reproduce. Little is known about how random mutations affect these molecular properties and ultimately shape the evolutionary fate of a population. This knowledge is particularly crucial for predicting or controlling the evolution of antibiotic resistance in bacteria. The complexity of binding interactions and gene regulation suggests that a mutation to a single protein may have far-reaching effects throughout the cell. The goal of this project is to determine how mutations affect these molecular interactions and the resulting consequences for evolution in bacteria. Using a combination of theoretical and experimental approaches, it tests the hypothesis that protein-protein and regulatory interactions evolve rapidly and predictably in response to a mutational perturbation, while specific compensatory mutations that target individual protein traits, such as folding stability, and evolve over longer times. The project will first develop a multi-scale model that combines the biochemical kinetics of protein folding, binding, and regulation with the evolutionary dynamics of selection, mutation, and genetic drift. Computational simulations of the model will make experimental predictions. The project will then test these predictions by experimentally evolving E. coli with mutant dihydrofolate reductase (DHFR), an essential metabolic enzyme. Whole-genome sequencing and phenotyping of the evolved populations will allow comparison of the experiments with the theoretical predictions. This project will substantially increase our understanding of how mutations affect molecular interactions in cells, and how this shapes evolutionary outcomes.         PUBLIC HEALTH RELEVANCE: Antibiotic resistance is a growing threat to public health worldwide, but currently we do not understand how bacteria evolve resistance at the molecular level. My research seeks to characterize the molecular effects of mutations in bacteria and their consequences for evolution. This may contribute to predicting and ultimately controlling the evolution of antibiotic resistance.            ",Characterizing the Co-evolution of Protein-protein and Regulatory Interactions,8977564,F32GM116217,"['Address', 'Affect', 'Antibiotic Resistance', 'Antibiotics', 'Bacteria', 'Binding', 'Biochemical', 'Cell Shape', 'Cells', 'Computer Simulation', 'DNA', 'DNA Sequence Alteration', 'Dihydrofolate Reductase', 'Entropy', 'Enzymes', 'Escherichia coli', 'Evolution', 'Fellowship', 'Gene Expression Regulation', 'Genetic Drift', 'Genetic Epistasis', 'Genomics', 'Goals', 'Individual', 'Kinetics', 'Knowledge', 'Measures', 'Metabolic', 'Modeling', 'Molecular', 'Mutation', 'National Research Service Awards', 'Outcome', 'Phenotype', 'Population', 'Portraits', 'Process', 'Property', 'Proteins', 'Proteome', 'Public Health', 'Regulation', 'Research', 'Resistance', 'Shapes', 'Testing', 'Time', 'Ursidae Family', 'Work', 'base', 'chemical property', 'cost', 'environmental stressor', 'genetic regulatory protein', 'genome sequencing', 'in vivo', 'interest', 'microbial', 'microorganism', 'multi-scale modeling', 'mutant', 'pleiotropism', 'promoter', 'protein folding', 'protein protein interaction', 'public health relevance', 'research study', 'response', 'text searching', 'trait']",NIGMS,HARVARD UNIVERSITY,F32,2015,52406,0.23852201279118918
"Tracing the evolution of the human mutation rate DESCRIPTION (provided by applicant): All genetic variation is created by mutations, changes that arise due to DNA damage or copying mistakes during DNA replication. Mutations are frequent enough that, on average, a child's 3-billion base pair genome contains 74 new genetic variants that are not present in the genome of either parent. Such new mutations confer a higher disease risk than older mutations because they have not passed the test of surviving through several generations of parents and offspring. We aim to pinpoint how the human mutation rate has evolved as humans left Africa and adapted to diverse new environments across the globe.  One specific aim will follow up on my preliminary research which showed that Europeans experienced a mutation rate change after diverging from Africans and Asians. The primary evidence for this change is that European genomes have a higher burden than African or Asian genomes of the mutation type TCCTTC, where the trinucleotide ""TCC"" has experienced a mutation from ""C"" to ""T"" at its central site. We wish to and the genetic basis of this mutation rate change by looking at rare variants in mixed- ancestry Latino and African-American individuals. Specially, we will isolate young genetic variants that probably arose via mutation within the past 10-15 generations, after gene ow from Europe into the Americas had already begun. We will infer the genetic background (European, African, or Native American) upon which each new mutation arose and look for genomic regions where European ances- try correlates strongly with an excess of TCCTTC mutations. These will be the regions most likely to harbor a causal allele that changed the process of mutation accumulation in Europeans. This work has the potential to yield valuable insights into melanoma, a cancer that predominantly affects individuals of European ancestry and whose somatic mutational signature is dominated by TCCTTC.  A second specific aim is to look for other signatures of mutation rate change that have occurred within the human species or, more broadly, within the great apes. We will use a natural language processing technique called Latent Dirichlet Allocation (LDA) to identify collections of mutation types whose rates appear to be under common genetic control. A few mutation types besides TCCTTC show weak signals of rate differentiation between populations, and we will attempt to infer how many separate mutation rate change events are necessary to explain these signals. The admixture mapping technique from Specific Aim I can also be adapted to interrogate the genetic basis of other mutation rate changes that might have occurred in the recent past. These efforts should improve our understanding of the human mutation rate's genetic architecture and how mutation rates differ between populations. PUBLIC HEALTH RELEVANCE: All genetic variation is created by mutations, the copying mistakes that occasionally happen during DNA replication. There is evidence that children born with a higher burden of new mutations are at increased risk for autism, schizophrenia, and serious congenital diseases [1, 2, 3], but it is not well understood how much the human mutation rate varies and what genetic risk factors affect the mutation rate [4]. We aim to follow up on preliminary evidence that the Europeans have a higher mutation rate than Asians or Africans [5], looking for the genetic basis of this rate difference and investigating how often the mutation rate has changed during human evolution.",Tracing the evolution of the human mutation rate,9117987,F32GM116381,"['Acceleration', 'Affect', 'Africa', 'African', 'African American', 'Alleles', 'American', 'Americas', 'Architecture', 'Asians', 'Autistic Disorder', 'Base Pairing', 'Bayesian Analysis', 'Cancer Biology', 'Child', 'Chromosome Mapping', 'Collection', 'DNA Damage', 'DNA biosynthesis', 'Disease', 'Doctor of Philosophy', 'Employee Strikes', 'Environment', 'Europe', 'European', 'Event', 'Evolution', 'Exhibits', 'Generations', 'Genes', 'Genetic', 'Genetic Variation', 'Genome', 'Genomic Segment', 'Germ-Line Mutation', 'Health', 'Hereditary Disease', 'Human', 'Individual', 'Latino', 'Left', 'Machine Learning', 'Malignant Neoplasms', 'Maps', 'Mutation', 'Mutation Spectra', 'Native Americans', 'Natural Language Processing', 'Parents', 'Pongidae', 'Population', 'Process', 'Recording of previous events', 'Research', 'Risk', 'Risk Factors', 'Schizophrenia', 'Signal Transduction', 'Site', 'Somatic Mutation', 'Techniques', 'Testing', 'Time', 'Variant', 'Work', 'admixture mapping', 'base', 'design', 'developmental disease', 'disorder risk', 'experience', 'follow-up', 'genetic risk factor', 'genetic variant', 'improved', 'insight', 'learning strategy', 'melanoma', 'offspring', 'rare variant', 'rate of change', 'success', 'trait', 'transition mutation']",NIGMS,STANFORD UNIVERSITY,F32,2016,56118,0.3457928464799599
"Tracing the evolution of the human mutation rate DESCRIPTION (provided by applicant): All genetic variation is created by mutations, changes that arise due to DNA damage or copying mistakes during DNA replication. Mutations are frequent enough that, on average, a child's 3-billion base pair genome contains 74 new genetic variants that are not present in the genome of either parent. Such new mutations confer a higher disease risk than older mutations because they have not passed the test of surviving through several generations of parents and offspring. We aim to pinpoint how the human mutation rate has evolved as humans left Africa and adapted to diverse new environments across the globe.  One specific aim will follow up on my preliminary research which showed that Europeans experienced a mutation rate change after diverging from Africans and Asians. The primary evidence for this change is that European genomes have a higher burden than African or Asian genomes of the mutation type TCCTTC, where the trinucleotide ""TCC"" has experienced a mutation from ""C"" to ""T"" at its central site. We wish to and the genetic basis of this mutation rate change by looking at rare variants in mixed- ancestry Latino and African-American individuals. Specially, we will isolate young genetic variants that probably arose via mutation within the past 10-15 generations, after gene ow from Europe into the Americas had already begun. We will infer the genetic background (European, African, or Native American) upon which each new mutation arose and look for genomic regions where European ances- try correlates strongly with an excess of TCCTTC mutations. These will be the regions most likely to harbor a causal allele that changed the process of mutation accumulation in Europeans. This work has the potential to yield valuable insights into melanoma, a cancer that predominantly affects individuals of European ancestry and whose somatic mutational signature is dominated by TCCTTC.  A second specific aim is to look for other signatures of mutation rate change that have occurred within the human species or, more broadly, within the great apes. We will use a natural language processing technique called Latent Dirichlet Allocation (LDA) to identify collections of mutation types whose rates appear to be under common genetic control. A few mutation types besides TCCTTC show weak signals of rate differentiation between populations, and we will attempt to infer how many separate mutation rate change events are necessary to explain these signals. The admixture mapping technique from Specific Aim I can also be adapted to interrogate the genetic basis of other mutation rate changes that might have occurred in the recent past. These efforts should improve our understanding of the human mutation rate's genetic architecture and how mutation rates differ between populations. PUBLIC HEALTH RELEVANCE: All genetic variation is created by mutations, the copying mistakes that occasionally happen during DNA replication. There is evidence that children born with a higher burden of new mutations are at increased risk for autism, schizophrenia, and serious congenital diseases [1, 2, 3], but it is not well understood how much the human mutation rate varies and what genetic risk factors affect the mutation rate [4]. We aim to follow up on preliminary evidence that the Europeans have a higher mutation rate than Asians or Africans [5], looking for the genetic basis of this rate difference and investigating how often the mutation rate has changed during human evolution.",Tracing the evolution of the human mutation rate,8982093,F32GM116381,"['Acceleration', 'Admixture', 'Affect', 'Africa', 'African', 'African American', 'Alleles', 'American', 'Americas', 'Architecture', 'Asians', 'Autistic Disorder', 'Base Pairing', 'Bayesian Analysis', 'Cancer Biology', 'Child', 'Chromosome Mapping', 'Collection', 'DNA Damage', 'DNA biosynthesis', 'Disease', 'Doctor of Philosophy', 'Employee Strikes', 'Environment', 'Europe', 'European', 'Event', 'Evolution', 'Exhibits', 'Generations', 'Genes', 'Genetic', 'Genetic Variation', 'Genome', 'Genomic Segment', 'Germ-Line Mutation', 'Health', 'Hereditary Disease', 'Human', 'Individual', 'Latino', 'Left', 'Machine Learning', 'Malignant Neoplasms', 'Maps', 'Methods', 'Mutation', 'Mutation Spectra', 'Native Americans', 'Natural Language Processing', 'Parents', 'Pongidae', 'Population', 'Process', 'Recording of previous events', 'Research', 'Risk', 'Risk Factors', 'Schizophrenia', 'Signal Transduction', 'Site', 'Somatic Mutation', 'Techniques', 'Testing', 'Time', 'Variant', 'Work', 'base', 'design', 'developmental disease', 'disorder risk', 'experience', 'follow-up', 'genetic risk factor', 'genetic variant', 'improved', 'insight', 'melanoma', 'offspring', 'rare variant', 'success', 'trait', 'transition mutation']",NIGMS,STANFORD UNIVERSITY,F32,2015,50690,0.3457928464799599
"Tracing the evolution of the human mutation rate DESCRIPTION (provided by applicant): All genetic variation is created by mutations, changes that arise due to DNA damage or copying mistakes during DNA replication. Mutations are frequent enough that, on average, a child's 3-billion base pair genome contains 74 new genetic variants that are not present in the genome of either parent. Such new mutations confer a higher disease risk than older mutations because they have not passed the test of surviving through several generations of parents and offspring. We aim to pinpoint how the human mutation rate has evolved as humans left Africa and adapted to diverse new environments across the globe.  One specific aim will follow up on my preliminary research which showed that Europeans experienced a mutation rate change after diverging from Africans and Asians. The primary evidence for this change is that European genomes have a higher burden than African or Asian genomes of the mutation type TCCTTC, where the trinucleotide ""TCC"" has experienced a mutation from ""C"" to ""T"" at its central site. We wish to and the genetic basis of this mutation rate change by looking at rare variants in mixed- ancestry Latino and African-American individuals. Specially, we will isolate young genetic variants that probably arose via mutation within the past 10-15 generations, after gene ow from Europe into the Americas had already begun. We will infer the genetic background (European, African, or Native American) upon which each new mutation arose and look for genomic regions where European ances- try correlates strongly with an excess of TCCTTC mutations. These will be the regions most likely to harbor a causal allele that changed the process of mutation accumulation in Europeans. This work has the potential to yield valuable insights into melanoma, a cancer that predominantly affects individuals of European ancestry and whose somatic mutational signature is dominated by TCCTTC.  A second specific aim is to look for other signatures of mutation rate change that have occurred within the human species or, more broadly, within the great apes. We will use a natural language processing technique called Latent Dirichlet Allocation (LDA) to identify collections of mutation types whose rates appear to be under common genetic control. A few mutation types besides TCCTTC show weak signals of rate differentiation between populations, and we will attempt to infer how many separate mutation rate change events are necessary to explain these signals. The admixture mapping technique from Specific Aim I can also be adapted to interrogate the genetic basis of other mutation rate changes that might have occurred in the recent past. These efforts should improve our understanding of the human mutation rate's genetic architecture and how mutation rates differ between populations. PUBLIC HEALTH RELEVANCE: All genetic variation is created by mutations, the copying mistakes that occasionally happen during DNA replication. There is evidence that children born with a higher burden of new mutations are at increased risk for autism, schizophrenia, and serious congenital diseases [1, 2, 3], but it is not well understood how much the human mutation rate varies and what genetic risk factors affect the mutation rate [4]. We aim to follow up on preliminary evidence that the Europeans have a higher mutation rate than Asians or Africans [5], looking for the genetic basis of this rate difference and investigating how often the mutation rate has changed during human evolution.",Tracing the evolution of the human mutation rate,9278228,F32GM116381,"['Acceleration', 'Affect', 'Africa', 'African', 'African American', 'Alleles', 'American', 'Americas', 'Architecture', 'Asians', 'Autistic Disorder', 'Base Pairing', 'Bayesian Analysis', 'Cancer Biology', 'Child', 'Collection', 'DNA Damage', 'DNA biosynthesis', 'Disease', 'Doctor of Philosophy', 'Employee Strikes', 'Environment', 'Europe', 'European', 'Event', 'Evolution', 'Exhibits', 'Generations', 'Genes', 'Genetic', 'Genetic Variation', 'Genome', 'Genomic Segment', 'Germ-Line Mutation', 'Hereditary Disease', 'Human', 'Individual', 'Latino', 'Left', 'Machine Learning', 'Malignant Neoplasms', 'Maps', 'Mutation', 'Native Americans', 'Natural Language Processing', 'Parents', 'Pongidae', 'Population', 'Process', 'Recording of previous events', 'Research', 'Risk', 'Risk Factors', 'Schizophrenia', 'Signal Transduction', 'Site', 'Somatic Mutation', 'Techniques', 'Testing', 'Time', 'Variant', 'Work', 'admixture mapping', 'base', 'design', 'developmental disease', 'disorder risk', 'experience', 'follow-up', 'genetic risk factor', 'genetic variant', 'improved', 'insight', 'learning strategy', 'melanoma', 'offspring', 'public health relevance', 'rare variant', 'rate of change', 'success', 'trait', 'transition mutation']",NIGMS,STANFORD UNIVERSITY,F32,2017,36307,0.3457928464799599
"Tracing the evolution of the human mutation rate DESCRIPTION (provided by applicant): All genetic variation is created by mutations, changes that arise due to DNA damage or copying mistakes during DNA replication. Mutations are frequent enough that, on average, a child's 3-billion base pair genome contains 74 new genetic variants that are not present in the genome of either parent. Such new mutations confer a higher disease risk than older mutations because they have not passed the test of surviving through several generations of parents and offspring. We aim to pinpoint how the human mutation rate has evolved as humans left Africa and adapted to diverse new environments across the globe.  One specific aim will follow up on my preliminary research which showed that Europeans experienced a mutation rate change after diverging from Africans and Asians. The primary evidence for this change is that European genomes have a higher burden than African or Asian genomes of the mutation type TCCTTC, where the trinucleotide ""TCC"" has experienced a mutation from ""C"" to ""T"" at its central site. We wish to and the genetic basis of this mutation rate change by looking at rare variants in mixed- ancestry Latino and African-American individuals. Specially, we will isolate young genetic variants that probably arose via mutation within the past 10-15 generations, after gene ow from Europe into the Americas had already begun. We will infer the genetic background (European, African, or Native American) upon which each new mutation arose and look for genomic regions where European ances- try correlates strongly with an excess of TCCTTC mutations. These will be the regions most likely to harbor a causal allele that changed the process of mutation accumulation in Europeans. This work has the potential to yield valuable insights into melanoma, a cancer that predominantly affects individuals of European ancestry and whose somatic mutational signature is dominated by TCCTTC.  A second specific aim is to look for other signatures of mutation rate change that have occurred within the human species or, more broadly, within the great apes. We will use a natural language processing technique called Latent Dirichlet Allocation (LDA) to identify collections of mutation types whose rates appear to be under common genetic control. A few mutation types besides TCCTTC show weak signals of rate differentiation between populations, and we will attempt to infer how many separate mutation rate change events are necessary to explain these signals. The admixture mapping technique from Specific Aim I can also be adapted to interrogate the genetic basis of other mutation rate changes that might have occurred in the recent past. These efforts should improve our understanding of the human mutation rate's genetic architecture and how mutation rates differ between populations. PUBLIC HEALTH RELEVANCE: All genetic variation is created by mutations, the copying mistakes that occasionally happen during DNA replication. There is evidence that children born with a higher burden of new mutations are at increased risk for autism, schizophrenia, and serious congenital diseases [1, 2, 3], but it is not well understood how much the human mutation rate varies and what genetic risk factors affect the mutation rate [4]. We aim to follow up on preliminary evidence that the Europeans have a higher mutation rate than Asians or Africans [5], looking for the genetic basis of this rate difference and investigating how often the mutation rate has changed during human evolution.",Tracing the evolution of the human mutation rate,9397848,F32GM116381,"['Acceleration', 'Affect', 'Africa', 'African', 'African American', 'Alleles', 'American', 'Americas', 'Architecture', 'Asians', 'Autistic Disorder', 'Base Pairing', 'Bayesian Analysis', 'Cancer Biology', 'Child', 'Collection', 'DNA Damage', 'DNA biosynthesis', 'Disease', 'Doctor of Philosophy', 'Employee Strikes', 'Environment', 'Europe', 'European', 'Event', 'Evolution', 'Exhibits', 'Generations', 'Genes', 'Genetic', 'Genetic Variation', 'Genome', 'Genomic Segment', 'Germ-Line Mutation', 'Hereditary Disease', 'Human', 'Individual', 'Latino', 'Left', 'Machine Learning', 'Malignant Neoplasms', 'Maps', 'Mutation', 'Native Americans', 'Natural Language Processing', 'Parents', 'Pongidae', 'Population', 'Process', 'Recording of previous events', 'Research', 'Risk', 'Risk Factors', 'Schizophrenia', 'Signal Transduction', 'Site', 'Somatic Mutation', 'Techniques', 'Testing', 'Time', 'Variant', 'Work', 'admixture mapping', 'base', 'design', 'developmental disease', 'disorder risk', 'experience', 'follow-up', 'genetic risk factor', 'genetic variant', 'improved', 'insight', 'learning strategy', 'melanoma', 'offspring', 'public health relevance', 'rare variant', 'rate of change', 'success', 'trait', 'transition mutation']",NIGMS,STANFORD UNIVERSITY,F32,2017,510,0.3457928464799599
"Advancing Protein Engineering Using Artificial Intelligence and the ProtaBank Mutation Database PROJECT SUMMARY Therapeutic antibodies, specialized enzymes for drug manufacturing, small molecule drug screening agents, and other proteins have been instrumental in advancing biotechnology and medicine. Protein therapeutics alone represents a rapidly growing $100+ billion market with broad applications in the treatment of cancer, inflammatory and metabolic diseases, and numerous other disorders. Most of the antibodies and other protein therapeutics developed in the last several years have been engineered, leading to improvements in important properties such as efficacy, binding affinity, expression, stability, and immunogenicity. However, improving protein properties through sequence modification remains a challenging task. Artificial intelligence (AI), which has been enormously successful in several fields (e.g., image recognition, self-driving cars, natural language processing), is now being applied to protein engineering and has the potential to transform this field as well. AI and machine learning (ML) can take advantage of large and diverse datasets to identify correlations, predict beneficial mutations, and explore novel protein sequences in ways that are not possible using other techniques. Other advantages include the ability to simultaneously optimize multiple protein properties and explore sequence space more efficiently. In Phases I and II of this project, we developed the ProtaBank database as a central repository to store, organize, and annotate protein mutation data spanning a broad range of properties. ProtaBank is the largest and only database actively collecting such a comprehensive set of sequence mutation data and is growing rapidly due to the wealth of data being generated with advanced automation and next-generation sequencing techniques. ProtaBank's depth and breadth makes it an ideal data source to train ML models. This proposal aims to create the ProtaBank AI Platform to enable the use of AI and ML tools to apply the data in ProtaBank to engineer proteins. The platform will provide fully customizable computational tools and will invoke protein-specific knowledge to properly prepare data for use with ML models. An interface to popular ML frameworks will be provided so that scientists can use these techniques to discover new predictive algorithms and enhance their ability to design proteins with the desired properties. Specific aims include: (1) integrating peer validated ML methods and proprietary technology for protein engineering into the ProtaBank AI Platform, (2) developing dynamic ML dataset creation tools, (3) expanding and improving the ProtaBank database by reaching out to scientists to contribute data, (4) enhancing our data deposition tools, and (5) integrating ProtaBank with the Protein Data Bank structure database and other databases. ! Project Narrative Protein engineering has enabled significant advances in health care by playing a key role in the development of antibodies and other protein therapeutics (e.g., for the treatment of cancer, inflammatory and metabolic diseases, and other disorders), highly selective enzymes for drug manufacturing, and novel proteins for use in diagnostics and the identification of new small molecule drugs. This project will enable the power of artificial intelligence (AI) to be applied to accelerate the engineering of proteins with new and improved properties. AI approaches can capitalize on the large amounts of protein mutation data being generated and stored in our recently developed ProtaBank protein mutation database to transform the way in which protein therapeutics and reagents are discovered and developed.!",Advancing Protein Engineering Using Artificial Intelligence and the ProtaBank Mutation Database,9994932,R44GM117961,"['Affinity', 'Amino Acid Sequence', 'Antibodies', 'Artificial Intelligence', 'Automation', 'Automobile Driving', 'Base Sequence', 'Binding', 'Biological Assay', 'Biotechnology', 'Collection', 'Communities', 'Coupled', 'Data', 'Data Set', 'Data Sources', 'Databases', 'Deposition', 'Development', 'Diagnostic', 'Disease', 'Drug Screening', 'Engineering', 'Enzymes', 'Generations', 'Healthcare', 'Image', 'Inflammatory', 'Knowledge', 'Link', 'Machine Learning', 'Medicine', 'Metabolic Diseases', 'Meteor', 'Modeling', 'Modification', 'Mutation', 'Natural Language Processing', 'Pharmaceutical Preparations', 'Phase', 'Play', 'Preparation', 'Property', 'Protein Engineering', 'Proteins', 'Protocols documentation', 'Reagent', 'Research Personnel', 'Sampling', 'Scientist', 'Standardization', 'Structure', 'Techniques', 'Technology', 'Therapeutic antibodies', 'Training', 'base', 'cancer therapy', 'computerized tools', 'data submission', 'data warehouse', 'database structure', 'deep learning', 'design', 'flexibility', 'immunogenicity', 'improved', 'insight', 'learning strategy', 'machine learning method', 'multitask', 'next generation sequencing', 'novel', 'peer', 'prediction algorithm', 'protein structure', 'repository', 'small molecule', 'therapeutic protein', 'tool']",NIGMS,"PROTABIT, LLC",R44,2020,495160,0.12936373487096184
"Advancing Protein Engineering Using Artificial Intelligence and the ProtaBank Mutation Database PROJECT SUMMARY Therapeutic antibodies, specialized enzymes for drug manufacturing, small molecule drug screening agents, and other proteins have been instrumental in advancing biotechnology and medicine. Protein therapeutics alone represents a rapidly growing $100+ billion market with broad applications in the treatment of cancer, inflammatory and metabolic diseases, and numerous other disorders. Most of the antibodies and other protein therapeutics developed in the last several years have been engineered, leading to improvements in important properties such as efficacy, binding affinity, expression, stability, and immunogenicity. However, improving protein properties through sequence modification remains a challenging task. Artificial intelligence (AI), which has been enormously successful in several fields (e.g., image recognition, self-driving cars, natural language processing), is now being applied to protein engineering and has the potential to transform this field as well. AI and machine learning (ML) can take advantage of large and diverse datasets to identify correlations, predict beneficial mutations, and explore novel protein sequences in ways that are not possible using other techniques. Other advantages include the ability to simultaneously optimize multiple protein properties and explore sequence space more efficiently. In Phases I and II of this project, we developed the ProtaBank database as a central repository to store, organize, and annotate protein mutation data spanning a broad range of properties. ProtaBank is the largest and only database actively collecting such a comprehensive set of sequence mutation data and is growing rapidly due to the wealth of data being generated with advanced automation and next-generation sequencing techniques. ProtaBank's depth and breadth makes it an ideal data source to train ML models. This proposal aims to create the ProtaBank AI Platform to enable the use of AI and ML tools to apply the data in ProtaBank to engineer proteins. The platform will provide fully customizable computational tools and will invoke protein-specific knowledge to properly prepare data for use with ML models. An interface to popular ML frameworks will be provided so that scientists can use these techniques to discover new predictive algorithms and enhance their ability to design proteins with the desired properties. Specific aims include: (1) integrating peer validated ML methods and proprietary technology for protein engineering into the ProtaBank AI Platform, (2) developing dynamic ML dataset creation tools, (3) expanding and improving the ProtaBank database by reaching out to scientists to contribute data, (4) enhancing our data deposition tools, and (5) integrating ProtaBank with the Protein Data Bank structure database and other databases. ! Project Narrative Protein engineering has enabled significant advances in health care by playing a key role in the development of antibodies and other protein therapeutics (e.g., for the treatment of cancer, inflammatory and metabolic diseases, and other disorders), highly selective enzymes for drug manufacturing, and novel proteins for use in diagnostics and the identification of new small molecule drugs. This project will enable the power of artificial intelligence (AI) to be applied to accelerate the engineering of proteins with new and improved properties. AI approaches can capitalize on the large amounts of protein mutation data being generated and stored in our recently developed ProtaBank protein mutation database to transform the way in which protein therapeutics and reagents are discovered and developed.!",Advancing Protein Engineering Using Artificial Intelligence and the ProtaBank Mutation Database,9847841,R44GM117961,"['Affinity', 'Amino Acid Sequence', 'Antibodies', 'Artificial Intelligence', 'Automation', 'Automobile Driving', 'Base Sequence', 'Binding', 'Biological Assay', 'Biotechnology', 'Collection', 'Communities', 'Coupled', 'Data', 'Data Quality', 'Data Set', 'Data Sources', 'Databases', 'Deposition', 'Development', 'Diagnostic', 'Disease', 'Drug Screening', 'Engineering', 'Enzymes', 'Generations', 'Healthcare', 'Image', 'Inflammatory', 'Knowledge', 'Link', 'Machine Learning', 'Medicine', 'Metabolic Diseases', 'Meteor', 'Modeling', 'Modification', 'Mutation', 'Natural Language Processing', 'Pharmaceutical Preparations', 'Phase', 'Play', 'Preparation', 'Property', 'Protein Engineering', 'Proteins', 'Protocols documentation', 'Reagent', 'Research Personnel', 'Sampling', 'Scientist', 'Standardization', 'Structural Protein', 'Structure', 'Techniques', 'Technology', 'Therapeutic antibodies', 'Training', 'base', 'cancer therapy', 'computerized tools', 'data submission', 'data warehouse', 'database structure', 'deep learning', 'design', 'flexibility', 'immunogenicity', 'improved', 'insight', 'learning strategy', 'multitask', 'next generation sequencing', 'novel', 'peer', 'prediction algorithm', 'protein structure', 'repository', 'small molecule', 'therapeutic protein', 'tool']",NIGMS,"PROTABIT, LLC",R44,2019,990318,0.12936373487096184
"High-resolution map of human germline mutation patterns and inference of mutagenic mechanisms     DESCRIPTION (provided by applicant): Mutations are the ultimate source of genetic variation and one of the driving forces of evolution. Both the absolute mutation rate and the relative rate among mutation subtypes fluctuate along the genome, affected by adjacent nucleotide motifs and local features such as GC content and replication timing. Characterizing regional variation of mutation patterns is critical for understanding genome evolution and to identify variants causing genetic diseases. However, mutation rate and molecular spectrum are difficult to measure at high resolution, genomewide, and in an unbiased fashion. Estimates based on common variants and between- species substitutions are confounded by natural selection, population demographic history, and biased gene conversion (BGC). Methods relying on incidence rates of monogenic diseases or finding de novo variants by trio sequencing can inform global trends, but do not provide sufficient data to assess fine-scale local parameters. This study will overcome these limitations by using the extremely rare variants (ERVs) as a new data source to characterize patterns of recent germline variation in humans. ERVs, defined in this study as singletons in 30,000 samples, are becoming available via large-scale whole-genome sequencing (WGS) of population samples. Unlike common variants or substitutions, ERVs arose very recently and are largely unaffected by selection, BGC, etc. We will analyze 200-300 million singleton variants observed in 30,000 subjects at 20-30X coverage. The regional distribution of ERV subtypes will establish a quantitative atlas of the rate and spectrum of human germline mutations mostly unaltered by selection. We will share this resource with the research community and apply it to determine the impact of local genomic features and epigenomic attributes. We will use the systematic departures between ERVs and variants of higher frequencies (polymorphisms and substitutions) to infer local effects of selection, and this may uncover hitherto unknown functional regions of the genome. By comparing mutation signatures in ERVs with those in somatic variations observed in diverse cancers we will attribute distinct mutational signatures to known biochemical processes and thus infer the major contributors to new germline mutations in the human genome. This subtype-specific atlas will also be used to predict the probability of observing every possible single-base mutation in the genome, thus facilitating the interpretation of candidate causal variants of human diseases. We will assess mutation pattern differences among European Americans, African Americans and Latinos, and seek to discover genetic modifiers of germline mutation rate by finding functionally damaging mutations that show increased ERV counts in the surrounding genomic region, potentially identifying both known and previous unknown ""mutator"" genes that play a role in transmission fidelity in humans. This research will provide an essential resource to study the genesis and maintenance of germline mutations in humans. Understanding such a fundamental process will be the basis for a deeper understanding of human evolution and diseases. PUBLIC HEALTH RELEVANCE: We will study the patterns of inherited mutations in humans using approximately 250 million extremely rare DNA variants in human populations. Our results will allow the prediction of the rate of new mutations at every site in the genome based on features of the surrounding DNA sequence, thus providing a common resource to study the arrival and maintenance of mutations in humans. Understanding such a basic process is important for answering fundamental questions in human evolution, the cause of inherited diseases, and the role of DNA abnormality in cancer and aging.",High-resolution map of human germline mutation patterns and inference of mutagenic mechanisms,9702844,R01GM118928,"['Address', 'Affect', 'African American', 'Aging', 'Algorithms', 'Alleles', 'American', 'Atlases', 'Biochemical Process', 'Biological Factors', 'Biological Process', 'Biology', 'Child', 'Chromatin', 'Communities', 'Complex', 'DNA', 'DNA Sequence', 'Data', 'Data Analyses', 'Data Set', 'Data Sources', 'Demographic Factors', 'Dependence', 'Disease', 'Environmental Risk Factor', 'European', 'Evolution', 'Family', 'Foundations', 'Frequencies', 'Future', 'Gene Conversion', 'Generations', 'Genes', 'Genetic', 'Genetic Diseases', 'Genetic Polymorphism', 'Genetic Recombination', 'Genetic Variation', 'Genome', 'Genomic Segment', 'Genomics', 'Germ-Line Mutation', 'Guanine + Cytosine Composition', 'Hereditary Disease', 'High-Throughput Nucleotide Sequencing', 'Human', 'Human Genetics', 'Human Genome', 'Incidence', 'Individual', 'Inherited', 'Latino', 'Machine Learning', 'Maintenance', 'Malignant Neoplasms', 'Maps', 'Measures', 'Mendelian disorder', 'Methods', 'Mismatch Repair', 'Modeling', 'Molecular', 'Mutagenesis', 'Mutation', 'Natural Selections', 'Nucleotides', 'Parents', 'Pathogenicity', 'Pattern', 'Play', 'Population', 'Positioning Attribute', 'Probability', 'Process', 'Recording of previous events', 'Research', 'Resolution', 'Resource Sharing', 'Resources', 'Rest', 'Role', 'Sampling', 'Selection Bias', 'Site', 'Somatic Mutation', 'Source', 'Techniques', 'Technology', 'Tissues', 'Variant', 'Weight', 'actionable mutation', 'base', 'causal variant', 'data sharing', 'density', 'driving force', 'epigenomics', 'genetic analysis', 'genome sequencing', 'genome-wide', 'human disease', 'human model', 'improved', 'next generation sequencing', 'prototype', 'public health relevance', 'rare variant', 'repository', 'transmission process', 'trend', 'web server', 'whole genome']",NIGMS,UNIVERSITY OF MICHIGAN AT ANN ARBOR,R01,2019,300191,0.2137030741282121
"High-resolution map of human germline mutation patterns and inference of mutagenic mechanisms     DESCRIPTION (provided by applicant): Mutations are the ultimate source of genetic variation and one of the driving forces of evolution. Both the absolute mutation rate and the relative rate among mutation subtypes fluctuate along the genome, affected by adjacent nucleotide motifs and local features such as GC content and replication timing. Characterizing regional variation of mutation patterns is critical for understanding genome evolution and to identify variants causing genetic diseases. However, mutation rate and molecular spectrum are difficult to measure at high resolution, genomewide, and in an unbiased fashion. Estimates based on common variants and between- species substitutions are confounded by natural selection, population demographic history, and biased gene conversion (BGC). Methods relying on incidence rates of monogenic diseases or finding de novo variants by trio sequencing can inform global trends, but do not provide sufficient data to assess fine-scale local parameters. This study will overcome these limitations by using the extremely rare variants (ERVs) as a new data source to characterize patterns of recent germline variation in humans. ERVs, defined in this study as singletons in 30,000 samples, are becoming available via large-scale whole-genome sequencing (WGS) of population samples. Unlike common variants or substitutions, ERVs arose very recently and are largely unaffected by selection, BGC, etc. We will analyze 200-300 million singleton variants observed in 30,000 subjects at 20-30X coverage. The regional distribution of ERV subtypes will establish a quantitative atlas of the rate and spectrum of human germline mutations mostly unaltered by selection. We will share this resource with the research community and apply it to determine the impact of local genomic features and epigenomic attributes. We will use the systematic departures between ERVs and variants of higher frequencies (polymorphisms and substitutions) to infer local effects of selection, and this may uncover hitherto unknown functional regions of the genome. By comparing mutation signatures in ERVs with those in somatic variations observed in diverse cancers we will attribute distinct mutational signatures to known biochemical processes and thus infer the major contributors to new germline mutations in the human genome. This subtype-specific atlas will also be used to predict the probability of observing every possible single-base mutation in the genome, thus facilitating the interpretation of candidate causal variants of human diseases. We will assess mutation pattern differences among European Americans, African Americans and Latinos, and seek to discover genetic modifiers of germline mutation rate by finding functionally damaging mutations that show increased ERV counts in the surrounding genomic region, potentially identifying both known and previous unknown ""mutator"" genes that play a role in transmission fidelity in humans. This research will provide an essential resource to study the genesis and maintenance of germline mutations in humans. Understanding such a fundamental process will be the basis for a deeper understanding of human evolution and diseases. PUBLIC HEALTH RELEVANCE: We will study the patterns of inherited mutations in humans using approximately 250 million extremely rare DNA variants in human populations. Our results will allow the prediction of the rate of new mutations at every site in the genome based on features of the surrounding DNA sequence, thus providing a common resource to study the arrival and maintenance of mutations in humans. Understanding such a basic process is important for answering fundamental questions in human evolution, the cause of inherited diseases, and the role of DNA abnormality in cancer and aging.",High-resolution map of human germline mutation patterns and inference of mutagenic mechanisms,9494629,R01GM118928,"['Address', 'Affect', 'African American', 'Aging', 'Algorithms', 'Alleles', 'American', 'Atlases', 'Biochemical Process', 'Biological Factors', 'Biological Process', 'Biology', 'Child', 'Chromatin', 'Communities', 'Complex', 'DNA', 'DNA Sequence', 'Data', 'Data Analyses', 'Data Set', 'Data Sources', 'Demographic Factors', 'Dependence', 'Disease', 'Environmental Risk Factor', 'European', 'Evolution', 'Family', 'Foundations', 'Frequencies', 'Future', 'Gene Conversion', 'Generations', 'Genes', 'Genetic', 'Genetic Diseases', 'Genetic Polymorphism', 'Genetic Recombination', 'Genetic Variation', 'Genome', 'Genomic Segment', 'Genomics', 'Germ-Line Mutation', 'Guanine + Cytosine Composition', 'Hereditary Disease', 'High-Throughput Nucleotide Sequencing', 'Human', 'Human Genetics', 'Human Genome', 'Incidence', 'Individual', 'Inherited', 'Internet', 'Latino', 'Machine Learning', 'Maintenance', 'Malignant Neoplasms', 'Maps', 'Measures', 'Mendelian disorder', 'Methods', 'Mismatch Repair', 'Modeling', 'Molecular', 'Mutagenesis', 'Mutation', 'Natural Selections', 'Nucleotides', 'Parents', 'Pathogenicity', 'Pattern', 'Play', 'Population', 'Positioning Attribute', 'Probability', 'Process', 'Recording of previous events', 'Research', 'Resolution', 'Resource Sharing', 'Resources', 'Rest', 'Role', 'Sampling', 'Selection Bias', 'Site', 'Somatic Mutation', 'Source', 'Techniques', 'Technology', 'Tissues', 'Variant', 'Weight', 'actionable mutation', 'base', 'data sharing', 'density', 'driving force', 'epigenomics', 'genetic analysis', 'genetic variant', 'genome sequencing', 'genome-wide', 'human disease', 'human model', 'improved', 'next generation sequencing', 'prototype', 'public health relevance', 'rare variant', 'repository', 'transmission process', 'trend', 'whole genome']",NIGMS,UNIVERSITY OF MICHIGAN AT ANN ARBOR,R01,2018,300473,0.2137030741282121
"High-resolution map of human germline mutation patterns and inference of mutagenic mechanisms     DESCRIPTION (provided by applicant): Mutations are the ultimate source of genetic variation and one of the driving forces of evolution. Both the absolute mutation rate and the relative rate among mutation subtypes fluctuate along the genome, affected by adjacent nucleotide motifs and local features such as GC content and replication timing. Characterizing regional variation of mutation patterns is critical for understanding genome evolution and to identify variants causing genetic diseases. However, mutation rate and molecular spectrum are difficult to measure at high resolution, genomewide, and in an unbiased fashion. Estimates based on common variants and between- species substitutions are confounded by natural selection, population demographic history, and biased gene conversion (BGC). Methods relying on incidence rates of monogenic diseases or finding de novo variants by trio sequencing can inform global trends, but do not provide sufficient data to assess fine-scale local parameters. This study will overcome these limitations by using the extremely rare variants (ERVs) as a new data source to characterize patterns of recent germline variation in humans. ERVs, defined in this study as singletons in 30,000 samples, are becoming available via large-scale whole-genome sequencing (WGS) of population samples. Unlike common variants or substitutions, ERVs arose very recently and are largely unaffected by selection, BGC, etc. We will analyze 200-300 million singleton variants observed in 30,000 subjects at 20-30X coverage. The regional distribution of ERV subtypes will establish a quantitative atlas of the rate and spectrum of human germline mutations mostly unaltered by selection. We will share this resource with the research community and apply it to determine the impact of local genomic features and epigenomic attributes. We will use the systematic departures between ERVs and variants of higher frequencies (polymorphisms and substitutions) to infer local effects of selection, and this may uncover hitherto unknown functional regions of the genome. By comparing mutation signatures in ERVs with those in somatic variations observed in diverse cancers we will attribute distinct mutational signatures to known biochemical processes and thus infer the major contributors to new germline mutations in the human genome. This subtype-specific atlas will also be used to predict the probability of observing every possible single-base mutation in the genome, thus facilitating the interpretation of candidate causal variants of human diseases. We will assess mutation pattern differences among European Americans, African Americans and Latinos, and seek to discover genetic modifiers of germline mutation rate by finding functionally damaging mutations that show increased ERV counts in the surrounding genomic region, potentially identifying both known and previous unknown ""mutator"" genes that play a role in transmission fidelity in humans. This research will provide an essential resource to study the genesis and maintenance of germline mutations in humans. Understanding such a fundamental process will be the basis for a deeper understanding of human evolution and diseases. PUBLIC HEALTH RELEVANCE: We will study the patterns of inherited mutations in humans using approximately 250 million extremely rare DNA variants in human populations. Our results will allow the prediction of the rate of new mutations at every site in the genome based on features of the surrounding DNA sequence, thus providing a common resource to study the arrival and maintenance of mutations in humans. Understanding such a basic process is important for answering fundamental questions in human evolution, the cause of inherited diseases, and the role of DNA abnormality in cancer and aging.",High-resolution map of human germline mutation patterns and inference of mutagenic mechanisms,9275505,R01GM118928,"['Address', 'Affect', 'African American', 'Aging', 'Algorithms', 'Alleles', 'American', 'Atlases', 'Biochemical Process', 'Biological Factors', 'Biological Process', 'Biology', 'Child', 'Chromatin', 'Communities', 'Complex', 'DNA', 'DNA Sequence', 'Data', 'Data Analyses', 'Data Set', 'Data Sources', 'Demographic Factors', 'Dependence', 'Disease', 'Environmental Risk Factor', 'European', 'Evolution', 'Family', 'Foundations', 'Frequencies', 'Future', 'Gene Conversion', 'Generations', 'Genes', 'Genetic', 'Genetic Polymorphism', 'Genetic Recombination', 'Genetic Variation', 'Genome', 'Genomic Segment', 'Genomics', 'Germ-Line Mutation', 'Guanine + Cytosine Composition', 'Hereditary Disease', 'High-Throughput Nucleotide Sequencing', 'Human', 'Human Genetics', 'Human Genome', 'Incidence', 'Individual', 'Inherited', 'Internet', 'Latino', 'Machine Learning', 'Maintenance', 'Malignant Neoplasms', 'Maps', 'Measures', 'Mendelian disorder', 'Methods', 'Mismatch Repair', 'Modeling', 'Molecular', 'Mutagenesis', 'Mutation', 'Natural Selections', 'Nucleotides', 'Parents', 'Pathogenicity', 'Pattern', 'Play', 'Population', 'Positioning Attribute', 'Probability', 'Process', 'Recording of previous events', 'Research', 'Resolution', 'Resource Sharing', 'Resources', 'Rest', 'Role', 'Sampling', 'Selection Bias', 'Site', 'Somatic Mutation', 'Source', 'Techniques', 'Technology', 'Tissues', 'Variant', 'Weight', 'actionable mutation', 'base', 'data sharing', 'density', 'driving force', 'epigenomics', 'genetic analysis', 'genetic variant', 'genome sequencing', 'genome-wide', 'human disease', 'improved', 'next generation sequencing', 'prototype', 'public health relevance', 'rare variant', 'repository', 'transmission process', 'trend', 'whole genome']",NIGMS,UNIVERSITY OF MICHIGAN AT ANN ARBOR,R01,2017,300742,0.2137030741282121
"High-resolution map of human germline mutation patterns and inference of mutagenic mechanisms     DESCRIPTION (provided by applicant): Mutations are the ultimate source of genetic variation and one of the driving forces of evolution. Both the absolute mutation rate and the relative rate among mutation subtypes fluctuate along the genome, affected by adjacent nucleotide motifs and local features such as GC content and replication timing. Characterizing regional variation of mutation patterns is critical for understanding genome evolution and to identify variants causing genetic diseases. However, mutation rate and molecular spectrum are difficult to measure at high resolution, genomewide, and in an unbiased fashion. Estimates based on common variants and between- species substitutions are confounded by natural selection, population demographic history, and biased gene conversion (BGC). Methods relying on incidence rates of monogenic diseases or finding de novo variants by trio sequencing can inform global trends, but do not provide sufficient data to assess fine-scale local parameters. This study will overcome these limitations by using the extremely rare variants (ERVs) as a new data source to characterize patterns of recent germline variation in humans. ERVs, defined in this study as singletons in 30,000 samples, are becoming available via large-scale whole-genome sequencing (WGS) of population samples. Unlike common variants or substitutions, ERVs arose very recently and are largely unaffected by selection, BGC, etc. We will analyze 200-300 million singleton variants observed in 30,000 subjects at 20-30X coverage. The regional distribution of ERV subtypes will establish a quantitative atlas of the rate and spectrum of human germline mutations mostly unaltered by selection. We will share this resource with the research community and apply it to determine the impact of local genomic features and epigenomic attributes. We will use the systematic departures between ERVs and variants of higher frequencies (polymorphisms and substitutions) to infer local effects of selection, and this may uncover hitherto unknown functional regions of the genome. By comparing mutation signatures in ERVs with those in somatic variations observed in diverse cancers we will attribute distinct mutational signatures to known biochemical processes and thus infer the major contributors to new germline mutations in the human genome. This subtype-specific atlas will also be used to predict the probability of observing every possible single-base mutation in the genome, thus facilitating the interpretation of candidate causal variants of human diseases. We will assess mutation pattern differences among European Americans, African Americans and Latinos, and seek to discover genetic modifiers of germline mutation rate by finding functionally damaging mutations that show increased ERV counts in the surrounding genomic region, potentially identifying both known and previous unknown ""mutator"" genes that play a role in transmission fidelity in humans. This research will provide an essential resource to study the genesis and maintenance of germline mutations in humans. Understanding such a fundamental process will be the basis for a deeper understanding of human evolution and diseases.         PUBLIC HEALTH RELEVANCE: We will study the patterns of inherited mutations in humans using approximately 250 million extremely rare DNA variants in human populations. Our results will allow the prediction of the rate of new mutations at every site in the genome based on features of the surrounding DNA sequence, thus providing a common resource to study the arrival and maintenance of mutations in humans. Understanding such a basic process is important for answering fundamental questions in human evolution, the cause of inherited diseases, and the role of DNA abnormality in cancer and aging.            ",High-resolution map of human germline mutation patterns and inference of mutagenic mechanisms,9083570,R01GM118928,"['Address', 'Affect', 'African American', 'Aging', 'Algorithms', 'Alleles', 'American', 'Atlases', 'Biochemical Process', 'Biological Factors', 'Biological Process', 'Biology', 'Child', 'Chromatin', 'Communities', 'Complex', 'DNA', 'DNA Sequence', 'Data', 'Data Analyses', 'Data Set', 'Data Sources', 'Demographic Factors', 'Dependence', 'Disease', 'Environmental Risk Factor', 'European', 'Evolution', 'Family', 'Foundations', 'Frequencies', 'Future', 'Gene Conversion', 'Generations', 'Genes', 'Genetic', 'Genetic Polymorphism', 'Genetic Recombination', 'Genetic Variation', 'Genome', 'Genomic Segment', 'Genomics', 'Germ-Line Mutation', 'Guanine + Cytosine Composition', 'Hereditary Disease', 'High-Throughput Nucleotide Sequencing', 'Human', 'Human Genetics', 'Human Genome', 'Incidence', 'Individual', 'Inherited', 'Internet', 'Latino', 'Machine Learning', 'Maintenance', 'Malignant Neoplasms', 'Maps', 'Measures', 'Mendelian disorder', 'Methods', 'Mismatch Repair', 'Modeling', 'Molecular', 'Mutagenesis', 'Mutation', 'Natural Selections', 'Nucleotides', 'Parents', 'Pathogenicity', 'Pattern', 'Play', 'Population', 'Positioning Attribute', 'Probability', 'Process', 'Recording of previous events', 'Research', 'Resolution', 'Resource Sharing', 'Resources', 'Rest', 'Role', 'Sampling', 'Selection Bias', 'Site', 'Somatic Mutation', 'Source', 'Techniques', 'Technology', 'Time', 'Tissues', 'Variant', 'Weight', 'actionable mutation', 'base', 'data sharing', 'density', 'driving force', 'epigenomics', 'genetic evolution', 'genome sequencing', 'genome-wide', 'human disease', 'improved', 'next generation sequencing', 'prototype', 'public health relevance', 'rare variant', 'repository', 'transmission process', 'trend', 'whole genome']",NIGMS,UNIVERSITY OF MICHIGAN AT ANN ARBOR,R01,2016,300999,0.2137030741282121
"Molecular impact of mutations in monogenic disease and cancer ABSTRACT Nextgenerationgenomescalesequencingofpatientsisnowbecomingroutinefortwoclassesofdisease:rare Mendeliantraitsandcancer.Infavorablecases,thesedataallowidentificationofrelevantmutationsandthus aiddiagnosisandtherapy.Inbothclassesofdisease,themostcommontypeofmutationismissense-single base changes that result in an amino acid substitution in a protein. Uncertainty as to the impact of these mutationsoninvivoproteinactivityhasresultedinaveryconservativeapproachtotheirinterpretationinthe clinic, so causing many missed opportunities for targeted treatment. The goal of this project is to use a combinationofthreestrategiestomaketheinterpretationofthesemutationsmuchmoreapplicableintheclinic. Therearealreadyalargenumberofcomputationalmethodsthatattempttodeterminetheimpactofmissense mutationsonfunction,andthereissubstantialevidencethatthesehaveusefulaccuracy.Theprimarydifficulty isthattheaccuracyinanyparticularcaseisnotreliablycalibrated.Therefore,ourfirstaimistouseacombination ofthesemethodstodevelopanapproachfocusedonmorereliableestimatesfortheprobabilityofhighimpact on protein function (i.e. more confident P values). The second aim is to maximize the utilization of three- dimensionalstructuralinformation,largelyignoredbymostcomputationalmethods.Alargefractionofmissense mutationsintheseclassesofdiseaseactbydestabilizingproteinstructureandknowledgeofstructureallows thesetobeidentifiedwithmuchhigherreliability.Also,structureprovidesaframeworkfordetailedannotation andcomprehensionoffunction.Tofacilitatetheutilizationofstructure,wewillimplementamodelingplatform thatleveragesavailableexperimentalinformationtomaximizethestructuraldataavailableforanalyzingmutation impact. An important aspect of the platform is incorporation of methods for evaluating the reliability of the structuralfeaturesrelevanttoanalysisofeachmutation.Inthethirdaimwewillbuildspecificfunctionalmodels foreachproteinofinterest,integratinginformationfromcurrentdatabases,theliterature,andcommunityinput, soastoprovidetherichestpossiblebackgroundagainstwhichtojudgetheimpactofmutations.Proteopedia,a wellestablishedmediawikiforproteins,willbeusedtoprovideanintegratedviewoftext,data,andstructure.A keycomponentoftheinformationresourcewillbecontributionsfromcurators,whowillprovideannotationand alsosolicitinputfromotherexperts.Thisaspectoftheprojectbuildsonexperiencewithothercrowdsourcing endeavors, including CASP, CAGI and Proteopedia.  There will be three primary outcomes from the project: First,improvedreliabilityfortheinterpretationofmissensemutations.Second,aprototypemutationannotation proceduresuitableforuseinaclinicalsetting.Third,theresourcewillprovideinformationofbenefittoarange ofotherscientists,thusfacilitatingtheanalysisofdiseaserelatedmutations.  NARRATIVE Genome scale DNA sequencing is now contributing to diagnosis and therapy in cases of rare human diseaseandcancer.Fullexploitationofthesedataiscurrentlyhamperedbyinadequateunderstanding ofwhichDNAchangesaffectproteinfunctionsoastocontributetodisease.Thisprojectaimstodevelop themethodsandtoolsneededtoremovethatobstacle.",Molecular impact of mutations in monogenic disease and cancer,9504498,R01GM120364,"['AIDS diagnosis', 'AIDS therapy', 'Address', 'Affect', 'Amino Acid Substitution', 'Clinic', 'Clinical', 'Communities', 'Comprehension', 'Computer Analysis', 'Computer software', 'Computing Methodologies', 'Consensus', 'DNA', 'DNA sequencing', 'Data', 'Databases', 'Diagnosis', 'Dimensions', 'Disease', 'Goals', 'Information Resources', 'Knowledge', 'Literature', 'Machine Learning', 'Malignant Neoplasms', 'Mendelian disorder', 'Methods', 'Missense Mutation', 'Modeling', 'Molecular', 'Mutation', 'Mutation Analysis', 'Patients', 'Play', 'Probability', 'Procedures', 'Process', 'Proteins', 'Rare Diseases', 'Reporting', 'Resources', 'Role', 'Scientist', 'Structural Models', 'Structure', 'Tertiary Protein Structure', 'Text', 'Uncertainty', 'base', 'clinically relevant', 'crowdsourcing', 'experience', 'genome-wide', 'human disease', 'human model', 'improved', 'in vivo', 'interest', 'learning strategy', 'next generation', 'primary outcome', 'protein function', 'protein protein interaction', 'protein structure', 'prototype', 'targeted treatment', 'tool', 'trait', 'wiki']",NIGMS,"UNIV OF MARYLAND, COLLEGE PARK",R01,2018,336086,0.2932984833767121
"Molecular impact of mutations in monogenic disease and cancer ABSTRACT Nextgenerationgenomescalesequencingofpatientsisnowbecomingroutinefortwoclassesofdisease:rare Mendeliantraitsandcancer.Infavorablecases,thesedataallowidentificationofrelevantmutationsandthus aiddiagnosisandtherapy.Inbothclassesofdisease,themostcommontypeofmutationismissense-single base changes that result in an amino acid substitution in a protein. Uncertainty as to the impact of these mutationsoninvivoproteinactivityhasresultedinaveryconservativeapproachtotheirinterpretationinthe clinic, so causing many missed opportunities for targeted treatment. The goal of this project is to use a combinationofthreestrategiestomaketheinterpretationofthesemutationsmuchmoreapplicableintheclinic. Therearealreadyalargenumberofcomputationalmethodsthatattempttodeterminetheimpactofmissense mutationsonfunction,andthereissubstantialevidencethatthesehaveusefulaccuracy.Theprimarydifficulty isthattheaccuracyinanyparticularcaseisnotreliablycalibrated.Therefore,ourfirstaimistouseacombination ofthesemethodstodevelopanapproachfocusedonmorereliableestimatesfortheprobabilityofhighimpact on protein function (i.e. more confident P values). The second aim is to maximize the utilization of three- dimensionalstructuralinformation,largelyignoredbymostcomputationalmethods.Alargefractionofmissense mutationsintheseclassesofdiseaseactbydestabilizingproteinstructureandknowledgeofstructureallows thesetobeidentifiedwithmuchhigherreliability.Also,structureprovidesaframeworkfordetailedannotation andcomprehensionoffunction.Tofacilitatetheutilizationofstructure,wewillimplementamodelingplatform thatleveragesavailableexperimentalinformationtomaximizethestructuraldataavailableforanalyzingmutation impact. An important aspect of the platform is incorporation of methods for evaluating the reliability of the structuralfeaturesrelevanttoanalysisofeachmutation.Inthethirdaimwewillbuildspecificfunctionalmodels foreachproteinofinterest,integratinginformationfromcurrentdatabases,theliterature,andcommunityinput, soastoprovidetherichestpossiblebackgroundagainstwhichtojudgetheimpactofmutations.Proteopedia,a wellestablishedmediawikiforproteins,willbeusedtoprovideanintegratedviewoftext,data,andstructure.A keycomponentoftheinformationresourcewillbecontributionsfromcurators,whowillprovideannotationand alsosolicitinputfromotherexperts.Thisaspectoftheprojectbuildsonexperiencewithothercrowdsourcing endeavors, including CASP, CAGI and Proteopedia.  There will be three primary outcomes from the project: First,improvedreliabilityfortheinterpretationofmissensemutations.Second,aprototypemutationannotation proceduresuitableforuseinaclinicalsetting.Third,theresourcewillprovideinformationofbenefittoarange ofotherscientists,thusfacilitatingtheanalysisofdiseaserelatedmutations.  NARRATIVE Genome scale DNA sequencing is now contributing to diagnosis and therapy in cases of rare human diseaseandcancer.Fullexploitationofthesedataiscurrentlyhamperedbyinadequateunderstanding ofwhichDNAchangesaffectproteinfunctionsoastocontributetodisease.Thisprojectaimstodevelop themethodsandtoolsneededtoremovethatobstacle.",Molecular impact of mutations in monogenic disease and cancer,9356560,R01GM120364,"['AIDS diagnosis', 'Address', 'Affect', 'Amino Acid Substitution', 'Clinic', 'Clinical', 'Communities', 'Comprehension', 'Computer Analysis', 'Computer software', 'Computing Methodologies', 'Consensus', 'DNA', 'DNA sequencing', 'Data', 'Databases', 'Diagnosis', 'Dimensions', 'Disease', 'Goals', 'Human', 'Information Resources', 'Knowledge', 'Literature', 'Machine Learning', 'Malignant Neoplasms', 'Mendelian disorder', 'Methods', 'Missense Mutation', 'Modeling', 'Molecular', 'Mutation', 'Mutation Analysis', 'Patients', 'Play', 'Probability', 'Procedures', 'Process', 'Proteins', 'Rare Diseases', 'Reporting', 'Resources', 'Role', 'Scientist', 'Structural Models', 'Structure', 'Tertiary Protein Structure', 'Text', 'Uncertainty', 'base', 'clinically relevant', 'crowdsourcing', 'experience', 'genome-wide', 'human disease', 'improved', 'in vivo', 'interest', 'learning strategy', 'next generation', 'primary outcome', 'protein protein interaction', 'protein structure', 'prototype', 'targeted treatment', 'tool', 'trait', 'wiki']",NIGMS,"UNIV OF MARYLAND, COLLEGE PARK",R01,2017,343120,0.2932984833767121
"Molecular impact of mutations in monogenic disease and cancer ABSTRACT Nextgenerationgenomescalesequencingofpatientsisnowbecomingroutinefortwoclassesofdisease:rare Mendeliantraitsandcancer.Infavorablecases,thesedataallowidentificationofrelevantmutationsandthus aiddiagnosisandtherapy.Inbothclassesofdisease,themostcommontypeofmutationismissense-single base changes that result in an amino acid substitution in a protein. Uncertainty as to the impact of these mutationsoninvivoproteinactivityhasresultedinaveryconservativeapproachtotheirinterpretationinthe clinic, so causing many missed opportunities for targeted treatment. The goal of this project is to use a combinationofthreestrategiestomaketheinterpretationofthesemutationsmuchmoreapplicableintheclinic. Therearealreadyalargenumberofcomputationalmethodsthatattempttodeterminetheimpactofmissense mutationsonfunction,andthereissubstantialevidencethatthesehaveusefulaccuracy.Theprimarydifficulty isthattheaccuracyinanyparticularcaseisnotreliablycalibrated.Therefore,ourfirstaimistouseacombination ofthesemethodstodevelopanapproachfocusedonmorereliableestimatesfortheprobabilityofhighimpact on protein function (i.e. more confident P values). The second aim is to maximize the utilization of three- dimensionalstructuralinformation,largelyignoredbymostcomputationalmethods.Alargefractionofmissense mutationsintheseclassesofdiseaseactbydestabilizingproteinstructureandknowledgeofstructureallows thesetobeidentifiedwithmuchhigherreliability.Also,structureprovidesaframeworkfordetailedannotation andcomprehensionoffunction.Tofacilitatetheutilizationofstructure,wewillimplementamodelingplatform thatleveragesavailableexperimentalinformationtomaximizethestructuraldataavailableforanalyzingmutation impact. An important aspect of the platform is incorporation of methods for evaluating the reliability of the structuralfeaturesrelevanttoanalysisofeachmutation.Inthethirdaimwewillbuildspecificfunctionalmodels foreachproteinofinterest,integratinginformationfromcurrentdatabases,theliterature,andcommunityinput, soastoprovidetherichestpossiblebackgroundagainstwhichtojudgetheimpactofmutations.Proteopedia,a wellestablishedmediawikiforproteins,willbeusedtoprovideanintegratedviewoftext,data,andstructure.A keycomponentoftheinformationresourcewillbecontributionsfromcurators,whowillprovideannotationand alsosolicitinputfromotherexperts.Thisaspectoftheprojectbuildsonexperiencewithothercrowdsourcing endeavors, including CASP, CAGI and Proteopedia.  There will be three primary outcomes from the project: First,improvedreliabilityfortheinterpretationofmissensemutations.Second,aprototypemutationannotation proceduresuitableforuseinaclinicalsetting.Third,theresourcewillprovideinformationofbenefittoarange ofotherscientists,thusfacilitatingtheanalysisofdiseaserelatedmutations.  NARRATIVE Genome scale DNA sequencing is now contributing to diagnosis and therapy in cases of rare human diseaseandcancer.Fullexploitationofthesedataiscurrentlyhamperedbyinadequateunderstanding ofwhichDNAchangesaffectproteinfunctionsoastocontributetodisease.Thisprojectaimstodevelop themethodsandtoolsneededtoremovethatobstacle.",Molecular impact of mutations in monogenic disease and cancer,9156099,R01GM120364,"['Address', 'Affect', 'Amino Acid Substitution', 'Clinic', 'Clinical', 'Communities', 'Comprehension', 'Computer Analysis', 'Computer software', 'Computing Methodologies', 'Consensus', 'DNA', 'DNA Sequence', 'Data', 'Databases', 'Diagnosis', 'Disease', 'Goals', 'Human', 'Information Resources', 'Knowledge', 'Literature', 'Machine Learning', 'Malignant Neoplasms', 'Mendelian disorder', 'Methods', 'Missense Mutation', 'Modeling', 'Molecular', 'Mutation', 'Mutation Analysis', 'Patients', 'Play', 'Probability', 'Procedures', 'Process', 'Proteins', 'Rare Diseases', 'Reporting', 'Resources', 'Role', 'Scientist', 'Structural Models', 'Structure', 'Tertiary Protein Structure', 'Text', 'Uncertainty', 'base', 'clinically relevant', 'crowdsourcing', 'data structure', 'experience', 'genome-wide', 'human disease', 'improved', 'in vivo', 'interest', 'learning strategy', 'next generation', 'primary outcome', 'protein function', 'protein protein interaction', 'protein structure', 'prototype', 'targeted treatment', 'tool', 'trait', 'wiki']",NIGMS,"UNIV OF MARYLAND, COLLEGE PARK",R01,2016,372928,0.2932984833767121
"Unraveling molecular and system-level mechanisms of human disease-associated protein mutations Project Summary Although a quickly expanding catalogue of protein mutations have been discovered, including those that cause human diseases or confer drug resistance, mechanistic understanding and prediction of functional consequences of these mutations remain rather limited. There is a critical need to develop novel, multiscale computational frameworks that are rigorous and generalizable to help close the ever-increasing gap between phenotypic data and mechanistic knowledge about the mutations and to develop effective therapeutic strategies.  My long-term research goals are two folds: (1) to unravel how a change in protein sequence ripples through various aspects of molecular and system-levels to a change in cellular function and cause human diseases or confer drug resistance; and (2) to translate learned mechanistic knowledge to effective drug-design strategies for human diseases and drug resistance. Toward these goals I propose to advance and combine the strengths of computational molecular biology (structural modeling and design for proteins or protein interactions) and computational systems biology (pathway/network-level topology and dynamics) and follow a novel, formal paradigm to develop methods that systematically identify mechanisms underlying various stages of consequence propagation (from conformation, molecular and system-level variables, to cellular functions, where intermediates can be skipped if necessary). In the forward direction of propagating consequences, I will determine, explain and understand mutational consequences at various levels with machine learning, causal analysis, and combinatorial optimization, starting with known or modelled changes at various levels. In the inverse direction of designing consequences, I will follow known or learned mechanistic hypotheses and develop efficient combinatorial optimization methods to design mutagenesis experiments or screen / design ligands for desired perturbations at various levels, which would test and refine corresponding hypotheses directly and translate mechanistic hypotheses to therapeutic strategies. Mechanisms underlying distal (potentially allosteric) mutations, multiple mutations within a protein or across proteins as well as systems pharmacology strategies will also be rigorously determined in the process.  The expected outcomes from the innovative project will include two main components. The first will be both biophysical principles of proteins and integrative understanding of biomedical systems, which will be organized in a database for public access. The second will be translating mechanistic insights into therapeutic intervention strategies to treat diseases. In particular, targeted experiments (mutagenesis or ligand-binding) will be designed following known or discovered mechanistic hypotheses. This project will involve close collaboration with structural biologists and clinician-scientists who are active collaborators of the PI. Project Narrative Genetic mutations, many of which lead to protein mutations, are often associated with human diseases: they often directly cause diseases or contribute to their progressions. Understanding mechanisms by which these mutations lead to significant functional consequences is of extreme importance to developing effective therapeutics to cure diseases and ameliorate drug resistance.",Unraveling molecular and system-level mechanisms of human disease-associated protein mutations,10007852,R35GM124952,"['Amino Acid Sequence', 'Biophysics', 'Catalogs', 'Cell physiology', 'Collaborations', 'Combinatorial Optimization', 'Computational Molecular Biology', 'DNA Sequence Alteration', 'Databases', 'Disease', 'Disease Resistance', 'Distal', 'Drug Design', 'Drug resistance', 'Goals', 'Intervention', 'Knowledge', 'Lead', 'Ligand Binding', 'Ligands', 'Machine Learning', 'Methods', 'Modeling', 'Molecular', 'Molecular Conformation', 'Mutagenesis', 'Mutation', 'Outcome', 'Pathway interactions', 'Pharmacology', 'Process', 'Protein Engineering', 'Proteins', 'Research', 'Scientist', 'Structural Biologist', 'Structural Models', 'System', 'Systems Biology', 'Testing', 'Therapeutic', 'Therapeutic Intervention', 'Translating', 'Treatment Efficacy', 'computer framework', 'design', 'experimental study', 'human disease', 'innovation', 'insight', 'novel', 'phenotypic data']",NIGMS,TEXAS ENGINEERING EXPERIMENT STATION,R35,2020,335245,0.24610167426973167
"Unraveling molecular and system-level mechanisms of human disease-associated protein mutations Project Summary Although a quickly expanding catalogue of protein mutations have been discovered, including those that cause human diseases or confer drug resistance, mechanistic understanding and prediction of functional consequences of these mutations remain rather limited. There is a critical need to develop novel, multiscale computational frameworks that are rigorous and generalizable to help close the ever-increasing gap between phenotypic data and mechanistic knowledge about the mutations and to develop effective therapeutic strategies.  My long-term research goals are two folds: (1) to unravel how a change in protein sequence ripples through various aspects of molecular and system-levels to a change in cellular function and cause human diseases or confer drug resistance; and (2) to translate learned mechanistic knowledge to effective drug-design strategies for human diseases and drug resistance. Toward these goals I propose to advance and combine the strengths of computational molecular biology (structural modeling and design for proteins or protein interactions) and computational systems biology (pathway/network-level topology and dynamics) and follow a novel, formal paradigm to develop methods that systematically identify mechanisms underlying various stages of consequence propagation (from conformation, molecular and system-level variables, to cellular functions, where intermediates can be skipped if necessary). In the forward direction of propagating consequences, I will determine, explain and understand mutational consequences at various levels with machine learning, causal analysis, and combinatorial optimization, starting with known or modelled changes at various levels. In the inverse direction of designing consequences, I will follow known or learned mechanistic hypotheses and develop efficient combinatorial optimization methods to design mutagenesis experiments or screen / design ligands for desired perturbations at various levels, which would test and refine corresponding hypotheses directly and translate mechanistic hypotheses to therapeutic strategies. Mechanisms underlying distal (potentially allosteric) mutations, multiple mutations within a protein or across proteins as well as systems pharmacology strategies will also be rigorously determined in the process.  The expected outcomes from the innovative project will include two main components. The first will be both biophysical principles of proteins and integrative understanding of biomedical systems, which will be organized in a database for public access. The second will be translating mechanistic insights into therapeutic intervention strategies to treat diseases. In particular, targeted experiments (mutagenesis or ligand-binding) will be designed following known or discovered mechanistic hypotheses. This project will involve close collaboration with structural biologists and clinician-scientists who are active collaborators of the PI. Project Narrative Genetic mutations, many of which lead to protein mutations, are often associated with human diseases: they often directly cause diseases or contribute to their progressions. Understanding mechanisms by which these mutations lead to significant functional consequences is of extreme importance to developing effective therapeutics to cure diseases and ameliorate drug resistance.",Unraveling molecular and system-level mechanisms of human disease-associated protein mutations,9774239,R35GM124952,"['Amino Acid Sequence', 'Biophysics', 'Catalogs', 'Cell physiology', 'Collaborations', 'Combinatorial Optimization', 'Computational Molecular Biology', 'DNA Sequence Alteration', 'Databases', 'Disease', 'Disease Resistance', 'Distal', 'Drug Design', 'Drug resistance', 'Goals', 'Intervention', 'Knowledge', 'Lead', 'Ligand Binding', 'Ligands', 'Machine Learning', 'Methods', 'Modeling', 'Molecular', 'Molecular Conformation', 'Mutagenesis', 'Mutation', 'Outcome', 'Pathway interactions', 'Pharmacology', 'Process', 'Protein Engineering', 'Proteins', 'Research', 'Scientist', 'Structural Biologist', 'Structural Models', 'System', 'Systems Biology', 'Testing', 'Therapeutic', 'Therapeutic Intervention', 'Translating', 'Treatment Efficacy', 'computer framework', 'design', 'experimental study', 'human disease', 'innovation', 'insight', 'novel', 'phenotypic data']",NIGMS,TEXAS ENGINEERING EXPERIMENT STATION,R35,2019,335245,0.24610167426973167
"Unraveling molecular and system-level mechanisms of human disease-associated protein mutations Project Summary Although a quickly expanding catalogue of protein mutations have been discovered, including those that cause human diseases or confer drug resistance, mechanistic understanding and prediction of functional consequences of these mutations remain rather limited. There is a critical need to develop novel, multiscale computational frameworks that are rigorous and generalizable to help close the ever-increasing gap between phenotypic data and mechanistic knowledge about the mutations and to develop effective therapeutic strategies.  My long-term research goals are two folds: (1) to unravel how a change in protein sequence ripples through various aspects of molecular and system-levels to a change in cellular function and cause human diseases or confer drug resistance; and (2) to translate learned mechanistic knowledge to effective drug-design strategies for human diseases and drug resistance. Toward these goals I propose to advance and combine the strengths of computational molecular biology (structural modeling and design for proteins or protein interactions) and computational systems biology (pathway/network-level topology and dynamics) and follow a novel, formal paradigm to develop methods that systematically identify mechanisms underlying various stages of consequence propagation (from conformation, molecular and system-level variables, to cellular functions, where intermediates can be skipped if necessary). In the forward direction of propagating consequences, I will determine, explain and understand mutational consequences at various levels with machine learning, causal analysis, and combinatorial optimization, starting with known or modelled changes at various levels. In the inverse direction of designing consequences, I will follow known or learned mechanistic hypotheses and develop efficient combinatorial optimization methods to design mutagenesis experiments or screen / design ligands for desired perturbations at various levels, which would test and refine corresponding hypotheses directly and translate mechanistic hypotheses to therapeutic strategies. Mechanisms underlying distal (potentially allosteric) mutations, multiple mutations within a protein or across proteins as well as systems pharmacology strategies will also be rigorously determined in the process.  The expected outcomes from the innovative project will include two main components. The first will be both biophysical principles of proteins and integrative understanding of biomedical systems, which will be organized in a database for public access. The second will be translating mechanistic insights into therapeutic intervention strategies to treat diseases. In particular, targeted experiments (mutagenesis or ligand-binding) will be designed following known or discovered mechanistic hypotheses. This project will involve close collaboration with structural biologists and clinician-scientists who are active collaborators of the PI. Project Narrative Genetic mutations, many of which lead to protein mutations, are often associated with human diseases: they often directly cause diseases or contribute to their progressions. Understanding mechanisms by which these mutations lead to significant functional consequences is of extreme importance to developing effective therapeutics to cure diseases and ameliorate drug resistance.",Unraveling molecular and system-level mechanisms of human disease-associated protein mutations,9564155,R35GM124952,"['Amino Acid Sequence', 'Biophysics', 'Catalogs', 'Cell physiology', 'Collaborations', 'Combinatorial Optimization', 'Computational Molecular Biology', 'DNA Sequence Alteration', 'Databases', 'Disease', 'Disease Resistance', 'Distal', 'Drug Design', 'Drug resistance', 'Goals', 'Intervention', 'Knowledge', 'Lead', 'Ligand Binding', 'Ligands', 'Machine Learning', 'Methods', 'Modeling', 'Molecular', 'Molecular Conformation', 'Mutagenesis', 'Mutation', 'Outcome', 'Pathway interactions', 'Pharmacology', 'Process', 'Protein Engineering', 'Proteins', 'Research', 'Scientist', 'Structural Biologist', 'Structural Models', 'System', 'Systems Biology', 'Testing', 'Therapeutic', 'Therapeutic Intervention', 'Translating', 'Treatment Efficacy', 'computer framework', 'design', 'experimental study', 'human disease', 'innovation', 'insight', 'novel', 'phenotypic data']",NIGMS,TEXAS ENGINEERING EXPERIMENT STATION,R35,2018,335245,0.24610167426973167
"Unraveling molecular and system-level mechanisms of human disease-associated protein mutations Project Summary Although a quickly expanding catalogue of protein mutations have been discovered, including those that cause human diseases or confer drug resistance, mechanistic understanding and prediction of functional consequences of these mutations remain rather limited. There is a critical need to develop novel, multiscale computational frameworks that are rigorous and generalizable to help close the ever-increasing gap between phenotypic data and mechanistic knowledge about the mutations and to develop effective therapeutic strategies.  My long-term research goals are two folds: (1) to unravel how a change in protein sequence ripples through various aspects of molecular and system-levels to a change in cellular function and cause human diseases or confer drug resistance; and (2) to translate learned mechanistic knowledge to effective drug-design strategies for human diseases and drug resistance. Toward these goals I propose to advance and combine the strengths of computational molecular biology (structural modeling and design for proteins or protein interactions) and computational systems biology (pathway/network-level topology and dynamics) and follow a novel, formal paradigm to develop methods that systematically identify mechanisms underlying various stages of consequence propagation (from conformation, molecular and system-level variables, to cellular functions, where intermediates can be skipped if necessary). In the forward direction of propagating consequences, I will determine, explain and understand mutational consequences at various levels with machine learning, causal analysis, and combinatorial optimization, starting with known or modelled changes at various levels. In the inverse direction of designing consequences, I will follow known or learned mechanistic hypotheses and develop efficient combinatorial optimization methods to design mutagenesis experiments or screen / design ligands for desired perturbations at various levels, which would test and refine corresponding hypotheses directly and translate mechanistic hypotheses to therapeutic strategies. Mechanisms underlying distal (potentially allosteric) mutations, multiple mutations within a protein or across proteins as well as systems pharmacology strategies will also be rigorously determined in the process.  The expected outcomes from the innovative project will include two main components. The first will be both biophysical principles of proteins and integrative understanding of biomedical systems, which will be organized in a database for public access. The second will be translating mechanistic insights into therapeutic intervention strategies to treat diseases. In particular, targeted experiments (mutagenesis or ligand-binding) will be designed following known or discovered mechanistic hypotheses. This project will involve close collaboration with structural biologists and clinician-scientists who are active collaborators of the PI. Project Narrative Genetic mutations, many of which lead to protein mutations, are often associated with human diseases: they often directly cause diseases or contribute to their progressions. Understanding mechanisms by which these mutations lead to significant functional consequences is of extreme importance to developing effective therapeutics to cure diseases and ameliorate drug resistance.",Unraveling molecular and system-level mechanisms of human disease-associated protein mutations,9382414,R35GM124952,"['Amino Acid Sequence', 'Biophysics', 'Catalogs', 'Cell physiology', 'Collaborations', 'Combinatorial Optimization', 'Computational Molecular Biology', 'DNA Sequence Alteration', 'Databases', 'Disease', 'Disease Resistance', 'Distal', 'Drug Design', 'Drug resistance', 'Goals', 'Intervention', 'Knowledge', 'Lead', 'Ligand Binding', 'Ligands', 'Machine Learning', 'Methods', 'Modeling', 'Molecular', 'Molecular Conformation', 'Mutagenesis', 'Mutation', 'Outcome', 'Pathway interactions', 'Pharmacology', 'Process', 'Protein Engineering', 'Proteins', 'Research', 'Scientist', 'Structural Biologist', 'Structural Models', 'System', 'Systems Biology', 'Testing', 'Therapeutic', 'Therapeutic Intervention', 'Translating', 'Treatment Efficacy', 'computer framework', 'design', 'experimental study', 'human disease', 'innovation', 'insight', 'novel', 'phenotypic data']",NIGMS,TEXAS ENGINEERING EXPERIMENT STATION,R35,2017,335245,0.24610167426973167
"Synergistic integration of topology and machine learning for the predictions of protein-ligand binding affinities and mutation impacts Project Summary Fundamental challenges that hinder the current understanding of biomolecular systems are their tremendous complexity, high dimensionality and excessively large data sets associated with their geometric modeling and simulations. These challenges call for innovative strategies for handling massive biomolecular datasets. Topology, in contrast to geometry, provides a unique tool for dimensionality reduction and data simplification. However, traditional topology typically incurs with excessive reduction in geometric information. Persistent homology is a new branch of topology that is able to bridge traditional topology and geometry, but suffers from neglecting biological information. Built upon PIs recent work in the topological data analysis of biomolecules, this project will explore how to integrate topological data analysis and machine learning to significantly improve the current state-of-the-art predictions of protein-ligand binding and mutation impact established in the PIs preliminary studies. These improvements will be achieved through developing physics-embedded topological methodologies and advanced deep learning architectures for tackling heterogeneous biomolecular data sets arising from a variety of physical and biological considerations. Finally, the PI will establish robust databases and online servers for the proposed predictions. Project Narrative The project concerns the integration of topological data analysis and machine learning architectures for the predictions of protein-ligand binding affinities and mutation induced protein stability changes from massive data sets. This new data approach has considerable impact for future generation methods in computational biophysics and drug design.",Synergistic integration of topology and machine learning for the predictions of protein-ligand binding affinities and mutation impacts,9989158,R01GM126189,"['3-Dimensional', 'Address', 'Affinity', 'Architecture', 'Big Data', 'Binding', 'Binding Proteins', 'Bioinformatics', 'Biological', 'Biological Sciences', 'Biophysics', 'Characteristics', 'Chemicals', 'Classification', 'Complex', 'Computer software', 'DNA Sequence', 'Data', 'Data Analyses', 'Data Science', 'Data Set', 'Databases', 'Development', 'Diagnosis', 'Dimensions', 'Drug Design', 'Electrostatics', 'Elements', 'Free Energy', 'Freedom', 'Future Generations', 'Geometry', 'Handwriting', 'Image Analysis', 'Induced Mutation', 'Ions', 'Learning', 'Ligand Binding', 'Ligands', 'Lipids', 'Machine Learning', 'Medical', 'Membrane', 'Membrane Proteins', 'Metals', 'Methodology', 'Methods', 'Mutation', 'Physics', 'Plant Roots', 'Proteins', 'Psychological Transfer', 'Site', 'Speech', 'System', 'Techniques', 'Thermodynamics', 'Work', 'algebraic topology', 'base', 'cofactor', 'data warehouse', 'deep learning', 'deep learning algorithm', 'direct application', 'diverse data', 'high dimensionality', 'improved', 'innovation', 'language processing', 'large datasets', 'learning algorithm', 'learning strategy', 'machine learning algorithm', 'metallicity', 'models and simulation', 'multi-task learning', 'multitask', 'mutant', 'neglect', 'next generation', 'search engine', 'tool', 'trend', 'user-friendly']",NIGMS,MICHIGAN STATE UNIVERSITY,R01,2020,318777,0.1252891220412407
"Synergistic integration of topology and machine learning for the predictions of protein-ligand binding affinities and mutation impacts Project Summary Fundamental challenges that hinder the current understanding of biomolecular systems are their tremendous complexity, high dimensionality and excessively large data sets associated with their geometric modeling and simulations. These challenges call for innovative strategies for handling massive biomolecular datasets. Topology, in contrast to geometry, provides a unique tool for dimensionality reduction and data simplification. However, traditional topology typically incurs with excessive reduction in geometric information. Persistent homology is a new branch of topology that is able to bridge traditional topology and geometry, but suffers from neglecting biological information. Built upon PIs recent work in the topological data analysis of biomolecules, this project will explore how to integrate topological data analysis and machine learning to significantly improve the current state-of-the-art predictions of protein-ligand binding and mutation impact established in the PIs preliminary studies. These improvements will be achieved through developing physics-embedded topological methodologies and advanced deep learning architectures for tackling heterogeneous biomolecular data sets arising from a variety of physical and biological considerations. Finally, the PI will establish robust databases and online servers for the proposed predictions. Project Narrative The project concerns the integration of topological data analysis and machine learning architectures for the predictions of protein-ligand binding affinities and mutation induced protein stability changes from massive data sets. This new data approach has considerable impact for future generation methods in computational biophysics and drug design.",Synergistic integration of topology and machine learning for the predictions of protein-ligand binding affinities and mutation impacts,9756427,R01GM126189,"['3-Dimensional', 'Address', 'Affinity', 'Architecture', 'Big Data', 'Binding', 'Binding Proteins', 'Bioinformatics', 'Biological', 'Biological Sciences', 'Biophysics', 'Characteristics', 'Chemicals', 'Classification', 'Complex', 'Computer software', 'DNA Sequence', 'Data', 'Data Analyses', 'Data Science', 'Data Set', 'Databases', 'Development', 'Diagnosis', 'Dimensions', 'Drug Design', 'Electrostatics', 'Elements', 'Free Energy', 'Freedom', 'Future Generations', 'Geometry', 'Handwriting', 'Image Analysis', 'Induced Mutation', 'Ions', 'Learning', 'Ligand Binding', 'Ligands', 'Lipids', 'Machine Learning', 'Medical', 'Membrane', 'Membrane Proteins', 'Metals', 'Methodology', 'Methods', 'Mutation', 'Physics', 'Plant Roots', 'Proteins', 'Psychological Transfer', 'Site', 'Speech', 'System', 'Techniques', 'Thermodynamics', 'Work', 'algebraic topology', 'base', 'cofactor', 'data warehouse', 'deep learning', 'deep learning algorithm', 'direct application', 'high dimensionality', 'improved', 'innovation', 'language processing', 'learning algorithm', 'learning strategy', 'machine learning algorithm', 'metallicity', 'models and simulation', 'multi-task learning', 'multitask', 'mutant', 'neglect', 'next generation', 'search engine', 'tool', 'trend', 'user-friendly']",NIGMS,MICHIGAN STATE UNIVERSITY,R01,2019,319267,0.1252891220412407
"Synergistic integration of topology and machine learning for the predictions of protein-ligand binding affinities and mutation impacts Project Summary Fundamental challenges that hinder the current understanding of biomolecular systems are their tremendous complexity, high dimensionality and excessively large data sets associated with their geometric modeling and simulations. These challenges call for innovative strategies for handling massive biomolecular datasets. Topology, in contrast to geometry, provides a unique tool for dimensionality reduction and data simplification. However, traditional topology typically incurs with excessive reduction in geometric information. Persistent homology is a new branch of topology that is able to bridge traditional topology and geometry, but suffers from neglecting biological information. Built upon PIs recent work in the topological data analysis of biomolecules, this project will explore how to integrate topological data analysis and machine learning to significantly improve the current state-of-the-art predictions of protein-ligand binding and mutation impact established in the PIs preliminary studies. These improvements will be achieved through developing physics-embedded topological methodologies and advanced deep learning architectures for tackling heterogeneous biomolecular data sets arising from a variety of physical and biological considerations. Finally, the PI will establish robust databases and online servers for the proposed predictions. Project Narrative The project concerns the integration of topological data analysis and machine learning architectures for the predictions of protein-ligand binding affinities and mutation induced protein stability changes from massive data sets. This new data approach has considerable impact for future generation methods in computational biophysics and drug design.",Synergistic integration of topology and machine learning for the predictions of protein-ligand binding affinities and mutation impacts,9591863,R01GM126189,"['Address', 'Affinity', 'Algorithms', 'Architecture', 'Big Data', 'Binding', 'Binding Proteins', 'Bioinformatics', 'Biological', 'Biological Sciences', 'Biophysics', 'Characteristics', 'Chemicals', 'Classification', 'Complex', 'Computer software', 'DNA Sequence', 'Data', 'Data Analyses', 'Data Science', 'Data Set', 'Databases', 'Development', 'Diagnosis', 'Dimensions', 'Drug Design', 'Electrostatics', 'Elements', 'Free Energy', 'Freedom', 'Future Generations', 'Geometry', 'Handwriting', 'Image Analysis', 'Induced Mutation', 'Ions', 'Learning', 'Ligand Binding', 'Ligands', 'Lipids', 'Machine Learning', 'Medical', 'Membrane', 'Membrane Proteins', 'Metals', 'Methodology', 'Methods', 'Mutation', 'Physics', 'Plant Roots', 'Proteins', 'Psychological Transfer', 'Site', 'Speech', 'System', 'Techniques', 'Thermodynamics', 'Work', 'algebraic topology', 'base', 'cofactor', 'data warehouse', 'deep learning', 'direct application', 'high dimensionality', 'improved', 'innovation', 'language processing', 'learning strategy', 'metallicity', 'models and simulation', 'multitask', 'mutant', 'neglect', 'next generation', 'search engine', 'tool', 'trend', 'user-friendly']",NIGMS,MICHIGAN STATE UNIVERSITY,R01,2018,319737,0.1252891220412407
"Synergistic integration of topology and machine learning for the predictions of protein-ligand binding affinities and mutation impacts Project Summary The success of the ongoing battle with coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) depends crucially on the availability of effective diagnostics, vaccines, antibody therapeutics, and small-molecular drugs. Although SARS-CoV-2 mutates slower than the viruses that cause the flu and the common cold, it has had more than 8300 observed single mutations on its genome of 29,900 nucleotides by June 1, 2020. We show that these mutations might have devastating effects on COVID-19 diagnostics, vaccines, antibody therapeutics, and small-molecular drugs (J. Chem. Inf. Model. In press). We will develop new artificial intelligence (AI) to forecast SARS-CoV-2 future mutations. Leveraging on state-of-art methods developed under the present R01 award, we will design mutation- resistant vaccines, antibody therapeutics, and small-molecular drugs. The CPUs and GPUs requested in this supplement will be essential for my lab to continue the research of the present R01 award and to apply the methods developed in this award to attack fundamental problems in combating COVID-19. Project Narrative The project concerns the forecasting of SARS-CoV-2 mutations and the design of mutation- resistant vaccines, antibody therapeutics, and small-molecular drugs using artificial intelligence (AI) and advanced mathematics. The requested CPUs and GPUs will enable us to addresses potential threats in combating COVID-19.",Synergistic integration of topology and machine learning for the predictions of protein-ligand binding affinities and mutation impacts,10189006,R01GM126189,"['2019-nCoV', 'Address', 'Adopted', 'Affinity', 'Antibodies', 'Antibody Affinity', 'Artificial Intelligence', 'Attention', 'Award', 'Binding', 'Binding Proteins', 'COVID-19', 'COVID-19 vaccine', 'Cells', 'Common Cold', 'Conflict (Psychology)', 'Coronavirus', 'Crystallization', 'Development', 'Diagnostic', 'Diagnostic Reagent', 'Diagnostic tests', 'Drug resistance', 'Drug usage', 'Evolution', 'Failure', 'Future', 'Genetic Transcription', 'Genome', 'Goals', 'Grant', 'Heterogeneity', 'Induced Mutation', 'Influenza A virus', 'Machine Learning', 'Manuscripts', 'Mathematics', 'Medicine', 'Methods', 'Mission', 'Modeling', 'Modification', 'Molecular', 'Mutate', 'Mutation', 'National Institute of General Medical Sciences', 'Nucleotides', 'Peptidyl-Dipeptidase A', 'Pharmaceutical Preparations', 'Phase', 'Preventive measure', 'Preventive vaccine', 'Process', 'Proteins', 'RNA Viruses', 'Recurrence', 'Reporting', 'Research', 'Rhinovirus', 'SARS coronavirus', 'Severe Acute Respiratory Syndrome', 'Site', 'Structure', 'Therapeutic', 'Therapeutic antibodies', 'Time', 'Vaccines', 'Viral', 'Virulence', 'Virus', 'Work', 'antigen antibody binding', 'autoencoder', 'base', 'combat', 'design', 'experience', 'flu', 'improved', 'inhibitor/antagonist', 'news', 'pandemic disease', 'protein folding', 'receptor', 'receptor binding', 'reconstruction', 'resistance mutation', 'success', 'vaccine development']",NIGMS,MICHIGAN STATE UNIVERSITY,R01,2020,116389,0.2077448253952248
"Evolutionary Human Genomics: Demography, Natural Selection, and Transcriptional Regulation To be fully understood, the human genome must be considered in the context of evolution. The activities that have dominated human genomics for three decades  such as genome sequencing and annotation, interrogation with high-throughput biochemical assays, and the identification of associations between genetic variants and diseases  have been enormously informative, but these descriptive studies must eventually be understood within the theoretical framework of evolutionary genetics. We must continue to press forward from the what? to the why? and how? of human genetics.  The goal of my laboratory is to interpret high-throughput genomic data from an evolutionary perspective. Drawing from ideas and techniques in molecular evolution, population genetics, statistics, and computer science, we aim both to understand the evolutionary forces that have shaped human genomes, and to use evolution to shed light on the phenotypic importance of particular sequences. Our recent activities have focused in three major areas: (1)  reconstruction  of  features  of  human  evolution  based  on  genome  sequences;  (2)  prediction  of  the  fitness consequences  of  human  mutations;  and  (3)  the  study  of  transcriptional  regulation  and  its  evolution  in primates.   We have reported major findings in each of these areas, including the existence of gene flow from early modern humans to Eastern Neandertals, a map of fitness consequences for mutations across the human genome, and an analysis showing that the architecture of transcription initiation is highly similar at enhancers and promoters in the human genome.  Here we propose to extend our research substantially in each of these areas, working together with a broad range  of  experimental  and  theoretical  collaborators.    Our  new  goals  include  the  development  of  improved methods for reconstructing human demography, with a focus on ancient gene flow; extensions of our ancestral recombination graph (ARG) sampling methods to accommodate much larger samples sizes, with applications in association mapping and the detection of natural selection; two complementary machine-learning approaches for  improving  the  prediction  of  fitness  consequences  from  sequence  data;  an  experimental  collaboration  to leverage CRISPR-Cas9 screens in characterizing noncoding mutations; a multi-pronged study of the sequence determinants of RNA stability and their implications for the evolution of transcription units; and development of a new probabilistic model for turnover of regulatory elements.  Together, these projects will address a wide variety of fundamental questions about the function and evolution of sequences in the human genome. Vast quantities of genomic data are now available to describe patterns of genetic variation within  human populations and across species, and various measures of biochemical activity along the human  genome. These data need to be interpreted in light of the fundamental forces of mutation,  recombination, natural selection, and genetic drift that have shaped genetic variation. This  proposal describes a series of projects that make use of new computational, statistical, and  theoretical methods to address fundamental questions in human evolutionary genetics, including how  humans arose   from our archaic hominin and ape cousins, how human populations diverged from one  another, how new mutations influence human health and fitness, and how regulatory sequences  contribute to unique aspects of human biology.","Evolutionary Human Genomics: Demography, Natural Selection, and Transcriptional Regulation",9486266,R35GM127070,"['Address', 'Architecture', 'Area', 'Biochemical', 'Biological Assay', 'CRISPR screen', 'Collaborations', 'Data', 'Demography', 'Detection', 'Development', 'Enhancers', 'Evolution', 'Genes', 'Genetic', 'Genetic Diseases', 'Genetic Drift', 'Genetic Recombination', 'Genetic Transcription', 'Genetic Variation', 'Genome', 'Goals', 'Graph', 'Health', 'Human', 'Human Biology', 'Human Genetics', 'Human Genome', 'Laboratories', 'Light', 'Machine Learning', 'Maps', 'Measures', 'Methods', 'Modernization', 'Molecular Evolution', 'Mutation', 'Natural Selections', 'Pattern', 'Phenotype', 'Pongidae', 'Population', 'Population Genetics', 'Primates', 'RNA Stability', 'Regulatory Element', 'Reporting', 'Research', 'Sample Size', 'Sampling', 'Series', 'Statistical Models', 'Techniques', 'Transcription Initiation', 'Transcriptional Regulation', 'Untranslated RNA', 'base', 'computer science', 'fitness', 'genetic variant', 'genome analysis', 'genome annotation', 'genome sequencing', 'genomic data', 'human genomics', 'improved', 'promoter', 'reconstruction', 'statistics']",NIGMS,COLD SPRING HARBOR LABORATORY,R35,2018,479215,0.13927877574792566
"Evolutionary Human Genomics: Demography, Natural Selection, and Transcriptional Regulation To be fully understood, the human genome must be considered in the context of evolution. The activities that have dominated human genomics for three decades  such as genome sequencing and annotation, interrogation with high-throughput biochemical assays, and the identification of associations between genetic variants and diseases  have been enormously informative, but these descriptive studies must eventually be understood within the theoretical framework of evolutionary genetics. We must continue to press forward from the what? to the why? and how? of human genetics.  The goal of my laboratory is to interpret high-throughput genomic data from an evolutionary perspective. Drawing from ideas and techniques in molecular evolution, population genetics, statistics, and computer science, we aim both to understand the evolutionary forces that have shaped human genomes, and to use evolution to shed light on the phenotypic importance of particular sequences. Our recent activities have focused in three major areas: (1)  reconstruction  of  features  of  human  evolution  based  on  genome  sequences;  (2)  prediction  of  the  fitness consequences  of  human  mutations;  and  (3)  the  study  of  transcriptional  regulation  and  its  evolution  in primates.   We have reported major findings in each of these areas, including the existence of gene flow from early modern humans to Eastern Neandertals, a map of fitness consequences for mutations across the human genome, and an analysis showing that the architecture of transcription initiation is highly similar at enhancers and promoters in the human genome.  Here we propose to extend our research substantially in each of these areas, working together with a broad range  of  experimental  and  theoretical  collaborators.    Our  new  goals  include  the  development  of  improved methods for reconstructing human demography, with a focus on ancient gene flow; extensions of our ancestral recombination graph (ARG) sampling methods to accommodate much larger samples sizes, with applications in association mapping and the detection of natural selection; two complementary machine-learning approaches for  improving  the  prediction  of  fitness  consequences  from  sequence  data;  an  experimental  collaboration  to leverage CRISPR-Cas9 screens in characterizing noncoding mutations; a multi-pronged study of the sequence determinants of RNA stability and their implications for the evolution of transcription units; and development of a new probabilistic model for turnover of regulatory elements.  Together, these projects will address a wide variety of fundamental questions about the function and evolution of sequences in the human genome. Vast quantities of genomic data are now available to describe patterns of genetic variation within  human populations and across species, and various measures of biochemical activity along the human  genome. These data need to be interpreted in light of the fundamental forces of mutation,  recombination, natural selection, and genetic drift that have shaped genetic variation. This  proposal describes a series of projects that make use of new computational, statistical, and  theoretical methods to address fundamental questions in human evolutionary genetics, including how  humans arose   from our archaic hominin and ape cousins, how human populations diverged from one  another, how new mutations influence human health and fitness, and how regulatory sequences  contribute to unique aspects of human biology.","Evolutionary Human Genomics: Demography, Natural Selection, and Transcriptional Regulation",9876220,R35GM127070,"['Address', 'Architecture', 'Area', 'Biochemical', 'Biological Assay', 'CRISPR screen', 'Collaborations', 'Data', 'Demography', 'Detection', 'Development', 'Enhancers', 'Evolution', 'Genes', 'Genetic', 'Genetic Diseases', 'Genetic Drift', 'Genetic Recombination', 'Genetic Transcription', 'Genetic Variation', 'Genome', 'Goals', 'Graph', 'Health', 'Human', 'Human Biology', 'Human Genetics', 'Human Genome', 'Laboratories', 'Light', 'Machine Learning', 'Maps', 'Measures', 'Methods', 'Modernization', 'Molecular Evolution', 'Mutation', 'Natural Selections', 'Pattern', 'Phenotype', 'Pongidae', 'Population', 'Population Genetics', 'Primates', 'RNA Stability', 'Regulatory Element', 'Reporting', 'Research', 'Sample Size', 'Sampling', 'Series', 'Statistical Models', 'Techniques', 'Transcription Initiation', 'Transcriptional Regulation', 'Untranslated RNA', 'base', 'computer science', 'fitness', 'genetic variant', 'genome analysis', 'genome annotation', 'genome sequencing', 'genomic data', 'human genomics', 'improved', 'promoter', 'reconstruction', 'statistics']",NIGMS,COLD SPRING HARBOR LABORATORY,R35,2020,479215,0.13927877574792566
"Evolutionary Human Genomics: Demography, Natural Selection, and Transcriptional Regulation To be fully understood, the human genome must be considered in the context of evolution. The activities that have dominated human genomics for three decades  such as genome sequencing and annotation, interrogation with high-throughput biochemical assays, and the identification of associations between genetic variants and diseases  have been enormously informative, but these descriptive studies must eventually be understood within the theoretical framework of evolutionary genetics. We must continue to press forward from the what? to the why? and how? of human genetics.  The goal of my laboratory is to interpret high-throughput genomic data from an evolutionary perspective. Drawing from ideas and techniques in molecular evolution, population genetics, statistics, and computer science, we aim both to understand the evolutionary forces that have shaped human genomes, and to use evolution to shed light on the phenotypic importance of particular sequences. Our recent activities have focused in three major areas: (1)  reconstruction  of  features  of  human  evolution  based  on  genome  sequences;  (2)  prediction  of  the  fitness consequences  of  human  mutations;  and  (3)  the  study  of  transcriptional  regulation  and  its  evolution  in primates.   We have reported major findings in each of these areas, including the existence of gene flow from early modern humans to Eastern Neandertals, a map of fitness consequences for mutations across the human genome, and an analysis showing that the architecture of transcription initiation is highly similar at enhancers and promoters in the human genome.  Here we propose to extend our research substantially in each of these areas, working together with a broad range  of  experimental  and  theoretical  collaborators.    Our  new  goals  include  the  development  of  improved methods for reconstructing human demography, with a focus on ancient gene flow; extensions of our ancestral recombination graph (ARG) sampling methods to accommodate much larger samples sizes, with applications in association mapping and the detection of natural selection; two complementary machine-learning approaches for  improving  the  prediction  of  fitness  consequences  from  sequence  data;  an  experimental  collaboration  to leverage CRISPR-Cas9 screens in characterizing noncoding mutations; a multi-pronged study of the sequence determinants of RNA stability and their implications for the evolution of transcription units; and development of a new probabilistic model for turnover of regulatory elements.  Together, these projects will address a wide variety of fundamental questions about the function and evolution of sequences in the human genome. Vast quantities of genomic data are now available to describe patterns of genetic variation within  human populations and across species, and various measures of biochemical activity along the human  genome. These data need to be interpreted in light of the fundamental forces of mutation,  recombination, natural selection, and genetic drift that have shaped genetic variation. This  proposal describes a series of projects that make use of new computational, statistical, and  theoretical methods to address fundamental questions in human evolutionary genetics, including how  humans arose   from our archaic hominin and ape cousins, how human populations diverged from one  another, how new mutations influence human health and fitness, and how regulatory sequences  contribute to unique aspects of human biology.","Evolutionary Human Genomics: Demography, Natural Selection, and Transcriptional Regulation",9658531,R35GM127070,"['Address', 'Architecture', 'Area', 'Biochemical', 'Biological Assay', 'CRISPR screen', 'Collaborations', 'Data', 'Demography', 'Detection', 'Development', 'Enhancers', 'Evolution', 'Genes', 'Genetic', 'Genetic Diseases', 'Genetic Drift', 'Genetic Recombination', 'Genetic Transcription', 'Genetic Variation', 'Genome', 'Goals', 'Graph', 'Health', 'Human', 'Human Biology', 'Human Genetics', 'Human Genome', 'Laboratories', 'Light', 'Machine Learning', 'Maps', 'Measures', 'Methods', 'Modernization', 'Molecular Evolution', 'Mutation', 'Natural Selections', 'Pattern', 'Phenotype', 'Pongidae', 'Population', 'Population Genetics', 'Primates', 'RNA Stability', 'Regulatory Element', 'Reporting', 'Research', 'Sample Size', 'Sampling', 'Series', 'Statistical Models', 'Techniques', 'Transcription Initiation', 'Transcriptional Regulation', 'Untranslated RNA', 'base', 'computer science', 'fitness', 'genetic variant', 'genome analysis', 'genome annotation', 'genome sequencing', 'genomic data', 'human genomics', 'improved', 'promoter', 'reconstruction', 'statistics']",NIGMS,COLD SPRING HARBOR LABORATORY,R35,2019,479215,0.13927877574792566
"The Evolution of Gene Regulation and Human Disease PROJECT SUMMARY Genetic variants that disrupt the functionality of regulatory sequences, and thereby alter gene expression levels, are major contributors to both evolutionary divergence between species and differences in risk for complex disease among humans. However, due to the complexity of the gene regulatory programs encoded in mammalian genomes and their rapid turnover between species, evaluating the function of non-protein-coding mutations is challenging. This is a major roadblock to tracing the evolution of human-specific biology. In addition, since the majority of disease-associated variants are non-coding, it impairs our ability to map the genetics of complex disease.  The long-term mission of my lab is to interpret the complex gene regulatory programs encoded in the human genome and accurately model the effects of genetic mutations to these elements on phenotypes relevant to disease and human evolution. We work toward these goals by integrating cutting-edge machine learning, statistical modeling of evolution, and the analysis of genotypes and phenotypes from large-scale clinical biobanks. In particular, my lab is uniquely well positioned to build on our previous work to address the following fundamental questions:  1. How have evolutionary transitions on the human-lineage modified the genomein particular gene  regulatory programsto produce human-specific biology? And how do these modifications relate to  human-specific disease risk?  2. What are the combinatorial rules underlying how TF binding patterns specify precise control of gene  regulation? And how do these gene regulatory programs evolve between species?  3. How do genetic and epigenetic mechanisms interact to specify the dynamic gene regulatory programs  that drive cellular development? And how are these programs perturbed in disease?  4. How can we interpret non-protein-coding mutations identified in patient genomes to inform treatment  and preventative care? Our work will produce much-needed methods for understanding the effects of mutations to gene regulatory regions and identify mutations responsible for differences in disease risk between human populations. PROJECT NARRATIVE The genetic mutations that distinguish humans from other great apes and that influence risk for complex disease are mostly found outside of genes. Many of these mutations influence when and where genes are expressed. However, we do not know how to interpret the effects of most such mutations on gene regulation, disease risk, or human evolution, we will develop computational models that leverage machine learning, evolutionary patterns, and large-scale clinical biobanks to identify mutations that disrupt proper control of genes and lead to disease.",The Evolution of Gene Regulation and Human Disease,9904747,R35GM127087,"['Address', 'Binding', 'Biology', 'Clinical', 'Code', 'Complex', 'Computer Models', 'DNA Sequence Alteration', 'Disease', 'Elements', 'Epigenetic Process', 'Evolution', 'Gene Expression', 'Gene Expression Regulation', 'Genes', 'Genetic', 'Genome', 'Genotype', 'Goals', 'Human', 'Human Genome', 'Impairment', 'Lead', 'Machine Learning', 'Maps', 'Methods', 'Mission', 'Modeling', 'Modification', 'Mutation', 'Nucleic Acid Regulatory Sequences', 'Patients', 'Pattern', 'Phenotype', 'Pongidae', 'Population', 'Positioning Attribute', 'Preventive care', 'Regulator Genes', 'Risk', 'Specific qualifier value', 'Statistical Models', 'To specify', 'Untranslated RNA', 'Variant', 'Work', 'biobank', 'cellular development', 'combinatorial', 'disorder risk', 'genetic variant', 'human disease', 'mammalian genome', 'programs', 'species difference']",NIGMS,VANDERBILT UNIVERSITY,R35,2020,86356,0.23031251926496857
"The Evolution of Gene Regulation and Human Disease PROJECT SUMMARY Genetic variants that disrupt the functionality of regulatory sequences, and thereby alter gene expression levels, are major contributors to both evolutionary divergence between species and differences in risk for complex disease among humans. However, due to the complexity of the gene regulatory programs encoded in mammalian genomes and their rapid turnover between species, evaluating the function of non-protein-coding mutations is challenging. This is a major roadblock to tracing the evolution of human-specific biology. In addition, since the majority of disease-associated variants are non-coding, it impairs our ability to map the genetics of complex disease.  The long-term mission of my lab is to interpret the complex gene regulatory programs encoded in the human genome and accurately model the effects of genetic mutations to these elements on phenotypes relevant to disease and human evolution. We work toward these goals by integrating cutting-edge machine learning, statistical modeling of evolution, and the analysis of genotypes and phenotypes from large-scale clinical biobanks. In particular, my lab is uniquely well positioned to build on our previous work to address the following fundamental questions:  1. How have evolutionary transitions on the human-lineage modified the genomein particular gene  regulatory programsto produce human-specific biology? And how do these modifications relate to  human-specific disease risk?  2. What are the combinatorial rules underlying how TF binding patterns specify precise control of gene  regulation? And how do these gene regulatory programs evolve between species?  3. How do genetic and epigenetic mechanisms interact to specify the dynamic gene regulatory programs  that drive cellular development? And how are these programs perturbed in disease?  4. How can we interpret non-protein-coding mutations identified in patient genomes to inform treatment  and preventative care? Our work will produce much-needed methods for understanding the effects of mutations to gene regulatory regions and identify mutations responsible for differences in disease risk between human populations. PROJECT NARRATIVE The genetic mutations that distinguish humans from other great apes and that influence risk for complex disease are mostly found outside of genes. Many of these mutations influence when and where genes are expressed. However, we do not know how to interpret the effects of most such mutations on gene regulation, disease risk, or human evolution, we will develop computational models that leverage machine learning, evolutionary patterns, and large-scale clinical biobanks to identify mutations that disrupt proper control of genes and lead to disease.",The Evolution of Gene Regulation and Human Disease,9673749,R35GM127087,"['Address', 'Binding', 'Biology', 'Clinical', 'Code', 'Complex', 'Computer Simulation', 'DNA Sequence Alteration', 'Disease', 'Elements', 'Epigenetic Process', 'Evolution', 'Gene Expression', 'Gene Expression Regulation', 'Genes', 'Genetic', 'Genome', 'Genotype', 'Goals', 'Human', 'Human Genome', 'Impairment', 'Lead', 'Machine Learning', 'Maps', 'Methods', 'Mission', 'Modeling', 'Modification', 'Mutation', 'Nucleic Acid Regulatory Sequences', 'Patients', 'Pattern', 'Phenotype', 'Pongidae', 'Population', 'Positioning Attribute', 'Preventive care', 'Regulator Genes', 'Risk', 'Specific qualifier value', 'Statistical Models', 'To specify', 'Untranslated RNA', 'Variant', 'Work', 'biobank', 'cellular development', 'combinatorial', 'disorder risk', 'genetic variant', 'human disease', 'mammalian genome', 'programs', 'species difference']",NIGMS,VANDERBILT UNIVERSITY,R35,2019,392270,0.23031251926496857
"The Evolution of Gene Regulation and Human Disease PROJECT SUMMARY Genetic variants that disrupt the functionality of regulatory sequences, and thereby alter gene expression levels, are major contributors to both evolutionary divergence between species and differences in risk for complex disease among humans. However, due to the complexity of the gene regulatory programs encoded in mammalian genomes and their rapid turnover between species, evaluating the function of non-protein-coding mutations is challenging. This is a major roadblock to tracing the evolution of human-specific biology. In addition, since the majority of disease-associated variants are non-coding, it impairs our ability to map the genetics of complex disease.  The long-term mission of my lab is to interpret the complex gene regulatory programs encoded in the human genome and accurately model the effects of genetic mutations to these elements on phenotypes relevant to disease and human evolution. We work toward these goals by integrating cutting-edge machine learning, statistical modeling of evolution, and the analysis of genotypes and phenotypes from large-scale clinical biobanks. In particular, my lab is uniquely well positioned to build on our previous work to address the following fundamental questions:  1. How have evolutionary transitions on the human-lineage modified the genomein particular gene  regulatory programsto produce human-specific biology? And how do these modifications relate to  human-specific disease risk?  2. What are the combinatorial rules underlying how TF binding patterns specify precise control of gene  regulation? And how do these gene regulatory programs evolve between species?  3. How do genetic and epigenetic mechanisms interact to specify the dynamic gene regulatory programs  that drive cellular development? And how are these programs perturbed in disease?  4. How can we interpret non-protein-coding mutations identified in patient genomes to inform treatment  and preventative care? Our work will produce much-needed methods for understanding the effects of mutations to gene regulatory regions and identify mutations responsible for differences in disease risk between human populations. PROJECT NARRATIVE The genetic mutations that distinguish humans from other great apes and that influence risk for complex disease are mostly found outside of genes. Many of these mutations influence when and where genes are expressed. However, we do not know how to interpret the effects of most such mutations on gene regulation, disease risk, or human evolution, we will develop computational models that leverage machine learning, evolutionary patterns, and large-scale clinical biobanks to identify mutations that disrupt proper control of genes and lead to disease.",The Evolution of Gene Regulation and Human Disease,9486376,R35GM127087,"['Address', 'Binding', 'Biology', 'Clinical', 'Code', 'Complex', 'Computer Simulation', 'DNA Sequence Alteration', 'Disease', 'Elements', 'Epigenetic Process', 'Evolution', 'Gene Expression', 'Gene Expression Regulation', 'Genes', 'Genetic', 'Genome', 'Genotype', 'Goals', 'Human', 'Human Genome', 'Impairment', 'Lead', 'Machine Learning', 'Maps', 'Methods', 'Mission', 'Modeling', 'Modification', 'Mutation', 'Nucleic Acid Regulatory Sequences', 'Patients', 'Pattern', 'Phenotype', 'Pongidae', 'Population', 'Positioning Attribute', 'Preventive care', 'Regulator Genes', 'Risk', 'Specific qualifier value', 'Statistical Models', 'To specify', 'Untranslated RNA', 'Variant', 'Work', 'biobank', 'cellular development', 'combinatorial', 'disorder risk', 'genetic variant', 'human disease', 'mammalian genome', 'programs', 'species difference']",NIGMS,VANDERBILT UNIVERSITY,R35,2018,226333,0.23031251926496857
"Computational approaches for identifying epigenomic contexts of somatic mutations ABSTRACT During normal development, aging, and diseases such as cancer, DNA damage due to endogenous and external factors, and repair defects result in accumulation of different types of somatic mutations including single nucleotide substitutions, small InDels, copy number alterations, translocations, and ploidy changes. While a vast majority of somatic mutations in the genome are not disease drivers, their patterns of genetic changes and associated context can provide insights into past exposure to mutagens, mechanisms of DNA damage and repair defects, and extent of genomic instability, which are important for understanding disease etiology, minimizing hazardous environmental exposure, and also predicting efficacy of emerging treatment strategies such as immunotherapy. A number of mutation signatures have been identified based on local sequence contexts to address this need. But, mechanisms of DNA damage and repair preferences depend on both local sequence and epigenomic contexts, and it remains to be understood whether epigenomic contexts of emerging mutation signatures can provide critical, complementary etiological insights at a genome-wide scale, which are not apparent from sequence contexts alone. This is of fundamental importance, because (i) etiology of many of the emerging mutation signatures is currently unknown, (ii) DNA damage response and repair depends on tissue contexts, and defects in core DNA repair genes often result in cancer development in tissue-specific manner, and (iii) differences in the extent of DNA damage and repair between stem and differentiated cells within the same tissues have consequences for aging and disease incidence rates. Built logically on our previous works, we propose to develop computational approaches to determine the impact of epigenomic contexts on the patterns of somatic mutations within and across tissue types, and validate computational predictions using targeted experiments. In Aim-1, we will develop an epigenomic context preference map for emerging mutation signatures. In Aim-2, we will determine the basis of tissue-dependent differences in mutation profiles attributed to DNA repair defects. In Aim-3, we will predict the extent of cell lineage-dependent patterns of mutation accumulation from the mutational landscape of terminal cells. I am currently an early stage investigator, and the proposal is aligned with my long-term goal to identify fundamental principles of mutability and evolvability of somatic genomes. Our project will deliver novel resources and knowledge for addressing questions regarding genomic integrity during development and aging, and diseases such as cancer. ! PUBLIC HEALTH RELEVANCE: The proposed project will use computational biology approaches to determine epigenomic context preference for somatic mutations, and use that to infer tissue-dependent changes in mutation patterns. Our results will provide fundamental insights into aspects of genome maintenance, which is important for advancing our understanding of cancer etiology, reducing exposure to mutagenic factors, and also predicting efficacy of emerging treatment strategies. !",Computational approaches for identifying epigenomic contexts of somatic mutations,9737246,R01GM129066,"['Address', 'Affect', 'Aging', 'Biometry', 'Blood', 'Cancer Etiology', 'Cancer Relapse', 'Cell Differentiation process', 'Cell Line', 'Cell Lineage', 'Cells', 'Chromatin', 'Clinical', 'Computational Biology', 'DNA Damage', 'DNA Repair', 'DNA Repair Gene', 'DNA Repair Pathway', 'Data', 'Defect', 'Development', 'Disease', 'Doctor of Philosophy', 'Environmental Exposure', 'Epigenetic Process', 'Etiology', 'Evolution', 'Exposure to', 'Genome', 'Genomic DNA', 'Genomic Instability', 'Genomics', 'Goals', 'Immunotherapy', 'Incidence', 'Knowledge', 'Least-Squares Analysis', 'Location', 'Maintenance', 'Malignant Neoplasms', 'Maps', 'Modeling', 'Mutagenesis', 'Mutagens', 'Mutation', 'Nuclear', 'Nucleotides', 'Pathway interactions', 'Pattern', 'Ploidies', 'Point Mutation', 'Process', 'Publishing', 'Radiation Tolerance', 'Research Personnel', 'Resources', 'Role', 'Somatic Mutation', 'Source', 'Stem cells', 'Tissues', 'Work', 'base', 'cancer genomics', 'computer framework', 'epigenomics', 'experimental study', 'genome integrity', 'genome-wide', 'human tissue', 'improved', 'insertion/deletion mutation', 'insight', 'markov model', 'medical schools', 'novel', 'preference', 'public health relevance', 'random forest', 'repaired', 'response', 'stem', 'transcriptomics', 'treatment strategy']",NIGMS,RBHS -CANCER INSTITUTE OF NEW JERSEY,R01,2019,336177,0.20969151215652768
"Computational approaches for identifying epigenomic contexts of somatic mutations ABSTRACT During normal development, aging, and diseases such as cancer, DNA damage due to endogenous and external factors, and repair defects result in accumulation of different types of somatic mutations including single nucleotide substitutions, small InDels, copy number alterations, translocations, and ploidy changes. While a vast majority of somatic mutations in the genome are not disease drivers, their patterns of genetic changes and associated context can provide insights into past exposure to mutagens, mechanisms of DNA damage and repair defects, and extent of genomic instability, which are important for understanding disease etiology, minimizing hazardous environmental exposure, and also predicting efficacy of emerging treatment strategies such as immunotherapy. A number of mutation signatures have been identified based on local sequence contexts to address this need. But, mechanisms of DNA damage and repair preferences depend on both local sequence and epigenomic contexts, and it remains to be understood whether epigenomic contexts of emerging mutation signatures can provide critical, complementary etiological insights at a genome-wide scale, which are not apparent from sequence contexts alone. This is of fundamental importance, because (i) etiology of many of the emerging mutation signatures is currently unknown, (ii) DNA damage response and repair depends on tissue contexts, and defects in core DNA repair genes often result in cancer development in tissue-specific manner, and (iii) differences in the extent of DNA damage and repair between stem and differentiated cells within the same tissues have consequences for aging and disease incidence rates. Built logically on our previous works, we propose to develop computational approaches to determine the impact of epigenomic contexts on the patterns of somatic mutations within and across tissue types, and validate computational predictions using targeted experiments. In Aim-1, we will develop an epigenomic context preference map for emerging mutation signatures. In Aim-2, we will determine the basis of tissue-dependent differences in mutation profiles attributed to DNA repair defects. In Aim-3, we will predict the extent of cell lineage-dependent patterns of mutation accumulation from the mutational landscape of terminal cells. I am currently an early stage investigator, and the proposal is aligned with my long-term goal to identify fundamental principles of mutability and evolvability of somatic genomes. Our project will deliver novel resources and knowledge for addressing questions regarding genomic integrity during development and aging, and diseases such as cancer. ! PUBLIC HEALTH RELEVANCE: The proposed project will use computational biology approaches to determine epigenomic context preference for somatic mutations, and use that to infer tissue-dependent changes in mutation patterns. Our results will provide fundamental insights into aspects of genome maintenance, which is important for advancing our understanding of cancer etiology, reducing exposure to mutagenic factors, and also predicting efficacy of emerging treatment strategies. !",Computational approaches for identifying epigenomic contexts of somatic mutations,9902467,R01GM129066,"['Address', 'Affect', 'Aging', 'Biometry', 'Blood', 'Cancer Etiology', 'Cancer Relapse', 'Cell Differentiation process', 'Cell Line', 'Cell Lineage', 'Cells', 'Chromatin', 'Clinical', 'Computational Biology', 'DNA Damage', 'DNA Repair', 'DNA Repair Gene', 'DNA Repair Pathway', 'Data', 'Defect', 'Development', 'Disease', 'Doctor of Philosophy', 'Environmental Exposure', 'Epigenetic Process', 'Etiology', 'Evolution', 'Exposure to', 'Genome', 'Genomic DNA', 'Genomic Instability', 'Genomics', 'Goals', 'Immunotherapy', 'Incidence', 'Knowledge', 'Least-Squares Analysis', 'Location', 'Maintenance', 'Malignant Neoplasms', 'Maps', 'Modeling', 'Mutagenesis', 'Mutagens', 'Mutation', 'Nuclear', 'Nucleotides', 'Pathway interactions', 'Pattern', 'Ploidies', 'Point Mutation', 'Process', 'Publishing', 'Radiation Tolerance', 'Research Personnel', 'Resources', 'Role', 'Somatic Mutation', 'Source', 'Tissues', 'Work', 'base', 'cancer genomics', 'computer framework', 'epigenomics', 'experimental study', 'genome integrity', 'genome-wide', 'human tissue', 'improved', 'insertion/deletion mutation', 'insight', 'markov model', 'medical schools', 'novel', 'preference', 'public health relevance', 'random forest', 'repaired', 'response', 'stem', 'stem cells', 'tissue stem cells', 'transcriptomics', 'treatment strategy']",NIGMS,RBHS -CANCER INSTITUTE OF NEW JERSEY,R01,2020,324350,0.20969151215652768
"The adaptive potential of translational regulation Project Summary/Abstract  Our current understanding of the adaptive effects of mutation is largely limited to alterations in protein coding sequence and disruption of transcriptional cis-regulatory promoters. Very little is known about how mutations alter translation, or the role these mutations play in adaptation and evolution. This project seeks to address this gap by identifying the functional effect of mutations on translation. To accomplish this I will first identify mutations that arise from adaptation to various nutrient limited environments. I will then use expression profiling (e.g. RNA-seq, ribosome profiling, and RATE-seq) to identify the effect these mutations have on translation, as well as other levels of gene expression. This will provide insight into the magnitude of effect mutations have on translation and their relative rate. Furthermore, to fully characterize the role synonymous mutations have on fitness I will be using a deep scanning synonymous mutation library. To understand the role tRNA abundance plays in the fitness effect of a given synonymous mutations, I will also be evaluating fitness within tRNA under- and over-expression backgrounds. Because of the closely coupled nature of translation rates and mRNA decay, I will also characterize the effect synonymous mutations have on mRNA decay using RATE-seq. My analysis of the functional effects of these mutations on gene expression, particularly within the genetic background and environment in which they arose, will allow for the development of a machine learning algorithm that can use sequence and annotation features to predict the effect of a mutation on gene expression. This tool will aid future research into the effect mutations have of gene expression by allowing the identification of high-confidence candidates for further evaluation.  This project will be conducted at New York Universitys Center for Genomics and Systems Biology, whose mission is to answer otherwise intractable biological questions using applied experimental and computational approaches. The Center houses numerous facilities and cores that will be instrumental in the performance of this work. The collaborative atmosphere and multi-disciplinary nature of NYUs research communities that will enable me to stay abreast of developments in related fields and to rapidly communicate my research to interested parties. I will be trained under the guidance of Dr. David Gresham, an excellent researcher working on complementing long-term evolution experiments with gene expression studies to characterize the adaptive potential of the regulation of gene expression. Project Narrative The translation of mRNA into protein is a critical step in gene expression that is tightly regulated with mis-regulation of translation being a hallmark of many human pathologies. Understanding how mutations can alter the regulation of translation is an understudied but important aspect of adaptation and evolution. Ultimately, without an understanding of the adaptive potential of translation we have an incomplete, and imperfect, picture of the underlying genetic causes of numerous forms of cancer and genetic diseases.",The adaptive potential of translational regulation,9893712,F32GM131573,"['Address', 'Affect', 'Amino Acid Sequence', 'Biological', 'Biological Assay', 'Biology', 'Code', 'Communities', 'Complement', 'Computer software', 'Coupled', 'Data', 'Development', 'Disease', 'Elements', 'Environment', 'Evaluation', 'Evolution', 'Expression Profiling', 'Frequencies', 'Gene Expression', 'Gene Expression Regulation', 'Generations', 'Genes', 'Genetic', 'Genetic Diseases', 'Genetic Transcription', 'Genetic Translation', 'Genetic Variation', 'Genome', 'Genomics', 'Goals', 'Human Pathology', 'Laboratories', 'Libraries', 'Literature', 'Machine Learning', 'Malignant Neoplasms', 'Measures', 'Mission', 'Modeling', 'Modernization', 'Mutation', 'Nature', 'New York', 'Nutrient', 'Open Reading Frames', 'Pathology', 'Performance at work', 'Phenotype', 'Play', 'Population', 'Proteins', 'Regulation', 'Regulator Genes', 'Regulatory Element', 'Research', 'Research Personnel', 'Ribosomes', 'Role', 'Scanning', 'Site', 'Stress', 'Systems Biology', 'Testing', 'Training', 'Transfer RNA', 'Translation Initiation', 'Translational Regulation', 'Translations', 'Universities', 'Untranslated RNA', 'Variant', 'Work', 'analytical tool', 'cancer genetics', 'collaborative environment', 'driver mutation', 'environmental change', 'experimental study', 'fitness', 'genome sequencing', 'insight', 'interest', 'mRNA Decay', 'mRNA Transcript Degradation', 'machine learning algorithm', 'multidisciplinary', 'mutation screening', 'novel', 'preservation', 'promoter', 'response', 'ribosome profiling', 'tool', 'transcriptome sequencing', 'whole genome']",NIGMS,NEW YORK UNIVERSITY,F32,2020,65310,0.29619297273033096
"The adaptive potential of translational regulation Project Summary/Abstract  Our current understanding of the adaptive effects of mutation is largely limited to alterations in protein coding sequence and disruption of transcriptional cis-regulatory promoters. Very little is known about how mutations alter translation, or the role these mutations play in adaptation and evolution. This project seeks to address this gap by identifying the functional effect of mutations on translation. To accomplish this I will first identify mutations that arise from adaptation to various nutrient limited environments. I will then use expression profiling (e.g. RNA-seq, ribosome profiling, and RATE-seq) to identify the effect these mutations have on translation, as well as other levels of gene expression. This will provide insight into the magnitude of effect mutations have on translation and their relative rate. Furthermore, to fully characterize the role synonymous mutations have on fitness I will be using a deep scanning synonymous mutation library. To understand the role tRNA abundance plays in the fitness effect of a given synonymous mutations, I will also be evaluating fitness within tRNA under- and over-expression backgrounds. Because of the closely coupled nature of translation rates and mRNA decay, I will also characterize the effect synonymous mutations have on mRNA decay using RATE-seq. My analysis of the functional effects of these mutations on gene expression, particularly within the genetic background and environment in which they arose, will allow for the development of a machine learning algorithm that can use sequence and annotation features to predict the effect of a mutation on gene expression. This tool will aid future research into the effect mutations have of gene expression by allowing the identification of high-confidence candidates for further evaluation.  This project will be conducted at New York Universitys Center for Genomics and Systems Biology, whose mission is to answer otherwise intractable biological questions using applied experimental and computational approaches. The Center houses numerous facilities and cores that will be instrumental in the performance of this work. The collaborative atmosphere and multi-disciplinary nature of NYUs research communities that will enable me to stay abreast of developments in related fields and to rapidly communicate my research to interested parties. I will be trained under the guidance of Dr. David Gresham, an excellent researcher working on complementing long-term evolution experiments with gene expression studies to characterize the adaptive potential of the regulation of gene expression. Project Narrative The translation of mRNA into protein is a critical step in gene expression that is tightly regulated with mis-regulation of translation being a hallmark of many human pathologies. Understanding how mutations can alter the regulation of translation is an understudied but important aspect of adaptation and evolution. Ultimately, without an understanding of the adaptive potential of translation we have an incomplete, and imperfect, picture of the underlying genetic causes of numerous forms of cancer and genetic diseases.",The adaptive potential of translational regulation,9683394,F32GM131573,"['Address', 'Affect', 'Amino Acid Sequence', 'Biological', 'Biological Assay', 'Biology', 'Code', 'Communities', 'Complement', 'Computer software', 'Coupled', 'Data', 'Development', 'Disease', 'Elements', 'Environment', 'Evaluation', 'Evolution', 'Expression Profiling', 'Frequencies', 'Gene Expression', 'Gene Expression Regulation', 'Generations', 'Genes', 'Genetic', 'Genetic Diseases', 'Genetic Transcription', 'Genetic Translation', 'Genetic Variation', 'Genome', 'Genomics', 'Goals', 'Human Pathology', 'Laboratories', 'Libraries', 'Literature', 'Machine Learning', 'Malignant Neoplasms', 'Measures', 'Mission', 'Modeling', 'Modernization', 'Mutation', 'Nature', 'New York', 'Nutrient', 'Open Reading Frames', 'Pathology', 'Performance at work', 'Phenotype', 'Play', 'Population', 'Proteins', 'Regulation', 'Regulator Genes', 'Regulatory Element', 'Research', 'Research Personnel', 'Ribosomes', 'Role', 'Scanning', 'Site', 'Stress', 'Systems Biology', 'Testing', 'Training', 'Transfer RNA', 'Translation Initiation', 'Translational Regulation', 'Translations', 'Universities', 'Untranslated RNA', 'Variant', 'Work', 'actionable mutation', 'analytical tool', 'cancer genetics', 'collaborative environment', 'environmental change', 'experimental study', 'fitness', 'genome sequencing', 'insight', 'interest', 'mRNA Decay', 'mRNA Transcript Degradation', 'machine learning algorithm', 'multidisciplinary', 'mutation screening', 'novel', 'preservation', 'promoter', 'response', 'ribosome profiling', 'tool', 'transcriptome sequencing', 'whole genome']",NIGMS,NEW YORK UNIVERSITY,F32,2019,61226,0.29619297273033096
"A combined computational and experimental approach to the evolution and role of the DNA sequence environment in targeting mutations to antibody V regions Project summary There is a fundamental gap in our understanding of how mutations are preferentially targeted to the variable (V) regions of the Immunoglobulin (Ig) loci during somatic hypermutation (SHM). The persistence of this gap has limited our understanding of the mutagenic mechanisms involving activation-induced deaminase (AID) in the immune response and in the role of AID in mis-targeting mutations leading to B-cell lymphomas and other cancers. The long-term goal of the proposed research is to understand the global targeting of mutations in immunity that are required to protect us from infections. As high-throughput data from human antibody immune responses became available, it provided us with new opportunities to generate hypotheses to explain the underlying mechanisms of SHM. We now propose to generate further hypotheses using computational models applied to additional databases and to validate these hypotheses using cellular and animal experiments. Our objective is to understand what directs SHM across the many human Ig heavy chain V-regions. Our central hypothesis is that the V-region SHM process is highly dependent on a DNA sequence signature(s) that drives mutations in a largely deterministic fashion. This hypothesis is supported by our preliminary results using human in vivo data from a few human V region genes and has begun to be validated using independent databases and experiments in human B cell lines. The rationale is that evaluations of computational data based upon biological mechanisms, together with appropriate biological experiments, will reveal the key differences between IGHV regions (IGHV 3-23, 4-34, 1-18, 1-02, etc.) that lead to the dominance of each of those V regions in the responses to medically important antigens. Our hypothesis will be tested by pursuing two specific aims: 1) identify the extent to which a DNA signature determines the mutation process in four individual human IGHV genes that are important in disease responses; 2) examine the relationship between AID hotspots and Pol hotspots across all the other human V region genes, thus rigorously defining a mutation targeting signature. Both aims will also entail studying human V region genes and modifications of them in human cell lines and in mice expressing a human V region to further confirm the signature and identify molecular mechanisms in vivo. Our approach is innovative because the computational models we are proposing will be mechanistically motivated focusing on the interaction between AID and Pol hotspots, thus testing molecular mechanisms as opposed to classic statistical models using whole V region sequences that ignore the underlying biology. In addition, to focus on mechanisms we will leverage new high-throughput data from human V regions that have not undergone antigen selection. Our results will be highly relevant to human IgV repertoire analyses from immune responses that are currently hard to interpret and will help future vaccine and therapeutic antibody development, as well as help to understand mutations in human malignancies where AID plays a key role. Project narrative The proposed research is relevant to public health because understanding the targeting of AID-mediated mutations across many human heavy chain V-regions will make it possible to develop vaccines that will lead more rapidly to better and more broadly protective antibodies to infectious agents and reveal the risk factors in the development of B-cell malignancies and gastric and other solid tumors where AID is implicated.",A combined computational and experimental approach to the evolution and role of the DNA sequence environment in targeting mutations to antibody V regions,9653955,R01AI132507,"['Affect', 'Alleles', 'Animal Experiments', 'Antibodies', 'Antibody Affinity', 'Antigens', 'Autoimmunity', 'B lymphoid malignancy', 'B-Cell Development', 'B-Cell Lymphomas', 'B-Lymphocytes', 'Biological', 'Biology', 'Cell Line', 'Chromatin', 'Complementarity Determining Regions', 'Computer Analysis', 'Computer Simulation', 'DNA', 'DNA Sequence', 'Data', 'Databases', 'Development', 'Disease', 'Environment', 'Enzyme Activation', 'Evaluation', 'Event', 'Evolution', 'Family', 'Feedback', 'Frequencies', 'Future', 'GTP-Binding Protein alpha Subunits, Gs', 'Gene-Modified', 'Genes', 'Goals', 'HIV', 'Heavy-Chain Immunoglobulins', 'Human', 'Human Cell Line', 'Immune response', 'Immunity', 'Immunoglobulin Somatic Hypermutation', 'Immunoglobulins', 'Individual', 'Infection', 'Infectious Agent', 'Influenza', 'Influenza Hemagglutinin', 'Knock-in', 'Lead', 'Location', 'Machine Learning', 'Malignant Neoplasms', 'Mediating', 'Medical', 'Mismatch Repair', 'Molecular', 'Mus', 'Mutate', 'Mutation', 'Outcome', 'Pattern', 'Play', 'Polymerase', 'Process', 'Public Health', 'Research', 'Risk Factors', 'Role', 'Site', 'Solid Neoplasm', 'Statistical Models', 'Stomach', 'Structure of germinal center of lymph node', 'Techniques', 'Testing', 'Therapeutic antibodies', 'Time', 'Transgenic Mice', 'Vaccines', 'Validation', 'Variant', 'activation-induced cytidine deaminase', 'base', 'chromatin modification', 'density', 'experimental study', 'genetic variant', 'human data', 'in vivo', 'in vivo Model', 'innovation', 'neutralizing antibody', 'recruit', 'repair enzyme', 'response', 'spatial relationship', 'vaccine response']",NIAID,ALBERT EINSTEIN COLLEGE OF MEDICINE,R01,2019,587448,0.23104602801349985
"A combined computational and experimental approach to the evolution and role of the DNA sequence environment in targeting mutations to antibody V regions Project summary There is a fundamental gap in our understanding of how mutations are preferentially targeted to the variable (V) regions of the Immunoglobulin (Ig) loci during somatic hypermutation (SHM). The persistence of this gap has limited our understanding of the mutagenic mechanisms involving activation-induced deaminase (AID) in the immune response and in the role of AID in mis-targeting mutations leading to B-cell lymphomas and other cancers. The long-term goal of the proposed research is to understand the global targeting of mutations in immunity that are required to protect us from infections. As high-throughput data from human antibody immune responses became available, it provided us with new opportunities to generate hypotheses to explain the underlying mechanisms of SHM. We now propose to generate further hypotheses using computational models applied to additional databases and to validate these hypotheses using cellular and animal experiments. Our objective is to understand what directs SHM across the many human Ig heavy chain V-regions. Our central hypothesis is that the V-region SHM process is highly dependent on a DNA sequence signature(s) that drives mutations in a largely deterministic fashion. This hypothesis is supported by our preliminary results using human in vivo data from a few human V region genes and has begun to be validated using independent databases and experiments in human B cell lines. The rationale is that evaluations of computational data based upon biological mechanisms, together with appropriate biological experiments, will reveal the key differences between IGHV regions (IGHV 3-23, 4-34, 1-18, 1-02, etc.) that lead to the dominance of each of those V regions in the responses to medically important antigens. Our hypothesis will be tested by pursuing two specific aims: 1) identify the extent to which a DNA signature determines the mutation process in four individual human IGHV genes that are important in disease responses; 2) examine the relationship between AID hotspots and Pol hotspots across all the other human V region genes, thus rigorously defining a mutation targeting signature. Both aims will also entail studying human V region genes and modifications of them in human cell lines and in mice expressing a human V region to further confirm the signature and identify molecular mechanisms in vivo. Our approach is innovative because the computational models we are proposing will be mechanistically motivated focusing on the interaction between AID and Pol hotspots, thus testing molecular mechanisms as opposed to classic statistical models using whole V region sequences that ignore the underlying biology. In addition, to focus on mechanisms we will leverage new high-throughput data from human V regions that have not undergone antigen selection. Our results will be highly relevant to human IgV repertoire analyses from immune responses that are currently hard to interpret and will help future vaccine and therapeutic antibody development, as well as help to understand mutations in human malignancies where AID plays a key role. Project narrative The proposed research is relevant to public health because understanding the targeting of AID-mediated mutations across many human heavy chain V-regions will make it possible to develop vaccines that will lead more rapidly to better and more broadly protective antibodies to infectious agents and reveal the risk factors in the development of B-cell malignancies and gastric and other solid tumors where AID is implicated.",A combined computational and experimental approach to the evolution and role of the DNA sequence environment in targeting mutations to antibody V regions,9518337,R01AI132507,"['Affect', 'Alleles', 'Animal Experiments', 'Antibodies', 'Antibody Affinity', 'Antigens', 'Autoimmunity', 'B lymphoid malignancy', 'B-Cell Development', 'B-Cell Lymphomas', 'B-Lymphocytes', 'Biological', 'Biology', 'Cell Line', 'Chromatin', 'Complementarity Determining Regions', 'Computer Analysis', 'Computer Simulation', 'DNA', 'DNA Sequence', 'Data', 'Databases', 'Development', 'Disease', 'Environment', 'Enzyme Activation', 'Evaluation', 'Event', 'Evolution', 'Family', 'Feedback', 'Frequencies', 'Future', 'GTP-Binding Protein alpha Subunits, Gs', 'Gene-Modified', 'Genes', 'Goals', 'HIV', 'Heavy-Chain Immunoglobulins', 'Human', 'Human Cell Line', 'Immune response', 'Immunity', 'Immunoglobulin Somatic Hypermutation', 'Immunoglobulins', 'Individual', 'Infection', 'Infectious Agent', 'Influenza', 'Influenza Hemagglutinin', 'Knock-in', 'Lead', 'Location', 'Machine Learning', 'Malignant Neoplasms', 'Mediating', 'Medical', 'Mismatch Repair', 'Molecular', 'Mus', 'Mutate', 'Mutation', 'Outcome', 'Pattern', 'Play', 'Polymerase', 'Process', 'Public Health', 'Research', 'Risk Factors', 'Role', 'Site', 'Solid Neoplasm', 'Statistical Models', 'Stomach', 'Structure of germinal center of lymph node', 'Techniques', 'Testing', 'Therapeutic antibodies', 'Time', 'Transgenic Mice', 'Vaccines', 'Validation', 'Variant', 'activation-induced cytidine deaminase', 'base', 'chromatin modification', 'density', 'experimental study', 'genetic variant', 'human data', 'in vivo', 'in vivo Model', 'innovation', 'neutralizing antibody', 'recruit', 'repair enzyme', 'response', 'spatial relationship', 'vaccine response']",NIAID,"ALBERT EINSTEIN COLLEGE OF MEDICINE, INC",R01,2018,537909,0.23104602801349985
"A combined computational and experimental approach to the evolution and role of the DNA sequence environment in targeting mutations to antibody V regions Project summary There is a fundamental gap in our understanding of how mutations are preferentially targeted to the variable (V) regions of the Immunoglobulin (Ig) loci during somatic hypermutation (SHM). The persistence of this gap has limited our understanding of the mutagenic mechanisms involving activation-induced deaminase (AID) in the immune response and in the role of AID in mis-targeting mutations leading to B-cell lymphomas and other cancers. The long-term goal of the proposed research is to understand the global targeting of mutations in immunity that are required to protect us from infections. As high-throughput data from human antibody immune responses became available, it provided us with new opportunities to generate hypotheses to explain the underlying mechanisms of SHM. We now propose to generate further hypotheses using computational models applied to additional databases and to validate these hypotheses using cellular and animal experiments. Our objective is to understand what directs SHM across the many human Ig heavy chain V-regions. Our central hypothesis is that the V-region SHM process is highly dependent on a DNA sequence signature(s) that drives mutations in a largely deterministic fashion. This hypothesis is supported by our preliminary results using human in vivo data from a few human V region genes and has begun to be validated using independent databases and experiments in human B cell lines. The rationale is that evaluations of computational data based upon biological mechanisms, together with appropriate biological experiments, will reveal the key differences between IGHV regions (IGHV 3-23, 4-34, 1-18, 1-02, etc.) that lead to the dominance of each of those V regions in the responses to medically important antigens. Our hypothesis will be tested by pursuing two specific aims: 1) identify the extent to which a DNA signature determines the mutation process in four individual human IGHV genes that are important in disease responses; 2) examine the relationship between AID hotspots and Pol hotspots across all the other human V region genes, thus rigorously defining a mutation targeting signature. Both aims will also entail studying human V region genes and modifications of them in human cell lines and in mice expressing a human V region to further confirm the signature and identify molecular mechanisms in vivo. Our approach is innovative because the computational models we are proposing will be mechanistically motivated focusing on the interaction between AID and Pol hotspots, thus testing molecular mechanisms as opposed to classic statistical models using whole V region sequences that ignore the underlying biology. In addition, to focus on mechanisms we will leverage new high-throughput data from human V regions that have not undergone antigen selection. Our results will be highly relevant to human IgV repertoire analyses from immune responses that are currently hard to interpret and will help future vaccine and therapeutic antibody development, as well as help to understand mutations in human malignancies where AID plays a key role. Project narrative The proposed research is relevant to public health because understanding the targeting of AID-mediated mutations across many human heavy chain V-regions will make it possible to develop vaccines that will lead more rapidly to better and more broadly protective antibodies to infectious agents and reveal the risk factors in the development of B-cell malignancies and gastric and other solid tumors where AID is implicated.",A combined computational and experimental approach to the evolution and role of the DNA sequence environment in targeting mutations to antibody V regions,10090262,R01AI132507,"['Affect', 'Alleles', 'Animal Experiments', 'Antibodies', 'Antibody Affinity', 'Antigens', 'Autoimmunity', 'B lymphoid malignancy', 'B-Cell Development', 'B-Cell Lymphomas', 'B-Lymphocytes', 'Biological', 'Biology', 'Cell Line', 'Chromatin', 'Complementarity Determining Regions', 'Computer Analysis', 'Computer Models', 'DNA', 'DNA Sequence', 'Data', 'Databases', 'Development', 'Disease', 'Environment', 'Enzyme Activation', 'Evaluation', 'Event', 'Evolution', 'Family', 'Feedback', 'Frequencies', 'Future', 'GTP-Binding Protein alpha Subunits, Gs', 'Gene-Modified', 'Genes', 'Goals', 'HIV', 'Heavy-Chain Immunoglobulins', 'Human', 'Human Cell Line', 'Immune response', 'Immunity', 'Immunoglobulin Somatic Hypermutation', 'Immunoglobulins', 'Individual', 'Infection', 'Infectious Agent', 'Influenza', 'Influenza Hemagglutinin', 'Knock-in', 'Lead', 'Location', 'Machine Learning', 'Malignant Neoplasms', 'Mediating', 'Medical', 'Mismatch Repair', 'Molecular', 'Mus', 'Mutate', 'Mutation', 'Outcome', 'Pattern', 'Play', 'Polymerase', 'Process', 'Public Health', 'Research', 'Risk Factors', 'Role', 'Site', 'Solid Neoplasm', 'Statistical Models', 'Stomach', 'Structure of germinal center of lymph node', 'Techniques', 'Testing', 'Therapeutic antibodies', 'Time', 'Transgenic Mice', 'Vaccines', 'Validation', 'Variant', 'activation-induced cytidine deaminase', 'base', 'chromatin modification', 'density', 'experimental study', 'genetic variant', 'human data', 'in vivo', 'in vivo Model', 'innovation', 'neutralizing antibody', 'recruit', 'repair enzyme', 'response', 'spatial relationship', 'vaccine response']",NIAID,ALBERT EINSTEIN COLLEGE OF MEDICINE,R01,2020,38074,0.23104602801349985
"A combined computational and experimental approach to the evolution and role of the DNA sequence environment in targeting mutations to antibody V regions Project summary There is a fundamental gap in our understanding of how mutations are preferentially targeted to the variable (V) regions of the Immunoglobulin (Ig) loci during somatic hypermutation (SHM). The persistence of this gap has limited our understanding of the mutagenic mechanisms involving activation-induced deaminase (AID) in the immune response and in the role of AID in mis-targeting mutations leading to B-cell lymphomas and other cancers. The long-term goal of the proposed research is to understand the global targeting of mutations in immunity that are required to protect us from infections. As high-throughput data from human antibody immune responses became available, it provided us with new opportunities to generate hypotheses to explain the underlying mechanisms of SHM. We now propose to generate further hypotheses using computational models applied to additional databases and to validate these hypotheses using cellular and animal experiments. Our objective is to understand what directs SHM across the many human Ig heavy chain V-regions. Our central hypothesis is that the V-region SHM process is highly dependent on a DNA sequence signature(s) that drives mutations in a largely deterministic fashion. This hypothesis is supported by our preliminary results using human in vivo data from a few human V region genes and has begun to be validated using independent databases and experiments in human B cell lines. The rationale is that evaluations of computational data based upon biological mechanisms, together with appropriate biological experiments, will reveal the key differences between IGHV regions (IGHV 3-23, 4-34, 1-18, 1-02, etc.) that lead to the dominance of each of those V regions in the responses to medically important antigens. Our hypothesis will be tested by pursuing two specific aims: 1) identify the extent to which a DNA signature determines the mutation process in four individual human IGHV genes that are important in disease responses; 2) examine the relationship between AID hotspots and Pol hotspots across all the other human V region genes, thus rigorously defining a mutation targeting signature. Both aims will also entail studying human V region genes and modifications of them in human cell lines and in mice expressing a human V region to further confirm the signature and identify molecular mechanisms in vivo. Our approach is innovative because the computational models we are proposing will be mechanistically motivated focusing on the interaction between AID and Pol hotspots, thus testing molecular mechanisms as opposed to classic statistical models using whole V region sequences that ignore the underlying biology. In addition, to focus on mechanisms we will leverage new high-throughput data from human V regions that have not undergone antigen selection. Our results will be highly relevant to human IgV repertoire analyses from immune responses that are currently hard to interpret and will help future vaccine and therapeutic antibody development, as well as help to understand mutations in human malignancies where AID plays a key role. Project narrative The proposed research is relevant to public health because understanding the targeting of AID-mediated mutations across many human heavy chain V-regions will make it possible to develop vaccines that will lead more rapidly to better and more broadly protective antibodies to infectious agents and reveal the risk factors in the development of B-cell malignancies and gastric and other solid tumors where AID is implicated.",A combined computational and experimental approach to the evolution and role of the DNA sequence environment in targeting mutations to antibody V regions,9882227,R01AI132507,"['Affect', 'Alleles', 'Animal Experiments', 'Antibodies', 'Antibody Affinity', 'Antigens', 'Autoimmunity', 'B lymphoid malignancy', 'B-Cell Development', 'B-Cell Lymphomas', 'B-Lymphocytes', 'Biological', 'Biology', 'Cell Line', 'Chromatin', 'Complementarity Determining Regions', 'Computer Analysis', 'Computer Models', 'DNA', 'DNA Sequence', 'Data', 'Databases', 'Development', 'Disease', 'Environment', 'Enzyme Activation', 'Evaluation', 'Event', 'Evolution', 'Family', 'Feedback', 'Frequencies', 'Future', 'GTP-Binding Protein alpha Subunits, Gs', 'Gene-Modified', 'Genes', 'Goals', 'HIV', 'Heavy-Chain Immunoglobulins', 'Human', 'Human Cell Line', 'Immune response', 'Immunity', 'Immunoglobulin Somatic Hypermutation', 'Immunoglobulins', 'Individual', 'Infection', 'Infectious Agent', 'Influenza', 'Influenza Hemagglutinin', 'Knock-in', 'Lead', 'Location', 'Machine Learning', 'Malignant Neoplasms', 'Mediating', 'Medical', 'Mismatch Repair', 'Molecular', 'Mus', 'Mutate', 'Mutation', 'Outcome', 'Pattern', 'Play', 'Polymerase', 'Process', 'Public Health', 'Research', 'Risk Factors', 'Role', 'Site', 'Solid Neoplasm', 'Statistical Models', 'Stomach', 'Structure of germinal center of lymph node', 'Techniques', 'Testing', 'Therapeutic antibodies', 'Time', 'Transgenic Mice', 'Vaccines', 'Validation', 'Variant', 'activation-induced cytidine deaminase', 'base', 'chromatin modification', 'density', 'experimental study', 'genetic variant', 'human data', 'in vivo', 'in vivo Model', 'innovation', 'neutralizing antibody', 'recruit', 'repair enzyme', 'response', 'spatial relationship', 'vaccine response']",NIAID,ALBERT EINSTEIN COLLEGE OF MEDICINE,R01,2020,591815,0.23104602801349985
"Understanding molecular rules governing protein allostery by deep mutational scanning Project Summary/Abstract Allostery is action at a distance in proteins. It is a property by which perturbation at one site of a protein causes an effect at a distant site of the protein. As nature's biological switches allosteric proteins regulate virtually every major process including catalysis, transcription, transport and signaling. Kinases, G-protein coupled receptors and nuclear receptors are therapeutically important allosteric proteins that play a major role in human health. Disruption of allosteric communication caused by mutations in these proteins is strongly associated with many types of disease abnormalities including cancer. Since the discovery of allostery in the 1960s, the molecular mechanism by which perturbation at one end of a protein is allosterically transmitted to the other end remains a mystery. Understanding molecular rules governing allostery is a fundamental problem in protein biochemistry and biophysics. Such rules may provide a deep insight into how proteins work through interactions between residues. Current approaches to studying allostery, which are biophysical, structural or computational, have two limitations. First, they provide an incomplete picture. Allostery involves the interplay of protein dynamics, structural changes and their effects on function. Probing each independently, as most studies do, does not give a complete understanding. Structure alone cannot explain dynamics, dynamical movement does not imply functional role, and functional studies may not provide insight into the underlying molecular causes. Second, detailed mechanistic studies of individual allosteric proteins while invaluable, are tedious, and cannot be scaled up to investigate many types of allosteric proteins. As a result, unifying heuristic rules would be difficult to infer from such individual case studies. The goal of my research is to develop a generalized, scalable method integrating structure, function and dynamics to understand, quantify and predict molecular drivers of protein allostery. With allosteric transcription factors as a model system, we will determine residues important for allostery (`hotspots') and their connectivity (`pathway') by deep mutational scanning, a method for large-scale functional characterization. We establish a critical link between structure and function by computationally modeling each mutation with Rosetta. We use machine learning on this rich sequence-structure-function dataset to recognize common molecular features (van der Waals, electrostatics, hydrogen bonds etc.) of allosteric hotspot residues, to build a predictive molecular model of allostery. Thus, we integrate high-throughput functional studies, structure-based modeling and machine learning to understand molecular rules governing allostery. Any allosteric protein whose activity can be coupled to a high-throughput screen, of which there are many, is amenable to our approach. Over time as the number and diversity of allosteric protein datasets increases, we expect that the accuracy and generalizability of predictions will continuously improve. Our long-term objective is to be able to (a) predict functional impact of thousands of mutations in disease-associated allosteric proteins revealed by genome sequencing (b) discover novel allosteric sites that improve selectivity and efficacy of drugs. Project Narrative GPCRs, nuclear receptors, ion channels and kinases are allosteric proteins that alone account for 44% of all human protein drug targets. We propose to develop a broad experimental and computational platform to understand molecular mechanism of allostery. This study will pave the way to explaining how dysfunction in allosteric proteins manifests into disease, and developing `smart' (allosteric) drugs that restore normal function.",Understanding molecular rules governing protein allostery by deep mutational scanning,9562195,DP2GM132682,"['Allosteric Site', 'Biological', 'Biological Models', 'Biophysics', 'Case Study', 'Catalysis', 'Communication', 'Computer Simulation', 'Coupled', 'Data Set', 'Disease', 'Distant', 'Drug Targeting', 'Electrostatics', 'Functional disorder', 'G-Protein-Coupled Receptors', 'Genetic Transcription', 'Goals', 'Health', 'Human', 'Hydrogen Bonding', 'Individual', 'Ion Channel', 'Link', 'Machine Learning', 'Malignant Neoplasms', 'Methods', 'Modeling', 'Molecular', 'Movement', 'Mutation', 'Nature', 'Nuclear Receptors', 'Pathway interactions', 'Pharmaceutical Preparations', 'Phosphotransferases', 'Play', 'Process', 'Property', 'Protein Biochemistry', 'Protein Dynamics', 'Proteins', 'Research', 'Role', 'Signal Transduction', 'Site', 'Structure', 'Therapeutic', 'Time', 'Work', 'base', 'drug efficacy', 'genome sequencing', 'heuristics', 'high throughput screening', 'improved', 'insight', 'molecular modeling', 'mutation screening', 'novel', 'scale up', 'transcription factor', 'virtual']",NIGMS,UNIVERSITY OF WISCONSIN-MADISON,DP2,2018,2146877,0.11124020012813486
"Development of New Genome Editing Agents Using RNA Modifying Enzymes Komor  Project Summary/Abstract - Development of New Genome Editing Agents Using RNA Modifying Enzymes  While targeted genome editing, the introduction of a specific modification in genomic DNA, has the potential to allow researchers to study and better understand mechanisms of human genetic diseases, traditional genome editing methods (including CRISPR-Cas9) that rely on the initial introduction of double stranded DNA breaks (DSB) suffer from modest genome editing efficiencies as well as unwanted gene alterations (indels), particularly when attempting to correct point mutations. Recently, a class of genome editing agents called single base editors was developed that does not involve DSBs, but rather uses a dCas9-tethered single-stranded DNA (ssDNA) modifying enzyme to directly chemically modify target nucleobases within a ~5 nucleotide window determined by the protospacer. Two classes of editors have been developed that use cytosine and adenine deamination chemistries to catalyze the conversion of CG base pairs to TA (CBEs), and AT base pairs to GC (ABEs), respectively. Here we propose the development and characterization of new base editors capable of facilitating new point mutations using methylation chemistry. We have use a bioinformatic approach to identify RNA modifying enzymes that have the potential to be repurposed into new base editors, and have rationally designed mutant libraries to use with directed evolution to convert these enzymes into base editors (Aim 1). Concurrently, we are developing a machine learning program that utilizes existing ssDNA modifying enzymes to identify putative mutations that will expand the substrate scope of the identified methyltransferases to ssDNA (Aim 2). Mutations identified from both strategies will then be tested and characterized for base editing in multiple orthogonal systems (Aim 3). The successful completion of the proposed work will represent a significant addition to existing base editing technologies, and will enable researchers to cleanly and efficiently install two additional types of point mutations into the genome of living cells, allowing researchers to quickly and effectively general model systems for the study of human genetic diseases. Komor  Project Narrative - Development of New Genome Editing Agents Using RNA Modifying Enzymes Base editing enables high efficiency genomic point mutation introduction in a variety of cell types and has the potential to allow researchers to better study human genetic diseases. We propose transformative improvements to current base editing technologies that will expand the types of point mutations that can be introduced by base editors. The tools developed here will enable researchers to cleanly and efficiently install additional types of point mutations into the genome of living cells for the study and potential treatment of human genetic diseases.",Development of New Genome Editing Agents Using RNA Modifying Enzymes,9876634,R21GM135736,"['Adenine', 'Adoption', 'Algorithms', 'Base Pairing', 'Bioinformatics', 'Biological Assay', 'Biological Models', 'CRISPR/Cas technology', 'Case Study', 'Cell Line', 'Cells', 'Chemicals', 'Chemistry', 'Communities', 'Cytosine', 'DNA', 'DNA Damage', 'DNA Double Strand Break', 'Deamination', 'Development', 'Directed Molecular Evolution', 'Engineering', 'Enzymes', 'Escherichia coli', 'Evolution', 'Gene Mutation', 'Generations', 'Genetic Diseases', 'Genome', 'Genomic DNA', 'Genomics', 'Human', 'Human Genetics', 'In Vitro', 'Individual', 'Inosine', 'Lesion', 'Libraries', 'Link', 'Machine Learning', 'Mammalian Cell', 'Measures', 'Mediating', 'Methods', 'Methylation', 'Methyltransferase', 'Modification', 'Mutation', 'Nucleotides', 'Pathogenicity', 'Point Mutation', 'Program Development', 'Proteins', 'Purines', 'Pyrimidine', 'RNA', 'Research Personnel', 'Single-Stranded DNA', 'Site', 'Specificity', 'System', 'Technology', 'Testing', 'Transfer RNA', 'Uracil', 'Variant', 'Work', 'adenosine deaminase', 'base', 'cell type', 'combat', 'design', 'genome editing', 'insertion/deletion mutation', 'machine learning algorithm', 'molecular dynamics', 'mutant', 'novel', 'nucleobase', 'preference', 'programs', 'tool', 'transition mutation', 'transversion mutation']",NIGMS,"UNIVERSITY OF CALIFORNIA, SAN DIEGO",R21,2019,205479,0.13671181397496238
"Computational Models of the Human Cell Cycle to Reveal Disease Mechanism and Inform Treatment PROJECT SUMMARY / ABSTRACT The overall goal of this project is to develop computational models that predict how the human cell cycle responds to clinically-relevant perturbations such as radiotherapy, targeted therapy, oncogenic mutation, and directed differentiation. These models will fill a significant void in our understanding of the mechanisms underlying the initiation, progression, and treatment of diseases that involve abnormal cell proliferation. Our approach is to use quantitative single-cell imaging to measure the molecular states of proliferating cells and to integrate these data into predictive modeling frameworks. We have assembled a cross-institutional team comprising a computational biologist, two cell biologists, and a physician scientist with specialization in radiation oncology. The team has a strong and productive history of collaboration with six joint publications to date. Aim 1 investigates the mechanism by which retinal epithelial cells respond to radiation-induced DNA damage during S phase to execute G2 arrest. Time-lapse imaging and deterministic modeling will predict: how the response to DNA damage is delayed until the S/G2 transition; how a small-molecule inhibitor of DNA repaircurrently involved in clinical trialintensifies the arrest response; and how loss of the tumor suppressor p53 renders cells refractory to combination therapy. Aim 2 asks how pancreatic epithelial cells with mutations in KRAS escape permanent cell cycle arrest. We will use high-content imaging to profile multiple signaling activities in single cells expressing oncogenic KRAS. These data will be used to construct a manifold representation of cell cycle progression that spans a two-week time course of oncogenic KRAS-mediated transformation. Computational analysis of the manifolds geometry will identify molecular branching points in G1 that govern the proliferation/arrest decision in pancreatic cells, and we will validate these predictions through small molecules and genetic manipulation. Aim 3 tests the hypothesis that human embryonic stem cells inherit cell-cycle-specific gene products (specifically, G1 regulators) from the previous G2 phase to promote pluripotency in daughter cells. We will combine mitosis-specific chromatin profiling with convolutional neural network-based image analysis to identify the mechanisms by which stem cells sustain rapid proliferation and pluripotency over multiple cell-cycle generations. Each aim yields both basic and applied knowledge, providing fundamental insights into cell cycle progression under perturbation and generating specific, molecular predictions to inform new treatment schemes. With an eye toward the future, predictive models of the human cell cycle will enable patient-specific treatments for diseases that are driven by abnormal cell proliferation. NARRATIVE Many human diseases involve abnormalities in the cell cyclethe process by which cells duplicate their DNA to form two daughter cells. This project will develop computational models that can predict how the human cell cycle responds to radiation and targeted therapy; a mutation commonly observed in pancreatic cancer; and treatments used to regenerate epithelial tissues from human stem cells. Successful completion of these aims will advance our basic understanding of the human cell cycle and inform our ability to treat disease by altering cell cycle progression.",Computational Models of the Human Cell Cycle to Reveal Disease Mechanism and Inform Treatment,10033514,R01GM138834,"['Abnormal Cell', 'Activity Cycles', 'Behavior', 'CCNE1 gene', 'Cell Cycle', 'Cell Cycle Arrest', 'Cell Cycle Progression', 'Cell Cycle Regulation', 'Cell Differentiation process', 'Cell Proliferation', 'Cell division', 'Cell model', 'Cells', 'Chemicals', 'Chromatin', 'Clinical Treatment', 'Clinical Trials', 'Collaborations', 'Combined Modality Therapy', 'Computer Analysis', 'Computer Models', 'Coupling', 'Cues', 'Cyclin D1', 'Cyclin-Dependent Kinases', 'DNA', 'DNA Binding', 'DNA Damage', 'DNA Repair', 'DNA Repair Inhibition', 'DNA biosynthesis', 'Data', 'Disease', 'Down-Regulation', 'Embryonic Development', 'Endoderm', 'Epithelial Cells', 'Eye', 'Family', 'Future', 'G2 Phase', 'Generations', 'Genetic', 'Genetic Transcription', 'Geometry', 'Goals', 'Growth', 'Growth Factor Receptors', 'Human', 'Image', 'Image Analysis', 'Immunofluorescence Immunologic', 'In Vitro', 'Inherited', 'Joints', 'KRAS2 gene', 'Knowledge', 'Learning', 'Link', 'Malignant Neoplasms', 'Malignant neoplasm of pancreas', 'Measures', 'Mediating', 'Messenger RNA', 'Mitosis', 'Mitotic', 'Modeling', 'Modernization', 'Molecular', 'Mothers', 'Mutate', 'Mutation', 'Network-based', 'Oncogenes', 'Oncogenic', 'Organ', 'PI3K/AKT', 'Pancreas', 'Pathway interactions', 'Pharmaceutical Preparations', 'Pharmacology', 'Physicians', 'Pluripotent Stem Cells', 'Process', 'Proliferating', 'Protein p53', 'Protocols documentation', 'Publications', 'RAS Family Gene', 'RAS genes', 'Radiation', 'Radiation Induced DNA Damage', 'Radiation Oncology', 'Radiation therapy', 'Recording of previous events', 'Refractory', 'Research', 'Resolution', 'Retina', 'S Phase', 'Scheme', 'Scientist', 'Signal Transduction', 'Stress', 'Testing', 'Therapeutic', 'Time', 'Tissues', 'cancer therapy', 'cell type', 'cellular imaging', 'chemotherapy', 'chromatin immunoprecipitation', 'clinically relevant', 'convolutional neural network', 'daughter cell', 'design', 'epithelium regeneration', 'expectation', 'extracellular', 'gene product', 'genetic manipulation', 'human disease', 'human embryonic stem cell', 'human model', 'human stem cells', 'human tissue', 'individualized medicine', 'induced pluripotent stem cell', 'insight', 'paracrine', 'pluripotency', 'predicting response', 'predictive modeling', 'response', 'small molecule', 'small molecule inhibitor', 'stem cells', 'targeted treatment', 'therapeutic DNA', 'transmission process', 'treatment response']",NIGMS,UNIV OF NORTH CAROLINA CHAPEL HILL,R01,2020,307051,0.07692080383679947
"Understanding modifiers of mendelian mutation penetrance using familial hypercholesterolemia as a model PROJECT SUMMARY / ABSTRACT Rare monogenic forms of common diseases have provided key fundamental insights about common disease. However, genetic, environmental, and stochastic elements influence risk for disease. Familial hypercholesterolemia (FH), an autosomal dominant disorder afflicting 1 in 250 linked to severe increases in LDL cholesterol and premature coronary heart disease (CHD) risk, is an ideal model to characterize modifiers of disease. Despite the presence of a strong genetic driver of hypercholesterolemia from FH mutations, we recently observed that half do not have the expected severe hypercholesterolemia. In this proposal, we outline several methods to discover and dissect the genetic and non-genetic factors influencing CHD risk conferred by FH mutations in humans and determine whether knowledge of these factors can improve risk discrimination among those with FH mutations. Our approach harnesses several multi-dimensional datasets: whole genome sequences, metabolomics, and cross-sectional and longitudinal cardiovascular phenotypes. In Aim 1, we will aggregate and curate 75,000 deep (30X) whole genome sequences and cardiovascular phenotypes. In Aim 2, we will discover genetic and non-genetic modifiers of LDL cholesterol and CHD risk in FH and evaluate their metabolomic consequences. In Aim 3, we will develop a method incorporating genetics and longitudinal non- genetic exposures for CHD risk stratification among ~4,000 with FH mutations in the Million Veteran Program. In addition to the proposed Aims, this five-year proposal outlines a comprehensive strategy for the principal investigator's (PI's) scientific and professional development in academic cardiovascular medicine. The research strategy builds upon the PI's prior research experience and clinical training. In addition to an undergraduate degree in Molecular Biology and master's degree in Biomedical Informatics, he completed post- graduate medical training in Internal Medicine and Cardiovascular Medicine. He recently developed a new preventive/genetic cardiology clinic focusing on the evaluation and management of those with or a family history of premature CHD, including those with FH, at Massachusetts General Hospital (MGH). This proposal now focuses on expanding his scientific skills in human genetics and genomics into new domains: integrative genomics, statistical genetics, clinical informatics, and risk modeling. The career development goals will be at achieved through a multi-faceted approach involving mentorship, collaboration, didactic coursework, conferences, and scientific investigation. This work will take place in a unique training environment comprised of MGH and the Broad Institute. Successful completion of this career development award will result in improved fundamental understanding of the determinants of CHD, result in the PI's transition to an independent physician-scientist, and provide a solid foundation from which he will apply for R01-level funding. PROJECT NARRATIVE / PUBLIC HEALTH RELEVANCE Cardiovascular disease, largely due to coronary heart disease (CHD), remains the leading cause of death in the United States and now worldwide despite current advances. Familial hypercholesterolemia is a relative common genetic disorder characterized by severe hypercholesterolemia and premature CHD but many carrying these mutations do not develop these consequences. This proposal seeks to define and characterize the factors modifying CHD risk among those with FH mutations; success has the potential to broadly identify new mechanisms of CHD and novel strategies for prevention.",Understanding modifiers of mendelian mutation penetrance using familial hypercholesterolemia as a model,9609507,K08HL140203,"['Adult', 'Affect', 'African', 'Amish', 'Bachelor&apos', 's Degree', 'Biochemical', 'Cardiology', 'Cardiovascular Diseases', 'Cardiovascular system', 'Catalogs', 'Cause of Death', 'Clinic', 'Clinical', 'Clinical Informatics', 'Cloud Computing', 'Collaborations', 'Computer Simulation', 'Coronary Arteriosclerosis', 'Coronary heart disease', 'DNA sequencing', 'Data', 'Data Set', 'Development', 'Discrimination', 'Disease', 'Disease Pathway', 'Electronic Health Record', 'Elements', 'Environment', 'Environmental Risk Factor', 'Ethnic Origin', 'European', 'Evaluation', 'Exposure to', 'Familial Hypercholesterolemia', 'Family history of', 'Foundations', 'Funding', 'Gene Mutation', 'General Hospitals', 'Generations', 'Genetic', 'Genetic Counseling', 'Genetic Diseases', 'Genomics', 'Genotype', 'Goals', 'Gold', 'Healthcare', 'Human', 'Human Genetics', 'Individual', 'Institutes', 'Internal Medicine', 'Investigation', 'K-Series Research Career Programs', 'Knowledge', 'LDL Cholesterol Lipoproteins', 'Lead', 'Leadership', 'Link', 'Lipids', 'Low-Density Lipoproteins', 'Massachusetts', 'Master&apos', 's Degree', 'Mediator of activation protein', 'Medical', 'Medicine', 'Mendelian disorder', 'Mentorship', 'Methods', 'Modeling', 'Molecular Biology', 'Mutation', 'National Heart, Lung, and Blood Institute', 'National Human Genome Research Institute', 'Network-based', 'Pathogenicity', 'Pathway Analysis', 'Pathway interactions', 'Penetrance', 'Phenotype', 'Physicians', 'Physiological', 'Population', 'Positioning Attribute', 'Prevalence', 'Prevention', 'Prevention strategy', 'Preventive', 'Preventive therapy', 'Principal Investigator', 'Quality Control', 'Research', 'Risk', 'Risk stratification', 'Scientist', 'Solid', 'Statistical Models', 'Technology', 'Testing', 'Time', 'Training', 'Trans-Omics for Precision Medicine', 'United States', 'United States National Institutes of Health', 'Variant', 'Veterans', 'Work', 'base', 'biobank', 'biomedical informatics', 'career development', 'cloud based', 'cohort', 'disorder risk', 'experience', 'genetic analysis', 'genome sequencing', 'genomic variation', 'heart disease risk', 'high risk', 'human disease', 'human genomics', 'hypercholesterolemia', 'improved', 'in vivo', 'insight', 'lifestyle factors', 'machine learning algorithm', 'metabolomics', 'next generation', 'non-genetic', 'novel', 'novel strategies', 'precision medicine', 'premature', 'programs', 'public health relevance', 'risk prediction model', 'skills', 'success', 'symposium', 'trait', 'whole genome']",NHLBI,MASSACHUSETTS GENERAL HOSPITAL,K08,2019,170003,0.16227676897602966
"Understanding modifiers of mendelian mutation penetrance using familial hypercholesterolemia as a model PROJECT SUMMARY / ABSTRACT Rare monogenic forms of common diseases have provided key fundamental insights about common disease. However, genetic, environmental, and stochastic elements influence risk for disease. Familial hypercholesterolemia (FH), an autosomal dominant disorder afflicting 1 in 250 linked to severe increases in LDL cholesterol and premature coronary heart disease (CHD) risk, is an ideal model to characterize modifiers of disease. Despite the presence of a strong genetic driver of hypercholesterolemia from FH mutations, we recently observed that half do not have the expected severe hypercholesterolemia. In this proposal, we outline several methods to discover and dissect the genetic and non-genetic factors influencing CHD risk conferred by FH mutations in humans and determine whether knowledge of these factors can improve risk discrimination among those with FH mutations. Our approach harnesses several multi-dimensional datasets: whole genome sequences, metabolomics, and cross-sectional and longitudinal cardiovascular phenotypes. In Aim 1, we will aggregate and curate 75,000 deep (30X) whole genome sequences and cardiovascular phenotypes. In Aim 2, we will discover genetic and non-genetic modifiers of LDL cholesterol and CHD risk in FH and evaluate their metabolomic consequences. In Aim 3, we will develop a method incorporating genetics and longitudinal non- genetic exposures for CHD risk stratification among ~4,000 with FH mutations in the Million Veteran Program. In addition to the proposed Aims, this five-year proposal outlines a comprehensive strategy for the principal investigator's (PI's) scientific and professional development in academic cardiovascular medicine. The research strategy builds upon the PI's prior research experience and clinical training. In addition to an undergraduate degree in Molecular Biology and master's degree in Biomedical Informatics, he completed post- graduate medical training in Internal Medicine and Cardiovascular Medicine. He recently developed a new preventive/genetic cardiology clinic focusing on the evaluation and management of those with or a family history of premature CHD, including those with FH, at Massachusetts General Hospital (MGH). This proposal now focuses on expanding his scientific skills in human genetics and genomics into new domains: integrative genomics, statistical genetics, clinical informatics, and risk modeling. The career development goals will be at achieved through a multi-faceted approach involving mentorship, collaboration, didactic coursework, conferences, and scientific investigation. This work will take place in a unique training environment comprised of MGH and the Broad Institute. Successful completion of this career development award will result in improved fundamental understanding of the determinants of CHD, result in the PI's transition to an independent physician-scientist, and provide a solid foundation from which he will apply for R01-level funding. PROJECT NARRATIVE / PUBLIC HEALTH RELEVANCE Cardiovascular disease, largely due to coronary heart disease (CHD), remains the leading cause of death in the United States and now worldwide despite current advances. Familial hypercholesterolemia is a relative common genetic disorder characterized by severe hypercholesterolemia and premature CHD but many carrying these mutations do not develop these consequences. This proposal seeks to define and characterize the factors modifying CHD risk among those with FH mutations; success has the potential to broadly identify new mechanisms of CHD and novel strategies for prevention.",Understanding modifiers of mendelian mutation penetrance using familial hypercholesterolemia as a model,9431712,K08HL140203,"['Adult', 'Affect', 'African', 'Algorithms', 'Amish', 'Bachelor&apos', 's Degree', 'Biochemical', 'Cardiology', 'Cardiovascular Diseases', 'Cardiovascular system', 'Catalogs', 'Cause of Death', 'Clinic', 'Clinical', 'Clinical Informatics', 'Cloud Computing', 'Collaborations', 'Computer Simulation', 'Coronary Arteriosclerosis', 'Coronary heart disease', 'DNA sequencing', 'Data', 'Data Set', 'Development', 'Discrimination', 'Disease', 'Disease Pathway', 'Electronic Health Record', 'Elements', 'Environment', 'Environmental Risk Factor', 'Ethnic Origin', 'European', 'Evaluation', 'Exposure to', 'Familial Hypercholesterolemia', 'Family history of', 'Foundations', 'Funding', 'Gene Mutation', 'General Hospitals', 'Generations', 'Genetic', 'Genetic Counseling', 'Genetic Diseases', 'Genomics', 'Genotype', 'Goals', 'Gold', 'Healthcare', 'Human', 'Human Genetics', 'Individual', 'Institutes', 'Internal Medicine', 'Investigation', 'K-Series Research Career Programs', 'Knowledge', 'LDL Cholesterol Lipoproteins', 'Lead', 'Leadership', 'Link', 'Lipids', 'Low-Density Lipoproteins', 'Machine Learning', 'Massachusetts', 'Master&apos', 's Degree', 'Mediator of activation protein', 'Medical', 'Medicine', 'Mendelian disorder', 'Mentorship', 'Methods', 'Modeling', 'Molecular Biology', 'Mutation', 'National Heart, Lung, and Blood Institute', 'National Human Genome Research Institute', 'Network-based', 'Pathogenicity', 'Pathway Analysis', 'Pathway interactions', 'Penetrance', 'Phenotype', 'Physicians', 'Physiological', 'Population', 'Positioning Attribute', 'Prevalence', 'Prevention', 'Prevention strategy', 'Preventive', 'Preventive therapy', 'Principal Investigator', 'Quality Control', 'Research', 'Risk', 'Risk stratification', 'Scientist', 'Solid', 'Statistical Models', 'Technology', 'Testing', 'Time', 'Training', 'Trans-Omics for Precision Medicine', 'United States', 'United States National Institutes of Health', 'Variant', 'Veterans', 'Work', 'base', 'biobank', 'biomedical informatics', 'career development', 'cloud based', 'cohort', 'disorder risk', 'experience', 'genetic analysis', 'genome sequencing', 'genomic variation', 'heart disease risk', 'high risk', 'human disease', 'human genomics', 'hypercholesterolemia', 'improved', 'in vivo', 'insight', 'lifestyle factors', 'metabolomics', 'next generation', 'non-genetic', 'novel', 'novel strategies', 'precision medicine', 'predictive modeling', 'premature', 'programs', 'public health relevance', 'skills', 'success', 'symposium', 'trait', 'whole genome']",NHLBI,MASSACHUSETTS GENERAL HOSPITAL,K08,2018,173296,0.16227676897602966
"A novel human T-cell platform to define biological effects of genome editing PROJECT SUMMARY Genome editing technologies have extraordinary potential as new genomic medicines that address underlying genetic causes of human disease; however, it remains challenging to predict their long-term safety, because we do not know the consequences of potential side effects of genome editing such as off-target mutations or immunogenicity. Our long-term goal is to understand and predict such unintended biological effects to advance the development of safe and effective therapies. T-cells are an ideal cellular model because: 1) they are highly relevant as the most widely used cells for development of therapeutic genome editing strategies (such as cell- based treatments for HIV and cancer) and 2) mature T-cells encode a diverse T-cell receptor repertoire that can be exploited as built-in cellular barcodes for quantifying clonal expansion or depletion in response to specific treatments. We, therefore, propose the following specific aims: 1) to predict which unintended editing sites have biological effects on human T-cells by integrating large-scale genome-wide activity and epigenomic profiles with state-of-the-art deep learning models and 2) to develop a human primary T-cell platform to detect functional effects of genome editing by measuring clonal representation, off-target mutation frequencies, immunogenicity, or gene expression. If successful, our experimental and predictive framework will profoundly increase confidence in the safety of the next generation of promising genome editing therapies. PROJECT NARRATIVE Genome editing technologies have extraordinary potential as the basis of new genomic medicines that address the underlying genetic causes of human disease; however, it is challenging to predict their long-term safety, because we do not know the consequences of potential unintended side effects of genome editing such as off- target mutations or immunogenicity. To define the biological effects of genome editing strategies, we will develop a human primary T-cell platform to sensitively detect functional effects coupled with an empirically-trained artificial intelligence models to predict them. Together, our platform will significantly improve confidence in safety assessments of promising genome editing therapeutics.",A novel human T-cell platform to define biological effects of genome editing,9678132,U01HL145793,"['Address', 'Advanced Development', 'Adverse effects', 'Affect', 'Artificial Intelligence', 'Benign', 'Biochemical', 'Bioinformatics', 'Biological', 'Biological Assay', 'Cell model', 'Cell physiology', 'Cells', 'Chromatin', 'Clonal Expansion', 'Complex', 'Coupled', 'DNA Methylation', 'Detection', 'Engineering', 'Epitopes', 'Frequencies', 'Gene Expression', 'Genes', 'Genetic', 'Genetic Diseases', 'Genetic Transcription', 'Genetic Variation', 'Genomic medicine', 'Genomics', 'Goals', 'HIV', 'Human', 'Human Genetics', 'Human Genome', 'Immunologic Deficiency Syndromes', 'In Vitro', 'Inherited', 'Machine Learning', 'Malignant Neoplasms', 'Maps', 'Mature T-Lymphocyte', 'Measures', 'Methods', 'Modeling', 'Mutation', 'Oncogenic', 'Organizational Change', 'Outcome', 'Peptide Library', 'Peripheral Blood Mononuclear Cell', 'Phenotype', 'Population', 'Proto-Oncogenes', 'Regulatory Element', 'Retroviral Vector', 'Ribonucleoproteins', 'Safety', 'Site', 'Site-Directed Mutagenesis', 'Standardization', 'Streptococcus pyogenes', 'T cell response', 'T-Cell Receptor', 'T-Lymphocyte', 'T-cell receptor repertoire', 'Technology', 'Testing', 'Therapeutic', 'Training', 'Variant', 'adaptive immune response', 'adverse outcome', 'base', 'comparative genomics', 'cytokine', 'deep learning', 'effective therapy', 'epigenomics', 'functional genomics', 'gene therapy', 'genome editing', 'genome-wide', 'genotoxicity', 'histone modification', 'human disease', 'immunogenic', 'immunogenicity', 'improved', 'in vivo', 'learning strategy', 'next generation', 'novel', 'novel therapeutics', 'response', 'safety testing', 'therapeutic development', 'therapeutic gene', 'therapeutic genome editing', 'transcriptome sequencing']",NHLBI,ST. JUDE CHILDREN'S RESEARCH HOSPITAL,U01,2018,651251,0.12325170204758766
"Physics-based precision medicine: computationally phenotyping myosin isoforms and cardiomyopathy mutations PROJECT SUMMARY/ABSTRACT  Myosins are a diverse and ubiquitous class of molecular motors that are responsible for generating much of the macroscopic force in the human body. The human genome encodes 38 different isoforms of myosin, and members of this group act as force sensors or generators for a diverse set of processes throughout the body. To serve this wide array of functions, each myosin isoform has been biophysically tuned for its physiological role. In fact, the tuning is so precise that missense variants in one myosin isoform, !-cardiac myosin, can cause a congenital cardiomyopathy that is the leading cause of sudden cardiac death in people under 30. And yet, it is unknown how particular variants cause disease, or how to infer the pathogenic potential for novel mutations.  Large differences in functional properties between myosin isoforms are not the result of large differences in coding sequence or overall topology. Neither foreknowledge of phylogeny nor crystal structure is sufcient to predict an isoform's biophysical properties. Furthermore, mutations causing disease frequently occur in regions of the protein far from the site of their deleterious effects. Poor understanding of the biophysical regulation of motor function has hampered the development of pharmaceuticals and the interpretation of human genomic data.  My goal is to establish a mechanistic understanding of myosin motors that is capable of predicting if and how sequence variation changes biophysical properties and can cause cardiac disease. Since myosin kinetics are not apparent from sequence or overall structure, they must be determined by other factors. I hypothesize that kinetic differences result from differences in the allosteric networks in these proteins. Allosteric network in this context refers to the coordinated conformational uctuations that give protein regulation the appearance of action at a distance. To test this hypothesis, we will use our unique combination of enormous computational power for molecular simulation and cutting-edge machine learning tools for analyzing protein allostery.  Aim 1 is to identify the biophysical determinants of myosin isoforms' differing speeds. To test our hypothesis that allosteric networks are responsible for modulating dynamics, I will use molecular simulations of different myosin isoforms and compare their allosteric networks with biochemical data about their properties. Aim 1 directly addresses outstanding questions about normal molecular-biological function of the heart, putting it in line with NHLBI overarching objective #1.  Aim 2 is to determine the difference, at atomic resolution, between healthy and diseased !-cardiac myosin. I hypothesize that the pathogenicity of variants with an unknown molecular etiology is a consequence of allosteric disruption, and will use our computational tools to test this hypothesis by simulating a set of known-pathogenic variants. This aim uses techniques from data science to understand the genetic determinants of health, and will apply equally well to rare alleles in under-represented groups as to majority groups. It is directly addresses NHLBI overarching objectives #3, #4, and #7. PROJECT NARRATIVE  Myosins are a closely-related group of molecules that are responsible for generating much of the force in the human body, including the heartbeat, the movement of limbs, and driving food through the stomach and intestines. Small changes to the myosin genes can have large effects: in healthy people, these give rise to different myosins that perform different functions, and mutations in some myosin genes can give rise to diseases that cause of sudden cardiac death. This proposal aims to learn, at the level of atoms and interatomic bonds, why and how these subtle changes to the myosin gene can create such large effects in the protein's function.",Physics-based precision medicine: computationally phenotyping myosin isoforms and cardiomyopathy mutations,9881184,F30HL146052,"['Actins', 'Address', 'Affinity', 'Appearance', 'Automobile Driving', 'Behavior', 'Binding', 'Binding Sites', 'Biochemical', 'Biological Process', 'Biophysics', 'Cardiac Myosins', 'Cardiomyopathies', 'Catalysis', 'Chemistry', 'Clinical', 'Code', 'Congenital cardiomyopathy', 'Crystallization', 'Data', 'Data Science', 'Development', 'Disease', 'Drug Binding Site', 'Etiology', 'Food', 'Genes', 'Genetic Determinism', 'Genetic Variation', 'Goals', 'Health', 'Heart Diseases', 'Human', 'Human Genome', 'Human body', 'Intestines', 'Kinetics', 'Learning', 'Machine Learning', 'Measures', 'Membrane Proteins', 'Methods', 'Modeling', 'Molecular', 'Molecular Conformation', 'Molecular Motors', 'Motor', 'Mutation', 'Myosin ATPase', 'National Heart, Lung, and Blood Institute', 'Pathogenicity', 'Patient risk', 'Pharmacologic Substance', 'Phenotype', 'Phylogeny', 'Physics', 'Physiological', 'Process', 'Property', 'Protein Analysis', 'Protein Isoforms', 'Protein Region', 'Proteins', 'Regulation', 'Relaxation', 'Resolution', 'Risk stratification', 'Role', 'Signal Transduction', 'Site', 'Solvents', 'Speed', 'Stomach', 'Structure', 'Surface', 'Techniques', 'Testing', 'Time', 'Underrepresented Groups', 'Variant', 'base', 'biophysical properties', 'computerized tools', 'disease-causing mutation', 'force sensor', 'genomic data', 'heart function', 'improved', 'insight', 'limb movement', 'member', 'millisecond', 'molecular dynamics', 'novel', 'precision medicine', 'protein function', 'prototype', 'rare variant', 'rat Ran 2 protein', 'simulation', 'sudden cardiac death', 'tool', 'whole genome']",NHLBI,WASHINGTON UNIVERSITY,F30,2020,48719,0.038698743990880975
"Physics-based precision medicine: computationally phenotyping myosin isoforms and cardiomyopathy mutations PROJECT SUMMARY/ABSTRACT  Myosins are a diverse and ubiquitous class of molecular motors that are responsible for generating much of the macroscopic force in the human body. The human genome encodes 38 different isoforms of myosin, and members of this group act as force sensors or generators for a diverse set of processes throughout the body. To serve this wide array of functions, each myosin isoform has been biophysically tuned for its physiological role. In fact, the tuning is so precise that missense variants in one myosin isoform, !-cardiac myosin, can cause a congenital cardiomyopathy that is the leading cause of sudden cardiac death in people under 30. And yet, it is unknown how particular variants cause disease, or how to infer the pathogenic potential for novel mutations.  Large differences in functional properties between myosin isoforms are not the result of large differences in coding sequence or overall topology. Neither foreknowledge of phylogeny nor crystal structure is sufcient to predict an isoform's biophysical properties. Furthermore, mutations causing disease frequently occur in regions of the protein far from the site of their deleterious effects. Poor understanding of the biophysical regulation of motor function has hampered the development of pharmaceuticals and the interpretation of human genomic data.  My goal is to establish a mechanistic understanding of myosin motors that is capable of predicting if and how sequence variation changes biophysical properties and can cause cardiac disease. Since myosin kinetics are not apparent from sequence or overall structure, they must be determined by other factors. I hypothesize that kinetic differences result from differences in the allosteric networks in these proteins. Allosteric network in this context refers to the coordinated conformational uctuations that give protein regulation the appearance of action at a distance. To test this hypothesis, we will use our unique combination of enormous computational power for molecular simulation and cutting-edge machine learning tools for analyzing protein allostery.  Aim 1 is to identify the biophysical determinants of myosin isoforms' differing speeds. To test our hypothesis that allosteric networks are responsible for modulating dynamics, I will use molecular simulations of different myosin isoforms and compare their allosteric networks with biochemical data about their properties. Aim 1 directly addresses outstanding questions about normal molecular-biological function of the heart, putting it in line with NHLBI overarching objective #1.  Aim 2 is to determine the difference, at atomic resolution, between healthy and diseased !-cardiac myosin. I hypothesize that the pathogenicity of variants with an unknown molecular etiology is a consequence of allosteric disruption, and will use our computational tools to test this hypothesis by simulating a set of known-pathogenic variants. This aim uses techniques from data science to understand the genetic determinants of health, and will apply equally well to rare alleles in under-represented groups as to majority groups. It is directly addresses NHLBI overarching objectives #3, #4, and #7. PROJECT NARRATIVE  Myosins are a closely-related group of molecules that are responsible for generating much of the force in the human body, including the heartbeat, the movement of limbs, and driving food through the stomach and intestines. Small changes to the myosin genes can have large effects: in healthy people, these give rise to different myosins that perform different functions, and mutations in some myosin genes can give rise to diseases that cause of sudden cardiac death. This proposal aims to learn, at the level of atoms and interatomic bonds, why and how these subtle changes to the myosin gene can create such large effects in the protein's function.",Physics-based precision medicine: computationally phenotyping myosin isoforms and cardiomyopathy mutations,9678589,F30HL146052,"['Actins', 'Address', 'Affinity', 'Appearance', 'Automobile Driving', 'Behavior', 'Binding', 'Binding Sites', 'Biochemical', 'Biological Process', 'Biophysics', 'Cardiac Myosins', 'Cardiomyopathies', 'Catalysis', 'Chemistry', 'Clinical', 'Code', 'Congenital cardiomyopathy', 'Crystallization', 'Data', 'Data Science', 'Development', 'Disease', 'Drug Binding Site', 'Etiology', 'Food', 'Genes', 'Genetic Determinism', 'Genetic Variation', 'Goals', 'Health', 'Heart Diseases', 'Human', 'Human Genome', 'Human body', 'Intestines', 'Kinetics', 'Learning', 'Machine Learning', 'Measures', 'Membrane Proteins', 'Methods', 'Modeling', 'Molecular', 'Molecular Conformation', 'Molecular Motors', 'Motor', 'Mutation', 'Myosin ATPase', 'National Heart, Lung, and Blood Institute', 'Pathogenicity', 'Patient risk', 'Pharmacologic Substance', 'Phenotype', 'Phylogeny', 'Physics', 'Physiological', 'Process', 'Property', 'Protein Analysis', 'Protein Isoforms', 'Protein Region', 'Proteins', 'Regulation', 'Relaxation', 'Resolution', 'Risk stratification', 'Role', 'Signal Transduction', 'Site', 'Solvents', 'Speed', 'Stomach', 'Structure', 'Surface', 'Techniques', 'Testing', 'Time', 'Underrepresented Groups', 'Variant', 'base', 'biophysical properties', 'computerized tools', 'disease-causing mutation', 'genomic data', 'heart function', 'improved', 'insight', 'limb movement', 'member', 'millisecond', 'molecular dynamics', 'novel', 'precision medicine', 'protein function', 'prototype', 'rare variant', 'rat Ran 2 protein', 'sensor', 'simulation', 'sudden cardiac death', 'tool', 'whole genome']",NHLBI,WASHINGTON UNIVERSITY,F30,2019,30442,0.038698743990880975
"Id3 and VSMC in Murine and Human Atherosclerosis Despite major advances in prevention and treatment of atherosclerotic cardiovascular disease (ASCVD), it remains a major cause of deaths worldwide. As ASCVD is a heritable and polygenic disorder, identification of ASCVD-associated single nucleotide polymorphisms (SNP) in humans and elucidation of their effect on ASCVD biology is needed to fully understand and impact on this unmet residual risk. One such human polymorphism in the ID3 gene (rs11574) was associated with ASCVD in 3 distinct human cohorts. Notably, this SNP significantly attenuates ID3 function and studies in pre-clinical models confirm a critical role for ID3 in atheroprotection. We have previously shown that loss of ID3 inhibits vascular smooth muscle cell (VSMC) proliferation and promotes VSMC expression of inflammatory factors, processes linked to increase atherosclerosis. In collaboration with Dr. Gary Owens, we have generated a mouse model with VSMC lineage tracing and VSMC-specific deletion of ID3 to study ID3-dependent VSMC specific changes during the course of lesion development in the context of the whole animal. We have developed a comprehensive CyTOF panel to identify and quantitate key cellular and intracellular changes in VSMC and other lesional cells in the aorta during the course of atherosclerosis development in these mice. To translate murine findings to humans, we have utilized CRISPR/Cas9 genetic engineering to knock out ID3 and produce the full allelic series of rs11574 in human cells and validated a reproducible system for differentiation of human inducible pluripotent stem cells (iPSCs) to VSMC. We will quantify the changes in VSMC phenotype in iPSC-derived VSMC with the full allelic series of rs11574. To further translate murine findings to humans, intravascular ultrasound virtual histology (IVUS-VH) will be measured in human coronary arteries and analyzed with cutting edge image analysis techniques in collaboration with Dr. Milan Sonka at the University of Iowa. As such, our group is uniquely poised to dissect the role of this ASCVD-associated SNP and translate findings to humans. We hypothesize: that loss of ID3 in VSMCs will inhibit VSMC growth and promote a phenotype that exacerbates vessel wall inflammation and atherosclerosis lesion development; that human ID3 encoded by the risk allele aggravates these atherogenic VSMC functions; and that human subjects with the risk allele have larger coronary plaques with increased fatty deposits, necrotic cores and calcification compared to subjects homozygous for the common allele. As atherosclerotic cardiovascular disease (ASCVD) is a heritable and polygenic disorder, identification of ASCVD-associated single nucleotide polymorphisms (SNP) in humans and elucidation of their effect on ASCVD biology is needed to fully understand and further impact on ASCVD morbidity and mortality. Human ID3 gene polymorphism at rs11574 is associated with ASCVD in three unique human cohorts. Preliminary data supports a key role for ID3 in vascular smooth muscle cell biology linked to ASCVD. In the current proposal, we will utilize a novel mouse model with VSMC lineage tracing and specific deletion of ID3 to elucidate the role of ID3 in promoting atherogenic VSMCs. We will then utilize CRISPR/Cas9 gene editing in human inducible pluripotent stem cell-derived VSMCs to identify the VSMC processes altered by the ID3 gene mutation linked to CVD. Lastly, we will determine if this ID3 gene mutation, alone or in combination with other gene mutations are associated with the amount and type of atherosclerotic plaque in human coronary arteries as measured by intravascular ultrasound virtual histology. Results have the potential to lead to novel targeted therapy for atherosclerosis.",Id3 and VSMC in Murine and Human Atherosclerosis,10004164,R01HL148109,"['Alanine', 'Alleles', 'Amino Acids', 'Animals', 'Aorta', 'Apolipoprotein E', 'Arterial Fatty Streak', 'Arteries', 'Atherosclerosis', 'Attenuated', 'Automobile Driving', 'Binding', 'Biology', 'Blood Vessels', 'CRISPR/Cas technology', 'Cause of Death', 'Cell Adhesion Molecules', 'Cell Count', 'Cell Lineage', 'Cell physiology', 'Cells', 'Cellular biology', 'Characteristics', 'Collaborations', 'Coronary Stenosis', 'Coronary artery', 'Cytometry', 'Data', 'Deposition', 'Development', 'Diabetes Mellitus', 'Disease', 'Gene Expression', 'Gene Mutation', 'Genes', 'Genetic Engineering', 'Genetic Polymorphism', 'Genetic Risk', 'Genomics', 'Growth', 'Heart', 'Heritability', 'Histology', 'Human', 'Image', 'Image Analysis', 'Immune', 'Inflammation', 'Inflammation Mediators', 'Inflammatory', 'Iowa', 'Knock-out', 'Lead', 'Lesion', 'Link', 'Measures', 'Medial', 'Mediating', 'Minor', 'Modeling', 'Molecular', 'Morbidity - disease rate', 'Multi-Ethnic Study of Atherosclerosis', 'Multivariate Analysis', 'Mus', 'Necrosis', 'Null Lymphocytes', 'Participant', 'Phenotype', 'Pluripotent Stem Cells', 'Pre-Clinical Model', 'Prevention', 'Process', 'Proteomics', 'Reproducibility', 'Research Design', 'Residual state', 'Reverse Transcriptase Polymerase Chain Reaction', 'Risk', 'Role', 'Series', 'Single Nucleotide Polymorphism', 'Smooth Muscle Myocytes', 'Stimulus', 'System', 'Techniques', 'Testing', 'Thick', 'Threonine', 'Translating', 'Tumor-infiltrating immune cells', 'Ultrasonography', 'Universities', 'Variant', 'Vascular Cell Adhesion Molecule-1', 'Vascular Smooth Muscle', 'calcification', 'cell growth', 'cohort', 'coronary artery calcium', 'coronary plaque', 'dimer', 'genome editing', 'human subject', 'indexing', 'machine learning algorithm', 'macrophage', 'mortality', 'mouse model', 'new therapeutic target', 'novel', 'oxidized low density lipoprotein', 'promoter', 'risk variant', 'transcriptome sequencing', 'vascular smooth muscle cell proliferation', 'virtual']",NHLBI,UNIVERSITY OF VIRGINIA,R01,2020,671017,0.08835582406538901
"Id3 and VSMC in Murine and Human Atherosclerosis Despite major advances in prevention and treatment of atherosclerotic cardiovascular disease (ASCVD), it remains a major cause of deaths worldwide. As ASCVD is a heritable and polygenic disorder, identification of ASCVD-associated single nucleotide polymorphisms (SNP) in humans and elucidation of their effect on ASCVD biology is needed to fully understand and impact on this unmet residual risk. One such human polymorphism in the ID3 gene (rs11574) was associated with ASCVD in 3 distinct human cohorts. Notably, this SNP significantly attenuates ID3 function and studies in pre-clinical models confirm a critical role for ID3 in atheroprotection. We have previously shown that loss of ID3 inhibits vascular smooth muscle cell (VSMC) proliferation and promotes VSMC expression of inflammatory factors, processes linked to increase atherosclerosis. In collaboration with Dr. Gary Owens, we have generated a mouse model with VSMC lineage tracing and VSMC-specific deletion of ID3 to study ID3-dependent VSMC specific changes during the course of lesion development in the context of the whole animal. We have developed a comprehensive CyTOF panel to identify and quantitate key cellular and intracellular changes in VSMC and other lesional cells in the aorta during the course of atherosclerosis development in these mice. To translate murine findings to humans, we have utilized CRISPR/Cas9 genetic engineering to knock out ID3 and produce the full allelic series of rs11574 in human cells and validated a reproducible system for differentiation of human inducible pluripotent stem cells (iPSCs) to VSMC. We will quantify the changes in VSMC phenotype in iPSC-derived VSMC with the full allelic series of rs11574. To further translate murine findings to humans, intravascular ultrasound virtual histology (IVUS-VH) will be measured in human coronary arteries and analyzed with cutting edge image analysis techniques in collaboration with Dr. Milan Sonka at the University of Iowa. As such, our group is uniquely poised to dissect the role of this ASCVD-associated SNP and translate findings to humans. We hypothesize: that loss of ID3 in VSMCs will inhibit VSMC growth and promote a phenotype that exacerbates vessel wall inflammation and atherosclerosis lesion development; that human ID3 encoded by the risk allele aggravates these atherogenic VSMC functions; and that human subjects with the risk allele have larger coronary plaques with increased fatty deposits, necrotic cores and calcification compared to subjects homozygous for the common allele. As atherosclerotic cardiovascular disease (ASCVD) is a heritable and polygenic disorder, identification of ASCVD-associated single nucleotide polymorphisms (SNP) in humans and elucidation of their effect on ASCVD biology is needed to fully understand and further impact on ASCVD morbidity and mortality. Human ID3 gene polymorphism at rs11574 is associated with ASCVD in three unique human cohorts. Preliminary data supports a key role for ID3 in vascular smooth muscle cell biology linked to ASCVD. In the current proposal, we will utilize a novel mouse model with VSMC lineage tracing and specific deletion of ID3 to elucidate the role of ID3 in promoting atherogenic VSMCs. We will then utilize CRISPR/Cas9 gene editing in human inducible pluripotent stem cell-derived VSMCs to identify the VSMC processes altered by the ID3 gene mutation linked to CVD. Lastly, we will determine if this ID3 gene mutation, alone or in combination with other gene mutations are associated with the amount and type of atherosclerotic plaque in human coronary arteries as measured by intravascular ultrasound virtual histology. Results have the potential to lead to novel targeted therapy for atherosclerosis.",Id3 and VSMC in Murine and Human Atherosclerosis,9801966,R01HL148109,"['Alanine', 'Alleles', 'Amino Acids', 'Animals', 'Aorta', 'Apolipoprotein E', 'Arterial Fatty Streak', 'Arteries', 'Atherosclerosis', 'Attenuated', 'Automobile Driving', 'Binding', 'Biology', 'Blood Vessels', 'CRISPR/Cas technology', 'Cause of Death', 'Cell Adhesion Molecules', 'Cell Count', 'Cell Lineage', 'Cell physiology', 'Cells', 'Cellular biology', 'Characteristics', 'Collaborations', 'Coronary Stenosis', 'Coronary artery', 'Cytometry', 'Data', 'Deposition', 'Development', 'Diabetes Mellitus', 'Disease', 'Gene Expression', 'Gene Mutation', 'Genes', 'Genetic Engineering', 'Genetic Polymorphism', 'Genetic Risk', 'Genomics', 'Growth', 'Heart', 'Heritability', 'Histology', 'Human', 'Image', 'Image Analysis', 'Immune', 'Inflammation', 'Inflammation Mediators', 'Inflammatory', 'Iowa', 'Knock-out', 'Lead', 'Lesion', 'Link', 'Measures', 'Medial', 'Mediating', 'Minor', 'Modeling', 'Molecular', 'Morbidity - disease rate', 'Multi-Ethnic Study of Atherosclerosis', 'Multivariate Analysis', 'Mus', 'Necrosis', 'Null Lymphocytes', 'Participant', 'Phenotype', 'Pluripotent Stem Cells', 'Pre-Clinical Model', 'Prevention', 'Process', 'Proteomics', 'Reproducibility', 'Research Design', 'Residual state', 'Reverse Transcriptase Polymerase Chain Reaction', 'Risk', 'Role', 'Series', 'Single Nucleotide Polymorphism', 'Smooth Muscle Myocytes', 'Stimulus', 'System', 'Techniques', 'Testing', 'Thick', 'Threonine', 'Translating', 'Tumor-infiltrating immune cells', 'Ultrasonography', 'Universities', 'Variant', 'Vascular Cell Adhesion Molecule-1', 'Vascular Smooth Muscle', 'calcification', 'cell growth', 'cohort', 'coronary artery calcium', 'coronary plaque', 'dimer', 'genome editing', 'human subject', 'indexing', 'machine learning algorithm', 'macrophage', 'mortality', 'mouse model', 'new therapeutic target', 'novel', 'oxidized low density lipoprotein', 'promoter', 'risk variant', 'transcriptome sequencing', 'vascular smooth muscle cell proliferation', 'virtual']",NHLBI,UNIVERSITY OF VIRGINIA,R01,2019,687622,0.08835582406538901
"Integrated Genomic Discovery and Functional Validation of Colorectal Cancer Loci    DESCRIPTION (provided by applicant): Colorectal carcinoma (CRC) arises from multiple mutations and genomic aberrations in distinct driver cancer genes that that in concert to spur neoplastic development and phenotype. This inherent genetic complexity greatly complicates both personalized diagnosis and treatment. Previously published studies have confined that large numbers of genes will be mutated or subject to genomic aberrations in CRC. A significant and emerging challenge for the post-genomic era is to identify which of these mutated genes are ""driver"" loci that functionally drive colon cancer development, versus ""passenger"" loci without functional relevance. Finally, it is of the highest priority that one forges these genetic observations with correlations of prognosis and clinical outcome. This can only be done if we better understand the unified biological ramifications of the combined and diverse multigenic driver background which act synergistically to promote CRC tumorigenesis. This proposal details an integrated analysis that will rely on the CRC genomic data generated by the Cancer Genome Atlas Project (TCGA) to discover novel candidate CRC genes and study multigenic CRC driver gene co-mutated / dysregulated modules within the genetic context of other drivers and provide biological validation in a powerful in vitro primary culture CRC model which can be engineered for multiple genetic events.  To accomplish these goals, we will develop and implement novel statistical methodologies for the integrative analysis of multiple TCGA genomic and clinical data sets. The goal is to identify and prioritize novel CRC genes either singly or as co-mutated modules in combination with other known ""driver"" CRC genes. We will use the rich TCGA data set to conduct an integrated CRC genomic analysis of point mutations, gene expression, copy number aberrations and methylation data. We will prioritize the discovery of mutations and other genomic aberrations of these novel CRC genes that are associated with specific clinical stages of disease and other clinical parameters.  These statistical and computational studies will then be directly coupled to rapid and robust functional target validation of candidate loci using our rigorously characterized in vitro primary intestinal culture methodology (Gotani et al, Nature Medicine, 2009), in which we have recently established the transforming activity of established CRC loci such as APC, KRAS and TP53. Genetic deletion and retroviral expression of shRNA, cDNA or mutants thereof will be utilized to evaluate putative individual driver loci, as well as combinatorial oncogene modules. This proposal directly addresses fundamental problems in the exploration and translation of novel colorectal cancer gene discovery in the context of clinical data which is available from TCGA. RELEVANCE (See instructions): Colorectal cancer (CRC) represents the third most commonly diagnosed cancer in the United States. This proposal utilizes a fusion of genomic analysis of a large population of patients, mathematical modeling and culture of intestinal fragments to functionally identify genes that are critical for colon cancer development. These studies have implications for generation of novel diagnostic and therapeutic strategies for colon cancer.           n/a",Integrated Genomic Discovery and Functional Validation of Colorectal Cancer Loci,8727268,U01CA151920,"['Address', 'Algorithm Design', 'Algorithms', 'Atlases', 'Bayesian Analysis', 'Biological', 'Biology', 'Clinical', 'Clinical Data', 'Colon Carcinoma', 'Colorectal Cancer', 'Complementary DNA', 'Copy Number Polymorphism', 'Coupled', 'Data', 'Data Set', 'Development', 'Diagnosis', 'Diagnostic', 'Disease', 'Engineering', 'Evaluation', 'Event', 'Future', 'Gene Expression', 'Gene Mutation', 'Generations', 'Genes', 'Genetic', 'Genome', 'Genomics', 'Goals', 'In Vitro', 'Individual', 'Instruction', 'Intestines', 'KRAS2 gene', 'Large Intestine Carcinoma', 'Literature', 'Machine Learning', 'Malignant Neoplasms', 'Measurement', 'Medicine', 'Methodology', 'Methods', 'Methylation', 'Modeling', 'Mutate', 'Mutation', 'Nature', 'Oncogenes', 'Oncologist', 'Outcome', 'Phenotype', 'Point Mutation', 'Principal Investigator', 'Publications', 'Publishing', 'Research', 'Somatic Mutation', 'Staging', 'Statistical Study', 'Surveys', 'Systems Biology', 'TP53 gene', 'Technology', 'The Cancer Genome Atlas', 'Translations', 'United States', 'Validation', 'Variant', 'authority', 'cancer diagnosis', 'cancer genome', 'cancer genomics', 'candidate validation', 'clinical phenotype', 'combinatorial', 'computer studies', 'exome', 'exome sequencing', 'experience', 'forging', 'gene discovery', 'intestinal epithelium', 'mathematical model', 'mutant', 'neoplastic', 'novel', 'novel diagnostics', 'novel strategies', 'novel therapeutics', 'outcome forecast', 'patient population', 'segregation', 'small hairpin RNA', 'statistics', 'tumorigenesis']",NCI,STANFORD UNIVERSITY,U01,2014,523201,0.14113247357618078
"Integrated Genomic Discovery and Functional Validation of Colorectal Cancer Loci    DESCRIPTION (provided by applicant): Colorectal carcinoma (CRC) arises from multiple mutations and genomic aberrations in distinct driver cancer genes that that in concert to spur neoplastic development and phenotype. This inherent genetic complexity greatly complicates both personalized diagnosis and treatment. Previously published studies have confined that large numbers of genes will be mutated or subject to genomic aberrations in CRC. A significant and emerging challenge for the post-genomic era is to identify which of these mutated genes are ""driver"" loci that functionally drive colon cancer development, versus ""passenger"" loci without functional relevance. Finally, it is of the highest priority that one forges these genetic observations with correlations of prognosis and clinical outcome. This can only be done if we better understand the unified biological ramifications of the combined and diverse multigenic driver background which act synergistically to promote CRC tumorigenesis. This proposal details an integrated analysis that will rely on the CRC genomic data generated by the Cancer Genome Atlas Project (TCGA) to discover novel candidate CRC genes and study multigenic CRC driver gene co-mutated / dysregulated modules within the genetic context of other drivers and provide biological validation in a powerful in vitro primary culture CRC model which can be engineered for multiple genetic events.  To accomplish these goals, we will develop and implement novel statistical methodologies for the integrative analysis of multiple TCGA genomic and clinical data sets. The goal is to identify and prioritize novel CRC genes either singly or as co-mutated modules in combination with other known ""driver"" CRC genes. We will use the rich TCGA data set to conduct an integrated CRC genomic analysis of point mutations, gene expression, copy number aberrations and methylation data. We will prioritize the discovery of mutations and other genomic aberrations of these novel CRC genes that are associated with specific clinical stages of disease and other clinical parameters.  These statistical and computational studies will then be directly coupled to rapid and robust functional target validation of candidate loci using our rigorously characterized in vitro primary intestinal culture methodology (Gotani et al, Nature Medicine, 2009), in which we have recently established the transforming activity of established CRC loci such as APC, KRAS and TP53. Genetic deletion and retroviral expression of shRNA, cDNA or mutants thereof will be utilized to evaluate putative individual driver loci, as well as combinatorial oncogene modules. This proposal directly addresses fundamental problems in the exploration and translation of novel colorectal cancer gene discovery in the context of clinical data which is available from TCGA. RELEVANCE (See instructions): Colorectal cancer (CRC) represents the third most commonly diagnosed cancer in the United States. This proposal utilizes a fusion of genomic analysis of a large population of patients, mathematical modeling and culture of intestinal fragments to functionally identify genes that are critical for colon cancer development. These studies have implications for generation of novel diagnostic and therapeutic strategies for colon cancer.           n/a",Integrated Genomic Discovery and Functional Validation of Colorectal Cancer Loci,8534039,U01CA151920,"['Address', 'Algorithms', 'Atlases', 'Bayesian Analysis', 'Biological', 'Biology', 'Clinical', 'Clinical Data', 'Colon Carcinoma', 'Colorectal Cancer', 'Complementary DNA', 'Copy Number Polymorphism', 'Coupled', 'Data', 'Data Set', 'Development', 'Diagnosis', 'Diagnostic', 'Disease', 'Engineering', 'Evaluation', 'Event', 'Future', 'Gene Expression', 'Gene Mutation', 'Generations', 'Genes', 'Genetic', 'Genome', 'Genomics', 'Goals', 'In Vitro', 'Individual', 'Instruction', 'Intestines', 'KRAS2 gene', 'Large Intestine Carcinoma', 'Literature', 'Machine Learning', 'Malignant Neoplasms', 'Measurement', 'Medicine', 'Methodology', 'Methods', 'Methylation', 'Modeling', 'Mutate', 'Mutation', 'Nature', 'Oncogenes', 'Oncologist', 'Outcome', 'Phenotype', 'Point Mutation', 'Principal Investigator', 'Publications', 'Publishing', 'Research', 'Somatic Mutation', 'Staging', 'Statistical Study', 'Surveys', 'Systems Biology', 'TP53 gene', 'Technology', 'The Cancer Genome Atlas', 'Translations', 'United States', 'Validation', 'Variant', 'authority', 'cancer diagnosis', 'cancer genome', 'cancer genomics', 'candidate validation', 'clinical phenotype', 'combinatorial', 'computer studies', 'design', 'exome', 'exome sequencing', 'experience', 'forging', 'gene discovery', 'intestinal epithelium', 'mathematical model', 'mutant', 'neoplastic', 'novel', 'novel diagnostics', 'novel strategies', 'novel therapeutics', 'outcome forecast', 'patient population', 'segregation', 'small hairpin RNA', 'statistics', 'tumorigenesis']",NCI,STANFORD UNIVERSITY,U01,2013,507962,0.14113247357618078
"Integrated Genomic Discovery and Functional Validation of Colorectal Cancer Loci    DESCRIPTION (provided by applicant): Colorectal carcinoma (CRC) arises from multiple mutations and genomic aberrations in distinct driver cancer genes that that in concert to spur neoplastic development and phenotype. This inherent genetic complexity greatly complicates both personalized diagnosis and treatment. Previously published studies have confined that large numbers of genes will be mutated or subject to genomic aberrations in CRC. A significant and emerging challenge for the post-genomic era is to identify which of these mutated genes are ""driver"" loci that functionally drive colon cancer development, versus ""passenger"" loci without functional relevance. Finally, it is of the highest priority that one forges these genetic observations with correlations of prognosis and clinical outcome. This can only be done if we better understand the unified biological ramifications of the combined and diverse multigenic driver background which act synergistically to promote CRC tumorigenesis. This proposal details an integrated analysis that will rely on the CRC genomic data generated by the Cancer Genome Atlas Project (TCGA) to discover novel candidate CRC genes and study multigenic CRC driver gene co-mutated / dysregulated modules within the genetic context of other drivers and provide biological validation in a powerful in vitro primary culture CRC model which can be engineered for multiple genetic events.  To accomplish these goals, we will develop and implement novel statistical methodologies for the integrative analysis of multiple TCGA genomic and clinical data sets. The goal is to identify and prioritize novel CRC genes either singly or as co-mutated modules in combination with other known ""driver"" CRC genes. We will use the rich TCGA data set to conduct an integrated CRC genomic analysis of point mutations, gene expression, copy number aberrations and methylation data. We will prioritize the discovery of mutations and other genomic aberrations of these novel CRC genes that are associated with specific clinical stages of disease and other clinical parameters.  These statistical and computational studies will then be directly coupled to rapid and robust functional target validation of candidate loci using our rigorously characterized in vitro primary intestinal culture methodology (Gotani et al, Nature Medicine, 2009), in which we have recently established the transforming activity of established CRC loci such as APC, KRAS and TP53. Genetic deletion and retroviral expression of shRNA, cDNA or mutants thereof will be utilized to evaluate putative individual driver loci, as well as combinatorial oncogene modules. This proposal directly addresses fundamental problems in the exploration and translation of novel colorectal cancer gene discovery in the context of clinical data which is available from TCGA. RELEVANCE (See instructions): Colorectal cancer (CRC) represents the third most commonly diagnosed cancer in the United States. This proposal utilizes a fusion of genomic analysis of a large population of patients, mathematical modeling and culture of intestinal fragments to functionally identify genes that are critical for colon cancer development. These studies have implications for generation of novel diagnostic and therapeutic strategies for colon cancer.           n/a",Integrated Genomic Discovery and Functional Validation of Colorectal Cancer Loci,8329613,U01CA151920,"['Address', 'Algorithms', 'Atlases', 'Bayesian Analysis', 'Biological', 'Biology', 'Clinical', 'Clinical Data', 'Colon Carcinoma', 'Colorectal Cancer', 'Complementary DNA', 'Copy Number Polymorphism', 'Coupled', 'Data', 'Data Set', 'Development', 'Diagnosis', 'Diagnostic', 'Disease', 'Engineering', 'Evaluation', 'Event', 'Future', 'Gene Expression', 'Gene Mutation', 'Generations', 'Genes', 'Genetic', 'Genome', 'Genomics', 'Goals', 'In Vitro', 'Individual', 'Instruction', 'Intestines', 'KRAS2 gene', 'Large Intestine Carcinoma', 'Literature', 'Machine Learning', 'Malignant Neoplasms', 'Measurement', 'Medicine', 'Methodology', 'Methods', 'Methylation', 'Modeling', 'Mutate', 'Mutation', 'Nature', 'Oncogenes', 'Oncologist', 'Outcome', 'Phenotype', 'Point Mutation', 'Principal Investigator', 'Publications', 'Publishing', 'Research', 'Somatic Mutation', 'Staging', 'Statistical Study', 'Surveys', 'Systems Biology', 'TP53 gene', 'Technology', 'The Cancer Genome Atlas', 'Translations', 'United States', 'Validation', 'Variant', 'authority', 'cancer diagnosis', 'cancer genome', 'cancer genomics', 'candidate validation', 'clinical phenotype', 'combinatorial', 'computer studies', 'design', 'exome', 'experience', 'forging', 'gene discovery', 'intestinal epithelium', 'mathematical model', 'mutant', 'neoplastic', 'novel', 'novel diagnostics', 'novel strategies', 'novel therapeutics', 'outcome forecast', 'patient population', 'segregation', 'small hairpin RNA', 'statistics', 'tumorigenesis']",NCI,STANFORD UNIVERSITY,U01,2012,541494,0.14113247357618078
"Integrated Genomic Discovery and Functional Validation of Colorectal Cancer Loci    DESCRIPTION (provided by applicant): Colorectal carcinoma (CRC) arises from multiple mutations and genomic aberrations in distinct driver cancer genes that that in concert to spur neoplastic development and phenotype. This inherent genetic complexity greatly complicates both personalized diagnosis and treatment. Previously published studies have confined that large numbers of genes will be mutated or subject to genomic aberrations in CRC. A significant and emerging challenge for the post-genomic era is to identify which of these mutated genes are ""driver"" loci that functionally drive colon cancer development, versus ""passenger"" loci without functional relevance. Finally, it is of the highest priority that one forges these genetic observations with correlations of prognosis and clinical outcome. This can only be done if we better understand the unified biological ramifications of the combined and diverse multigenic driver background which act synergistically to promote CRC tumorigenesis. This proposal details an integrated analysis that will rely on the CRC genomic data generated by the Cancer Genome Atlas Project (TCGA) to discover novel candidate CRC genes and study multigenic CRC driver gene co-mutated / dysregulated modules within the genetic context of other drivers and provide biological validation in a powerful in vitro primary culture CRC model which can be engineered for multiple genetic events.  To accomplish these goals, we will develop and implement novel statistical methodologies for the integrative analysis of multiple TCGA genomic and clinical data sets. The goal is to identify and prioritize novel CRC genes either singly or as co-mutated modules in combination with other known ""driver"" CRC genes. We will use the rich TCGA data set to conduct an integrated CRC genomic analysis of point mutations, gene expression, copy number aberrations and methylation data. We will prioritize the discovery of mutations and other genomic aberrations of these novel CRC genes that are associated with specific clinical stages of disease and other clinical parameters.  These statistical and computational studies will then be directly coupled to rapid and robust functional target validation of candidate loci using our rigorously characterized in vitro primary intestinal culture methodology (Gotani et al, Nature Medicine, 2009), in which we have recently established the transforming activity of established CRC loci such as APC, KRAS and TP53. Genetic deletion and retroviral expression of shRNA, cDNA or mutants thereof will be utilized to evaluate putative individual driver loci, as well as combinatorial oncogene modules. This proposal directly addresses fundamental problems in the exploration and translation of novel colorectal cancer gene discovery in the context of clinical data which is available from TCGA. RELEVANCE (See instructions): Colorectal cancer (CRC) represents the third most commonly diagnosed cancer in the United States. This proposal utilizes a fusion of genomic analysis of a large population of patients, mathematical modeling and culture of intestinal fragments to functionally identify genes that are critical for colon cancer development. These studies have implications for generation of novel diagnostic and therapeutic strategies for colon cancer.           n/a",Integrated Genomic Discovery and Functional Validation of Colorectal Cancer Loci,8178935,U01CA151920,"['Address', 'Algorithms', 'Atlases', 'Bayesian Analysis', 'Biological', 'Biology', 'Clinical', 'Clinical Data', 'Colon Carcinoma', 'Colorectal Cancer', 'Complementary DNA', 'Copy Number Polymorphism', 'Coupled', 'Data', 'Data Set', 'Development', 'Diagnosis', 'Diagnostic', 'Disease', 'Engineering', 'Evaluation', 'Event', 'Future', 'Gene Expression', 'Gene Mutation', 'Generations', 'Genes', 'Genetic', 'Genome', 'Genomics', 'Goals', 'In Vitro', 'Individual', 'Instruction', 'Intestines', 'KRAS2 gene', 'Large Intestine Carcinoma', 'Literature', 'Machine Learning', 'Malignant Neoplasms', 'Measurement', 'Medicine', 'Methodology', 'Methods', 'Methylation', 'Modeling', 'Mutate', 'Mutation', 'Nature', 'Oncogenes', 'Oncologist', 'Outcome', 'Phenotype', 'Point Mutation', 'Principal Investigator', 'Publications', 'Publishing', 'Research', 'Somatic Mutation', 'Staging', 'Statistical Study', 'Surveys', 'Systems Biology', 'TP53 gene', 'Technology', 'The Cancer Genome Atlas', 'Translations', 'United States', 'Validation', 'Variant', 'authority', 'cancer diagnosis', 'cancer genome', 'cancer genomics', 'candidate validation', 'clinical phenotype', 'combinatorial', 'computer studies', 'design', 'exome', 'experience', 'forging', 'gene discovery', 'intestinal epithelium', 'mathematical model', 'mutant', 'neoplastic', 'novel', 'novel diagnostics', 'novel strategies', 'novel therapeutics', 'outcome forecast', 'patient population', 'segregation', 'small hairpin RNA', 'statistics', 'tumorigenesis']",NCI,STANFORD UNIVERSITY,U01,2011,537462,0.14113247357618078
"Integrated Genomic Discovery and Functional Validation of Colorectal Cancer Loci DESCRIPTION (provided by applicant): Colorectal carcinoma (CRC) arises from multiple mutations and genomic aberrations in distinct driver cancer genes that that in concert to spur neoplastic development and phenotype. This inherent genetic complexity greatly complicates both personalized diagnosis and treatment. Previously published studies have confined that large numbers of genes will be mutated or subject to genomic aberrations in CRC. A significant and emerging challenge for the post-genomic era is to identify which of these mutated genes are ""driver"" loci that functionally drive colon cancer development, versus ""passenger"" loci without functional relevance. Finally, it is of the highest priority that one forges these genetic observations with correlations of prognosis and clinical outcome. This can only be done if we better understand the unified biological ramifications of the combined and diverse multigenic driver background which act synergistically to promote CRC tumorigenesis. This proposal details an integrated analysis that will rely on the CRC genomic data generated by the Cancer Genome Atlas Project (TCGA) to discover novel candidate CRC genes and study multigenic CRC driver gene co-mutated / dysregulated modules within the genetic context of other drivers and provide biological validation in a powerful in vitro primary culture CRC model which can be engineered for multiple genetic events.  To accomplish these goals, we will develop and implement novel statistical methodologies for the integrative analysis of multiple TCGA genomic and clinical data sets. The goal is to identify and prioritize novel CRC genes either singly or as co-mutated modules in combination with other known ""driver"" CRC genes. We will use the rich TCGA data set to conduct an integrated CRC genomic analysis of point mutations, gene expression, copy number aberrations and methylation data. We will prioritize the discovery of mutations and other genomic aberrations of these novel CRC genes that are associated with specific clinical stages of disease and other clinical parameters.  These statistical and computational studies will then be directly coupled to rapid and robust functional target validation of candidate loci using our rigorously characterized in vitro primary intestinal culture methodology (Gotani et al, Nature Medicine, 2009), in which we have recently established the transforming activity of established CRC loci such as APC, KRAS and TP53. Genetic deletion and retroviral expression of shRNA, cDNA or mutants thereof will be utilized to evaluate putative individual driver loci, as well as combinatorial oncogene modules. This proposal directly addresses fundamental problems in the exploration and translation of novel colorectal cancer gene discovery in the context of clinical data which is available from TCGA. RELEVANCE (See instructions): Colorectal cancer (CRC) represents the third most commonly diagnosed cancer in the United States. This proposal utilizes a fusion of genomic analysis of a large population of patients, mathematical modeling and culture of intestinal fragments to functionally identify genes that are critical for colon cancer development. These studies have implications for generation of novel diagnostic and therapeutic strategies for colon cancer. n/a",Integrated Genomic Discovery and Functional Validation of Colorectal Cancer Loci,8916038,U01CA151920,"['Address', 'Algorithm Design', 'Algorithms', 'Atlases', 'Bayesian Analysis', 'Biological', 'Biology', 'Clinical', 'Clinical Data', 'Colon Carcinoma', 'Colorectal Cancer', 'Complementary DNA', 'Copy Number Polymorphism', 'Coupled', 'Data', 'Data Set', 'Development', 'Diagnosis', 'Diagnostic', 'Disease', 'Engineering', 'Evaluation', 'Event', 'Future', 'Gene Expression', 'Gene Mutation', 'Generations', 'Genes', 'Genetic', 'Genomics', 'Goals', 'In Vitro', 'Individual', 'Instruction', 'Intestines', 'KRAS2 gene', 'Large Intestine Carcinoma', 'Literature', 'Machine Learning', 'Malignant Neoplasms', 'Measurement', 'Medicine', 'Methodology', 'Methods', 'Methylation', 'Modeling', 'Mutate', 'Mutation', 'Nature', 'Oncogenes', 'Oncologist', 'Outcome', 'Phenotype', 'Point Mutation', 'Principal Investigator', 'Publications', 'Publishing', 'Research', 'Somatic Mutation', 'Staging', 'Statistical Study', 'Surveys', 'Systems Biology', 'TP53 gene', 'Technology', 'The Cancer Genome Atlas', 'Translations', 'United States', 'Validation', 'Variant', 'authority', 'cancer diagnosis', 'cancer genome', 'cancer genomics', 'candidate validation', 'clinical phenotype', 'combinatorial', 'computer studies', 'exome', 'exome sequencing', 'experience', 'forging', 'gene discovery', 'genome-wide', 'intestinal epithelium', 'mathematical model', 'mutant', 'neoplastic', 'novel', 'novel diagnostics', 'novel strategies', 'novel therapeutics', 'outcome forecast', 'patient population', 'segregation', 'small hairpin RNA', 'statistics', 'tumorigenesis']",NCI,STANFORD UNIVERSITY,U01,2015,538250,0.14113247357618078
"A novel human T-cell platform to define biological effects of genome editing PROJECT SUMMARY Genome editing technologies have extraordinary potential as new genomic medicines that address underlying genetic causes of human disease; however, it remains challenging to predict their long-term safety, because we do not know the consequences of potential side effects of genome editing such as off-target mutations or immunogenicity. Our long-term goal is to understand and predict such unintended biological effects to advance the development of safe and effective therapies. T-cells are an ideal cellular model because: 1) they are highly relevant as the most widely used cells for development of therapeutic genome editing strategies (such as cell-based treatments for HIV and cancer) and 2) mature T-cells encode a diverse T-cell receptor repertoire that can be exploited as built-in cellular barcodes for quantifying clonal expansion or depletion in response to specific treatments. We, therefore, propose the following specific aims: 1) to predict which unintended editing sites have biological effects on human T-cells by integrating large-scale genome-wide activity and epigenomic profiles with state-of-the-art deep learning models and 2) to develop a human primary T-cell platform to detect functional effects of genome editing by measuring clonal representation, off-target mutation frequencies, immunogenicity, or gene expression. If successful, our experimental and predictive framework will profoundly increase confidence in the safety of the next generation of promising genome editing therapies. PROJECT NARRATIVE Genome editing technologies have extraordinary potential as the basis of new genomic medicines that address the underlying genetic causes of human disease; however, it is challenging to predict their long-term safety, because we do not know the consequences of potential unintended side effects of genome editing such as off-target mutations or immunogenicity. To define the biological effects of genome editing strategies, we will develop a human primary T-cell platform to sensitively detect functional effects coupled with an empirically-trained artificial intelligence models to predict them. Together, our platform will significantly improve confidence in safety assessments of promising genome editing therapeutics.",A novel human T-cell platform to define biological effects of genome editing,10016298,U01AI157189,"['Address', 'Advanced Development', 'Adverse effects', 'Affect', 'Artificial Intelligence', 'Bar Codes', 'Benign', 'Biochemical', 'Bioinformatics', 'Biological', 'Biological Assay', 'Cell model', 'Cell physiology', 'Cells', 'Chromatin', 'Clonal Expansion', 'Complex', 'Coupled', 'DNA Methylation', 'Detection', 'Engineering', 'Epitopes', 'Frequencies', 'Gene Expression', 'Genes', 'Genetic', 'Genetic Diseases', 'Genetic Transcription', 'Genetic Variation', 'Genomic medicine', 'Genomics', 'Goals', 'HIV', 'Human', 'Human Genetics', 'Human Genome', 'Immunologic Deficiency Syndromes', 'In Vitro', 'Inherited', 'Malignant Neoplasms', 'Maps', 'Mature T-Lymphocyte', 'Measures', 'Methods', 'Modeling', 'Mutation', 'Oncogenic', 'Organizational Change', 'Outcome', 'Peptide Library', 'Peripheral Blood Mononuclear Cell', 'Phenotype', 'Population', 'Proto-Oncogenes', 'Regulatory Element', 'Retroviral Vector', 'Ribonucleoproteins', 'Safety', 'Site', 'Site-Directed Mutagenesis', 'Standardization', 'Streptococcus pyogenes', 'T cell response', 'T-Cell Proliferation', 'T-Cell Receptor', 'T-Lymphocyte', 'T-cell receptor repertoire', 'Technology', 'Testing', 'Therapeutic', 'Training', 'Variant', 'adaptive immune response', 'adverse outcome', 'base', 'comparative genomics', 'cytokine', 'deep learning', 'effective therapy', 'epigenomics', 'functional genomics', 'gene therapy', 'genome editing', 'genome-wide', 'genotoxicity', 'histone modification', 'human disease', 'immunogenic', 'immunogenicity', 'improved', 'in vivo', 'machine learning method', 'next generation', 'novel', 'novel therapeutics', 'off-target mutation', 'off-target site', 'response', 'safety assessment', 'safety testing', 'side effect', 'therapeutic development', 'therapeutic gene', 'therapeutic genome editing', 'transcriptome sequencing']",NIAID,ST. JUDE CHILDREN'S RESEARCH HOSPITAL,U01,2020,610710,0.12325170204758766
"Predicting Transcriptional and Epigenetic Networks in Cancer from Sequencing Data Limitless replicative potential is a key hallmark of cancer and critically depends on telomere maintenance. Many cancers thus aberrantly reactivate the telomerase reverse transcriptase (TERT), a catalytic subunit of the telomerase complex that elongates telomere. It has been recently discovered that this common path to immortality in multiple cancers is through two activating point mutations in the TERT promoter (TERTp), found in more than 50 different cancer types, often at strikingly high frequencies, e.g. roughly 83% in glioblastomas (GBM) and 71% in melanomas. In the previous funding period, the PI has identified the molecular function of these highly recurrent mutations, demonstrating that the transcription factor (TF) GABP binds the mutant TERTp with exquisite specificity, but not the wild-type TERTp. The high prevalence of TERTp mutations across multiple cancer types and the selectivity of GABP recruitment to mutant TERTp thus provide an unprecedented opportunity for treating a large number of cancer patients with minimal toxicity to healthy cells. Despite the clear significance of this opportunity, however, several important questions surrounding the molecular functions and modulators of TERTp mutations remain poorly understood, hindering the development of effective and safe therapeutic strategies.  Our long-term goal is to establish a rigorous computational framework for understanding the aberrant transcriptional and epigenetic networks in cancers and to apply the resulting knowledge to devise novel therapeutic strategies that account for the genetic background of individual patients and that can a priori predict and avoid potential resistance mechanisms. The objective of our current renewal proposal is to develop powerful computational methods for transforming our knowledge about the non-coding TERTp mutations into an effective and safe molecular target. At the same time, the resulting methods will help resolve several outstanding challenges in the field of transcriptional gene regulation and have broad applications in cancer genomics. We will accomplish our objective my pursuing the following Aims: (1) Develop and test a computational framework for inferring sequence features that determine the distinct and shared binding patterns of paralogous TFs; (2) Develop and validate integrative tools for discovering the molecular basis of genetic interactions between germline variations and oncogenic mutations; (3) Develop and apply computational methods for studying the role of DNA helical phase between adjacent binding motifs in recruiting ETS factors to chromatin; (4) Perform a systematic genomic characterization of the effects of knocking out GABPB1L in TERTp-mutant cancer cells and healthy cells. The results of this proposal will have a broad impact on cancer research by providing powerful tools for studying paralogous oncogenic TFs and revealing novel insights into a highly promising therapeutic strategy. The proposed research will provide computational and bioinformatic resources for studying the binding pattern of paralogous oncogenic transcription factors. It will provide a computational framework for inferring the function of non-coding regulatory mutations and studying their interaction with common genetic variants. As an important application, we will systematically analyze a novel therapeutic strategy that has the potential to treat effectively a large number of patients across multiple cancer types harboring the recently discovered TERT promoter mutations.",Predicting Transcriptional and Epigenetic Networks in Cancer from Sequencing Data,9831048,R01CA163336,"['Address', 'Binding', 'Binding Sites', 'Cancer Patient', 'Cells', 'Chromatin', 'Complex', 'Computing Methodologies', 'DNA', 'DNA Sequence Alteration', 'Data', 'Development', 'Drug resistance', 'Epigenetic Process', 'Family', 'Family member', 'Frequencies', 'Funding', 'Gene Expression Regulation', 'Genetic', 'Genetic Transcription', 'Genome', 'Genomics', 'Glioblastoma', 'Goals', 'High Prevalence', 'Individual', 'Knock-out', 'Knowledge', 'Link', 'Machine Learning', 'Malignant Neoplasms', 'Mediating', 'Methods', 'Molecular', 'Molecular Target', 'Mutation', 'Nature', 'Oncogenic', 'Patients', 'Pattern', 'Phase', 'Point Mutation', 'Protein Isoforms', 'RNA-Directed DNA Polymerase', 'Recurrence', 'Research', 'Role', 'Somatic Mutation', 'Specificity', 'TERT gene', 'Techniques', 'Telomerase', 'Telomere Maintenance', 'Testing', 'Therapeutic', 'Time', 'Toxic effect', 'Transcriptional Regulation', 'Untranslated RNA', 'Validation', 'Variant', 'Work', 'anticancer research', 'base', 'bioinformatics resource', 'c-myc Genes', 'cancer cell', 'cancer genomics', 'cancer type', 'computer framework', 'computing resources', 'deep learning', 'dimer', 'genetic variant', 'genome-wide', 'individual patient', 'insight', 'knowledge of results', 'melanoma', 'member', 'mutant', 'novel', 'novel therapeutics', 'promoter', 'recruit', 'resistance mechanism', 'telomere', 'therapeutic target', 'tool', 'transcription factor', 'treatment response']",NCI,UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN,R01,2020,326848,0.24712543287955582
"Predicting Transcriptional and Epigenetic Networks in Cancer from Sequencing Data Limitless replicative potential is a key hallmark of cancer and critically depends on telomere maintenance. Many cancers thus aberrantly reactivate the telomerase reverse transcriptase (TERT), a catalytic subunit of the telomerase complex that elongates telomere. It has been recently discovered that this common path to immortality in multiple cancers is through two activating point mutations in the TERT promoter (TERTp), found in more than 50 different cancer types, often at strikingly high frequencies, e.g. roughly 83% in glioblastomas (GBM) and 71% in melanomas. In the previous funding period, the PI has identified the molecular function of these highly recurrent mutations, demonstrating that the transcription factor (TF) GABP binds the mutant TERTp with exquisite specificity, but not the wild-type TERTp. The high prevalence of TERTp mutations across multiple cancer types and the selectivity of GABP recruitment to mutant TERTp thus provide an unprecedented opportunity for treating a large number of cancer patients with minimal toxicity to healthy cells. Despite the clear significance of this opportunity, however, several important questions surrounding the molecular functions and modulators of TERTp mutations remain poorly understood, hindering the development of effective and safe therapeutic strategies.  Our long-term goal is to establish a rigorous computational framework for understanding the aberrant transcriptional and epigenetic networks in cancers and to apply the resulting knowledge to devise novel therapeutic strategies that account for the genetic background of individual patients and that can a priori predict and avoid potential resistance mechanisms. The objective of our current renewal proposal is to develop powerful computational methods for transforming our knowledge about the non-coding TERTp mutations into an effective and safe molecular target. At the same time, the resulting methods will help resolve several outstanding challenges in the field of transcriptional gene regulation and have broad applications in cancer genomics. We will accomplish our objective my pursuing the following Aims: (1) Develop and test a computational framework for inferring sequence features that determine the distinct and shared binding patterns of paralogous TFs; (2) Develop and validate integrative tools for discovering the molecular basis of genetic interactions between germline variations and oncogenic mutations; (3) Develop and apply computational methods for studying the role of DNA helical phase between adjacent binding motifs in recruiting ETS factors to chromatin; (4) Perform a systematic genomic characterization of the effects of knocking out GABPB1L in TERTp-mutant cancer cells and healthy cells. The results of this proposal will have a broad impact on cancer research by providing powerful tools for studying paralogous oncogenic TFs and revealing novel insights into a highly promising therapeutic strategy. The proposed research will provide computational and bioinformatic resources for studying the binding pattern of paralogous oncogenic transcription factors. It will provide a computational framework for inferring the function of non-coding regulatory mutations and studying their interaction with common genetic variants. As an important application, we will systematically analyze a novel therapeutic strategy that has the potential to treat effectively a large number of patients across multiple cancer types harboring the recently discovered TERT promoter mutations.",Predicting Transcriptional and Epigenetic Networks in Cancer from Sequencing Data,9609431,R01CA163336,"['Address', 'Binding', 'Binding Sites', 'Cancer Patient', 'Cells', 'Chromatin', 'Complex', 'Computing Methodologies', 'DNA', 'DNA Sequence Alteration', 'Data', 'Development', 'Drug resistance', 'Epigenetic Process', 'Family', 'Family member', 'Frequencies', 'Funding', 'Gene Expression Regulation', 'Genetic', 'Genetic Transcription', 'Genome', 'Genomics', 'Glioblastoma', 'Goals', 'High Prevalence', 'Individual', 'Knock-out', 'Knowledge', 'Link', 'Machine Learning', 'Malignant Neoplasms', 'Mediating', 'Methods', 'Molecular', 'Molecular Target', 'Mutation', 'Nature', 'Oncogenic', 'Patients', 'Pattern', 'Phase', 'Point Mutation', 'Protein Isoforms', 'RNA-Directed DNA Polymerase', 'Recurrence', 'Research', 'Role', 'Somatic Mutation', 'Specificity', 'TERT gene', 'Techniques', 'Telomerase', 'Telomere Maintenance', 'Testing', 'Therapeutic', 'Time', 'Toxic effect', 'Transcriptional Regulation', 'Untranslated RNA', 'Validation', 'Variant', 'Work', 'anticancer research', 'base', 'bioinformatics resource', 'c-myc Genes', 'cancer cell', 'cancer genomics', 'cancer type', 'computer framework', 'computing resources', 'deep learning', 'dimer', 'genetic variant', 'genome-wide', 'individual patient', 'insight', 'knowledge of results', 'melanoma', 'member', 'mutant', 'novel', 'novel therapeutics', 'promoter', 'recruit', 'resistance mechanism', 'telomere', 'therapeutic target', 'tool', 'transcription factor', 'treatment response']",NCI,UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN,R01,2019,317385,0.24712543287955582
"Predicting Transcriptional and Epigenetic Networks in Cancer from Sequencing Data Limitless replicative potential is a key hallmark of cancer and critically depends on telomere maintenance. Many cancers thus aberrantly reactivate the telomerase reverse transcriptase (TERT), a catalytic subunit of the telomerase complex that elongates telomere. It has been recently discovered that this common path to immortality in multiple cancers is through two activating point mutations in the TERT promoter (TERTp), found in more than 50 different cancer types, often at strikingly high frequencies, e.g. roughly 83% in glioblastomas (GBM) and 71% in melanomas. In the previous funding period, the PI has identified the molecular function of these highly recurrent mutations, demonstrating that the transcription factor (TF) GABP binds the mutant TERTp with exquisite specificity, but not the wild-type TERTp. The high prevalence of TERTp mutations across multiple cancer types and the selectivity of GABP recruitment to mutant TERTp thus provide an unprecedented opportunity for treating a large number of cancer patients with minimal toxicity to healthy cells. Despite the clear significance of this opportunity, however, several important questions surrounding the molecular functions and modulators of TERTp mutations remain poorly understood, hindering the development of effective and safe therapeutic strategies.  Our long-term goal is to establish a rigorous computational framework for understanding the aberrant transcriptional and epigenetic networks in cancers and to apply the resulting knowledge to devise novel therapeutic strategies that account for the genetic background of individual patients and that can a priori predict and avoid potential resistance mechanisms. The objective of our current renewal proposal is to develop powerful computational methods for transforming our knowledge about the non-coding TERTp mutations into an effective and safe molecular target. At the same time, the resulting methods will help resolve several outstanding challenges in the field of transcriptional gene regulation and have broad applications in cancer genomics. We will accomplish our objective my pursuing the following Aims: (1) Develop and test a computational framework for inferring sequence features that determine the distinct and shared binding patterns of paralogous TFs; (2) Develop and validate integrative tools for discovering the molecular basis of genetic interactions between germline variations and oncogenic mutations; (3) Develop and apply computational methods for studying the role of DNA helical phase between adjacent binding motifs in recruiting ETS factors to chromatin; (4) Perform a systematic genomic characterization of the effects of knocking out GABPB1L in TERTp-mutant cancer cells and healthy cells. The results of this proposal will have a broad impact on cancer research by providing powerful tools for studying paralogous oncogenic TFs and revealing novel insights into a highly promising therapeutic strategy. The proposed research will provide computational and bioinformatic resources for studying the binding pattern of paralogous oncogenic transcription factors. It will provide a computational framework for inferring the function of non-coding regulatory mutations and studying their interaction with common genetic variants. As an important application, we will systematically analyze a novel therapeutic strategy that has the potential to treat effectively a large number of patients across multiple cancer types harboring the recently discovered TERT promoter mutations.",Predicting Transcriptional and Epigenetic Networks in Cancer from Sequencing Data,9472091,R01CA163336,"['Address', 'Binding', 'Binding Sites', 'Cancer Patient', 'Cells', 'Chromatin', 'Complex', 'Computing Methodologies', 'DNA', 'DNA Sequence Alteration', 'Data', 'Development', 'Drug resistance', 'Epigenetic Process', 'Family', 'Family member', 'Frequencies', 'Funding', 'Gene Expression Regulation', 'Genetic', 'Genetic Transcription', 'Genome', 'Genomics', 'Glioblastoma', 'Goals', 'High Prevalence', 'Individual', 'Knock-out', 'Knowledge', 'Link', 'Machine Learning', 'Malignant Neoplasms', 'Mediating', 'Methods', 'Molecular', 'Molecular Target', 'Mutation', 'Nature', 'Oncogenic', 'Patients', 'Pattern', 'Phase', 'Point Mutation', 'Protein Isoforms', 'RNA-Directed DNA Polymerase', 'Recurrence', 'Research', 'Role', 'Somatic Mutation', 'Specificity', 'TERT gene', 'Techniques', 'Telomerase', 'Telomere Maintenance', 'Testing', 'Therapeutic', 'Time', 'Toxic effect', 'Transcriptional Regulation', 'Untranslated RNA', 'Validation', 'Variant', 'Work', 'anticancer research', 'base', 'bioinformatics resource', 'c-myc Genes', 'cancer cell', 'cancer genomics', 'cancer type', 'computer framework', 'computing resources', 'deep learning', 'dimer', 'genetic variant', 'genome-wide', 'individual patient', 'insight', 'knowledge of results', 'melanoma', 'member', 'mutant', 'novel', 'novel therapeutics', 'promoter', 'recruit', 'resistance mechanism', 'telomere', 'therapeutic target', 'tool', 'transcription factor', 'treatment response']",NCI,UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN,R01,2018,327546,0.24712543287955582
"Informatics Tools for High-throughput Analysis of Cancer Mutations     DESCRIPTION (provided by applicant): Large tumor exome sequencing projects have identified a very large number of mutations whose cancer relevance is not yet understood. To begin to address this need, our team has produced two web applications for high-throughput computational analysis of cancer mutations: the Cancer-Related Analysis of VAriants Toolkit (CRAVAT) and the Mutation Position Imaging Toolbox (MuPIT). CRAVAT accepts millions of mutations in a single batch upload and maps mutations from genomic coordinates to annotated transcripts and proteins. MuPIT currently accepts batch uploads of up to 2500 SNVs and maps from genomic coordinates onto X-ray crystal structures of proteins from Protein Data Bank (PDB). We propose to combine and harden CRAVAT and MuPIT into a single web application, in which we will substantially improve the tools, user interface, software infrastructure, integration with external data resources and tools used by the community, and support for protected data. The scope of all tools in the web application will be broadened to handle analysis of the full range of small-scale mutation consequence types found in cancer exomes.  CRAVAT analysis identifies mutations most likely to have deleterious impact on protein function and those that are most likely to confer a selective advantage to cancer cells (drivers), using classifiers developed by our team. Classifier scores are supplemented with annotations, including population allele frequencies, previous occurrence in tumor tissue types, and gene functional categories, enabling filtering (e.g. removing polymorphisms) and prioritization. Gene-level annotation and scoring, by aggregation of classifier scores from mutations in a cohort is also provided.  MuPIT maps mutations from genomic positions onto to protein structures and provides interactive viewing of mutations in the context of protein structure, and in relation to a variety of annotations. To enable prioritization of interesting mutations and genes, the application provides a preview describing each structure and all available annotations (e.g., binding sites, experimental mutagenesis results, polymorphic and disease- associated variants that have been previously documented). After selecting a PDB of interest, the user is led to an interactive visualization page. An enhanced Jmol applet displays all SNVs mapped onto the structure. Frequently, many SNVs in the input list can be mapped onto a single structure, revealing clustering patterns around key functional sites.  Based only on word-of-mouth, since the debut of the two applications in August 2012, CRAVAT has been utilized by 129 unique users from 39 countries, and it has analyzed 1,136 submitted jobs, totaling 27.9 million mutations. MuPIT has been utilized by 242 unique users from 25 countries, with 720 submitted jobs. (Source: Google Analytics).         PUBLIC HEALTH RELEVANCE: The proposed work will harden and develop web applications for the cancer genomics community to interpret small-scale mutations in cancer exomes. They are designed to handle very large number of mutations and to provide analysis targeted at researchers who are not bioinformatics experts. The work will contribute to understanding of the genetic complexity and heterogeneity of tumors and assist in discovery of new approaches for cancer prognosis and treatments.            ",Informatics Tools for High-throughput Analysis of Cancer Mutations,8735910,U01CA180956,"['Address', 'Binding Sites', 'Bioinformatics', 'Biological', 'Cancer Center', 'Cancer Prognosis', 'Categories', 'Classification', 'Collaborations', 'Communities', 'Computer Analysis', 'Computer software', 'Country', 'Data', 'Databases', 'Development', 'Diagnostic', 'Disease', 'Doctor of Medicine', 'Ensure', 'Gene Frequency', 'Gene Mutation', 'Genes', 'Genetic', 'Genetic Polymorphism', 'Genomics', 'Heterogeneity', 'Histocompatibility Testing', 'Housing', 'Image', 'Imagery', 'Informatics', 'Internet', 'Letters', 'Machine Learning', 'Malignant Neoplasms', 'Maps', 'Methods', 'Missense Mutation', 'Molecular', 'Mutagenesis', 'Mutate', 'Mutation', 'Mutation Analysis', 'Occupations', 'Pathway Analysis', 'Pattern', 'Pharmaceutical Preparations', 'Population', 'Positioning Attribute', 'Privacy', 'Production', 'Proteins', 'Publications', 'Qualifying', 'RNA Splicing', 'Research Infrastructure', 'Research Personnel', 'Resources', 'Roentgen Rays', 'Scientist', 'Secure', 'Site', 'Source', 'Structure', 'Technology', 'The Cancer Genome Atlas', 'Transcript', 'Translations', 'Tumor Tissue', 'Untranslated Regions', 'Update', 'Variant', 'Work', 'anticancer research', 'base', 'cancer cell', 'cancer classification', 'cancer genome', 'cancer genomics', 'cancer therapy', 'cloud based', 'cohort', 'data exchange', 'design', 'exome', 'exome sequencing', 'experience', 'high throughput analysis', 'improved', 'insertion/deletion mutation', 'insight', 'interest', 'microbial alkaline proteinase inhibitor', 'next generation sequencing', 'novel strategies', 'prognostic', 'protein function', 'protein structure', 'public health relevance', 'software development', 'tool', 'tumor', 'user-friendly', 'web interface', 'web services']",NCI,JOHNS HOPKINS UNIVERSITY,U01,2014,317146,0.3051289851694909
"Informatics Tools for High-throughput Analysis of Cancer Mutations  PROJECT SUMMARY  Large tumor exome sequencing projects have identified a very large number of mutations whose cancer relevance is not yet understood. To begin to address this need, our team has produced two web applications for high-throughput computational analysis of cancer mutations: the Cancer-Related Analysis of VAriants Toolkit (CRAVAT) and the Mutation Position Imaging Toolbox (MuPIT). CRAVAT accepts millions of mutations in a single batch upload and maps mutations from genomic coordinates to annotated transcripts and proteins. MuPIT currently accepts batch uploads of up to 2500 SNVs and maps from genomic coordinates onto X-ray crystal structures of proteins from Protein Data Bank (PDB). We propose to combine and harden CRAVAT and MuPIT into a single web application, in which we will substantially improve the tools, user interface, software infrastructure, integration with external data resources and tools used by the community, and support for protected data. The scope of all tools in the web application will be broadened to handle analysis of the full range of small-scale mutation consequence types found in cancer exomes.  CRAVAT analysis identifies mutations most likely to have deleterious impact on protein function and those that are most likely to confer a selective advantage to cancer cells (drivers), using classifiers developed by our team. Classifier scores are supplemented with annotations, including population allele frequencies, previous occurrence in tumor tissue types, and gene functional categories, enabling filtering (e.g. removing polymorphisms) and prioritization. Gene-level annotation and scoring, by aggregation of classifier scores from mutations in a cohort is also provided.  MuPIT maps mutations from genomic positions onto to protein structures and provides interactive viewing of mutations in the context of protein structure, and in relation to a variety of annotations. To enable prioritization of interesting mutations and genes, the application provides a preview describing each structure and all available annotations (e.g., binding sites, experimental mutagenesis results, polymorphic and disease- associated variants that have been previously documented). After selecting a PDB of interest, the user is led to an interactive visualization page. An enhanced Jmol applet displays all SNVs mapped onto the structure. Frequently, many SNVs in the input list can be mapped onto a single structure, revealing clustering patterns around key functional sites.  Based only on word-of-mouth, since the debut of the two applications in August 2012, CRAVAT has been utilized by 129 unique users from 39 countries, and it has analyzed 1,136 submitted jobs, totaling 27.9 million mutations. MuPIT has been utilized by 242 unique users from 25 countries, with 720 submitted jobs. (Source: Google Analytics). PUBLIC HEALTH RELEVANCE: The proposed work will harden and develop web applications for the cancer genomics community to interpret small-scale mutations in cancer exomes. They are designed to handle very large number of mutations and to provide analysis targeted at researchers who are not bioinformatics experts. The work will contribute to understanding of the genetic complexity and heterogeneity of tumors and assist in discovery of new approaches for cancer prognosis and treatments.            ",Informatics Tools for High-throughput Analysis of Cancer Mutations,8606625,U01CA180956,"['Address', 'Binding Sites', 'Bioinformatics', 'Biological', 'Cancer Center', 'Cancer Prognosis', 'Categories', 'Classification', 'Collaborations', 'Communities', 'Computer Analysis', 'Computer software', 'Country', 'Data', 'Databases', 'Development', 'Diagnostic', 'Disease', 'Doctor of Medicine', 'Ensure', 'Gene Frequency', 'Gene Mutation', 'Genes', 'Genetic', 'Genetic Polymorphism', 'Genomics', 'Heterogeneity', 'Histocompatibility Testing', 'Housing', 'Image', 'Imagery', 'Informatics', 'Internet', 'Letters', 'Machine Learning', 'Malignant Neoplasms', 'Maps', 'Methods', 'Missense Mutation', 'Molecular', 'Mutagenesis', 'Mutate', 'Mutation', 'Mutation Analysis', 'Occupations', 'Pathway Analysis', 'Pattern', 'Pharmaceutical Preparations', 'Population', 'Positioning Attribute', 'Privacy', 'Production', 'Proteins', 'Publications', 'Qualifying', 'RNA Splicing', 'Research Infrastructure', 'Research Personnel', 'Resources', 'Roentgen Rays', 'Scientist', 'Secure', 'Site', 'Source', 'Structure', 'Technology', 'The Cancer Genome Atlas', 'Transcript', 'Translations', 'Tumor Tissue', 'Untranslated Regions', 'Update', 'Variant', 'Work', 'anticancer research', 'base', 'cancer cell', 'cancer classification', 'cancer genome', 'cancer genomics', 'cancer therapy', 'cohort', 'data exchange', 'design', 'exome', 'exome sequencing', 'experience', 'high throughput analysis', 'improved', 'insertion/deletion mutation', 'insight', 'interest', 'microbial alkaline proteinase inhibitor', 'next generation sequencing', 'novel strategies', 'prognostic', 'protein function', 'protein structure', 'public health relevance', 'software development', 'tool', 'tumor', 'user-friendly', 'web interface', 'web services']",NCI,JOHNS HOPKINS UNIVERSITY,U01,2013,289971,0.3051289851694909
"Informatics Tools for High-throughput Analysis of Cancer Mutations DESCRIPTION (provided by applicant): Large tumor exome sequencing projects have identified a very large number of mutations whose cancer relevance is not yet understood. To begin to address this need, our team has produced two web applications for high-throughput computational analysis of cancer mutations: the Cancer-Related Analysis of VAriants Toolkit (CRAVAT) and the Mutation Position Imaging Toolbox (MuPIT). CRAVAT accepts millions of mutations in a single batch upload and maps mutations from genomic coordinates to annotated transcripts and proteins. MuPIT currently accepts batch uploads of up to 2500 SNVs and maps from genomic coordinates onto X-ray crystal structures of proteins from Protein Data Bank (PDB). We propose to combine and harden CRAVAT and MuPIT into a single web application, in which we will substantially improve the tools, user interface, software infrastructure, integration with external data resources and tools used by the community, and support for protected data. The scope of all tools in the web application will be broadened to handle analysis of the full range of small-scale mutation consequence types found in cancer exomes.  CRAVAT analysis identifies mutations most likely to have deleterious impact on protein function and those that are most likely to confer a selective advantage to cancer cells (drivers), using classifiers developed by our team. Classifier scores are supplemented with annotations, including population allele frequencies, previous occurrence in tumor tissue types, and gene functional categories, enabling filtering (e.g. removing polymorphisms) and prioritization. Gene-level annotation and scoring, by aggregation of classifier scores from mutations in a cohort is also provided.  MuPIT maps mutations from genomic positions onto to protein structures and provides interactive viewing of mutations in the context of protein structure, and in relation to a variety of annotations. To enable prioritization of interesting mutations and genes, the application provides a preview describing each structure and all available annotations (e.g., binding sites, experimental mutagenesis results, polymorphic and disease- associated variants that have been previously documented). After selecting a PDB of interest, the user is led to an interactive visualization page. An enhanced Jmol applet displays all SNVs mapped onto the structure. Frequently, many SNVs in the input list can be mapped onto a single structure, revealing clustering patterns around key functional sites.  Based only on word-of-mouth, since the debut of the two applications in August 2012, CRAVAT has been utilized by 129 unique users from 39 countries, and it has analyzed 1,136 submitted jobs, totaling 27.9 million mutations. MuPIT has been utilized by 242 unique users from 25 countries, with 720 submitted jobs. (Source: Google Analytics). PUBLIC HEALTH RELEVANCE: The proposed work will harden and develop web applications for the cancer genomics community to interpret small-scale mutations in cancer exomes. They are designed to handle very large number of mutations and to provide analysis targeted at researchers who are not bioinformatics experts. The work will contribute to understanding of the genetic complexity and heterogeneity of tumors and assist in discovery of new approaches for cancer prognosis and treatments.",Informatics Tools for High-throughput Analysis of Cancer Mutations,8910262,U01CA180956,"['Address', 'Binding Sites', 'Bioinformatics', 'Biological', 'Cancer Center', 'Cancer Prognosis', 'Categories', 'Classification', 'Collaborations', 'Communities', 'Computer Analysis', 'Computer software', 'Country', 'Data', 'Databases', 'Development', 'Disease', 'Doctor of Medicine', 'Ensure', 'Gene Frequency', 'Gene Mutation', 'Genes', 'Genetic', 'Genetic Polymorphism', 'Genomics', 'Health', 'Heterogeneity', 'Histocompatibility Testing', 'Housing', 'Image', 'Imagery', 'Informatics', 'Internet', 'Letters', 'Machine Learning', 'Malignant Neoplasms', 'Maps', 'Methods', 'Missense Mutation', 'Molecular', 'Mutagenesis', 'Mutate', 'Mutation', 'Mutation Analysis', 'Occupations', 'Pathway Analysis', 'Pattern', 'Pharmaceutical Preparations', 'Population', 'Positioning Attribute', 'Privacy', 'Production', 'Proteins', 'Publications', 'Qualifying', 'RNA Splicing', 'Research Infrastructure', 'Research Personnel', 'Resources', 'Roentgen Rays', 'Scientist', 'Secure', 'Site', 'Source', 'Structure', 'Technology', 'The Cancer Genome Atlas', 'Transcript', 'Translations', 'Tumor Tissue', 'Untranslated Regions', 'Update', 'Variant', 'Work', 'anticancer research', 'base', 'cancer cell', 'cancer classification', 'cancer genome', 'cancer genomics', 'cancer therapy', 'cloud based', 'cohort', 'data exchange', 'design', 'exome', 'exome sequencing', 'experience', 'high throughput analysis', 'improved', 'insertion/deletion mutation', 'insight', 'interest', 'next generation sequencing', 'novel strategies', 'personalized diagnostics', 'prognostic', 'protein function', 'protein structure', 'software development', 'tool', 'tumor', 'user-friendly', 'web interface', 'web services']",NCI,JOHNS HOPKINS UNIVERSITY,U01,2015,315948,0.3051289851694909
"Identification, Characterization, and Prediction of Cancer Driver Mutations in Regulatory Regions DESCRIPTION (provided by applicant): The goal of the proposed research training program is to provide me (Dr. Collin Melton) with additional training in areas that will accelerate my career development as I transition from a post-doctoral fellow in Dr. Michael Snyder's lab to an independent tenure track professor. The key elements of this plan are: Candidate: I have extensive training in experimental and computational approaches to studying biomedicine. Areas of additional focus for career development during the K99 mentored post-doctoral research phase include the acquisition of additional experimental skills and supplemental training in cancer biology, human genetics, human genomics, applied statistics, and parallel computing. Additionally, I will receive training in laboratory management, mentorship, and responsible conduct of research. This well-rounded plan will provide me with a skill set that will enable a facile transition from postdoctoral fellow to tenure track faculty. Environment: I have a valuable advisory committee with experts in the areas of genomics, genetics, and cancer biology to ensure my success in this training program and to guide me through the successful acquisition of a faculty job. These include my mentor Dr. Michael Snyder, my co-mentor Dr. James Ford and two advisors, Dr. Hanlee Ji and Dr. Anshul Kundaje. The environment at Stanford University in the Snyder lab and department of Genetics fosters productivity and collaboration with word class facilities, resources, and researchers. Research: My proposed research plan in cancer genomics is timely, relevant, and innovative. The majority of current research in cancer genomics has made groundbreaking progress in understanding the relevant DNA variation that occurs in coding regions of the genome; however, 97-98% of the human genome does not code for protein. This proposal focuses specifically on studying the regulatory regions of the human genome to identify, characterize, and interpret the impact of point mutations in these regulatory regions. The central hypothesis of this proposal is that point mutations in regulatory regions of the human genome drive cancer formation and the functional consequences of these mutations can be predicted using machine learning algorithms. Aim 1 proposes the statistical identification of regulatory regions which are mutated across cancer samples, Aim 2 proposes functional characterization of the prevalent mutations identified in Aim 1, and Aim 3 extends the analysis of characterizing the effects of mutations genome-wide through use of genomics approaches and proposes the use of machine learning to classify novel mutations as either disrupting, activating, or having no effect on regulatory element activity. Through its use of experimental datasets combined with predictive models for functional consequences of individual cancer variation, this research will further the goal of personalized genome interpretation for cancer therapy. PUBLIC HEALTH RELEVANCE: Every cancer patient's disease is caused by unique set of abnormal variation in the human genome. Advancing our understanding this variation aids in the development of new treatments and the proper application of existing treatments. This proposal focuses on understanding a particular type of cancer variation that occurs in regulatory regions of the human genome.","Identification, Characterization, and Prediction of Cancer Driver Mutations in Regulatory Regions",8931936,K99CA191093,"['Address', 'Advisory Committees', 'Algorithms', 'Alleles', 'American', 'Apoptosis', 'Area', 'Cancer Biology', 'Cancer Patient', 'Cancer cell line', 'Cause of Death', 'Cell Line', 'ChIP-seq', 'Clustered Regularly Interspaced Short Palindromic Repeats', 'Code', 'Collaborations', 'DNA', 'Data', 'Data Set', 'Development', 'Disease', 'Distal', 'Elements', 'Encyclopedia of DNA Elements', 'Ensure', 'Environment', 'Evaluation', 'Faculty', 'Fostering', 'Future', 'Gene Targeting', 'Genes', 'Genetic', 'Genome', 'Genomic approach', 'Genomics', 'Goals', 'Health', 'Hela Cells', 'Human', 'Human Genetics', 'Human Genome', 'Individual', 'Laboratories', 'Machine Learning', 'Malignant Neoplasms', 'Mentors', 'Mentorship', 'Mutate', 'Mutation', 'Normal Cell', 'Nucleic Acid Regulatory Sequences', 'Occupations', 'Phase', 'Point Mutation', 'Postdoctoral Fellow', 'Productivity', 'Proteins', 'Regimen', 'Regulatory Element', 'Research', 'Research Personnel', 'Research Training', 'Resources', 'Role', 'Sample Size', 'Sampling', 'Site', 'The Cancer Genome Atlas', 'Therapeutic', 'Training', 'Training Programs', 'United States', 'Universities', 'Untranslated RNA', 'Variant', 'Vision', 'base', 'cancer genome', 'cancer genomics', 'cancer therapy', 'cancer type', 'carcinogenesis', 'career development', 'epigenomics', 'genome sequencing', 'genome-wide', 'innovation', 'interest', 'migration', 'mutant', 'novel', 'parallel computer', 'predictive modeling', 'professor', 'responsible research conduct', 'skills', 'statistics', 'success', 'trend', 'tumor progression']",NCI,STANFORD UNIVERSITY,K99,2015,116122,0.1550097184958041
"Identification, Characterization, and Prediction of Cancer Driver Mutations in Regulatory Regions     DESCRIPTION (provided by applicant): The goal of the proposed research training program is to provide me (Dr. Collin Melton) with additional training in areas that will accelerate my career development as I transition from a post-doctoral fellow in Dr. Michael Snyder's lab to an independent tenure track professor. The key elements of this plan are: Candidate: I have extensive training in experimental and computational approaches to studying biomedicine. Areas of additional focus for career development during the K99 mentored post-doctoral research phase include the acquisition of additional experimental skills and supplemental training in cancer biology, human genetics, human genomics, applied statistics, and parallel computing. Additionally, I will receive training in laboratory management, mentorship, and responsible conduct of research. This well-rounded plan will provide me with a skill set that will enable a facile transition from postdoctoral fellow to tenure track faculty. Environment: I have a valuable advisory committee with experts in the areas of genomics, genetics, and cancer biology to ensure my success in this training program and to guide me through the successful acquisition of a faculty job. These include my mentor Dr. Michael Snyder, my co-mentor Dr. James Ford and two advisors, Dr. Hanlee Ji and Dr. Anshul Kundaje. The environment at Stanford University in the Snyder lab and department of Genetics fosters productivity and collaboration with word class facilities, resources, and researchers. Research: My proposed research plan in cancer genomics is timely, relevant, and innovative. The majority of current research in cancer genomics has made groundbreaking progress in understanding the relevant DNA variation that occurs in coding regions of the genome; however, 97-98% of the human genome does not code for protein. This proposal focuses specifically on studying the regulatory regions of the human genome to identify, characterize, and interpret the impact of point mutations in these regulatory regions. The central hypothesis of this proposal is that point mutations in regulatory regions of the human genome drive cancer formation and the functional consequences of these mutations can be predicted using machine learning algorithms. Aim 1 proposes the statistical identification of regulatory regions which are mutated across cancer samples, Aim 2 proposes functional characterization of the prevalent mutations identified in Aim 1, and Aim 3 extends the analysis of characterizing the effects of mutations genome-wide through use of genomics approaches and proposes the use of machine learning to classify novel mutations as either disrupting, activating, or having no effect on regulatory element activity. Through its use of experimental datasets combined with predictive models for functional consequences of individual cancer variation, this research will further the goal of personalized genome interpretation for cancer therapy.         PUBLIC HEALTH RELEVANCE: Every cancer patient's disease is caused by unique set of abnormal variation in the human genome. Advancing our understanding this variation aids in the development of new treatments and the proper application of existing treatments. This proposal focuses on understanding a particular type of cancer variation that occurs in regulatory regions of the human genome.        The written critiques of individual reviewers are provided in essentially unedited form in this section. Please note that these critiques and criteria scores were prepared prior to the meeting and may not have been revised subsequent to any discussions at the review meeting. The ""Resume and Summary of Discussion"" section above summarizes the final opinions of the committee.                ","Identification, Characterization, and Prediction of Cancer Driver Mutations in Regulatory Regions",8805723,K99CA191093,"['Address', 'Advisory Committees', 'Algorithms', 'Alleles', 'American', 'Apoptosis', 'Area', 'Cancer Biology', 'Cancer Patient', 'Cancer cell line', 'Cause of Death', 'Cell Line', 'ChIP-seq', 'Clustered Regularly Interspaced Short Palindromic Repeats', 'Code', 'Collaborations', 'Critiques', 'DNA', 'Data', 'Data Set', 'Development', 'Disease', 'Distal', 'Elements', 'Encyclopedia of DNA Elements', 'Ensure', 'Environment', 'Evaluation', 'Faculty', 'Fostering', 'Functional RNA', 'Future', 'Gene Targeting', 'Genes', 'Genetic', 'Genome', 'Genomics', 'Goals', 'Hela Cells', 'Human', 'Human Genetics', 'Human Genome', 'Individual', 'Laboratories', 'Machine Learning', 'Malignant Neoplasms', 'Mentors', 'Mentorship', 'Mutate', 'Mutation', 'Normal Cell', 'Nucleic Acid Regulatory Sequences', 'Occupations', 'Phase', 'Point Mutation', 'Postdoctoral Fellow', 'Productivity', 'Proteins', 'Regimen', 'Regulatory Element', 'Research', 'Research Personnel', 'Research Training', 'Resources', 'Role', 'Sample Size', 'Sampling', 'Site', 'The Cancer Genome Atlas', 'Therapeutic', 'Training', 'Training Programs', 'United States', 'Universities', 'Variant', 'Vision', 'Writing', 'base', 'cancer genome', 'cancer genomics', 'cancer therapy', 'cancer type', 'carcinogenesis', 'career development', 'epigenomics', 'genome sequencing', 'genome-wide', 'innovation', 'interest', 'meetings', 'migration', 'mutant', 'novel', 'parallel computer', 'predictive modeling', 'professor', 'public health relevance', 'responsible research conduct', 'skills', 'statistics', 'success', 'trend', 'tumor progression']",NCI,STANFORD UNIVERSITY,K99,2014,116122,0.1530274345770501
"Integrative approach for predicting cancer driver genes     DESCRIPTION (provided by applicant): Carcinogenesis, progression of normal cells to malignant cancer, derives from hallmark capabilities of cancer driven by acquiring (somatic) mutations in ""driver genes"" with a selective advantage for cellular proliferation and potentially metastasis. A major motivation for modern cancer genomics studies is to decipher the genetic architecture of cancer by discovering new driver genes. The most widely-used approaches to predict and prioritize driver genes are based on statistics of mutation frequencies. Several methods have been proposed to identify genes with an excessive number of somatic mutations [9-11], known as significantly mutated genes. I propose to address two major limitations of this approach. First, these methods are insufficiently statistically powered given the amount of sequencing data currently available [15]. I will improve statistical power by leveraging diverse information in cancer genomics currently available into a developed machine learning method. Second, there is little objective clarity about the true effectiveness of these methods [11, 14], since there is no agreed-upon gold standard of driver genes, with the exception of a few well-known drivers. I will develop a framework to compare the effectiveness of driver gene prediction methods, in the absence of a gold standard. Both effectively and efficiently identifying cancer driver genes is a matter of great importance to science funding policy towards cancer genomics. PUBLIC HEALTH RELEVANCE: Large sequencing studies have revolutionized our capability to identify the genetic architecture of cancer. However, effectively integrating this stream of big data to identify specific driver genes has remained troublesome. My proposed research project aims to develop an integrative machine learning method that leverages diverse features in cancer genomics to improve predictions of cancer driver genes, and to utilize a principled approach for evaluating the performance of any such method.",Integrative approach for predicting cancer driver genes,9322626,F31CA200266,"['Address', 'Algorithms', 'Architecture', 'Big Data', 'Cell Proliferation', 'Characteristics', 'Data', 'Effectiveness', 'Evaluation', 'Frequencies', 'Funding', 'Gene Mutation', 'Genes', 'Genetic', 'Gold', 'Machine Learning', 'Malignant - descriptor', 'Malignant Neoplasms', 'Methods', 'Modernization', 'Motivation', 'Mutate', 'Mutation', 'Neoplasm Metastasis', 'Normal Cell', 'Pattern', 'Performance', 'Play', 'Policies', 'Property', 'Research Project Grants', 'Sampling', 'Scheme', 'Science', 'Somatic Mutation', 'Stream', 'Supervision', 'Tumor Biology', 'Tumor Suppressor Genes', 'base', 'cancer genomics', 'carcinogenesis', 'compare effectiveness', 'improved', 'learning strategy', 'novel', 'public health relevance', 'statistics', 'transcriptome']",NCI,JOHNS HOPKINS UNIVERSITY,F31,2017,44044,0.12877349910679933
"Integrative approach for predicting cancer driver genes     DESCRIPTION (provided by applicant): Carcinogenesis, progression of normal cells to malignant cancer, derives from hallmark capabilities of cancer driven by acquiring (somatic) mutations in ""driver genes"" with a selective advantage for cellular proliferation and potentially metastasis. A major motivation for modern cancer genomics studies is to decipher the genetic architecture of cancer by discovering new driver genes. The most widely-used approaches to predict and prioritize driver genes are based on statistics of mutation frequencies. Several methods have been proposed to identify genes with an excessive number of somatic mutations [9-11], known as significantly mutated genes. I propose to address two major limitations of this approach. First, these methods are insufficiently statistically powered given the amount of sequencing data currently available [15]. I will improve statistical power by leveraging diverse information in cancer genomics currently available into a developed machine learning method. Second, there is little objective clarity about the true effectiveness of these methods [11, 14], since there is no agreed-upon gold standard of driver genes, with the exception of a few well-known drivers. I will develop a framework to compare the effectiveness of driver gene prediction methods, in the absence of a gold standard. Both effectively and efficiently identifying cancer driver genes is a matter of great importance to science funding policy towards cancer genomics.         PUBLIC HEALTH RELEVANCE: Large sequencing studies have revolutionized our capability to identify the genetic architecture of cancer. However, effectively integrating this stream of big data to identify specific driver genes has remained troublesome. My proposed research project aims to develop an integrative machine learning method that leverages diverse features in cancer genomics to improve predictions of cancer driver genes, and to utilize a principled approach for evaluating the performance of any such method.            ",Integrative approach for predicting cancer driver genes,9152184,F31CA200266,"['Address', 'Algorithms', 'Architecture', 'Big Data', 'Cell Proliferation', 'Characteristics', 'Data', 'Effectiveness', 'Evaluation', 'Frequencies', 'Funding', 'Genes', 'Genetic', 'Gold', 'Machine Learning', 'Malignant - descriptor', 'Malignant Neoplasms', 'Methods', 'Motivation', 'Mutate', 'Mutation', 'Neoplasm Metastasis', 'Normal Cell', 'Pattern', 'Performance', 'Play', 'Policies', 'Property', 'Research Project Grants', 'Sampling', 'Scheme', 'Science', 'Somatic Mutation', 'Statistical Bias', 'Stream', 'Tumor Biology', 'Tumor Suppressor Genes', 'base', 'cancer genomics', 'carcinogenesis', 'compare effectiveness', 'improved', 'learning strategy', 'novel', 'public health relevance', 'statistics', 'transcriptome']",NCI,JOHNS HOPKINS UNIVERSITY,F31,2016,43576,0.12877349910679933
"Integrative approach for predicting cancer driver genes     DESCRIPTION (provided by applicant): Carcinogenesis, progression of normal cells to malignant cancer, derives from hallmark capabilities of cancer driven by acquiring (somatic) mutations in ""driver genes"" with a selective advantage for cellular proliferation and potentially metastasis. A major motivation for modern cancer genomics studies is to decipher the genetic architecture of cancer by discovering new driver genes. The most widely-used approaches to predict and prioritize driver genes are based on statistics of mutation frequencies. Several methods have been proposed to identify genes with an excessive number of somatic mutations [9-11], known as significantly mutated genes. I propose to address two major limitations of this approach. First, these methods are insufficiently statistically powered given the amount of sequencing data currently available [15]. I will improve statistical power by leveraging diverse information in cancer genomics currently available into a developed machine learning method. Second, there is little objective clarity about the true effectiveness of these methods [11, 14], since there is no agreed-upon gold standard of driver genes, with the exception of a few well-known drivers. I will develop a framework to compare the effectiveness of driver gene prediction methods, in the absence of a gold standard. Both effectively and efficiently identifying cancer driver genes is a matter of great importance to science funding policy towards cancer genomics.         PUBLIC HEALTH RELEVANCE: Large sequencing studies have revolutionized our capability to identify the genetic architecture of cancer. However, effectively integrating this stream of big data to identify specific driver genes has remained troublesome. My proposed research project aims to develop an integrative machine learning method that leverages diverse features in cancer genomics to improve predictions of cancer driver genes, and to utilize a principled approach for evaluating the performance of any such method.            ",Integrative approach for predicting cancer driver genes,8982803,F31CA200266,"['Address', 'Algorithms', 'Architecture', 'Big Data', 'Cell Proliferation', 'Characteristics', 'Data', 'Effectiveness', 'Evaluation', 'Frequencies', 'Funding', 'Gene Expression Profile', 'Genes', 'Genetic', 'Gold', 'Machine Learning', 'Malignant - descriptor', 'Malignant Neoplasms', 'Methods', 'Motivation', 'Mutate', 'Mutation', 'Neoplasm Metastasis', 'Normal Cell', 'Pattern', 'Performance', 'Play', 'Policies', 'Property', 'Research Project Grants', 'Sampling', 'Scheme', 'Science', 'Somatic Mutation', 'Statistical Bias', 'Stream', 'Tumor Biology', 'Tumor Suppressor Genes', 'base', 'cancer genomics', 'carcinogenesis', 'compare effectiveness', 'improved', 'novel', 'public health relevance', 'statistics']",NCI,JOHNS HOPKINS UNIVERSITY,F31,2015,43120,0.12877349910679933
"Determinants of pancreatic cancer and malignant melanoma phenotypes in CDKN2A hereditary kindreds This proposal addresses Provocative Question #2. We will use innovative approaches to investigate how CDKN2A (which encodes p16) mutation carriers develop different cancer phenotypes (pancreatic cancer vs melanoma vs no cancer), and include both genetic and non-genetic factors. We have identified 4 large, multi- generational kindreds with a founder CDKN2A deleterious mutation (L16R, 47T>G). Our preliminary observations demonstrate that this mutant has lower expression and decreased ability to regulate cell cycle progression compared to wild type protein. Our sequencing studies of kindred members with different cancer phenotypes have identified potential variants in novel genes that modify risk (LGR6, a co-receptor of Wnt signaling and COL11A1, which participates in oncogenic signaling, including TGFbeta). We will determine the ability of the p16 mutant to promote transformation and how it is influenced by interaction with the above candidate modifier genes, LGR6 or COL11A1, in pancreatic cancer and melanoma. We will also develop novel computational models using machine deep learning, to generate networks that capture high dimensional features to integrate gene, biology, and cancer phenotype. This approach will be extended to kindreds with other CDKN2A mutations. Our Specific Aims are to: (1) Identify genotypes of potential modifier genes in multiple kindreds that feature pancreatic cancer and melanoma and known to carry CDKN2A germline mutations. We will use genome wide variant coverage of germline DNA from CDKN2A carriers from the 4 large L16R kindreds, plus additional members in 42 other similar CDKN2A kindreds. We will identify candidate modifier genes in the kindreds by rule-based statistical genetic analysis of genotypes. (2) Define the impact of CDKN2A L16R mutation on the function of p16 and its interplay with candidate modifier genes. We will elucidate the biological significance of mutations in CDKN2A and candidate modifier genes using functional and high throughput methodologies by analyzing the mechanism underlying the interplay between p16 and modifier genes; define new pathways cooperating with this interplay using a combination of genome wide studies to assess transformation in cells carrying p16 mutant or wild-type background using well established in vitro and in vivo models. (3) Develop a deep learning network model to integrate genetic, biological and epidemiological data to accurately infer pancreatic cancer and melanoma phenotypes and age of onset in mutation carriers. We will apply a convolutional neural network, a deep learning algorithm in the training dataset, develop a back-propagation algorithm to fine tune weights, and construct mutation-gene networks to capture high-dimensional features for each disease subclass. We will acquire and disseminate new knowledge and tools to the scientific community. Our integrated methods and approach will bring insight into how different cancer phenotypes can occur with identical predisposing mutations, which can be applied to other cancer syndromes with similar challenges. PROJECT NARRATIVE This proposal addresses Provocative Question #2. We will use innovative approaches to investigate how CDKN2A (which encodes p16) mutation carriers develop different phenotypes (pancreatic cancer vs melanoma vs no cancer), and include both genetic and non-genetic factors. Using 4 large, multi-generational kindreds with a founder CDKN2A deleterious mutation and other kindreds, we will define the mechanism underlying the interplay between CDKN2A and other factors. We will develop novel computational models using machine deep learning, that integrate gene, biology, and cancer phenotype. We will share our new knowledge and tools with the scientific community, and bring insights to apply to other challenging cancer syndromes.",Determinants of pancreatic cancer and malignant melanoma phenotypes in CDKN2A hereditary kindreds,9978727,R01CA208517,"['Address', 'Affect', 'Age', 'Age of Onset', 'Algorithms', 'Alleles', 'Alzheimer&apos', 's disease brain', 'Back', 'Biological', 'Biology', 'Brain Neoplasms', 'CDKN2A gene', 'Cancer Gene Mutation', 'Cancer-Predisposing Gene', 'Cell Cycle Progression', 'Cells', 'Code', 'Communities', 'Computer Models', 'Cyclin-Dependent Kinase Inhibitor 2A', 'DNA', 'Data', 'Data Set', 'Development', 'Diagnosis', 'Discrimination', 'Disease', 'Environmental Exposure', 'Etiology', 'Gene Expression', 'Gene Frequency', 'Gene Mutation', 'Gene-Modified', 'Generations', 'Genes', 'Genetic', 'Genome', 'Genotype', 'Germ-Line Mutation', 'In Vitro', 'Individual', 'Inherited', 'Knowledge', 'Light', 'Malignant Neoplasms', 'Malignant neoplasm of pancreas', 'Measures', 'Methodology', 'Methods', 'Minor', 'Modeling', 'Molecular', 'Mutation', 'Oncogenic', 'Pathway interactions', 'Pattern', 'Penetrance', 'Performance', 'Phenotype', 'Process', 'Proteins', 'Proteomics', 'Risk', 'Signal Transduction', 'Smoking', 'Sun Exposure', 'Syndrome', 'Testing', 'Training', 'Transforming Growth Factor beta', 'Variant', 'WNT Signaling Pathway', 'Weight', 'base', 'bead chip', 'cancer genome', 'cell growth', 'convolutional neural network', 'deep learning', 'deep learning algorithm', 'disease phenotype', 'epidemiologic data', 'epigenomics', 'genetic analysis', 'genetic variant', 'genome-wide', 'genome-wide analysis', 'high dimensionality', 'in vivo', 'in vivo Model', 'innovation', 'insight', 'interest', 'kindred', 'leukemia', 'melanoma', 'member', 'metaplastic cell transformation', 'mutant', 'mutation carrier', 'network models', 'non-genetic', 'novel', 'novel diagnostics', 'novel therapeutic intervention', 'overexpression', 'protein expression', 'receptor', 'tool', 'transcriptome sequencing', 'transmission process', 'tumorigenesis']",NCI,MAYO CLINIC ROCHESTER,R01,2020,590577,0.24184209262427062
"Determinants of pancreatic cancer and malignant melanoma phenotypes in CDKN2A hereditary kindreds This proposal addresses Provocative Question #2. We will use innovative approaches to investigate how CDKN2A (which encodes p16) mutation carriers develop different cancer phenotypes (pancreatic cancer vs melanoma vs no cancer), and include both genetic and non-genetic factors. We have identified 4 large, multi- generational kindreds with a founder CDKN2A deleterious mutation (L16R, 47T>G). Our preliminary observations demonstrate that this mutant has lower expression and decreased ability to regulate cell cycle progression compared to wild type protein. Our sequencing studies of kindred members with different cancer phenotypes have identified potential variants in novel genes that modify risk (LGR6, a co-receptor of Wnt signaling and COL11A1, which participates in oncogenic signaling, including TGFbeta). We will determine the ability of the p16 mutant to promote transformation and how it is influenced by interaction with the above candidate modifier genes, LGR6 or COL11A1, in pancreatic cancer and melanoma. We will also develop novel computational models using machine deep learning, to generate networks that capture high dimensional features to integrate gene, biology, and cancer phenotype. This approach will be extended to kindreds with other CDKN2A mutations. Our Specific Aims are to: (1) Identify genotypes of potential modifier genes in multiple kindreds that feature pancreatic cancer and melanoma and known to carry CDKN2A germline mutations. We will use genome wide variant coverage of germline DNA from CDKN2A carriers from the 4 large L16R kindreds, plus additional members in 42 other similar CDKN2A kindreds. We will identify candidate modifier genes in the kindreds by rule-based statistical genetic analysis of genotypes. (2) Define the impact of CDKN2A L16R mutation on the function of p16 and its interplay with candidate modifier genes. We will elucidate the biological significance of mutations in CDKN2A and candidate modifier genes using functional and high throughput methodologies by analyzing the mechanism underlying the interplay between p16 and modifier genes; define new pathways cooperating with this interplay using a combination of genome wide studies to assess transformation in cells carrying p16 mutant or wild-type background using well established in vitro and in vivo models. (3) Develop a deep learning network model to integrate genetic, biological and epidemiological data to accurately infer pancreatic cancer and melanoma phenotypes and age of onset in mutation carriers. We will apply a convolutional neural network, a deep learning algorithm in the training dataset, develop a back-propagation algorithm to fine tune weights, and construct mutation-gene networks to capture high-dimensional features for each disease subclass. We will acquire and disseminate new knowledge and tools to the scientific community. Our integrated methods and approach will bring insight into how different cancer phenotypes can occur with identical predisposing mutations, which can be applied to other cancer syndromes with similar challenges. PROJECT NARRATIVE This proposal addresses Provocative Question #2. We will use innovative approaches to investigate how CDKN2A (which encodes p16) mutation carriers develop different phenotypes (pancreatic cancer vs melanoma vs no cancer), and include both genetic and non-genetic factors. Using 4 large, multi-generational kindreds with a founder CDKN2A deleterious mutation and other kindreds, we will define the mechanism underlying the interplay between CDKN2A and other factors. We will develop novel computational models using machine deep learning, that integrate gene, biology, and cancer phenotype. We will share our new knowledge and tools with the scientific community, and bring insights to apply to other challenging cancer syndromes.",Determinants of pancreatic cancer and malignant melanoma phenotypes in CDKN2A hereditary kindreds,9741068,R01CA208517,"['Address', 'Affect', 'Age', 'Age of Onset', 'Algorithms', 'Alleles', 'Alzheimer&apos', 's Disease', 'Back', 'Biological', 'Biology', 'Brain Neoplasms', 'CDKN2A gene', 'Cancer Gene Mutation', 'Cancer-Predisposing Gene', 'Cell Cycle Progression', 'Cells', 'Code', 'Communities', 'Computer Simulation', 'Cyclin-Dependent Kinase Inhibitor 2A', 'DNA', 'Data', 'Data Set', 'Development', 'Diagnosis', 'Discrimination', 'Disease', 'Environmental Exposure', 'Etiology', 'Gene Expression', 'Gene Frequency', 'Gene Mutation', 'Gene-Modified', 'Generations', 'Genes', 'Genetic', 'Genome', 'Genotype', 'Germ-Line Mutation', 'In Vitro', 'Individual', 'Inherited', 'Knowledge', 'Light', 'Malignant Neoplasms', 'Malignant neoplasm of pancreas', 'Measures', 'Methodology', 'Methods', 'Minor', 'Modeling', 'Molecular', 'Mutation', 'Oncogenic', 'Pathway interactions', 'Pattern', 'Penetrance', 'Performance', 'Phenotype', 'Process', 'Proteins', 'Proteomics', 'Risk', 'Signal Transduction', 'Smoking', 'Sun Exposure', 'Syndrome', 'Testing', 'Training', 'Transforming Growth Factor beta', 'Variant', 'WNT Signaling Pathway', 'Weight', 'base', 'bead chip', 'cancer genome', 'cell growth', 'convolutional neural network', 'deep learning', 'deep learning algorithm', 'disease phenotype', 'epidemiologic data', 'epigenomics', 'feeding', 'genetic analysis', 'genetic variant', 'genome-wide', 'genome-wide analysis', 'high dimensionality', 'in vivo', 'in vivo Model', 'innovation', 'insight', 'interest', 'kindred', 'leukemia', 'melanoma', 'member', 'metaplastic cell transformation', 'mutant', 'mutation carrier', 'network models', 'non-genetic', 'novel', 'novel diagnostics', 'novel therapeutic intervention', 'overexpression', 'protein expression', 'receptor', 'tool', 'transcriptome sequencing', 'transmission process', 'tumorigenesis']",NCI,MAYO CLINIC ROCHESTER,R01,2019,583253,0.24184209262427062
"Determinants of pancreatic cancer and malignant melanoma phenotypes in CDKN2A hereditary kindreds This proposal addresses Provocative Question #2. We will use innovative approaches to investigate how CDKN2A (which encodes p16) mutation carriers develop different cancer phenotypes (pancreatic cancer vs melanoma vs no cancer), and include both genetic and non-genetic factors. We have identified 4 large, multi- generational kindreds with a founder CDKN2A deleterious mutation (L16R, 47T>G). Our preliminary observations demonstrate that this mutant has lower expression and decreased ability to regulate cell cycle progression compared to wild type protein. Our sequencing studies of kindred members with different cancer phenotypes have identified potential variants in novel genes that modify risk (LGR6, a co-receptor of Wnt signaling and COL11A1, which participates in oncogenic signaling, including TGFbeta). We will determine the ability of the p16 mutant to promote transformation and how it is influenced by interaction with the above candidate modifier genes, LGR6 or COL11A1, in pancreatic cancer and melanoma. We will also develop novel computational models using machine deep learning, to generate networks that capture high dimensional features to integrate gene, biology, and cancer phenotype. This approach will be extended to kindreds with other CDKN2A mutations. Our Specific Aims are to: (1) Identify genotypes of potential modifier genes in multiple kindreds that feature pancreatic cancer and melanoma and known to carry CDKN2A germline mutations. We will use genome wide variant coverage of germline DNA from CDKN2A carriers from the 4 large L16R kindreds, plus additional members in 42 other similar CDKN2A kindreds. We will identify candidate modifier genes in the kindreds by rule-based statistical genetic analysis of genotypes. (2) Define the impact of CDKN2A L16R mutation on the function of p16 and its interplay with candidate modifier genes. We will elucidate the biological significance of mutations in CDKN2A and candidate modifier genes using functional and high throughput methodologies by analyzing the mechanism underlying the interplay between p16 and modifier genes; define new pathways cooperating with this interplay using a combination of genome wide studies to assess transformation in cells carrying p16 mutant or wild-type background using well established in vitro and in vivo models. (3) Develop a deep learning network model to integrate genetic, biological and epidemiological data to accurately infer pancreatic cancer and melanoma phenotypes and age of onset in mutation carriers. We will apply a convolutional neural network, a deep learning algorithm in the training dataset, develop a back-propagation algorithm to fine tune weights, and construct mutation-gene networks to capture high-dimensional features for each disease subclass. We will acquire and disseminate new knowledge and tools to the scientific community. Our integrated methods and approach will bring insight into how different cancer phenotypes can occur with identical predisposing mutations, which can be applied to other cancer syndromes with similar challenges. PROJECT NARRATIVE This proposal addresses Provocative Question #2. We will use innovative approaches to investigate how CDKN2A (which encodes p16) mutation carriers develop different phenotypes (pancreatic cancer vs melanoma vs no cancer), and include both genetic and non-genetic factors. Using 4 large, multi-generational kindreds with a founder CDKN2A deleterious mutation and other kindreds, we will define the mechanism underlying the interplay between CDKN2A and other factors. We will develop novel computational models using machine deep learning, that integrate gene, biology, and cancer phenotype. We will share our new knowledge and tools with the scientific community, and bring insights to apply to other challenging cancer syndromes.",Determinants of pancreatic cancer and malignant melanoma phenotypes in CDKN2A hereditary kindreds,9518680,R01CA208517,"['Address', 'Affect', 'Age', 'Age of Onset', 'Algorithms', 'Alleles', 'Alzheimer&apos', 's Disease', 'Back', 'Biological', 'Biological Neural Networks', 'Biology', 'Brain Neoplasms', 'CDKN2A gene', 'Cancer Gene Mutation', 'Cancer-Predisposing Gene', 'Cell Cycle Progression', 'Cells', 'Code', 'Communities', 'Computer Simulation', 'Cyclin-Dependent Kinase Inhibitor 2A', 'DNA', 'Data', 'Data Set', 'Development', 'Diagnosis', 'Discrimination', 'Disease', 'Environmental Exposure', 'Etiology', 'Gene Expression', 'Gene Frequency', 'Gene Mutation', 'Gene-Modified', 'Generations', 'Genes', 'Genetic', 'Genome', 'Genotype', 'Germ-Line Mutation', 'In Vitro', 'Individual', 'Inherited', 'Knowledge', 'Light', 'Malignant Neoplasms', 'Malignant neoplasm of pancreas', 'Measures', 'Methodology', 'Methods', 'Minor', 'Modeling', 'Molecular', 'Mutation', 'Oncogenic', 'Pathway interactions', 'Pattern', 'Penetrance', 'Performance', 'Phenotype', 'Process', 'Proteins', 'Proteomics', 'Risk', 'Signal Transduction', 'Smoking', 'Sun Exposure', 'Syndrome', 'Testing', 'Training', 'Transforming Growth Factor beta', 'Variant', 'WNT Signaling Pathway', 'Weight', 'base', 'bead chip', 'cancer genome', 'cell growth', 'deep learning', 'disease phenotype', 'epidemiologic data', 'epigenomics', 'feeding', 'genetic analysis', 'genetic variant', 'genome-wide', 'genome-wide analysis', 'high dimensionality', 'in vivo', 'in vivo Model', 'innovation', 'insight', 'interest', 'kindred', 'leukemia', 'melanoma', 'member', 'metaplastic cell transformation', 'mutant', 'mutation carrier', 'network models', 'non-genetic', 'novel', 'novel diagnostics', 'novel therapeutic intervention', 'overexpression', 'protein expression', 'receptor', 'tool', 'transcriptome sequencing', 'transmission process', 'tumorigenesis']",NCI,MAYO CLINIC ROCHESTER,R01,2018,601292,0.24184209262427062
"Determinants of pancreatic cancer and malignant melanoma phenotypes in CDKN2A hereditary kindreds This proposal addresses Provocative Question #2. We will use innovative approaches to investigate how CDKN2A (which encodes p16) mutation carriers develop different cancer phenotypes (pancreatic cancer vs melanoma vs no cancer), and include both genetic and non-genetic factors. We have identified 4 large, multi- generational kindreds with a founder CDKN2A deleterious mutation (L16R, 47T>G). Our preliminary observations demonstrate that this mutant has lower expression and decreased ability to regulate cell cycle progression compared to wild type protein. Our sequencing studies of kindred members with different cancer phenotypes have identified potential variants in novel genes that modify risk (LGR6, a co-receptor of Wnt signaling and COL11A1, which participates in oncogenic signaling, including TGFbeta). We will determine the ability of the p16 mutant to promote transformation and how it is influenced by interaction with the above candidate modifier genes, LGR6 or COL11A1, in pancreatic cancer and melanoma. We will also develop novel computational models using machine deep learning, to generate networks that capture high dimensional features to integrate gene, biology, and cancer phenotype. This approach will be extended to kindreds with other CDKN2A mutations. Our Specific Aims are to: (1) Identify genotypes of potential modifier genes in multiple kindreds that feature pancreatic cancer and melanoma and known to carry CDKN2A germline mutations. We will use genome wide variant coverage of germline DNA from CDKN2A carriers from the 4 large L16R kindreds, plus additional members in 42 other similar CDKN2A kindreds. We will identify candidate modifier genes in the kindreds by rule-based statistical genetic analysis of genotypes. (2) Define the impact of CDKN2A L16R mutation on the function of p16 and its interplay with candidate modifier genes. We will elucidate the biological significance of mutations in CDKN2A and candidate modifier genes using functional and high throughput methodologies by analyzing the mechanism underlying the interplay between p16 and modifier genes; define new pathways cooperating with this interplay using a combination of genome wide studies to assess transformation in cells carrying p16 mutant or wild-type background using well established in vitro and in vivo models. (3) Develop a deep learning network model to integrate genetic, biological and epidemiological data to accurately infer pancreatic cancer and melanoma phenotypes and age of onset in mutation carriers. We will apply a convolutional neural network, a deep learning algorithm in the training dataset, develop a back-propagation algorithm to fine tune weights, and construct mutation-gene networks to capture high-dimensional features for each disease subclass. We will acquire and disseminate new knowledge and tools to the scientific community. Our integrated methods and approach will bring insight into how different cancer phenotypes can occur with identical predisposing mutations, which can be applied to other cancer syndromes with similar challenges. PROJECT NARRATIVE This proposal addresses Provocative Question #2. We will use innovative approaches to investigate how CDKN2A (which encodes p16) mutation carriers develop different phenotypes (pancreatic cancer vs melanoma vs no cancer), and include both genetic and non-genetic factors. Using 4 large, multi-generational kindreds with a founder CDKN2A deleterious mutation and other kindreds, we will define the mechanism underlying the interplay between CDKN2A and other factors. We will develop novel computational models using machine deep learning, that integrate gene, biology, and cancer phenotype. We will share our new knowledge and tools with the scientific community, and bring insights to apply to other challenging cancer syndromes.",Determinants of pancreatic cancer and malignant melanoma phenotypes in CDKN2A hereditary kindreds,9334146,R01CA208517,"['Address', 'Affect', 'Age', 'Age of Onset', 'Algorithms', 'Alleles', 'Alzheimer&apos', 's Disease', 'Back', 'Biological', 'Biological Neural Networks', 'Biology', 'Brain Neoplasms', 'CDKN2A gene', 'Cancer-Predisposing Gene', 'Cell Cycle Progression', 'Cells', 'Code', 'Communities', 'Computer Simulation', 'Cyclin-Dependent Kinase Inhibitor 2A', 'DNA', 'Data', 'Data Set', 'Development', 'Diagnosis', 'Discrimination', 'Disease', 'Environmental Exposure', 'Etiology', 'Gene Expression', 'Gene Frequency', 'Gene Mutation', 'Gene-Modified', 'Generations', 'Genes', 'Genetic', 'Genome', 'Genotype', 'Germ-Line Mutation', 'In Vitro', 'Individual', 'Inherited', 'Knowledge', 'Learning', 'Light', 'Malignant Neoplasms', 'Malignant neoplasm of pancreas', 'Measures', 'Methodology', 'Methods', 'Minor', 'Modeling', 'Molecular', 'Mutation', 'Oncogenic', 'Pathway interactions', 'Pattern', 'Penetrance', 'Performance', 'Phenotype', 'Process', 'Proteins', 'Proteomics', 'Risk', 'Signal Transduction', 'Smoking', 'Sun Exposure', 'Syndrome', 'Testing', 'Training', 'Transforming Growth Factor beta', 'Variant', 'WNT Signaling Pathway', 'Weight', 'base', 'bead chip', 'cancer genome', 'cell growth', 'disease phenotype', 'epidemiologic data', 'epigenomics', 'feeding', 'genetic analysis', 'genetic variant', 'genome-wide', 'genome-wide analysis', 'high dimensionality', 'in vivo', 'in vivo Model', 'innovation', 'insight', 'interest', 'kindred', 'learning network', 'leukemia', 'melanoma', 'member', 'metaplastic cell transformation', 'mutant', 'mutation carrier', 'network models', 'non-genetic', 'novel', 'novel diagnostics', 'novel therapeutic intervention', 'overexpression', 'protein expression', 'receptor', 'tool', 'transcriptome sequencing', 'transmission process', 'tumorigenesis']",NCI,MAYO CLINIC ROCHESTER,R01,2017,590577,0.24184209262427062
"Determinants of pancreatic cancer and malignant melanoma phenotypes in CDKN2A hereditary kindreds This proposal addresses Provocative Question #2. We will use innovative approaches to investigate how CDKN2A (which encodes p16) mutation carriers develop different cancer phenotypes (pancreatic cancer vs melanoma vs no cancer), and include both genetic and non-genetic factors. We have identified 4 large, multi- generational kindreds with a founder CDKN2A deleterious mutation (L16R, 47T>G). Our preliminary observations demonstrate that this mutant has lower expression and decreased ability to regulate cell cycle progression compared to wild type protein. Our sequencing studies of kindred members with different cancer phenotypes have identified potential variants in novel genes that modify risk (LGR6, a co-receptor of Wnt signaling and COL11A1, which participates in oncogenic signaling, including TGFbeta). We will determine the ability of the p16 mutant to promote transformation and how it is influenced by interaction with the above candidate modifier genes, LGR6 or COL11A1, in pancreatic cancer and melanoma. We will also develop novel computational models using machine deep learning, to generate networks that capture high dimensional features to integrate gene, biology, and cancer phenotype. This approach will be extended to kindreds with other CDKN2A mutations. Our Specific Aims are to: (1) Identify genotypes of potential modifier genes in multiple kindreds that feature pancreatic cancer and melanoma and known to carry CDKN2A germline mutations. We will use genome wide variant coverage of germline DNA from CDKN2A carriers from the 4 large L16R kindreds, plus additional members in 42 other similar CDKN2A kindreds. We will identify candidate modifier genes in the kindreds by rule-based statistical genetic analysis of genotypes. (2) Define the impact of CDKN2A L16R mutation on the function of p16 and its interplay with candidate modifier genes. We will elucidate the biological significance of mutations in CDKN2A and candidate modifier genes using functional and high throughput methodologies by analyzing the mechanism underlying the interplay between p16 and modifier genes; define new pathways cooperating with this interplay using a combination of genome wide studies to assess transformation in cells carrying p16 mutant or wild-type background using well established in vitro and in vivo models. (3) Develop a deep learning network model to integrate genetic, biological and epidemiological data to accurately infer pancreatic cancer and melanoma phenotypes and age of onset in mutation carriers. We will apply a convolutional neural network, a deep learning algorithm in the training dataset, develop a back-propagation algorithm to fine tune weights, and construct mutation-gene networks to capture high-dimensional features for each disease subclass. We will acquire and disseminate new knowledge and tools to the scientific community. Our integrated methods and approach will bring insight into how different cancer phenotypes can occur with identical predisposing mutations, which can be applied to other cancer syndromes with similar challenges. PROJECT NARRATIVE This proposal addresses Provocative Question #2. We will use innovative approaches to investigate how CDKN2A (which encodes p16) mutation carriers develop different phenotypes (pancreatic cancer vs melanoma vs no cancer), and include both genetic and non-genetic factors. Using 4 large, multi-generational kindreds with a founder CDKN2A deleterious mutation and other kindreds, we will define the mechanism underlying the interplay between CDKN2A and other factors. We will develop novel computational models using machine deep learning, that integrate gene, biology, and cancer phenotype. We will share our new knowledge and tools with the scientific community, and bring insights to apply to other challenging cancer syndromes.",Determinants of pancreatic cancer and malignant melanoma phenotypes in CDKN2A hereditary kindreds,9172003,R01CA208517,"['Address', 'Affect', 'Age', 'Age of Onset', 'Algorithms', 'Alleles', 'Alzheimer&apos', 's Disease', 'Back', 'Biological', 'Biological Neural Networks', 'Brain Neoplasms', 'CDKN2A gene', 'Cancer Biology', 'Cancer Gene Mutation', 'Cell Cycle Progression', 'Cells', 'Code', 'Communities', 'Computer Simulation', 'Cyclin-Dependent Kinase Inhibitor 2A', 'DNA', 'Data', 'Data Set', 'Development', 'Diagnosis', 'Discrimination', 'Disease', 'Environmental Exposure', 'Epidemiology', 'Etiology', 'Gene Expression', 'Gene Frequency', 'Gene Mutation', 'Gene-Modified', 'Genes', 'Genetic', 'Genome', 'Genotype', 'Germ-Line Mutation', 'Group Processes', 'In Vitro', 'Individual', 'Inherited', 'Knowledge', 'Learning', 'Light', 'Malignant Neoplasms', 'Malignant neoplasm of pancreas', 'Measures', 'Methodology', 'Methods', 'Minor', 'Modeling', 'Molecular', 'Mutation', 'Oncogenic', 'Pathway interactions', 'Pattern', 'Penetrance', 'Performance', 'Phenotype', 'Processed Genes', 'Proteins', 'Proteomics', 'Risk', 'Signal Transduction', 'Smoking', 'Sun Exposure', 'Syndrome', 'Testing', 'Training', 'Transforming Growth Factor beta', 'Variant', 'Weight', 'base', 'bead chip', 'cancer genome', 'cell growth', 'disease phenotype', 'epigenomics', 'feeding', 'genetic analysis', 'genetic variant', 'genome-wide', 'genome-wide analysis', 'in vivo', 'in vivo Model', 'innovation', 'insight', 'interest', 'kindred', 'learning network', 'leukemia', 'melanoma', 'member', 'metaplastic cell transformation', 'mutant', 'mutation carrier', 'network models', 'non-genetic', 'novel', 'novel diagnostics', 'novel therapeutic intervention', 'overexpression', 'protein expression', 'receptor', 'tool', 'transcriptome sequencing', 'transmission process', 'tumorigenesis']",NCI,MAYO CLINIC ROCHESTER,R01,2016,578620,0.24184209262427062
"Integration of comprehensive cancer mutation and expression-associated data for biomarker evaluation and discovery ABSTRACT Current technologies for cancer genomics research generate petabytes of data that are dispersed across multiple archives in a non-standard fashion. This dispersal poses major challenges to comprehensive analyses based on the integration of such data. Two common types of secondary data generated from sequencing- based studies involve mutation and gene expression associated with the cancer state as inferred from comparing matched tumor and normal samples. Massive collaborations like the Cancer Genome Atlas (TCGA) and the International Cancer Genomic Consortium (ICGC) are instrumental in facilitating the generation of the sequence data and providing a modicum of standardization through best practices, but they do not always follow the same standards between projects. Moreover, proprietary databases like the Catalogue of Somatic Mutations in Cancer (COSMIC) generally store and annotate data in a format uniquely optimized for their own database to meet individual business needs. Thus, integrating mutation and expression data across resources involves a massive undertaking with efforts devoted to data curation, unification, harmonization, and appropriate annotation for proper representation at a central location. Additionally, it is difficult to comprehensively collect and map protein functional sites to the mutation sites from a variety of databases such as UniProt, RefSeq, and many others because the underlying sequences in these databases can be different. To address this challenge, the Early Detection Research Network (EDRN) Associate Membership funded the development of BioMuta and BioXpress, cancer-associated mutation and expression databases, respectively, to provide access to unified data from several popular cancer repositories and functional data from well-known molecular biology resources. Links to BioMuta are available through the EDRN portal and UniProt. The focus of the proposed project is to provide a custom portal encompassing up-to-date releases of BioMuta and BioXpress leveraging the existing EDRN framework and data. This will provide a broader understanding of the cancer landscape moving toward the proteomic space and working synergistically with other ITCR resources. To supplement these data, we further propose to integrate normal expression data across several species that can be used to derive a deeper understanding of the cancer-associated expression profiles. Text-mining support will also be applied to the identified cancer-related mutation and expression profiles for evidence to aid in interpretation of the findings. It is expected that such large-scale integration of cancer data and supporting information will not only benefit cancer research, but will also become a critical necessity for ensuring the most efficient synthesis of information and therefore the earliest detection methods possible. NARRATIVE The proposed research will simultaneously streamline and advance cancer biomarker identification pipelines by making various and numerous pre-analyzed cancer-relevant mutation and expression data, mapped to protein functional site data and protein functional information, available in a unified manner through a single user interface.",Integration of comprehensive cancer mutation and expression-associated data for biomarker evaluation and discovery,9689426,U01CA215010,"['Address', 'Advanced Malignant Neoplasm', 'Anatomy', 'Archives', 'Biological', 'Biological Markers', 'Businesses', 'Catalogs', 'Clinical', 'Clinical Data', 'Code', 'Collaborations', 'Communities', 'Complement', 'Custom', 'Data', 'Databases', 'Detection', 'Development', 'Disease', 'Early Detection Research Network', 'Early Diagnosis', 'Educational workshop', 'Ensure', 'Expression Profiling', 'Funding', 'Gene Expression', 'Generations', 'Genes', 'Goals', 'Individual', 'Infrastructure', 'International', 'Knowledge', 'Life', 'Link', 'Location', 'Malignant Neoplasms', 'Maps', 'Metadata', 'Methods', 'MicroRNAs', 'Molecular Biology', 'Mutation', 'NCI Thesaurus', 'Network Infrastructure', 'Ontology', 'Outcome', 'Pathway interactions', 'Pattern', 'Pilot Projects', 'Process', 'Proteins', 'Proteomics', 'Publications', 'Publishing', 'Recommendation', 'Research', 'Research Personnel', 'Resources', 'Sampling', 'Services', 'Site', 'Somatic Mutation', 'Source', 'Standardization', 'System', 'Technology', 'The Cancer Genome Atlas', 'Tissue-Specific Gene Expression', 'Tissues', 'Update', 'Visit', 'anticancer research', 'base', 'biomarker discovery', 'biomarker evaluation', 'biomarker identification', 'biomarker validation', 'cancer gene expression', 'cancer genomics', 'community involvement', 'differential expression', 'improved', 'information model', 'open source', 'petabyte', 'repository', 'text searching', 'tool', 'transcriptome sequencing', 'tumor', 'user-friendly', 'web portal']",NCI,GEORGE WASHINGTON UNIVERSITY,U01,2019,476699,0.25242411407502524
"Integration of comprehensive cancer mutation and expression-associated data for biomarker evaluation and discovery ABSTRACT Current technologies for cancer genomics research generate petabytes of data that are dispersed across multiple archives in a non-standard fashion. This dispersal poses major challenges to comprehensive analyses based on the integration of such data. Two common types of secondary data generated from sequencing- based studies involve mutation and gene expression associated with the cancer state as inferred from comparing matched tumor and normal samples. Massive collaborations like the Cancer Genome Atlas (TCGA) and the International Cancer Genomic Consortium (ICGC) are instrumental in facilitating the generation of the sequence data and providing a modicum of standardization through best practices, but they do not always follow the same standards between projects. Moreover, proprietary databases like the Catalogue of Somatic Mutations in Cancer (COSMIC) generally store and annotate data in a format uniquely optimized for their own database to meet individual business needs. Thus, integrating mutation and expression data across resources involves a massive undertaking with efforts devoted to data curation, unification, harmonization, and appropriate annotation for proper representation at a central location. Additionally, it is difficult to comprehensively collect and map protein functional sites to the mutation sites from a variety of databases such as UniProt, RefSeq, and many others because the underlying sequences in these databases can be different. To address this challenge, the Early Detection Research Network (EDRN) Associate Membership funded the development of BioMuta and BioXpress, cancer-associated mutation and expression databases, respectively, to provide access to unified data from several popular cancer repositories and functional data from well-known molecular biology resources. Links to BioMuta are available through the EDRN portal and UniProt. The focus of the proposed project is to provide a custom portal encompassing up-to-date releases of BioMuta and BioXpress leveraging the existing EDRN framework and data. This will provide a broader understanding of the cancer landscape moving toward the proteomic space and working synergistically with other ITCR resources. To supplement these data, we further propose to integrate normal expression data across several species that can be used to derive a deeper understanding of the cancer-associated expression profiles. Text-mining support will also be applied to the identified cancer-related mutation and expression profiles for evidence to aid in interpretation of the findings. It is expected that such large-scale integration of cancer data and supporting information will not only benefit cancer research, but will also become a critical necessity for ensuring the most efficient synthesis of information and therefore the earliest detection methods possible. NARRATIVE The proposed research will simultaneously streamline and advance cancer biomarker identification pipelines by making various and numerous pre-analyzed cancer-relevant mutation and expression data, mapped to protein functional site data and protein functional information, available in a unified manner through a single user interface.",Integration of comprehensive cancer mutation and expression-associated data for biomarker evaluation and discovery,9477546,U01CA215010,"['Address', 'Advanced Malignant Neoplasm', 'Anatomy', 'Archives', 'Biological', 'Biological Markers', 'Businesses', 'Catalogs', 'Clinical', 'Clinical Data', 'Code', 'Collaborations', 'Communities', 'Complement', 'Custom', 'Data', 'Databases', 'Detection', 'Development', 'Disease', 'Early Detection Research Network', 'Early Diagnosis', 'Educational workshop', 'Ensure', 'Expression Profiling', 'Funding', 'Gene Expression', 'Generations', 'Genes', 'Goals', 'Individual', 'International', 'Knowledge', 'Life', 'Link', 'Location', 'Malignant Neoplasms', 'Maps', 'Metadata', 'Methods', 'MicroRNAs', 'Molecular Biology', 'Mutation', 'NCI Thesaurus', 'Network Infrastructure', 'Ontology', 'Outcome', 'Pathway interactions', 'Pattern', 'Pilot Projects', 'Process', 'Proteins', 'Proteomics', 'Publications', 'Publishing', 'Recommendation', 'Research', 'Research Infrastructure', 'Research Personnel', 'Resources', 'Sampling', 'Services', 'Site', 'Somatic Mutation', 'Source', 'Standardization', 'System', 'Technology', 'The Cancer Genome Atlas', 'Tissue-Specific Gene Expression', 'Tissues', 'Update', 'Visit', 'anticancer research', 'base', 'biomarker discovery', 'biomarker evaluation', 'biomarker identification', 'biomarker validation', 'cancer gene expression', 'cancer genomics', 'differential expression', 'improved', 'information model', 'open source', 'petabyte', 'repository', 'text searching', 'tool', 'transcriptome sequencing', 'tumor', 'user-friendly', 'web portal']",NCI,GEORGE WASHINGTON UNIVERSITY,U01,2018,412470,0.25242411407502524
"Integration of comprehensive cancer mutation and expression-associated data for biomarker evaluation and discovery ABSTRACT Current technologies for cancer genomics research generate petabytes of data that are dispersed across multiple archives in a non-standard fashion. This dispersal poses major challenges to comprehensive analyses based on the integration of such data. Two common types of secondary data generated from sequencing- based studies involve mutation and gene expression associated with the cancer state as inferred from comparing matched tumor and normal samples. Massive collaborations like the Cancer Genome Atlas (TCGA) and the International Cancer Genomic Consortium (ICGC) are instrumental in facilitating the generation of the sequence data and providing a modicum of standardization through best practices, but they do not always follow the same standards between projects. Moreover, proprietary databases like the Catalogue of Somatic Mutations in Cancer (COSMIC) generally store and annotate data in a format uniquely optimized for their own database to meet individual business needs. Thus, integrating mutation and expression data across resources involves a massive undertaking with efforts devoted to data curation, unification, harmonization, and appropriate annotation for proper representation at a central location. Additionally, it is difficult to comprehensively collect and map protein functional sites to the mutation sites from a variety of databases such as UniProt, RefSeq, and many others because the underlying sequences in these databases can be different. To address this challenge, the Early Detection Research Network (EDRN) Associate Membership funded the development of BioMuta and BioXpress, cancer-associated mutation and expression databases, respectively, to provide access to unified data from several popular cancer repositories and functional data from well-known molecular biology resources. Links to BioMuta are available through the EDRN portal and UniProt. The focus of the proposed project is to provide a custom portal encompassing up-to-date releases of BioMuta and BioXpress leveraging the existing EDRN framework and data. This will provide a broader understanding of the cancer landscape moving toward the proteomic space and working synergistically with other ITCR resources. To supplement these data, we further propose to integrate normal expression data across several species that can be used to derive a deeper understanding of the cancer-associated expression profiles. Text-mining support will also be applied to the identified cancer-related mutation and expression profiles for evidence to aid in interpretation of the findings. It is expected that such large-scale integration of cancer data and supporting information will not only benefit cancer research, but will also become a critical necessity for ensuring the most efficient synthesis of information and therefore the earliest detection methods possible. NARRATIVE The proposed research will simultaneously streamline and advance cancer biomarker identification pipelines by making various and numerous pre-analyzed cancer-relevant mutation and expression data, mapped to protein functional site data and protein functional information, available in a unified manner through a single user interface.",Integration of comprehensive cancer mutation and expression-associated data for biomarker evaluation and discovery,9296729,U01CA215010,"['Address', 'Advanced Malignant Neoplasm', 'Anatomy', 'Archives', 'Biological', 'Biological Markers', 'Businesses', 'Catalogs', 'Clinical', 'Clinical Data', 'Code', 'Collaborations', 'Communities', 'Complement', 'Custom', 'Data', 'Databases', 'Detection', 'Development', 'Disease', 'Early Detection Research Network', 'Early Diagnosis', 'Educational workshop', 'Ensure', 'Funding', 'Gene Expression', 'Generations', 'Genes', 'Goals', 'Individual', 'International', 'Knowledge', 'Life', 'Link', 'Location', 'Malignant Neoplasms', 'Maps', 'Metadata', 'Methods', 'MicroRNAs', 'Molecular Biology', 'Molecular Profiling', 'Mutation', 'NCI Thesaurus', 'Network Infrastructure', 'Ontology', 'Outcome', 'Pathway interactions', 'Pattern', 'Pilot Projects', 'Process', 'Proteins', 'Proteomics', 'Publications', 'Publishing', 'Recommendation', 'Research', 'Research Infrastructure', 'Research Personnel', 'Resources', 'Sampling', 'Services', 'Site', 'Somatic Mutation', 'Source', 'Standardization', 'System', 'Technology', 'The Cancer Genome Atlas', 'Tissue-Specific Gene Expression', 'Tissues', 'Update', 'Validation', 'Visit', 'anticancer research', 'base', 'biomarker discovery', 'biomarker evaluation', 'biomarker identification', 'cancer gene expression', 'cancer genomics', 'differential expression', 'improved', 'information model', 'open source', 'petabyte', 'repository', 'text searching', 'tool', 'transcriptome sequencing', 'tumor', 'user-friendly', 'web portal']",NCI,GEORGE WASHINGTON UNIVERSITY,U01,2017,449998,0.25242411407502524
"Deep learning-based approach to identify non-coding cancer drivers that alter chromatin conformation Summary Most variants obtained from tumor whole-genome sequences (WGS) occur in non- coding regions of the genome. Although variants in protein-coding regions have received the majority of attention, numerous studies have now noted the importance of non- coding variants in cancer. Identification of functional non-coding variants that drive tumor growth remains a challenge and a bottleneck for the use of whole-genome sequencing in the clinic. Cancer drivers are generally identified by the high frequency at which their mutations occur across patients. However, mutation rate is highly heterogeneous in non- coding regions and many non-driver elements show higher mutation frequency than others, such as regions bound by transcription factors in melanoma or regions replicating late during cell division in colon cancer. In this proposal, we will use high- throughput pooled CRISPR screen and novel computational methods to predict non- coding cancer drivers. We will quantitatively measure the impact of thousands of non- coding mutations using our innovative high-throughput CRISPR screen that directly ties modifications in the native context of the non-coding genome (i.e. not a reporter assay) to a cancer relevant phenotype (cell growth). The results of the screen will be used as training data for the development of NC_Driver, a computational cancer driver prediction tool. NC_Driver will integrate the signals of high functional impact with the recurrence of variants across multiple tumor samples to identify the non-coding mutations under positive selection in cancer. We will identify drivers in promoters, enhancers and CTCF insulators. CTCF insulators are the most mutated yet least studied regulatory elements in the cancer genome. Using this integrative experimental and computational approach, we will identify high-confidence candidate drivers. Finally, we will perform functional evaluation of prioritized non-coding drivers in colorectal and prostate cancers. We will use CRISPR/Cas9 genome editing in patient-derived cell cultures to test 20 high-ranking candidate driver promoter/enhancer/insulator mutations. Overall, this proposal addresses the critical need to identify drivers in the non-coding genome and over long- term enable the maximal benefit of genome sequencing for each patient. Project Narrative Cancer genomes contain thousands of mutations but only a few of them play an important role in cancer proliferation and are called drivers. Most of the mutations occur in regions of the genome that do not make proteins, yet the majority of previous studies have focused on protein-coding regions. In this proposal, we will use integrative computational and experimental approaches to identify drivers in the non-protein-coding regions of the genome.",Deep learning-based approach to identify non-coding cancer drivers that alter chromatin conformation,9831005,R01CA218668,"['Accounting', 'Address', 'Attention', 'Benchmarking', 'Biological Assay', 'CRISPR screen', 'CRISPR/Cas technology', 'Cancer Patient', 'Catalogs', 'Cell Culture Techniques', 'Cell Line', 'Cell Survival', 'Cell division', 'Cells', 'Chromatin', 'Clinic', 'Clustered Regularly Interspaced Short Palindromic Repeats', 'Code', 'Colon', 'Colon Carcinoma', 'Colorectal Cancer', 'Computer Simulation', 'Computing Methodologies', 'DNA Sequence', 'Data', 'Development', 'Disease', 'Dissection', 'Elements', 'Enhancers', 'Evaluation', 'Frequencies', 'Gene Expression', 'Genes', 'Genetic', 'Genome', 'Heterogeneity', 'Institutes', 'Knock-in', 'Learning', 'Malignant Neoplasms', 'Malignant neoplasm of prostate', 'Measures', 'Methods', 'Modification', 'Molecular Conformation', 'Mutagenesis', 'Mutate', 'Mutation', 'Nature', 'Open Reading Frames', 'Parents', 'Patients', 'Phenotype', 'Play', 'Prostate', 'Proteins', 'Recurrence', 'Regulatory Element', 'Reporter', 'Research', 'Role', 'Running', 'Sampling', 'Screening Result', 'Signal Transduction', 'Somatic Mutation', 'Statistical Algorithm', 'Structure', 'Targeted Resequencing', 'Testing', 'Training', 'Transcript', 'Untranslated RNA', 'Validation', 'Variant', 'Xenograft procedure', 'actionable mutation', 'base', 'biobank', 'cancer genome', 'cancer type', 'cell growth', 'cohort', 'colon cancer cell line', 'deep learning', 'genome editing', 'genome sequencing', 'genome-wide', 'high throughput screening', 'innovation', 'knock-down', 'melanoma', 'novel', 'precision medicine', 'promoter', 'tool', 'transcription factor', 'tumor', 'tumor growth', 'tumor heterogeneity', 'tumor microenvironment', 'tumorigenesis', 'tumorigenic', 'whole genome']",NCI,WEILL MEDICAL COLL OF CORNELL UNIV,R01,2019,113967,0.16889000858934705
"Reverse Sensitivity Analysis for Identifying Predictive Proteomics Signatures of Cancer Title: Reverse Sensitivity Analysis for Identifying Proteomics Signatures of Cancer Abstract Cancer is a complex disease in which genetic disruptions in cell signaling networks are known to play a significant role. A major aim of cancer systems biology is to build models that can predict the impact of these genetic disruptions to guide therapeutic interventions (i.e. personalized medicine). A prominent driver of cancer cell growth is signaling pathway deregulation from mutations in key regulatory nodes and loss/gain in gene copy number (CNV). However, current mathematical modeling approaches do not adequately capture the impact of these genetic changes. Reasons for this include the poorly understood layers of regulation between gene expression and protein activity, and limitations in most modeling and protein measurement technologies. In addition, there is a paucity of overarching hypotheses that can link specific gene expression or mutation patterns to the cancer phenotype. Recent work by our group has resolved some of the technical challenges that have hindered the application of proteomics technologies to cancer systems biology research. It has also suggested a new approach for using quantitative proteomics data to understand mechanisms driving cancer cell behavior. Using an ultrasensitive, targeted proteomics platform that can measure both abundance and phosphorylation of proteins present at only hundreds of copies per cell, we found that signaling pathways appeared to be controlled by only a limited number of key nodes whose activity is tightly regulated through low abundance and feedback phosphorylation. We propose to build on these findings by critically testing the hypothesis that CNV and genetic mutations dysregulate signaling pathways in cancer by shifting control from tightly regulated nodes to poorly regulated ones. This will be done by systematically identifying key regulatory nodes of normal and cancer cells using CRISPRa/i screens, determine the relationship between protein abundance and signaling pathway activities using ultrasensitive targeted proteomics and phosphoproteomics and then use these data to semi-automatically generate mathematical models of the functional topology of the signaling pathways. Specifically, we propose to: 1) Use targeted CRISPR gene perturbation libraries to identify the regulatory topologies of signaling pathways important in cancer and how they are disrupted by common cancer mutations, 2) Use the CRISPR perturbation and proteomics data to semi-automatically build predictive models of cancer cell signaling pathways, and 3) Combine modeling and perturbation screens to understand how feedback regulation in cancer contributes to drug resistance. This work will result in simplified, computationally tractable yet mechanistic models of signaling pathways and provide network maps of feedback and crosstalk circuits that can be used to rapidly map the regulatory state of cells. Most important, it will provide a generic platform for translating protein abundance and phosphorylation patterns into a state snapshot of cancers that can lead to predicting their response to specific drugs. Narrative Cancer is an extremely complex disease which is frequently caused by signaling pathway deregulation from genetic mutation or loss/gain in gene copy number. Modern analytical techniques have provided a wealth of data on the molecular changes associated with cancer mutations, but it has been extremely difficult to use this information to design targeted therapies. We propose a new methodology that combines CRISPR-based targeted screens, advanced proteomics technologies, and a new mathematical modeling approach for identifying proteomics signatures of altered signaling pathways in cancer that can be used to build predictive models and explore mechanisms of drug resistance.",Reverse Sensitivity Analysis for Identifying Predictive Proteomics Signatures of Cancer,9923630,U01CA227544,"['Address', 'Affect', 'Automobile Driving', 'Behavior', 'Biological Models', 'Breast Cancer cell line', 'Breast Epithelial Cells', 'CRISPR library', 'Cancer Cell Growth', 'Cells', 'Clustered Regularly Interspaced Short Palindromic Repeats', 'Complex', 'Computer Models', 'DNA Sequence Alteration', 'Data', 'Development', 'Disease', 'Drug resistance', 'Feedback', 'Flow Cytometry', 'Gene Dosage', 'Gene Expression', 'Gene Mutation', 'Gene Proteins', 'Generations', 'Genes', 'Genetic', 'Lead', 'Libraries', 'Link', 'Machine Learning', 'Malignant Neoplasms', 'Maps', 'Measurement', 'Measures', 'Methodology', 'Methods', 'Modeling', 'Modernization', 'Molecular', 'Mutate', 'Mutation', 'Normal Cell', 'Pathway interactions', 'Pattern', 'Pharmaceutical Preparations', 'Phenotype', 'Phosphorylation', 'Play', 'Predictive Cancer Model', 'Proteins', 'Proteomics', 'Proto-Oncogene Proteins c-akt', 'Reagent', 'Regulation', 'Research', 'Resistance', 'Role', 'Signal Pathway', 'Signal Transduction', 'Systems Biology', 'Techniques', 'Technology', 'Testing', 'Therapeutic Intervention', 'Translating', 'Work', 'base', 'cancer cell', 'cancer type', 'cell behavior', 'design', 'experimental study', 'mathematical model', 'melanoma', 'novel strategies', 'personalized medicine', 'phosphoproteomics', 'predictive modeling', 'proteomic signature', 'response', 'screening', 'targeted treatment', 'tool']",NCI,BATTELLE PACIFIC NORTHWEST LABORATORIES,U01,2020,715682,0.10782315501630904
"Reverse Sensitivity Analysis for Identifying Predictive Proteomics Signatures of Cancer Title: Reverse Sensitivity Analysis for Identifying Proteomics Signatures of Cancer Abstract Cancer is a complex disease in which genetic disruptions in cell signaling networks are known to play a significant role. A major aim of cancer systems biology is to build models that can predict the impact of these genetic disruptions to guide therapeutic interventions (i.e. personalized medicine). A prominent driver of cancer cell growth is signaling pathway deregulation from mutations in key regulatory nodes and loss/gain in gene copy number (CNV). However, current mathematical modeling approaches do not adequately capture the impact of these genetic changes. Reasons for this include the poorly understood layers of regulation between gene expression and protein activity, and limitations in most modeling and protein measurement technologies. In addition, there is a paucity of overarching hypotheses that can link specific gene expression or mutation patterns to the cancer phenotype. Recent work by our group has resolved some of the technical challenges that have hindered the application of proteomics technologies to cancer systems biology research. It has also suggested a new approach for using quantitative proteomics data to understand mechanisms driving cancer cell behavior. Using an ultrasensitive, targeted proteomics platform that can measure both abundance and phosphorylation of proteins present at only hundreds of copies per cell, we found that signaling pathways appeared to be controlled by only a limited number of key nodes whose activity is tightly regulated through low abundance and feedback phosphorylation. We propose to build on these findings by critically testing the hypothesis that CNV and genetic mutations dysregulate signaling pathways in cancer by shifting control from tightly regulated nodes to poorly regulated ones. This will be done by systematically identifying key regulatory nodes of normal and cancer cells using CRISPRa/i screens, determine the relationship between protein abundance and signaling pathway activities using ultrasensitive targeted proteomics and phosphoproteomics and then use these data to semi-automatically generate mathematical models of the functional topology of the signaling pathways. Specifically, we propose to: 1) Use targeted CRISPR gene perturbation libraries to identify the regulatory topologies of signaling pathways important in cancer and how they are disrupted by common cancer mutations, 2) Use the CRISPR perturbation and proteomics data to semi-automatically build predictive models of cancer cell signaling pathways, and 3) Combine modeling and perturbation screens to understand how feedback regulation in cancer contributes to drug resistance. This work will result in simplified, computationally tractable yet mechanistic models of signaling pathways and provide network maps of feedback and crosstalk circuits that can be used to rapidly map the regulatory state of cells. Most important, it will provide a generic platform for translating protein abundance and phosphorylation patterns into a state snapshot of cancers that can lead to predicting their response to specific drugs. Narrative Cancer is an extremely complex disease which is frequently caused by signaling pathway deregulation from genetic mutation or loss/gain in gene copy number. Modern analytical techniques have provided a wealth of data on the molecular changes associated with cancer mutations, but it has been extremely difficult to use this information to design targeted therapies. We propose a new methodology that combines CRISPR-based targeted screens, advanced proteomics technologies, and a new mathematical modeling approach for identifying proteomics signatures of altered signaling pathways in cancer that can be used to build predictive models and explore mechanisms of drug resistance.",Reverse Sensitivity Analysis for Identifying Predictive Proteomics Signatures of Cancer,9731187,U01CA227544,"['Address', 'Affect', 'Automobile Driving', 'Behavior', 'Biological Models', 'Breast Cancer cell line', 'Breast Epithelial Cells', 'CRISPR library', 'Cancer Cell Growth', 'Cells', 'Clustered Regularly Interspaced Short Palindromic Repeats', 'Complex', 'Computer Simulation', 'DNA Sequence Alteration', 'Data', 'Development', 'Disease', 'Drug resistance', 'Feedback', 'Flow Cytometry', 'Gene Dosage', 'Gene Expression', 'Gene Mutation', 'Gene Proteins', 'Generations', 'Genes', 'Genetic', 'Lead', 'Libraries', 'Link', 'Machine Learning', 'Malignant Neoplasms', 'Maps', 'Measurement', 'Measures', 'Methodology', 'Methods', 'Modeling', 'Modernization', 'Molecular', 'Mutate', 'Mutation', 'Normal Cell', 'Pathway interactions', 'Pattern', 'Pharmaceutical Preparations', 'Phenotype', 'Phosphorylation', 'Play', 'Predictive Cancer Model', 'Proteins', 'Proteomics', 'Proto-Oncogene Proteins c-akt', 'Reagent', 'Regulation', 'Research', 'Resistance', 'Role', 'Signal Pathway', 'Signal Transduction', 'Systems Biology', 'Techniques', 'Technology', 'Testing', 'Therapeutic Intervention', 'Translating', 'Work', 'base', 'cancer cell', 'cancer type', 'cell behavior', 'design', 'experimental study', 'mathematical model', 'melanoma', 'novel strategies', 'personalized medicine', 'phosphoproteomics', 'predictive modeling', 'proteomic signature', 'response', 'screening', 'targeted treatment', 'tool']",NCI,BATTELLE PACIFIC NORTHWEST LABORATORIES,U01,2019,608348,0.10782315501630904
"A statistical framework to systematically characterize cancer driver mutations in noncoding genomic regions PROJECT SUMMARY Cancer genomes typically harbor a substantial number of somatic mutations. Relatively few driver mutations actually alter the function of proteins in tumor cells, whereas most mutations are considered to be functionally neutral passenger mutations. Over the past decade, the search for cancer driver mutations has focused on coding regions and several mutational significance algorithms have been developed for coding mutations. The contribution of mutations in noncoding regulatory regions to tumor formation largely remains unknown and current mutational significance algorithms are not designed to detect driver mutations in noncoding regions, due to biological differences between coding and noncoding mutations. The emerging availability of large whole- genome sequencing datasets (e.g. PCAWG and HMF datasets) creates an ample opportunity to develop new mutational significance algorithms that are particularly designed for the interpretation of noncoding regions. Recently, we have developed a new statistical approach that identifies driver mutations in coding regions based on the nucleotide context. Critically, consideration of the nucleotide context around mutations does not require prior knowledge for functional consequences associated with these mutations. Hence, we hypothesize that generalizing our nucleotide context model to noncoding regions will uncover novel noncoding driver mutations that cannot be detected using the mutational significance approaches currently available. For this purpose, we will develop a statistical framework that incorporates the biological differences between coding and noncoding mutations and that is specifically designed to detect driver mutations in noncoding regions. Specifically, we will consider the context-dependent distribution of passenger mutations, modeling of the background mutation rate, accurately partition the background mutation rate, model the sequence composition of the reference genome, and account for coverage fluctuation. We will then combine these statistical components by computing an independent product of their underlying probabilities. We will derive a significance p-value using a Monte-Carlo simulation approach, and use FDR for multiple hypothesis test correction. This strategy will allow us to accurately estimate the significance of somatic mutations in noncoding genomic regions. We will next apply this statistical framework to whole-genome sequencing data of 5,523 tumor patients, thereby deriving a comprehensive list of candidate driver mutations in noncoding regions. Finally, we will investigate whether noncoding mutations are overrepresented in transcription factor binding sites, regulate gene expression levels, induce alternative splicing, or affect epigenomic states. Upon the completion of this project, we will have developed and applied a statistical framework for discovery of significant somatic mutations in noncoding regions, and defined the mutational landscape of the non-coding cancer genome. All aspects of the methods developed and applied in this project will be made open source and developed in an online platform. PROJECT NARRATIVE While coding cancer driver mutations have been characterized in detail over the past decade, the contribution of noncoding mutations to tumor formation remains - apart from few examples (e.g. mutations in TERT promoters) - largely unknown. Recently, large-scale whole-genome sequencing datasets have been made available, but a major bottleneck for the biological and clinical interpretation of these cancer whole-genome cohorts is the lack of statistical models that identify driver mutations in noncoding regions. We developed a new statistical approach that characterizes driver mutations based on their surrounding nucleotide context in coding regions, and herein we propose a concrete plan to generalize our computational model to noncoding regions, apply our model to aggregated whole-genome sequencing data of 5,523 tumor patients (PCAWG, HMF datasets), and define the noncoding driver and passenger mutational landscape for biological discovery and focused clinical application.",A statistical framework to systematically characterize cancer driver mutations in noncoding genomic regions,10260680,R21CA242861,"['Address', 'Affect', 'Algorithms', 'Alternative Splicing', 'Attention', 'Binding Sites', 'Biological', 'Biological Process', 'Biology', 'Clinical', 'Code', 'Communities', 'Computational Biology', 'Computer Models', 'Data', 'Data Set', 'Development', 'Gene Expression', 'Gene Expression Regulation', 'Genomic Segment', 'Immunotherapy', 'Knowledge', 'Machine Learning', 'Malignant Neoplasms', 'Mediating', 'Methods', 'Microsatellite Instability', 'Modeling', 'Monte Carlo Method', 'Mutation', 'Nucleic Acid Regulatory Sequences', 'Nucleotides', 'Outcome', 'Patients', 'Pattern', 'Play', 'Positioning Attribute', 'Probability', 'Process', 'Role', 'Somatic Mutation', 'Statistical Models', 'Stratification', 'Testing', 'The Cancer Genome Atlas', 'Untranslated RNA', 'base', 'cancer genome', 'cancer immunotherapy', 'checkpoint therapy', 'clinical application', 'clinical effect', 'cohort', 'design', 'driver mutation', 'epigenomics', 'exome sequencing', 'genome sequencing', 'genome-wide', 'immune checkpoint blockade', 'immunogenicity', 'large datasets', 'malignant breast neoplasm', 'melanoma', 'mutant', 'neoantigens', 'neoplastic cell', 'novel', 'open source', 'predicting response', 'promoter', 'protein function', 'reference genome', 'response', 'targeted treatment', 'transcription factor', 'tumor', 'whole genome']",NCI,DANA-FARBER CANCER INST,R21,2020,177000,0.32560919373632513
"A statistical framework to systematically characterize cancer driver mutations in noncoding genomic regions PROJECT SUMMARY Cancer genomes typically harbor a substantial number of somatic mutations. Relatively few driver mutations actually alter the function of proteins in tumor cells, whereas most mutations are considered to be functionally neutral passenger mutations. Over the past decade, the search for cancer driver mutations has focused on coding regions and several mutational significance algorithms have been developed for coding mutations. The contribution of mutations in noncoding regulatory regions to tumor formation largely remains unknown and current mutational significance algorithms are not designed to detect driver mutations in noncoding regions, due to biological differences between coding and noncoding mutations. The emerging availability of large whole- genome sequencing datasets (e.g. PCAWG and HMF datasets) creates an ample opportunity to develop new mutational significance algorithms that are particularly designed for the interpretation of noncoding regions. Recently, we have developed a new statistical approach that identifies driver mutations in coding regions based on the nucleotide context. Critically, consideration of the nucleotide context around mutations does not require prior knowledge for functional consequences associated with these mutations. Hence, we hypothesize that generalizing our nucleotide context model to noncoding regions will uncover novel noncoding driver mutations that cannot be detected using the mutational significance approaches currently available. For this purpose, we will develop a statistical framework that incorporates the biological differences between coding and noncoding mutations and that is specifically designed to detect driver mutations in noncoding regions. Specifically, we will consider the context-dependent distribution of passenger mutations, modeling of the background mutation rate, accurately partition the background mutation rate, model the sequence composition of the reference genome, and account for coverage fluctuation. We will then combine these statistical components by computing an independent product of their underlying probabilities. We will derive a significance p-value using a Monte-Carlo simulation approach, and use FDR for multiple hypothesis test correction. This strategy will allow us to accurately estimate the significance of somatic mutations in noncoding genomic regions. We will next apply this statistical framework to whole-genome sequencing data of 5,523 tumor patients, thereby deriving a comprehensive list of candidate driver mutations in noncoding regions. Finally, we will investigate whether noncoding mutations are overrepresented in transcription factor binding sites, regulate gene expression levels, induce alternative splicing, or affect epigenomic states. Upon the completion of this project, we will have developed and applied a statistical framework for discovery of significant somatic mutations in noncoding regions, and defined the mutational landscape of the non-coding cancer genome. All aspects of the methods developed and applied in this project will be made open source and developed in an online platform. PROJECT NARRATIVE While coding cancer driver mutations have been characterized in detail over the past decade, the contribution of noncoding mutations to tumor formation remains - apart from few examples (e.g. mutations in TERT promoters) - largely unknown. Recently, large-scale whole-genome sequencing datasets have been made available, but a major bottleneck for the biological and clinical interpretation of these cancer whole-genome cohorts is the lack of statistical models that identify driver mutations in noncoding regions. We developed a new statistical approach that characterizes driver mutations based on their surrounding nucleotide context in coding regions, and herein we propose a concrete plan to generalize our computational model to noncoding regions, apply our model to aggregated whole-genome sequencing data of 5,523 tumor patients (PCAWG, HMF datasets), and define the noncoding driver and passenger mutational landscape for biological discovery and focused clinical application.",A statistical framework to systematically characterize cancer driver mutations in noncoding genomic regions,9957082,R21CA242861,"['Address', 'Affect', 'Algorithms', 'Alternative Splicing', 'Attention', 'Binding Sites', 'Biological', 'Biological Process', 'Biology', 'Clinical', 'Code', 'Communities', 'Computational Biology', 'Computer Models', 'Data', 'Data Set', 'Development', 'Gene Expression', 'Gene Expression Regulation', 'Genomic Segment', 'Immunotherapy', 'Knowledge', 'Machine Learning', 'Malignant Neoplasms', 'Mediating', 'Methods', 'Microsatellite Instability', 'Modeling', 'Monte Carlo Method', 'Mutation', 'Nucleic Acid Regulatory Sequences', 'Nucleotides', 'Outcome', 'Patients', 'Pattern', 'Play', 'Positioning Attribute', 'Probability', 'Process', 'Role', 'Somatic Mutation', 'Statistical Models', 'Stratification', 'Testing', 'The Cancer Genome Atlas', 'Untranslated RNA', 'base', 'cancer genome', 'cancer immunotherapy', 'checkpoint therapy', 'clinical application', 'clinical effect', 'cohort', 'design', 'driver mutation', 'epigenomics', 'exome sequencing', 'genome sequencing', 'genome-wide', 'immune checkpoint blockade', 'immunogenicity', 'large datasets', 'malignant breast neoplasm', 'melanoma', 'mutant', 'neoantigens', 'neoplastic cell', 'novel', 'open source', 'predicting response', 'promoter', 'protein function', 'reference genome', 'response', 'targeted treatment', 'transcription factor', 'tumor', 'whole genome']",NCI,DANA-FARBER CANCER INST,R21,2020,193576,0.32560919373632513
"A statistical framework to systematically characterize cancer driver mutations in noncoding genomic regions PROJECT SUMMARY Cancer genomes typically harbor a substantial number of somatic mutations. Relatively few driver mutations actually alter the function of proteins in tumor cells, whereas most mutations are considered to be functionally neutral passenger mutations. Over the past decade, the search for cancer driver mutations has focused on coding regions and several mutational significance algorithms have been developed for coding mutations. The contribution of mutations in noncoding regulatory regions to tumor formation largely remains unknown and current mutational significance algorithms are not designed to detect driver mutations in noncoding regions, due to biological differences between coding and noncoding mutations. The emerging availability of large whole- genome sequencing datasets (e.g. PCAWG and HMF datasets) creates an ample opportunity to develop new mutational significance algorithms that are particularly designed for the interpretation of noncoding regions. Recently, we have developed a new statistical approach that identifies driver mutations in coding regions based on the nucleotide context. Critically, consideration of the nucleotide context around mutations does not require prior knowledge for functional consequences associated with these mutations. Hence, we hypothesize that generalizing our nucleotide context model to noncoding regions will uncover novel noncoding driver mutations that cannot be detected using the mutational significance approaches currently available. For this purpose, we will develop a statistical framework that incorporates the biological differences between coding and noncoding mutations and that is specifically designed to detect driver mutations in noncoding regions. Specifically, we will consider the context-dependent distribution of passenger mutations, modeling of the background mutation rate, accurately partition the background mutation rate, model the sequence composition of the reference genome, and account for coverage fluctuation. We will then combine these statistical components by computing an independent product of their underlying probabilities. We will derive a significance p-value using a Monte-Carlo simulation approach, and use FDR for multiple hypothesis test correction. This strategy will allow us to accurately estimate the significance of somatic mutations in noncoding genomic regions. We will next apply this statistical framework to whole-genome sequencing data of 5,523 tumor patients, thereby deriving a comprehensive list of candidate driver mutations in noncoding regions. Finally, we will investigate whether noncoding mutations are overrepresented in transcription factor binding sites, regulate gene expression levels, induce alternative splicing, or affect epigenomic states. Upon the completion of this project, we will have developed and applied a statistical framework for discovery of significant somatic mutations in noncoding regions, and defined the mutational landscape of the non-coding cancer genome. All aspects of the methods developed and applied in this project will be made open source and developed in an online platform. PROJECT NARRATIVE While coding cancer driver mutations have been characterized in detail over the past decade, the contribution of noncoding mutations to tumor formation remains - apart from few examples (e.g. mutations in TERT promoters) - largely unknown. Recently, large-scale whole-genome sequencing datasets have been made available, but a major bottleneck for the biological and clinical interpretation of these cancer whole-genome cohorts is the lack of statistical models that identify driver mutations in noncoding regions. We developed a new statistical approach that characterizes driver mutations based on their surrounding nucleotide context in coding regions, and herein we propose a concrete plan to generalize our computational model to noncoding regions, apply our model to aggregated whole-genome sequencing data of 5,523 tumor patients (PCAWG, HMF datasets), and define the noncoding driver and passenger mutational landscape for biological discovery and focused clinical application.",A statistical framework to systematically characterize cancer driver mutations in noncoding genomic regions,9825986,R21CA242861,"['Address', 'Affect', 'Algorithms', 'Alternative Splicing', 'Attention', 'Binding Sites', 'Biological', 'Biological Process', 'Biology', 'Clinical', 'Code', 'Communities', 'Computational Biology', 'Computer Simulation', 'Data', 'Data Set', 'Development', 'Gene Expression', 'Gene Expression Regulation', 'Genomic Segment', 'Immunotherapy', 'Knowledge', 'Machine Learning', 'Malignant Neoplasms', 'Mediating', 'Methods', 'Microsatellite Instability', 'Modeling', 'Monte Carlo Method', 'Mutation', 'Nucleic Acid Regulatory Sequences', 'Nucleotides', 'Outcome', 'Patients', 'Pattern', 'Play', 'Positioning Attribute', 'Probability', 'Process', 'Role', 'Somatic Mutation', 'Statistical Models', 'Stratification', 'Testing', 'The Cancer Genome Atlas', 'Untranslated RNA', 'actionable mutation', 'base', 'cancer genome', 'cancer immunotherapy', 'checkpoint therapy', 'clinical application', 'clinical effect', 'cohort', 'design', 'epigenomics', 'exome sequencing', 'genome sequencing', 'genome-wide', 'immune checkpoint blockade', 'immunogenicity', 'malignant breast neoplasm', 'melanoma', 'mutant', 'neoantigens', 'neoplastic cell', 'novel', 'open source', 'predicting response', 'promoter', 'protein function', 'reference genome', 'response', 'targeted treatment', 'transcription factor', 'tumor', 'whole genome']",NCI,DANA-FARBER CANCER INST,R21,2019,232291,0.32560919373632513
"Clinicopathologic and Genetic Profiling through Machine Learning and Natural Language Processing for Precision Lung Cancer Management PROJECT SUMMARY/ABSTRACT Lung cancer is the second-most common type of cancer and the leading cause of cancer death in men and women. Among the different types of lung cancer, non-small cell lung cancer (NSCLC) is the most common type and it constitutes 85% to 90% of all lung cancer cases. Current cancer research has shown that multiple somatic mutations affect the sensitivity of patients to various drugs used for NSCLC treatment. These mutations are essential factors for determining the most effective, personalized treatment for each NSCLC patient; however, most NSCLC patients develop resistance to these targeted therapies in their first year of treatment. Many mechanisms of this resistance are still unknown. Designing and prescribing better targeted therapies for NSCLC patients requires further understanding, particularly with respect to the relationship between NSCLC tumors pathological and clinical findings, genetic profiles, and targeted therapy responses/resistance. Currently, there is no computational method to connect observations and findings from pathology reports, medical records, somatic mutations, and the targeted therapy resistance. This project provides a plan to build a novel computational method to identify statistically significant associations between the pathological findings of NSCLC tumors and the presence of clinically-actionable somatic mutations. Furthermore, these associations, in combination with an innovative set of feature analysis from pathology reports and electronic medical records, will be leveraged to build and validate a machine-learning model to identify NSCLC patients with clinically-actionable somatic mutations. Finally, the associated clinical, pathological, and genetic findings for NSCLC patients will be used in a new machine-learning framework to predict patients time-to-resistance to targeted therapies. The required data to build and validate the proposed models in this project will be obtained through a collaboration with the Department of Pathologys Laboratory for Clinical Genomics and Advanced Technologies at Dartmouth-Hitchcock Medical Center. In addition to internal validation, the investigators in this proposal established a collaboration with the Department of Pathology at the University of Vermont Medical Center to apply and validate the developed models on an external data source. Upon successful implementation of this bioinformatics approach, the developed models will be able to reveal statistically significant links between clinical and pathological findings, clinically-actionable somatic mutations, and targeted-therapy responses for a better understanding of NSCLC tumor development and treatment. The proposed approach will provide an accurate, fast, and inexpensive pre- selection method for screening NSCLC patients with clinically-actionable mutations for translational research and precision medicine. Furthermore, the proposed machine-learning method to identify NSCLC patients resistance to targeted therapies will help healthcare providers to select the best treatment strategies for these patients, improve their health outcomes, and establish this precision medicine paradigm for other types of cancer. PROJECT NARRATIVE Resistance to targeted therapies severely limits the ability to treat non-small cell lung cancer (NSCLC) patients. This project proposes a novel computational approach to find statistically-significant links between pathological and clinical findings, clinically-actionable mutations, and targeted-therapy responses for NSCLC patients. The outcomes of this proposal can assist healthcare providers to identify the most effective strategy for NSCLC treatment, improve public health, and promote precision medicine.",Clinicopathologic and Genetic Profiling through Machine Learning and Natural Language Processing for Precision Lung Cancer Management,10023259,R01CA249758,"['Affect', 'Architecture', 'Attention', 'Bioinformatics', 'Biological Markers', 'Cancer Etiology', 'Cancer Patient', 'Cessation of life', 'Characteristics', 'Clinical', 'Clinical Data', 'Clinical Decision Support Systems', 'Collaborations', 'Colorectal Cancer', 'Computer Models', 'Computerized Medical Record', 'Computing Methodologies', 'DNA Sequence Alteration', 'Data', 'Data Set', 'Data Sources', 'Development', 'Drug resistance', 'Drug usage', 'Family', 'Foundations', 'Genetic', 'Genomics', 'Glioblastoma', 'Health', 'Health Personnel', 'Healthcare', 'Information Retrieval', 'Knowledge', 'Laboratories', 'Link', 'Machine Learning', 'Malignant neoplasm of lung', 'Measures', 'Medical', 'Medical Records', 'Medical center', 'Methodology', 'Methods', 'Modeling', 'Mutation', 'Natural Language Processing', 'Non-Small-Cell Lung Carcinoma', 'Ontology', 'Outcome', 'Pathologic', 'Pathology', 'Pathology Report', 'Pathway interactions', 'Patients', 'Pattern', 'Performance', 'Pharmaceutical Preparations', 'Public Health', 'Recording of previous events', 'Recurrence', 'Research Personnel', 'Resistance', 'Resistance development', 'Second Primary Cancers', 'Semantics', 'Smoking Status', 'Somatic Mutation', 'Statistical Methods', 'Technology', 'Testing', 'Time', 'Tissues', 'Translational Research', 'Tumor Pathology', 'United States National Institutes of Health', 'Universities', 'Validation', 'Vermont', 'Woman', 'Work', 'actionable mutation', 'anticancer research', 'base', 'cancer cell', 'cancer therapy', 'cancer type', 'clinically actionable', 'demographics', 'design', 'electronic data', 'genetic profiling', 'improved', 'innovation', 'machine learning method', 'malignant breast neoplasm', 'melanoma', 'men', 'novel', 'personalized medicine', 'power analysis', 'precision medicine', 'resistance mechanism', 'response', 'screening', 'targeted cancer therapy', 'targeted treatment', 'treatment response', 'treatment strategy', 'tumor']",NCI,DARTMOUTH COLLEGE,R01,2020,375150,0.04909952117799148
"Clinicopathologic and Genetic Profiling through Machine Learning and Natural Language Processing for Precision Lung Cancer Management PROJECT SUMMARY/ABSTRACT Lung cancer is the second-most common type of cancer and the leading cause of cancer death in men and women. Among the different types of lung cancer, non-small cell lung cancer (NSCLC) is the most common type and it constitutes 85% to 90% of all lung cancer cases. Current cancer research has shown that multiple somatic mutations affect the sensitivity of patients to various drugs used for NSCLC treatment. These mutations are essential factors for determining the most effective, personalized treatment for each NSCLC patient; however, most NSCLC patients develop resistance to these targeted therapies in their first year of treatment. Many mechanisms of this resistance are still unknown. Designing and prescribing better targeted therapies for NSCLC patients requires further understanding, particularly with respect to the relationship between NSCLC tumors pathological and clinical findings, genetic profiles, and targeted therapy responses/resistance. Currently, there is no computational method to connect observations and findings from pathology reports, medical records, somatic mutations, and the targeted therapy resistance. This project provides a plan to build a novel computational method to identify statistically significant associations between the pathological findings of NSCLC tumors and the presence of clinically-actionable somatic mutations. Furthermore, these associations, in combination with an innovative set of feature analysis from pathology reports and electronic medical records, will be leveraged to build and validate a machine-learning model to identify NSCLC patients with clinically-actionable somatic mutations. Finally, the associated clinical, pathological, and genetic findings for NSCLC patients will be used in a new machine-learning framework to predict patients time-to-resistance to targeted therapies. The required data to build and validate the proposed models in this project will be obtained through a collaboration with the Department of Pathologys Laboratory for Clinical Genomics and Advanced Technologies at Dartmouth-Hitchcock Medical Center. In addition to internal validation, the investigators in this proposal established a collaboration with the Department of Pathology at the University of Vermont Medical Center to apply and validate the developed models on an external data source. Upon successful implementation of this bioinformatics approach, the developed models will be able to reveal statistically significant links between clinical and pathological findings, clinically-actionable somatic mutations, and targeted-therapy responses for a better understanding of NSCLC tumor development and treatment. The proposed approach will provide an accurate, fast, and inexpensive pre- selection method for screening NSCLC patients with clinically-actionable mutations for translational research and precision medicine. Furthermore, the proposed machine-learning method to identify NSCLC patients resistance to targeted therapies will help healthcare providers to select the best treatment strategies for these patients, improve their health outcomes, and establish this precision medicine paradigm for other types of cancer. PROJECT NARRATIVE Resistance to targeted therapies severely limits the ability to treat non-small cell lung cancer (NSCLC) patients. This project proposes a novel computational approach to find statistically-significant links between pathological and clinical findings, clinically-actionable mutations, and targeted-therapy responses for NSCLC patients. The outcomes of this proposal can assist healthcare providers to identify the most effective strategy for NSCLC treatment, improve public health, and promote precision medicine.",Clinicopathologic and Genetic Profiling through Machine Learning and Natural Language Processing for Precision Lung Cancer Management,9726144,R01CA249758,"['Affect', 'Architecture', 'Attention', 'Bioinformatics', 'Biological Markers', 'Cancer Etiology', 'Cancer Patient', 'Cessation of life', 'Characteristics', 'Clinical', 'Clinical Data', 'Clinical Decision Support Systems', 'Collaborations', 'Colorectal Cancer', 'Computer Simulation', 'Computerized Medical Record', 'Computing Methodologies', 'DNA Sequence Alteration', 'Data', 'Data Set', 'Data Sources', 'Development', 'Drug resistance', 'Drug usage', 'Family', 'Foundations', 'Genetic', 'Genomics', 'Glioblastoma', 'Health', 'Health Personnel', 'Healthcare', 'Knowledge', 'Laboratories', 'Link', 'Machine Learning', 'Malignant neoplasm of lung', 'Measures', 'Medical', 'Medical Records', 'Medical center', 'Methodology', 'Methods', 'Modeling', 'Mutation', 'Natural Language Processing', 'Non-Small-Cell Lung Carcinoma', 'Ontology', 'Outcome', 'Pathologic', 'Pathology', 'Pathology Report', 'Pathway interactions', 'Patients', 'Pattern', 'Performance', 'Pharmaceutical Preparations', 'Public Health', 'Recording of previous events', 'Recurrence', 'Research Personnel', 'Resistance', 'Resistance development', 'Second Primary Cancers', 'Semantics', 'Smoking Status', 'Somatic Mutation', 'Statistical Methods', 'Technology', 'Testing', 'Time', 'Tissues', 'Translational Research', 'Tumor Pathology', 'Tweens', 'United States National Institutes of Health', 'Universities', 'Validation', 'Vermont', 'Woman', 'Work', 'actionable mutation', 'anticancer research', 'base', 'cancer cell', 'cancer therapy', 'cancer type', 'clinically actionable', 'demographics', 'design', 'electronic data', 'genetic profiling', 'improved', 'innovation', 'learning strategy', 'malignant breast neoplasm', 'melanoma', 'men', 'novel', 'personalized medicine', 'power analysis', 'precision medicine', 'resistance mechanism', 'response', 'screening', 'targeted cancer therapy', 'targeted treatment', 'treatment response', 'treatment strategy', 'tumor']",NCI,DARTMOUTH COLLEGE,R01,2019,375150,0.04909952117799148
